



PROVIDED BY FINANCING ACTIVITIES

Cash and cash equivalents at beginning of period

Cash and cash equivalents at end of period

NON CASH FINANCING AND INVESTING ACTIVITIES: Related party non-current liability converted to note payable

ORGANIZATION AND NATURE OF BUSINESS

NanoViricides, Inc. (the "Company") is a clinical stage nano-biopharmaceutical company specializing in the discovery, development, and commercialization of drugs to combat viral infections using its unique and novel nanomedicines technology. NanoViricides possesses its own facility that supports research and development and drug discovery, drug candidate optimization, cGMP-compliant drug substance manufacturing, cGMP-compliant manufacturing and packaging of drug products for human clinical trials, and early commercialization. The Company has several drugs in various stages of development. NanoViricides, Inc. is domiciled under the laws of the State of Delaware, with its principal operations located in the State of Connecticut. The Company's fiscal year begins on July 1st and ends on the next June 30th of the calendar year. The Company operates in one reportable business segment. The Company devotes substantially all its activity to advancing research and development, including efforts in connection with clinical trials. The Company's lead drug candidate is the active pharmaceutical ingredient (API) NV-387. NV-387 is a broad-spectrum antiviral drug that has demonstrated strong activity in lethal lung infection animal model studies and is being developed to treat Coronavirus, RSV, Influenza and even an Orthopoxvirus model for Smallpox and MPox. The Company plans on developing NV-387 first as a treatment for RSV infection in pediatric patients. At present, NV-387 is in a Phase Ia/Ib human clinical trial for safety and tolerability in healthy subjects for the treatment of COVID-19, sponsored by our licensee and collaborator in India, Karveer Meditech Private Limited (the "KMPL"). All subjects have been discharged and follow-up visits have been completed as of approximately the end of December 2023. As top-line results of this clinical trial, there were no reported adverse events at all doses studied, and there were no drop-outs either, observations that are indicative of tolerability of the API NV-387. These results are consistent with the results of safety/tolerability studies in animals conducted in support of the clinical trial application. The Company is awaiting the final study report from this clinical trial for further regulatory advancement of NV-387 into a Phase II clinical trial. The Company is now working on developing the necessary datasets, documentation, and clinical trial pathway and trial designs, for a Phase II clinical trial application for the use of NV-387 for the treatment of RSV infection, as the Phase Ia/Ib study progresses into the data analysis phase. On August 14, 2024, the WHO declared a Public Health Emergency of International Concern (PHEIC) regarding the expanding epidemic of MPox infections in Central Africa. There is no drug currently available for the treatment of MPox. NV-387 has been found to possess activity against orthopoxvirus infection in animal model studies, making it a viable candidate for clinical trial as a treatment for MPox infection under the MEURI (Monitored Emergency Use of Unregistered and Investigational Interventions) WHO protocol. The Company is now in the process of defining a clinical protocol for such a Phase II clinical trial with its collaborators in preparation for a clinical trial application to the appropriate regulatory agency. Subsequent to the MPox and RSV Phase II clinical trials that are at high priority, the Company plans on expanding the indications of NV-387 to other respiratory viral infections including Influenza, Coronaviruses, and others. Additionally, the Company has previously developed a clinical drug candidate, NV-HHV-1 formulated as skin cream, for the treatment of Shingles. The Company plans on taking NV-HHV-1 into human clinical trials, and further develop the HerpeCide<sup>®</sup> program after the Phase II clinical trial of NV-387 for RSV, MPox, and possibly for multiple other indications, including Influenza. In the HerpeCide program alone, the Company has drug candidates against at least five indications at different stages of development. The Company's drug candidates against HSV-1, HSV-2, and HSV-2 are in advanced pre-clinical studies and are expected to follow the shingles drug candidate into human clinical trials. In addition, the Company has drug candidates against HIV/AIDS, Dengue, Ebola/Marburg, and other viruses. 7 Table of Contents The Company's drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (the "TheraCour"), a related party substantially owned by Dr. Anil Diwan, to which the Company has broad, exclusive licenses. The licenses are to entire fields and not limited to specific compounds. In all, the Company has exclusive, worldwide licenses for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV-1 and HSV-2), Influenza and Asian Bird Flu Virus, Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis virus, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes (re-stated), Varicella Zoster Virus (the "VZV") infections (i.e. Shingles and Chickenpox), and SARS-CoV-2 infections. Additionally, on September 23, 2024, the Company signed a Memorandum of Understanding (the "MoU") for all antiviral drug development with TheraCour whereby it has obtained a right of first refusal (ROFR) for all antiviral drug developments from TheraCour. This MoU expands the Company's abilities to opportunistically and rapidly develop novel drugs to treat viral infections of public health importance, even for those viruses that do not exist today and cannot be predicted. The MoU has also formalized the process of development of drugs for unlicensed viral indications leading later to appropriate license agreements. There was no compensation paid to or due to TheraCour as a result of this MoU. The Parties have also agreed in this MoU that any cash milestone payments related to development activities, that are awardable, will become payable only upon the Company having sufficient revenue, thus extending the provisions previously incorporated in the Amendment to the COVID License Agreement, to all present and future license agreements. In all cases, the discovery of ligands and polymer materials as well as formulations, the chemistry and chemical characterization, as well as process development and related work will be performed by TheraCour, a related party substantially owned by Dr. Anil Diwan, under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed. Upon commercialization, NanoViricides will pay 15% of net sales to TheraCour. Milestone payments were made or are specified in certain of the license agreements, details of which have been disclosed at the time the agreements were entered into. The Company negotiates and licenses specific verticals of therapeutic applications from TheraCour if promising drug candidates are found in early research and development against a virus target. TheraCour has not denied any such licenses when requested. The Company has out-licensed NV-CoV-2 and NV-CoV-2-R for further clinical drug development and commercialization in the territory of India to KMPL, a company of which Dr. Anil Diwan is a passive investor and advisor. KMPL has sponsored the NV-CoV-2 into Phase Ia/Ib human clinical trial, to study the safety and tolerability of the NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies formulations of the API NV-387 in healthy human subjects, described earlier. The clinical trial drug products, NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, were manufactured at the Company's Shelton campus. Under the agreement with KMPL, the Company will pay for the expenses of the clinical trials, and in return will benefit from having the data and reports made available for regulatory filings in other territories of the world. Upon commercialization, the Company will receive royalties from KMPL equal to 70% of sales net of costs to unaffiliated third parties. Note 2A - Liquidity and Going Concern The Company's condensed financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets and liquidation of liabilities in the normal course of business. As reflected in the condensed financial statements, the Company has an accumulated deficit at September 30, 2024 of approximately \$142.5 million and a net loss of approximately \$3.1 million and net cash used in operating activities of approximately \$2.6 million for the three months then ended. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future. Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs. The Company has not yet commenced any product commercialization. Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future. As of September 30, 2024, the Company had available cash and cash equivalents of approximately \$3.9 million. The Company's liabilities at September 30, 2024 were approximately \$1,633,000 including accounts payable of approximately \$713,000 payable to third parties, accounts payable to TheraCour of approximately \$637,000, and accrued expenses of approximately \$283,000. Management believes that the Company's cash and cash equivalents balance of approximately \$3.9 million, additional capital raised of approximately \$631,000, net of offering expenses, by ATM sales of our common stock from October 1, 2024 through November 7, 2024, and the Company's existing resources, including availability under its \$3 million line of credit will not be sufficient to fund the Company's planned operations and expenditures for at least 12 months from the date of the filing of this Form 10-Q. As a result, substantial doubt exists about the Company's ability to continue as a going concern. 8 Table of Contents The Company believes that it has several important milestones, including data from and final reports from the Phase Ia/Ib human clinical trial for the Company's broad-spectrum, antiviral drug NV-387. This Phase Ia/Ib human clinical trial is for evaluating the safety and tolerability of two oral formulations of NV-387, namely (i) NV-CoV-2 Oral Gummies, and (ii) NV-387 Oral Syrup, as described elsewhere, with COVID as the indication. The safety and tolerability data from this clinical trial is expected to be applicable as Phase Ia/Ib data for other indications of NV-387 as well, including RSV, MPox, Influenza and others. Additional milestones include Pre-IND and IND filing to the US FDA for RSV and clinical trial application for Phase II clinical trial of NV-387 for the treatment of RSV infection in adults with the goal towards further regulatory advancement and approval of NV-387 for the treatment of pediatric RSV infection. Additionally, the Company believes that NV-387 qualifies for a Phase II clinical trial for the treatment of MPOX infection in Central African nations under the MEURI protocol of WHO because there is no other treatment available for this epidemic that is declared by the WHO as a public health emergency of international concern (MEURI = Monitored Emergency Use of Unregistered and Investigational Interventions). We plan on initiating the Phase II study for MPOX as soon as feasible if the Company receives the appropriate regulatory clearances. Additionally, the Company continues toward developing the Pre-IND and IND applications for a Phase IIa clinical trial of NV-387 for the treatment of RSV infection in adults, to be followed by a Phase IIb/III clinical trial of NV-387 for the treatment of RSV infection in hospitalized pediatric patients. To this end, the Company is also evaluating the possibility of a Phase IIa clinical trial of a RSV Infection Challenge in Humans. Management believes that as these milestones are achieved, the Company would likely experience improvement in the liquidity of the Company's stock, and such improvement, if any, would enhance the Company's ability to raise funds on the public markets at terms that may be favorable to the terms offered at present. Management is actively exploring additional required funding through non-dilutive grants and contracts, partnering, debt or equity financing pursuant to its plan. There is no assurance that we will be successful in obtaining sufficient financing on terms acceptable to us to fund continuing operations. Management believes that it has on-going access to the capital markets including the AT-Market<sup>®</sup> (ATM) agreement with EF Hutton, the Sales Agent. There can be no assurance that the Company's plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The Company will need to raise additional capital to fund its long-term operations and research and development plans including human clinical trials for its various drug candidates until it generates revenue that reaches a level sufficient to provide self-sustaining cash flows. There can be no assurance that the Company will be able to raise the necessary capital or that it will be on acceptable terms. The accompanying financial statements do not include any adjustments that may result from the outcome of such unidentified uncertainties. Note 3A - Summary of Significant Accounting Policies Basis of Presentation - Interim Financial Information The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (the "U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying condensed financial statements and the information included under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations" should be read in conjunction with the Company's audited financial statements and related notes included in the Company's Form 10-K for the fiscal year ended June 30, 2024 filed with the SEC on September 27, 2024. The June 30, 2024 year-end balance sheet data in the accompanying interim condensed financial statements was derived from the audited financial statements. For a summary of significant accounting policies, see the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2024 filed on September 27, 2024. 9 Table of Contents Net Loss per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants and convertible preferred stock. The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive: Potentially Outstanding Dilutive Common Shares For the Three Months Ended September 30, 2024 and September 30, 2023 Warrants 6,577 7,719 The Company has 903,216 shares of Series A preferred stock outstanding as of September 30, 2024. Only in the event of a change of control of the Company each Series A preferred share is convertible to 3.5 shares of its new common stock. A change of control is defined as an event in which the Company's shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition of the Company or the Company's intellectual property. In the absence of a change of control event, the Series A preferred stock is not convertible into common stock, and does not carry any dividend rights or any other financial effects. At September 30, 2024, the number of potentially dilutive shares of the Company's common stock into which these Series A preferred shares can be converted into is 3,161,257, and is not included in diluted earnings per share since the shares are contingently convertible only upon a change of control. Recently Issued Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standard Updates (the "ASU's"). ASU's not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial statements. ASU 2024-03, Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires public business entities (PBEs) to disclose, in interim and annual reporting periods, additional information about certain expenses in the notes to financial statements. The requirements of ASU 2024-03 apply to all public business entities. The ASU requires disaggregated disclosure of income statement expenses for public business entities (PBEs). The ASU does not change the expense captions an entity presents on the face of the income statement; rather, it requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. ASU 2024-03 is effective for all PBEs for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. While the Company is currently evaluating the adoption impact of this ASU on its financial statements, the preliminary assessment is that the adoption of this standard is not expected to have a material effect on the Company's financial statements and the Company's disclosures. ASU 2023-09 Income Taxes (Topic 740) Improvements to Income Tax Disclosures. The amendments in this Update require that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income [or loss] by the applicable statutory income tax rate). Additionally, the ASU requires all entities to disclose the amount of income taxes paid disaggregated by federal, state, and foreign taxes, as well as individual jurisdictions where income taxes paid are equal to or greater than 5 percent of total income taxes paid. ASU 2023-09 is effective for annual periods beginning after December 31, 2024. Early adoption is permitted and this ASU should be applied on a prospective basis. While the Company is currently evaluating the adoption impact of this ASU on its financial statements, the preliminary assessment is that the adoption of this standard is not expected to have a material effect on the Company's financial statements and the Company's disclosures. ASU 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The requirements of this update require disclosure of significant segments expenses and increase the frequency of segment reporting to interim periods. The ASU is 10 Table of Contents effective for all public companies for fiscal years beginning after December 15, 2023 and for interim period beginning after December 15, 2024. Early adoption is permitted and is applicable to all periods presented in the financial statements unless retrospective application is impracticable. While the Company is currently evaluating the adoption impact of this ASU on its financial statements, the preliminary assessment is that the adoption of this standard is not expected to have a material effect on the Company's financial statements and the Company's disclosures. Note 4A - Related Party Transactions Related Parties Related parties with whom the Company had transactions are: Related Parties - A Relationship Dr. Anil Diwan Chairman, President, CEO, significant stockholder through his ownership of TheraCour, and Director of TheraCour Pharma, Inc. (the "TheraCour") An entity owned and controlled by Dr. Anil Diwan Karveer Meditech Private Limited (the "KMPL") An entity where Dr. Anil Diwan is a passive





of treatment with NV-387 with those of approved drugs, and found NV-387 treatment to be superior. We believe that NV-387 has strong prospects for regulatory approval in each of these indications. Novel Orthogonal Nanoviricidal Mechanism Has Many Benefits. Additionally, the NV-387 putative mechanism of action is orthogonal and complementary to that of the existing therapeutics, enabling combination therapy with the existing drugs in the market. NV-387 acts on the free virus outside cells blocking infection of new cells by destroying the virus. Existing antiviral therapeutics (except antibodies and entry inhibitors) act on the replication cycle of the virus (ex.: remdesivir, acyclovir, ribavirin, cidofovir, brincidofovir) inside cells, or exiting of the virus (ex.: oseltamivir, peramivir, tecovirimat) from inside cells. Thus combining the action outside the cells of NV-387 with the action inside the cells (or at exit) of these existing agents is expected to lead to complete blockage of any virus thus resulting in a rapid and complete cure. Combining multiple drugs also leads to reduction in emergence of viral resistance, as has been scientifically proven already. 21 Table of Contents Nanoviricidal Can Encapsulate Small Chemicals as Guests, Enabling Improved Pharmacokinetics and thus Activity of the Guest. Further, NV-387 also acts as a unique and novel drug delivery vehicle, similar in action to exosomes. Thus, encapsulation of remdesivir in NV-387 enabled oral delivery of NV-387 and the activity of the resulting drug, NV-387-g-Rp, given orally in lethally infected animals, was found to be superior to that of each of NV-387 and remdesivir (Vekurya@, Gilead). We have also developed our own, patent-pending replication inhibitor antiviral agents that can be encapsulated in NV-387 for improved antiviral activity in animal models, with the objective of curing long-term (long COVID) and lifelong (HSV-1, HSV-2, VZV, others) viral infections. Clinical Development Program: NV-387 Phase I Clinical Trial. In the Phase I human clinical trial, even at the highest dose level, dosed multiple times, NV-387 was found to be well tolerated, and there were no reported adverse events of the drug that was given orally. This clinical trial finding is consistent with the findings that the evaluation of safety of NV-387 in pre-clinical studies demonstrated a No-Observed-Adverse-Effects-Level (NOAEL) at 1,200 mg/Kg, and the Maximum Tolerable Dose level (MTD) at 1,500 mg/Kg in rats, which are very high numbers (high is good). Further, NV-387 was found to be non-mutagenic, non-immunogenic, non-allergenic, and non-genotoxic in IND-enabling studies. We therefore anticipate that NV-387 can be given to patients across all patient population, in age from infants to seniors, including immunocompromised persons, patients with co-morbidities, and others, when approved. This is in contrast to available antiviral therapeutics that, limited by their toxicity and metabolic effects, cannot be given to many pools of patients. Further Clinical Development of NV-387 Towards Drug Approvals: Multiple Indications for NV-387 Against Different Viral Infections Enable Maximizing Return on Investments While Fulfilling Unmet Medical Needs. We intend to initiate a Phase II clinical trial in India shortly after the Phase I final report becomes available. We are in discussions with subject matter experts in India regarding the best indication to go with in Phase II; RSV and Influenza being some of the choices. We also plan on initiating a Phase IIa clinical trial of NV-387 for the treatment of RSV infection under the US FDA (see further below). We are in the process of developing a Pre-IND application to the US FDA for this purpose. Our overall objective of the program is to evaluate NV-387 for commercialization as a treatment of infants to young children. We believe that our Phase IIa clinical trial design will enable us to proceed to a Phase II/III registration clinical trials in infants and young children with RSV infection. This is an unmet medical need. Each year in the United States, RSV leads to approximately 2.1 million outpatient (non-hospitalization) visits among children younger than 5 years old, resulting in 58,000-80,000 hospitalizations among children younger than 5 years old, and 100ae300 deaths in children younger than 5 years old, according to the CDC (<https://www.cdc.gov/rsv/research/index.html>). In light of the WHO public health emergency declaration regarding the MPOx epidemic in Central Africa, we have begun efforts to progress NV-387 for Phase II evaluation of efficacy in the treatment of MPOx virus infection. This is an unmet medical need since there is no drug available for the treatment of MPOx infection given the failure of tecovirimat in clinical trial. Additionally, we anticipate that NV-387 would be expected to be eligible for the development of Poxvirus therapeutics under the FDA ae3e Animal Rule ae3e. The Animal Rule program requires well-controlled GLP studies in specific animal poxvirus infection models as replacement of the Phase II/III human clinical trials, and ae3e Phase I human clinical trials to elucidate safety of the drug in human use. We plan to seek non-dilutive government funding for this indication. Multiple indications of NV-387 enable us to maximize return on investments. The Phase I safety and tolerability clinical trial would be generally applicable across all indications. All of IND-enabling non-clinical studies would also be reused, with the addition of animal model antiviral activity studies for the specific indication. The Chemistry, Manufacture, and Controls for the drug substance would remain substantially the same and potentially the drug product sections also could be reused. 22 Table of Contents Multiple Formulations Enable Treatment of All Segments of Patient Population with Varying Disease Severity, from Mild to Moderate to Severe and Hospitalized. We have successfully developed NV-387 formulations for different severities of viral diseases, and with different patient populations in mind. These include: (i) Oral ae3e Gummies ae3e for adults and older children. Oral gummies have an advantage over tablets in that the drug dissolves slowly in the mouth and does not require swallowing. Older adults as well as children with certain respiratory infections are known to have difficulty swallowing. (ii) Oral Syrup. In infants and younger children, the drug must be ae3e titrated ae3e on the basis of body weight or a similar parameter. A syrup form is best suited for this purpose. (iii) Solution for Injection, Infusion or Inhalation. For hospitalized patients with severe disease, injections and infusions are better suited to provide immediate antiviral action. A simple inhalation of the same solution using a standard available nebulizer enables direct delivery to lower respiratory system where the virus is causing lung damage that can lead to lung failure and potentially death. Unique, Novel Design Leading to Broad-Spectrum Activity of NV-387. NV-387 has such broad-spectrum activity because it is designed to mimic the attachment receptors to which viruses bind before infecting a cell. The family of attachment receptors mimicked by NV-387 is called Sulfated Proteoglycans (S-PG). This family includes glycosaminoglycans (ae3e GAGs ae3e), and proteoglycans containing heparan sulfate (HSPG), dermatan sulfate (DSPG), chondroitin sulfate (CSPG), and keratan sulfate (KSPG), among others. Over 90% of known pathogenic viruses bind to one or more of these S-PG class attachment receptors. These viruses include Coronaviruses, Paramyxoviruses (RSV - Respiratory Syncytial Virus, and HMPV- human Metapneumovirus), Dengue Viruses, Chikungunya Virus, Herpesviruses, Human Papillomavirus (HPV), HIV, Hendra and Nipah Viruses, Ebola and Marburg Viruses, and Poxviruses, among others (Cagno V, Tseligka ED, Jones ST, Tapparel C. Heparan Sulfate Proteoglycans and Viral Attachment: True Receptors or Adaptation Bias? Viruses. 2019 Jul 1;11(7):596. doi: 10.3390/v11070596. PMID: 31266258; PMCID: PMC6669472). Thus, a large number of virus families use these S-PG family attachment receptors to concentrate next to cells and thereby efficiently infect cells, with different virus families having preferences to one or more of such attachment factors. We believe our unique and successful mimicking of S-PG is responsible for the observed broad-spectrum activity of NV-387. NV-387 is an example of NanoViricidal Platform Modality #1 implementation discussed in our Annual report filed with the SEC on September 27, 2024. NV-387 is Unlikely The NanoViricidal Platform Technology has an important advantage in that no matter how much a virus changes in the field, it is unlikely to escape the nanoviricidal drug, because the nanoviricidal drug is designed to mimic the very features that the virus uses to bind to and enter cells. These specific molecular signature features on the cellular side do not change even as the virus mutates, and nanoviricidal drugs are designed to mimic these host-side features. In contrast viruses readily escape antibodies as drugs, as well as vaccine-induced immunity as they evolve in the field, as is well known from the COVID-19 pandemic as well as Influenza pandemics and the continuing HIV/AIDS pandemic. A safe and effective antiviral drug that the virus would not escape by mutations or field evolution is the holy grail of antiviral drug development. We believe that the NanoViricidal Platform technology meets this challenge. Further details of the NanoViricidal Platform Technology, the various Modalities of its implementation, and the extensive drug candidate developments that we have undertaken, have been discussed in our Annual Report filed with the SEC on September 27, 2024. 23 Table of Contents GMP-Compliant Manufacture of Nanoviricidal Drug Candidates in Our Own Facility. NanoViricidal is one of a few biopharma companies that has its own cGMP-compliant manufacturing facility. We have designed and developed a cGMP-capable drug substance and drug product manufacturing facility at our headquarters in Shelton, CT. The manufacturing facility comprises a Scale-Up Suite, Clean Room Suites (Class 1000 and Class 100) for Manufacture of the Drug Substances, and Formulation and Packaging Suites for our Drug Products. We believe our capabilities in manufacturing clinical drug products are now well established. We have manufactured multi-Kg scale clinical supply of drug substances as well as the oral drug products for NV-CoV-2 at our own facility, from synthesis all the way to fill-finish-labeling and packaging, simplifying and expediting the cGMP-compliant manufacturing operations. Our team has successfully and rapidly translated from the research scale production of several grams drug substance to Kg-scale cGMP-compliant manufacture for two different drug candidates, namely NV-HHV-1 and NV-CoV-2, in three different formulations, namely skin cream, oral syrup, and oral gummies, in a very short time span. This includes manufacture of the active ingredients (drug substances), the formulated drug products, and packaged drug products for clinical trials usage. Manufacturing nanomedicines, especially under cGMP conditions, has been identified as a major risk, and has led to failure of several nanomedicine programs. NanoViricidal co-founder Dr. Anil Diwan and our team have employed considerations for cGMP manufacture of our nanomedicines right from the design, development and optimization of the drug candidates, the polymers and ligands that go into them, as well as the processes employed right from the small research scale to the initial process verification batches. We have thus demonstrated that we have unique expertise in the industry of performing cGMP-compliant manufacture of multiple complex nanomedicine drugs, including cGMP manufacture of (a) drug substance from simple chemical starting materials, (b) the formulated drug product, and (c) the final packaged drug. This is a very significant milestone on the way of NanoViricidal becoming a fully integrated pharma company. We continue to improve the production processes and production scale. Our production capacity is anticipated to be more than sufficient for Phase I, Phase II and Phase III human clinical trials for all of our drugs in development. We believe that our drug manufacturing capacity is sufficient for initial market entry for our anti-RSV drug when approved. Our in-house cGMP production capability has resulted in and is expected to continue to result in significant cost savings across all our drug development programs. NanoViricidal is Fully Equipped for Rapid Antiviral Drug Development from Discovery to cGMP Drug Product Delivery for Clinical Trials; Which Makes NanoViricidal ae3e FIPCO ae3e. In addition to the manufacturing facility, we have on site specialized nanomedicines characterization facility with advanced instrumentation including Wyatt Dynamic Light Scattering instruments, Mass Spectrometry Equipment with ae3e Multiple Reaction Monitoring (MRM) ae3e capability, and others. We also have on site full-fledged chemistry laboratories to enable drug design, discovery, small scale synthesis, testing, and scale-up of drug candidates worthy of further development. We also have our own BSL2 Virology Lab for initial evaluation of our drug candidates in cell culture and other in vitro studies. Thus we are ae3e Fully-Integrated-Pharmaceutical Company ae3e (FIPCO) unlike most biopharma companies that do not possess the full suite of drug discovery, synthesis, testing, characterization, scale-up, as well as drug substance and drug product manufacture capabilities in house. 24 Table of Contents High Probability of Success in Clinical Trials for Drugs Based on NanoViricidal Platform Technology. We are now a clinical stage innovative drug development company, advancing from the research and development (ae3e R&D ae3e) stage into regulatory development of our drug candidates towards commercialization. We have been executing rapidly and efficiently, as well as in a cost-effective and productive manner, resulting in successful completion of the Phase I Safety and Tolerability clinical trial of our drug candidate, NV-CoV-2 (API NV-387). We believe that this successful completion with no reported adverse events, which is the most desirable outcome from Phase I clinical trial to establish safety and tolerability of the drug candidate NV-387 is a very important milestone enabling NV-387 to advance for multiple antiviral indications into Phase II efficacy clinical trials. Additionally, this Phase I bodes well for our entire platform technology as being capable of producing drug candidates that are capable of successfully completing Phase I safety and tolerability studies. In addition, our pre-clinical lethal virus infection animal model studies provide us the confidence that the drug candidates we advance into Phase II efficacy clinical trials would have a high probability of success. This is because in these animal studies, the animal model plays the role of ae3e test tube ae3e where the virus can proliferate, and our drugs are designed to directly attack the virus without interfering with functions of the host animal. Additionally, we design the studies to provide clear readout in terms of survival lifespan that can be used for ranking the activity of each tested drug, including already approved drugs where available. Our non-clinical programs are designed to minimize the risk of failure of our drug candidates in clinical trials. Specifically, we perform evaluation of antiviral activity in lethal studies in direct comparison with known approved drugs if available, and choose drug candidates that show at least comparable or superior activity to the approved ones. We employ lethal infection studies so that the survival time is a clear indicator of the antiviral activity, and can be used to rank relative activity of drug candidates. We believe our success rate of drug approval would be substantially better than industry averages because of the features of our nanoviricidal platform technology and the de-risking strategies we employ in drug development. The NanoViricidal Platform Technology: (i) Solving the Problem of Drug Escape by Virus Variants. We believe that our platform technology enables development of drugs that viruses would not escape from. In fact, during the pre-clinical development in the COVID program, we have successfully screened our drug candidates to be able to protect cells against infection by distinctly different coronaviruses. This broad-spectrum, pan-coronavirus drug development approach was adopted to ensure that our drug candidates should remain effective even as variants of SARS-CoV-2 continue to evolve in the field, just as we had already anticipated at the very beginning of the pandemic. Our nanoviricidal ae3e platform technology is based on biomimetic engineering that copies the features of the human cellular receptor of the virus. No matter how much the virus mutates, all virus variants bind to the same receptor in the same fashion. Thus our platform technology is inherently designed to combat the issue of viruses escaping drugs by generation of variants. We mimic the feature on the cellular protein at which the virus binds, and, using molecular modeling, design small molecules that act as ae3e ligands ae3e to bind to the virus surface glycoproteins as though the virus was binding to that cellular protein itself. This host-side chemical signature that the virus uses for infecting cells does not change even as the virus mutates, evolves and generates variants. We chemically synthesize the optimal ligands, and separately attach them to the polymeric micelle scaffold to generate a number of initial ae3e nanoviricidal ae3e drug candidates to screen against the virus. Thus the nanoviricidal is designed to ae3e look like ae3e the cell membrane with copious amounts of sites for the virus to bind to. When initial interaction of a few ligands with the virus particle takes place, the ae3e metastable ae3e nanoviricidal micelle is anticipated to shift its shape, inverting itself onto the virus particle promoted by the ae3e lipid-lipid mixing effect ae3e driven by the lipid chains normally on the interior of a nanoviricidal micelle and the lipid membrane that is on the virus surface. Such an attack on the virus particle is expected to de-stabilize the virus particle and uproot the surface glycoproteins it uses for fusing with a cell. Thus the virus would no longer be capable of infecting a cell. This process would result in complete blockage of the ae3e Re-Infection Cycle ae3e of the virus if successful. We call this mechanism ae3e Re-Infection Inhibition ae3e. This mechanism goes beyond the simple neutralization of the virus by antibodies, which requires the human immune system to further take care of the resulting virus-antibody complex. This mechanism also goes beyond the simple blocking of virus entry by small chemical entry inhibitors, which would require extremely high concentrations of the inhibitor to effect complete blockage of each virus particle based on mass-action considerations. 25 Table of Contents The nanoviricidal polymeric micelle is expected to be able to completely coat the virus particle. This is unlike the antiviral antibodies as well as small molecule entry inhibitors that can only partially block the virus particle whereby the virus would still remain capable of infecting a cell. Additionally, antibodies only tag the virus for recognition by the patient ae3e immune system for clearance. In contrast, a nanoviricidal is designed to complete the task of dismantling the machinery of the virus that enables it to infect cells. Mimicking the attachment receptor families may lead to extremely broad-spectrum drug candidates. We call this implementation NanoViricidal Platform Technology Modality #1. NV-387 is an example of this Modality #1, namely, Broad-Spectrum Antiviral Re-infection Inhibitors. NV-387 is designed to mimic key features required by viruses of the host-side sulfated proteoglycans that viruses use as attachment receptors. Mimicking the cognate receptor would lead to a narrower range but can be anticipated to have greater efficacy compared to mimicking the attachment receptor families. We call mimicking the cognate receptor the NanoViricidal Platform Technology Modality #2, or Specific Antiviral Re-infection Inhibitors. The NanoViricidal Platform Technology: (ii) Promising Potential Cures for Infections by Non-latency Viruses. Additionally, we are the only company that, to the best of our knowledge, is developing antiviral treatments that are designed to (a) directly attack the virus and disable it from infecting human cells (i.e. block the ae3e Re-Infection Cycle ae3e), and (b) simultaneously block the reproduction of the virus that has already gone inside a cell (i.e. block the ae3e Replication Cycle ae3e). Together, this strategy of a two-pronged attack against the virus, both inside the cell and outside the cell, and thus blocking the complete lifecycle of the virus, can be expected to result in a cure for coronaviruses and other viruses that do not become latent. We call this implementation, namely encapsulation of other active ingredients within the polymeric micelle of the virus-targeted nanoviricidal (which can be based on either Modality #1 or Modality #2), the NanoViricidal Platform Technology Modality #3. As an example of the Modality #3, we have developed NV-387-g-R, which comprises NV-387 that encapsulates Remdesivir, a known broad-spectrum antiviral drug that is already approved for COVID treatment of hospitalized patients. Although approved, the clinical effectiveness of Remdesivir is limited by its bodily metabolism. It is well known that this drug is highly active in cell culture studies, but the clinical results do not match the expectations corresponding to its cell culture effectiveness. We developed NV-387-g-R to overcome this issue and we have demonstrated that encapsulation within NV-387 successfully improves the PK/PD (pharmacokinetics and pharmacodynamics) profile of Remdesivir. The increased circulating lifetime and also concentration of intact Remdesivir should improve its effectiveness. Additionally, NV-387-g-R affords the synergistic effects of attacking the virus lifecycle by two orthogonal mechanisms, going well beyond the effects of Remdesivir alone. In NV-387-g-R, one component, NV-387, is designed to block the ae3e Re-Infection Cycle ae3e, and the encapsulated guest component, Remdesivir is known to block the ae3e Replication Cycle ae3e. Thus NV-387-g-R is designed to block the entire lifecycle of many viruses, not just

coronaviruses. This total attack on the complete lifecycle of the virus is expected to result in the most effective drug candidates. It is now well accepted that multiple antivirals together produce better effectiveness than single ones individually. Our strategy goes beyond simply a mix of multiple antivirals. Our unique, shape-shifting nanomedicine technology leads to substantial improvement in the pharmacokinetic properties of the guest antiviral drug. We have demonstrated this capability in the case of NV-387-g-R, as discussed above, wherein encapsulation of Remdesivir within the polymeric micelles of NV-387 protects the former drug from bodily metabolism in animal studies. This allows higher concentrations of the guest drug to be reached and simultaneously extends the effectiveness time period in comparison to the standard Veklury® (Gilead) formulation. The resulting drug, NV-387-g-R has not only significantly improved characteristics for its Remdesivir component, but additionally provides the novel re-infection blocking mechanism of NV-387; together enabling complete block of the viral lifecycle, which would potentially result in a cure. (Chakraborty A, Diwan A, Chiniga V, Arora V, Holkar P, Thakur Y, et al. (2022) Dual effects of NV-Cov-2 biomimetic polymer: An antiviral regimen against COVID-19. *PLoS One* 17(12): e0278963. <https://doi.org/10.1371/journal.pone.0278963>)

The NanoViricides Platform Technology: (iii) Routes of Administration Include Oral Route. It is generally believed that nanomedicines as a class would not have good bio-availability if taken orally. We believe that this biased opinion has unnecessarily resulted in curbing potential innovation to overcome the issue of oral bioavailability. In fact, we have found in pre-clinical animal studies that NV-387 was highly effective when given orally in combating a lethal lung infection that models the severe SARS-CoV-2 disease as seen with the delta variant. In comparing the effect on combating the infection by oral treatment versus injectable treatment, we believe that the bioavailability of the oral dosage forms is substantially good, and in the range of many approved oral drugs. In addition, the API NV-387 was found to be highly effective when given orally in the case of lethal lung RSV infection animal model, a lethal smallpox-emulating ectromelia footpad infection mouse model, a lethal smallpox-emulating ectromelia lung infection mouse model, as well as a lethal Influenza A/H3N2 lung infection mouse model, further substantiating the oral bio-availability of NV-387. These findings have enabled us to develop oral formulations of NV-387 for human clinical trials. We have successfully developed orally active formulations of our NV-387 in an oral syrup form, as well as an oral gummies (Achéveable Soft Solids) form. We believe that for mild to moderate viral infection disease, for pediatric, and for geriatric patients, the oral syrup and gummies forms would be highly advantageous over tablets, capsules, injections, infusions, or lung inhalations. The injectable formulation of NV-387 is expected to be valuable in the treatment of severe cases. Out-patient single dose injection treatment may be feasible if the effectiveness of NV-387 in human clinical trials matches that observed in pre-clinical animal studies. Further, this injectable formulation is designed to be deliverable also as an aerosol by a simple hand-held nebulizer device directly into lungs. Such inhalation, as an aerosol, is expected to provide greater benefits to more severe patients by providing high concentration of the drug locally in the lungs where the RSV, SARS-CoV-2, and Influenza viruses cause the most damage in severe cases. The Solution for Injection, Infusion and Inhalation of NV-387 would also be very important in pediatric as well as hospitalized cases. We believe that the extremely strong antiviral activity we have observed in cell culture studies and in lethal virus infection animal studies, in comparison to approved drugs is a strong positive indication of clinical success and potential regulatory approval of NV-387 for the different viral infection indications we are seeking. We believe we have demonstrated that we can rapidly develop different types of formulations for different routes of administration, such as injectable, skin cream, lotion, gel, and even oral, because of the inherent strength of the flexible and tailorable Nanoviricide Platform technology. The technology also enables us to develop nasal sprays and bronchial aerosols. We plan to develop the appropriate formulations as necessary. A Note on Nomenclature of NanoViricides Candidates: *g-R* denotes that the next component is encapsulated as a guest within the preceding nanoviricide. Thus NV-387-g-R refers to Remdesivir encapsulated as a guest within NV-387. Similarly NV-387-g-Rp refers to a pro-drug of Remdesivir (denoted Rp) is encapsulated as a guest within NV-387. *m-T* denotes that the next component is mixed in with the preceding nanoviricide. Thus NV-387-m-T refers to NV-387 and Tecovirimat mixed together in a formulation method. Developments During the Reported Period: During the three months ended September 30, 2024, we have focused on preparing regulatory documentation that will be necessary for primarily (i) a Phase II MPOX clinical trial of NV-387, and (ii) a Phase II RSV clinical trial of NV-387. We are in the process of designing a Phase II clinical trial protocol for the treatment of MPOX infection with NV-387 under the MEURI guidelines. We have also started working on a Phase II clinical trial protocol for the treatment of RSV infection. In addition, we have continued to further scale-up the manufacture of NV-387 in our cGMP-compliant facility, effectively doubling the prior batch size, in preparation for supplying the drug products for the Phase II clinical trials. We believe this scale will be sufficient for a Phase II clinical trial for MPOX or for a Phase II clinical trial for RSV. We will commission additional batches as we engage into additional clinical trials. We have initiated the production program for Phase II clinical supply of NV-387 drug products. We are also performing additional pre-clinical experiments to further understand the spectrum of antiviral activity of NV-387 towards obtaining information for regulatory advancement against different antiviral indications. 27 Table of Contents In the non-clinical studies leading to the Phase I clinical trial, NV-387 was found to be non-immunogenic, non-allergenic, non-mutagenic, non-toxic, as well as non-genotoxic. No adverse effects were reported in GLP Safety-Toxicology studies in multiple animal models including non-human primates (NHP, Cynomolgus monkeys). The NOAEL (No-Observed-Adverse-Events-Level) was 1,200 mg/Kg and MTD (Maximum Tolerable Dose) was 1,500 mg/Kg in rats, which are very high numbers (high is good). A Phase I clinical trial of (i) NV-387 Oral Syrup and (ii) NV-387 Oral Gummies formulations to evaluate Safety and Tolerability in healthy human subjects was completed with the discharge and final visit of the last subject at the end of December, 2023. There were no reported adverse events, and there were no drop-outs in this clinical trial of 72 subjects. Thus, the drug NV-387, in both of the oral formulations studied, namely oral syrup and oral gummies (a soft solid form that dissolves in the mouth), is deemed to be safe and well tolerated and can be further advanced into Phase II clinical trials, as per communications with the Data Safety and Monitoring Board (DSMB) for this clinical trial. We are awaiting a final report of the clinical trial. This statement regarding safety and tolerability will be evaluated, after we submit the final Phase I report, by the regulatory agency. The results of the Phase I clinical trial are consistent with our non-clinical findings. Thus NV-387 can now be advanced into Phase II human clinical trials against the different antiviral indications within its antiviral activity spectrum. Update on Our COVID Program: The original plan for the Phase 1a/1b clinical trial was to include COVID patients in Phase 1b-COVID cohorts to obtain initial indications of efficacy and dosage requirement. The healthy injected portion of the clinical trial, which is the traditional Phase I clinical trial involving the evaluation of single-ascending-dose and multiple-ascending dose of the investigational medical product in healthy subjects was completed in December, 2023. Thereafter, efforts to find COVID patients were continued, and an additional clinical site was added during February 2024. In spite of this, the lack of obtaining PCR-positive COVID patients eligible for enrollment into the clinical trial became the obstacle. Our diligent efforts to identify COVID-19 participants for the clinical trial have been met with a notable absence of positive cases at the designated clinical trial site(s). Therefore, the Phase 1a/1b clinical trial was closed in April 2024, concluding the study as a traditional Phase I study. We note that we do not have any information regarding the activity of NV-387 (drug product NV-CoV-2) in COVID from this clinical trial because no COVID patients could be found for enrollment in the study. We believe that NV-387 has strong, clinically relevant, activity in treatment of COVID based on our pre-clinical studies that directly evaluated the activity of NV-387 in comparison with remdesivir, an approved drug for the treatment of COVID, and found that the activity of NV-387 was substantially superior to that of remdesivir. We have been in discussion with subject matter experts in the U.S. as well regarding potential clinical trials towards approval of NV-387 for COVID indication. While COVID still continues to be important globally, the prospect of conducting meaningful clinical trials in COVID patients has become substantially difficult. Long COVID remains an important disease in the U.S. However, it is multi-factorial, and conducting meaningful clinical trials is even more difficult than with COVID patients, and could result in lengthy and expensive clinical trial designs, not within the capabilities of small companies like us. Therefore, while we fully believe that (i) NV-387 has demonstrated strong pan-coronavirus antiviral activity in pre-clinical studies and therefore (ii) NV-387 is a viable clinical drug candidate for COVID treatment; (iii) NV-387 could be substantially superior to available drugs such as remdesivir and Paxlovid®, and (iv) NV-387 would be available to the entire patient population while the available drugs have severe limitations, regrettably, we have determined that we cannot take NV-387 forward for COVID indication with our limited resources. If resources become available for clinical trial of NV-387 for a subset of Long COVID patients with residual virus found in sensitive assays, then we would very much like to advance clinical trials to develop NV-387 for the Long COVID indication. This continues to be an unmet medical need. We are seeking to advance NV-387 for COVID and Long COVID indications via partnerships. 28 Table of Contents NV-387 Has Multiple Antiviral Indications Beyond COVID towards Regulatory Approvals: Knowing that NV-387 is designed to be broad-spectrum, over the previous three months we have continued to work towards understanding the extremely broad spectrum of antiviral activity of the API NV-387. Of the potential indications, we have decided to focus our resources on advancing NV-387 into clinical trials towards approval for RSV infection in pediatric patients, an unmet medical need. The results of the NV-387 Phase 1a/1b clinical trial indicate that NV-387 can be used: (i) across all ages from pediatrics to seniors; (ii) irrespective of co-morbidities such as diabetes, other pre-existing diseases, or immune compromised status of the individual; and (iii) at all levels of disease severity, from mild/moderate to severe to very severe (hospitalized patients). This capability of NV-387 is analogous to the highly successful antibiotics against bacteria. In contrast, currently available antiviral drugs have substantial limitations on the patient populations that they can be used in. For example, of the two remaining approved drugs for treatment of COVID, Paxlovid which is given orally, is not indicated for the treatment of COVID in patients without a risk factor for progression to severe COVID-19, whereas Remdesivir can only be used in hospitalized cases. Similarly ribavirin, indicated for RSV infection and other viral infections, is only indicated as a last resort because of severe toxicities. Other antivirals such as Cidofovir, Brincidofovir, etc. also have limitations due to toxicities. RSV causes severe infections primarily in infants and young children, persons over age of 60 and immune-compromised persons. Each year in the United States, an estimated 58,000<sup>â€</sup>80,000 children younger than 5 years old are hospitalized due to RSV infection. Globally, RSV is a common cause of childhood acute lower respiratory infection (ALRI, which includes pneumonia) and a major cause of hospital admissions in young children. Globally in 2015, 33 million episodes of RSV-ALRI, resulted in about 3.2 million hospital admissions, and 59,600 in-hospital deaths in children younger than 5 years. About 45% of hospital admissions and in-hospital deaths due to RSV-ALRI occur in children younger than 6 months. Two vaccines have recently been approved for RSV prophylaxis. Axyx (GSK), and Abrysvo (Pfizer) were approved in May, 2023 for use in adults over 60 years of age and both reduced severity of RSV infection. There are no vaccines currently approved for infants and children. However, there are no safe and effective therapeutics for RSV to date. Ribavirin, a highly toxic drug, is conditionally approved only for patients with high risk of progressively severe RSV disease, due to significant side effects including hemolytic anemia and kidney failure. Synagis (palivizumab), and recently approved Beyfortus (nirsevimab) are antibodies approved only for prophylactic use in children and infants at high risk of severe RSV infection, but neither is approved for treatment of RSV infection, which remains an unmet medical need. Our press release regarding NV-387 activity against a lethal lung infection animal model of smallpox/MPox in comparison to the approved drug tecovirimat was published on May 8, 2024 via AccessWire. Our press release regarding NV-387 activity leading to complete survival of animals in a lethal lung infection animal model of RSV in comparison to the toxic drug ribavirin was published on May 14, 2024 via AccessWire. Our Other Drug Development Programs: NV-HHV-1, Our Drug Candidate for Treatment of Shingles Rash: Previously, we have developed a clinical drug candidate NV-HHV-1 and formulated it as a skin cream for the treatment of Shingles. We plan on undertaking clinical trials of NV-HHV-1 after NV-387 RSV Phase II clinical trials. We have performed cGMP-like manufacture of both the active pharmaceutical ingredient (the API in NV-HHV-1 i.e. NV-360), and the fully formulated skin cream (the drug product candidate), at our own facilities at ~1kg scale (API basis) with attendant significant time, project management, and cost savings as opposed to going to an external contract manufacturer. Approximately 10Kg of fully formulated drug product was manufactured. We believe this scale is sufficient for the requirements of Phase I and Phase II human clinical trials of NV-HHV-1. 29 Table of Contents: Previously, NV-HHV-1 was found to have antiviral activity against HSV-1 as well as HSV-2 in animal models. The antiviral ligand in NV-HHV-1 is designed to mimic the host protein HVEM (Herpesvirus Entry Mediator) that almost all herpesvirus family viruses use for cell entry as a cognate receptor. We plan on pursuing indications of NV-HHV-1 skin cream formulation for the treatment of (i) Shingles rash (VZV), (ii) Chickenpox rash (VZV), (iii) HSV-1 *â€*cold sores, and (iv) HSV-2 *â€*genital ulcers. In addition, we are also developing a systemic drug for the treatment of herpesvirus family infections, based on the same API NV-360 that we believe will be superior to acyclovir related drugs, the current workhorse drugs for HSV-1 and HSV-2. While acyclovir and related drugs are also given for severe shingles, they do not work very well. This is because these drugs require first phosphorylation by the viral Thymidylate Kinase (v-TK) enzyme, which is not very active in VZV. Other Pre-clinical Drug Programs: We also have drug candidates against HIV that have shown antiviral activity in cell culture studies as well as in SCID-hu Thy-Liv mouse model studies. We plan on undertaking further development of the HIV drug in partnership because of the expensive nature of the development. Additionally, we have developed drug candidates in the past against several other viral infections including Influenza viruses, H5N1 bird flu virus (successful cell culture studies using two different H5N1 strains in Vietnam), Adenoviral epidemic kerato-conjunctivitis (EKC) (successful animal study in rabbits). We also have drug development programs to treat Dengue viruses and Ebola/Marburg viruses. All of our drug programs are established to target what we believe are unmet medical needs. Both the safety and effectiveness of any new drug has to be determined experimentally. The safety of a nanoviricide drug is expected to depend upon the safety of the nanomedicine portion as well as the safety of the antiviral ligand. We have observed excellent indications in the evaluation of safety of our broad-spectrum antiviral drug candidate NV-387 as well as that of NV-360, our herpesvirus family specific antiviral drug candidate to date in non-clinical studies including IND-enabling safety pharmacology studies. Further, NV-387 has successfully completed Phase I human clinical trial with no adverse events, indicating an excellent level of safety. The final determination of safety and efficacy of a drug rests with the regional drug regulatory authority such as the US FDA, EU EMEA, India CDSCO/DCGI, UK MHRA and others. Our timelines depend upon several assumptions, many of which are outside the control of the Company, and thus are subject to delays. We are currently focused on the development of NV-387 with the goal of the treatment of pediatric RSV infection with urgency. Further, we continue to perform pre-clinical investigations to expand the usage of NV-387 as an antiviral drug against other viruses to improve return on investment, ROI. Additionally, we are also performing topical drug development against several indications related to infections by herpes family viruses. Our Campus in Shelton, CT/Our campus at Shelton, CT, is fully operative. With our R&D discovery labs, analytical labs, the bio labs for virology R&D, the process scale-up production facility, and the cGMP-capable manufacturing facility established at our Shelton campus, we are in a strong position to move our drug development programs into the clinic rapidly. Process Scale-Up Production Capability: The process scale-up area is operational at kilogram to multi-kg scales for different chemical synthesis and processing steps. It comprises reactors and process vessels on chassis or skids, ranging from 250mL to 100L capacities, as needed. Many of the reactors and vessels have been designed by us for specific tasks related to our unique manufacturing processes. 30 Table of Contents: cGMP Production Capability: Our versatile, customizable cGMP-capable manufacturing facility is designed to support the production of multi-kilogram-scale quantities of any of our nanoviricides drugs. In addition, it is designed to support the production of the drug in any formulation such as injectable, oral, skin cream, eye drops, lotions, etc. The production scale is designed so that clinical batches for Phase I, Phase II, and Phase III can be made in this facility. The clean room suite contains areas suitable for the production of sterile injectable drug formulations, which require special considerations. We also have a manufacturing suite for cGMP-compliant Oral Drug Product Formulation, Fill, and Packaging. We manufactured and delivered the clinical NV-387 oral syrup and oral gummies (semi-solids) drug products in this suite using equipment that we had custom-designed and fabricated in the U.S. We plan to produce multiple batches of a drug product in our facility. At the appropriate time as required we plan to register the facility as a cGMP manufacturing facility with the FDA. Our BSL-2 Certified Virology Lab: We have significantly enhanced our internal anti-viral cell culture testing capabilities at our Shelton campus. Our Virology Research Lab suite has a BSL-2 (Biological Safety Level 2) certification from the State of Connecticut. This suite comprises three individual virology workrooms, enabling us to work on several different viruses and strains at the same time. This facility is designed only for cell culture studies on viruses, and no animal studies can be conducted at any of our own facilities. We have established several different types of assays for screening of drug candidates against Coronaviruses, SARS-CoV-2 Pseudoviruses, VZV, HSV-1, HSV-2, Influenza viruses, RSV, Ectromelia virus (a stand-in for MPOX and Smallpox viruses), among others in this lab. Our BSL-2 Virological capability has been instrumental in our rapid development of potential drug candidates for further investigation towards human clinical trials. We believe that having developed the internal capabilities for cell culture testing of our ligands and nanoviricides against a variety of viruses has substantially strengthened and accelerated our drug development programs. NanoViricides Business Strategy in Brief: We intend to perform the regulatory filings and own all the regulatory licenses for the drugs we are currently developing. We will develop these drugs in part via subcontracts to TheraCour, the exclusive source for these nanomaterials. We plan to market these drugs either on our own or in conjunction with marketing partners. We also plan to actively pursue co-development, as well as other licensing agreements with pharmaceutical companies. Such agreements may entail up-front payments, milestone payments, royalties, and/or cost sharing, profit sharing and many other instruments that may bring early revenues. Such licensing and/or co-development agreements may shape the manufacturing and development options that we may pursue. There can be no assurance that we will be able to enter into co-development or other licensing agreements. We have kept our capital expenditures to a minimum in the past, and we

intend to continue to do the same, in order to conserve our cash for drug development purposes, and in order to minimize additional capital requirements. As a risk factor, we have limited experience with pharmaceutical drug development. Thus, our budget estimates are not based on experience, but rather based on advice given by our associates and consultants. As such these budget estimates may not be accurate. In addition, the actual work to be performed is not known at this time, other than a broad outline, as is normal with any scientific work. As further work is performed, additional work may become necessary or change in plans or workload may occur. Such changes may have an adverse impact on our estimated budget. Such changes may also have an adverse impact on our projected timeline of drug development. We plan to take NV-387 into Phase III/IV clinical trials for treatment of RSV infections. We plan on obtaining non-dilutive funding for the poxvirus drug development program. We plan on seeking partnerships for our COVID program as well as our RSV, Poxvirus, and other programs, as these programs mature further. 31 Table of Contents We have previously substantially completed IND-enabling studies for a drug candidate for the treatment of shingles rash caused by reactivation of the chickenpox virus (aka varicella-zoster virus, VZV). We plan on taking the shingles drug candidate into human clinical trials after phase II clinical trials of our NV-387 drug candidate for RSV. As a risk factor, we recognize that the FDA may require additional studies to be done before approving the IND for any of our programs. Assuming that the FDA allows us to conduct human clinical studies as we intend to propose, we believe that this coming year's work plan will lead us to obtain certain information about the safety and efficacy of NV-387 in human clinical studies for the treatment of RSV and/or MPOX infection. If our studies are not successful, we will have to develop additional drug candidates and perform further studies. If our studies are successful, then we expect to be able to undertake further additional studies as necessary towards drug approval or licensure from regulatory agencies. As a strategy, we plan to develop the same drug, once initial clinical trials towards a first approval of the drug are completed, for commercial approval for additional indications, such as pediatric applications, special case applications for certain classes of immuno-compromised patients, among others, provided that appropriate levels of funding is available. We believe that adding further indications would significantly expand market penetration and improve return on investment for our drugs. Collaborations, Agreements and Contracts On March 27, 2023, we entered into a License Agreement (the "License Agreement") with Karveer Meditech Private Limited, India ("Karveer"), whereby we granted to KMPL a limited, non-transferable, exclusive license for the development and commercialization and further use, sale, or offer of sale of the Licensed Product(s) NV-CoV-2 and NV-CoV-2-R (the "Two Clinical Test Drug Candidates") in the Territory of India, and as part of the drug evaluation and development, KMPL agreed to sponsor the clinical test drug candidates for Phase I and Phase II clinical trials and act as clinical trials manager. The Company shall have rights to the data generated by KMPL in the clinical trials for use in other jurisdictions, and KMPL shall provide to the Company with applicable reports and data. The license conveyed pursuant to the Agreement shall have no set term, and will continue for the period during which KMPL uses the Company's proprietary technologies. In return, the Company will reimburse KMPL for all direct and indirect costs incurred for the clinical trials, as well as a customary fee of 30% of such costs. Further pursuant to the Agreement, KMPL shall pay the Company 70% of any invoiced commercial net sales of either or both of the Two Clinical Test Drug Candidates to unaffiliated third parties; there will be no minimum royalties, nor any license maintenance fees. KMPL is a related party in that Dr. Anil Diwan, our President, co-founder, and Executive Chairman, is also a co-founder and passive investor in KMPL. KMPL has successfully obtained required regulatory permissions to conduct clinical evaluation of NV-CoV-2 that contains the active ingredient NV-387, as a COVID treatment in India, on or about January 30, 2023. Previously, on September 15, 2021, we signed a Master Services Agreement with KMPL in which KMPL declared its intent to license NV-COV-2 and NV-CoV-2-R (both of which contain the active ingredient NV-387; NV-CoV-2-R being remdesivir encapsulated within NV-387) for commercialization in India, and undertook the responsibility to obtain necessary licenses and regulatory approvals as would be needed for the clinical evaluation and commercialization of the drugs in India. No binding licensing activity took place under that earlier agreement. Subsequently KMPL proceeded to develop and file the required regulatory documents including a clinical trials application with the regulatory authority in India. KMPL has retained a local clinical research organization (CRO) for the purpose of developing such documents and planning and executing the clinical trials. We helped KMPL with assembling the necessary datasets and information. Around June, 2023, began the Phase 1a/1b clinical trial of NV-CoV-2. The healthy subjects part of the single ascending dose ("SAD") and the multiple ascending dose ("MAD") clinical trial cohorts were completed at the end of December, 2023. KMPL and we spent the next several months in an attempt to initiate the COVID-patient part of the proposed Phase 1a/1b. However, by the time we were able to obtain the required approvals for engaging a different clinical site where COVID patients existed when we initiated our efforts, the COVID wave was gone and it did not become possible to recruit COVID patients. The clinical trial was therefore completed as safety and tolerability study of NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies in healthy subjects only. We have not engaged any other new collaborators during the reported quarter. 32 Table of Contents Patents, Proprietary Rights: Intellectual Property "Recent events NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from ALLEXCEL. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. We intend to obtain a license for poxviruses, enteroviruses, RSV and other viruses that we engage into research for, if the initial research is successful. TheraCour has not denied any licenses requested by us to date. Our business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at the Company's foundation in 2005. In September 2021, we entered into a world-wide, exclusive, sub-licensable, license, COVID-19 License Agreement, to use, promote, offer for sale, import, export, sell and distribute drugs that treat COVID-19 infections, using TheraCour's proprietary as well as patented technology and intellectual property. These licenses are not limited to underlying patents, but also include the know-how, trade secrets, and other important knowledge base that is utilized for developing the drugs and making them successful. In addition, these extremely broad licenses are not limited to some specific chemical structures, but comprise all possible structures that we could deploy against the particular virus, based on these technologies. Further, the licenses are held by NanoViricides for worldwide use. These are described in our most current Annual Report. COVID Related Drugs: Patent Coverage and Lifetime Two International PCT patent applications have been filed relating to the application of the TheraCour polymeric micelle technology to drug development for Coronavirus antiviral drugs including ones for the treatment of COVID. PCT/US21/39050 was filed on June 25, 2021. Additionally, PCT/US22/35210 was filed on June 28, 2022, with a request for the same priority date as that of the prior PCT/US21/39050 application. These broad patents cover new compositions of matter, methods of making them (processes), drug formulations, and uses of the articles of manufacture. The patents resulting from these are expected to have expiry dates extending at least into the year 2043, with additional specific extensions possible in various countries based on regulatory extensions for pharmaceutical products. All ensuing patents will be automatically exclusively licensed to NanoViricides for anti-coronavirus drugs pursuant to the COVID-19 License Agreement. We have licenses to key patents, patent applications and rights to proprietary and patent-pending technologies related to our compounds, products and technologies, but we cannot be certain that issued patents will be enforceable or provide adequate protection or that pending patent applications will result in issued patents. Table 1: Update on recent Intellectual Property, Patents, and Pending Patents Licensed by the Company - PCT/US21/39050A - SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-COVID-19 AGENTS Applied: June 25, 2021 Ca. 2043 (estimated) PCT Application filed. TheraCour Pharma, Inc. [Exclusive License] PCT/US22/35210A - SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-COVID-19 AGENTS (\*\*): Applied: June 28, 2022 Ca. 2043 (estimated) PCT Application filed. TheraCour Pharma, Inc. [Exclusive License].\*: The PCT application PCT/US22/35210 was filed with request for priority of PCT/US21/39050. 33 Table of Contents Analysis of Financial Condition, and Result of Operations As of September 30, 2024, we had cash and cash equivalents of \$3,866,289, prepaid expenses of \$175,133 and net property and equipment of \$7,365,681. Accounts payable and accrued expenses were \$1,632,706, inclusive of accounts payables to a related party of \$636,550. Stockholders' equity was \$10,107,791 at September 30, 2024. In comparison, as of June 30, 2024, we had \$4,797,778 in cash and cash equivalents, prepaid expenses of \$172,742 and \$7,512,463 of net property and equipment. Our liabilities at June 30, 2024 were \$1,358,776 including accounts payable of \$376,270 payable to third parties and accounts payable to TheraCour of \$720,039, and accrued expenses of \$262,467. During the three month period ended September 30, 2024, we used approximately \$2.6 million in cash toward operating activities. This was substantial greater than the prior one year ago period primarily due to certain one-time costs related to investor outreach activities and certain required additional non-clinical studies to advance NV-387 into Phase II. During the three month period ended September 30, 2023, we used approximately \$1.2 million in cash toward operating activities. Research and Development Costs We do not maintain separate accounting line items for each project in development. We maintain aggregate expense records for all research and development conducted. Because at this time all of our projects share a common core material, we allocate expenses across all projects at each period-end for purposes of providing accounting basis for each project. Project costs are allocated based upon labor hours performed for each project. Far fewer man-hours are spent on the projects at low priority than the projects at high priority. In the reported quarter, we have focused exclusively on our NV-387 drug development program. We have continued to work on development of documents for initiating a Phase II clinical trial for using NV-387 as a treatment for MPOX infections in Central Africa, and on developing a Phase II clinical trial application for the development of NV-387 for the treatment of pediatric RSV infections in the U.S. Results of Operations Revenues The Company is a biopharmaceutical company and did not have any revenue for the three month periods ended September 30, 2024 and 2023. Research and Development Expenses "Research and development expenses for the three months ended September 30, 2024 increased \$466,426 to \$1,933,091 from \$1,466,665 for the three months ended September 30, 2023. The increase in research and development expenses for the three months ended September 30, 2024 is due to an increase in laboratory fees. General and Administration Expenses "General and administrative expenses for the three months ended September 30, 2024 increased \$699,817 to \$1,234,743 from \$534,926 for the three months ended September 30, 2023. The increase in general and administrative expenses for the three months ended September 30, 2024 is due to an increase in professional fees associated with investor outreach. Interest Income "Interest income for the three months ended September 30, 2024 decreased \$58,315 to \$41,023, from \$99,338 for the three months ended September 30, 2023. The decrease in interest income for the three months ended September 30, 2024 is due to a decrease in cash balances during the three month period ended September 30, 2024. Interest Expense "Interest expense for the three months ended September 30, 2024 decreased \$36,493 to \$0.00 from \$36,493 for the three months ended September 30, 2023. The decrease in interest expense for the three months ended September 30, 2024 is a result of the interest accrued on the \$1,500,000 convertible promissory note issued in lieu of a cash milestone payment. On October 27, 2023, TheraCour cancelled all of the accrued interest on the Note and converted the principal of the Note to Series A preferred shares. Income Taxes "There is no provision for income taxes due to ongoing operating losses. Net Loss "For the three months ended September 30, 2024, the Company had a net loss of \$3,126,811 or \$0.23 per share compared to a net loss of \$1,968,746 or \$0.17 per share for the three months ended September 30, 2023. The increase in the net loss for the periods presented is attributable to the factors discussed above. Liquidity and Capital Resources As of September 30, 2024 we had \$3,866,289 in cash and cash equivalents. 34 Table of Contents The Company's condensed financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets and liquidation of liabilities in the normal course of business. As reflected in the condensed financial statements, the Company has an accumulated deficit at September 30, 2024 of approximately \$142.5 million and a net loss of approximately \$3.13 million and net cash used in operating activities of approximately \$2.6 million for the three months then ended. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future. Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs. The Company has not yet commenced any product commercialization. Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future. As of September 30, 2024, the Company had available cash and cash equivalents of approximately \$3.9 million. The Company's liabilities at September 30, 2024 were approximately \$1.6 million including accounts payable of approximately \$713,000 payable to third parties, accounts payable to TheraCour of approximately \$637,000, and accrued expenses of approximately \$283,000. The Company raised additional capital of approximately \$631,000, net of offering expenses, by ATM sales of our common stock from October 1, 2024 through November 7, 2024. Management believes that the Company's existing resources, including availability under its \$3 million line of credit will not be sufficient to fund the Company's planned operations and expenditures for at least 12 months from the date of the filing of this Form 10-Q. As a result substantial doubt exists about the Company's ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon controlling its overall expenses and identifying and securing additional financing. Management has considered several options for financing the net working capital deficit as well as to obtain additional funds that will be needed for future human clinical trials. Management believes that we will be achieving several important milestones, including release of the Phase I clinical trial final report, a pre-IND application for use of NV-387 in RSV infections as an antiviral, and a clinical trial applications (including US FDA IND) for use of NV-387 to treat RSV and/or MPOX, and other important respiratory diseases, in the ensuing year. Management believes that as it achieves these milestones, there would be improvement in the liquidity of the Company's stock, and that would improve our ability to raise funds on the public markets at terms that may be more favorable to the terms we are offered at present. Management believes that it has on-going access to the capital markets under an "At-The-Market" (ATM) agreement with EF Hutton that became active around April 5, 2024. Management believes that the Company's stock is currently undervalued in contrast to its asset value, based on the potential of NV-387 alone. Management believes that as our investor outreach program expands and bears fruit, this deviation should be lessened, enabling access to public markets for equity funding at reasonable valuations. In addition, Management plans to solicit funds by mortgaging its existing fully owned campus and cGMP manufacturing facilities in Shelton, CT, in order to free up a portion of the fixed capital for use as liquid working capital. These facilities were recently valued at \$12 to \$15 Million by industry experts. However, there is no guarantee that we will be able to raise funds on reasonable terms acceptable to us, or at all. In addition, Management continues to adjust its planned expenditures, activities, and programs, in accordance with budgetary constraints and in accordance with its expectations of obtaining additional financing. Management is also taking steps for seeking to license NV-387 to potential partners. Such licenses, if effected, would result in an initial payment at signing, milestone payments as the program advances, and royalty payments from future sales. We do not currently have a licensed partner other than KMPL and there is no guarantee that we can enter into such licensing agreement that provides substantial cash value to us. KMPL has enabled clinical trials of NV-387, our lead drug candidate, in India. Management is actively exploring additional required funding through debt or equity financing pursuant to its plan. There is no assurance that we will be successful in obtaining sufficient financing on terms acceptable to us to fund continuing operations. To cover the shortfall, we intend to pursue non-diluting funding sources such as government grants and contracts as well as licensing agreements with other pharmaceutical companies in addition to equity-based financing. There can be no assurance that we will be able to obtain such additional capital resources or that such financing will be on terms that are favorable to us. We cannot provide assurance that our plans will not change or that changed circumstances will not result in the depletion of the capital resources more rapidly than we currently anticipate. The accompanying unaudited financial statements do not include any adjustments that may result from the outcome of such unidentified uncertainties. We do not anticipate any major capital costs going forward in the near future. We intend to seek collaborations to develop NV-387 drug further towards approvals by FDA as well as international regulatory authorities. We believe that we have several important milestones that we will be achieving in the current year. Management believes that as it achieves these milestones, our ability to raise additional funds in the public markets would be enhanced. There can be no assurance that we will be able to raise the necessary capital or that it will be on acceptable terms. 35 Table of Contents We do not have direct experience in taking a drug through human clinical trials at present. In addition, we depend upon external collaborators, service providers and consultants for much of our drug development work. Our estimates for external costs are based on various preliminary discussions and "soft" quotes from contract research organizations that provide pre-clinical and clinical studies support. The estimates are also based on certain time estimates for achievement of various objectives. If we miss these time estimates or if the actual costs of the development are greater than the early estimates we have at present, our drug development cost estimates may be substantially greater than anticipated now. In that case, we may have to re-prioritize our programs and/or seek additional funding. Off Balance Sheet Arrangements We have not entered into any off-balance sheet arrangements during the three months ended September 30, 2024. ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. We are a smaller reporting company as defined by 17.C.F.R. and are not required to provide information under this item. 4. CONTROLS AND PROCEDURES Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") are controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed,

summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the "SEC"). Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and our chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance that the above objectives have been met. As of September 30, 2024, an evaluation was carried out under the supervision and with the participation of our management, including our President and our Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(f) under the Securities Exchange Act of 1934). Based on this evaluation, our President and our Chief Financial Officer have concluded that the Company's disclosure controls and procedures are effective as of September 30, 2024. Management's Report on Internal Control Over Financial Reporting Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness, as of September 30, 2024, of our internal control over financial reporting based on the framework in 2013 Internal Control "Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under this framework, our management concluded that our internal control over financial reporting was effective as of September 30, 2024. Changes in Internal Control Over Financial Reporting There were no material changes in our system of internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934) during the three months ended September 30, 2024 that has materially affected, or is likely to materially affect, our internal control over financial reporting.

**TABLE OF CONTENTS**

**PART II. OTHER INFORMATION**

**1. LEGAL PROCEEDINGS** From time to time, the Company may be a party to legal proceedings in the ordinary course of our business in addition to those described below. The Company does not, however, expect such other legal proceedings to have a material adverse effect on our business, financial condition or results of operations. There are no legal proceedings against the Company to the best of the Company's knowledge as of the date hereof and to the Company's knowledge, no action, suit or proceeding has been threatened against the Company.

**1A. RISK FACTORS** We are a smaller reporting company as defined by 17 C.F.R. and are not required to provide information under this item.

**2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS** On April 15, 2024, the Company entered into a new ATM sales agreement with E.F. Hutton Securities, the Sales Agent, pursuant to which the Company may offer and sell, from time to time, through or to the Sales Agent, shares of common stock having an aggregate offering price of up to \$50 million. From July 1, 2024 through September 30, 2024 the Company sold 893,006 shares of common stock at an average price of approximately \$1.98 per share. The shares were issued pursuant to a prospectus supplement dated May 5, 2023 and filed with the Securities and Exchange Commission on May 5, 2023 in connection with the Company's shelf registration statement on Form S-3, as amended (File No. 333-271706, which became effective on May 22, 2023). The net proceeds to the Company from the offering was approximately \$1,710,000 after placement agent fees and other estimated offering expenses. The Company accounted for the proceeds of the ATM Offering, approximately, as follows:

Gross proceeds	\$ 1,764,000
Less: offering costs and expenses	\$ 54,000
Net proceeds from issuance of common stock	\$ 1,710,000

As of July 1, 2024 the Company and Dr. Anil Diwan entered into an extension of his employment agreement for a period of one year from July 1, 2024 through June 30, 2025 under the same general terms and conditions. The Company granted Dr. Anil Diwan an award of 10,204 shares of the Company's Series A preferred stock. The shares shall be vested in quarterly installments of 2,551 shares on September 30, 2024, December 31, 2024, March 31, 2025 and June 30, 2025 and are subject to forfeiture. The Company recognized non-cash compensation expense related to the issuance of the Series A preferred stock of \$12,458 for the three months ended September 30, 2024. The balance of \$37,375 will be recognized as the remaining 7,653 shares vest and service is rendered for the remaining nine months ended June 30, 2025. For the three months ended September 30, 2024, the Company's Board of Directors authorized the issuance of 387 of fully vested shares of its Series A preferred stock for employee compensation. The Company recorded expense of \$1,950 for the three months ended September 30, 2024 related to this issuance. There is currently no market for the shares of Series A preferred stock and they can only be converted into shares of common stock upon a change of control of the Company as more fully described in the Certificate of Designation. The Company, therefore, estimated the fair value of the Series A preferred stock granted to various employees and others on the date of grant. The conversion of the shares is triggered by a change of control. The fair value of the Series A Convertible preferred stock at each issuance was estimated based upon the price of the Company's common stock after an application for a reasonable discount for lack of marketability. The Scientific Advisory Board was granted in August 2024 fully vested warrants to purchase 286 shares of common stock with an exercise price of \$2.35 per share expiring in August 2028. The fair value of the warrants was \$229 for the three months ended September 30, 2024 and was recorded as consulting expense.

**3. Table of Contents** The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following assumptions:

Expected life (year)	4.4
Expected volatility	54.18%
Expected annual rate of quarterly dividends	0.00%
Risk-free rate (3-month)	3.85%

For the three months ended September 30, 2024, the Company's Board of Directors authorized the issuance of 19,713 fully vested shares of the Company's common stock with a restrictive legend for consulting services. The Company recorded an expense of \$34,500 for the three months ended September 30, 2024, which is reflective of the fair value of the common stock on the dates of issuance. For the three months ended September 30, 2024, the Company's Board of Directors authorized the issuance of 6,039 fully vested shares of its common stock with a restrictive legend for director services. The Company recorded an expense of \$11,250 for the three months ended September 30, 2024, which is reflective of the fair value of the common stock on the dates of issuance. All of the securities referred to above were issued without registration under the Securities Act of 1933, as amended (the "Securities Act") in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as provided in Rule 506(b) of Regulation D promulgated thereunder. None of the foregoing securities as well as common stock issuable upon conversion or exercise of such securities, have been registered under the Securities Act or any other applicable laws and are deemed restricted securities, and unless so registered may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act.

**4. DEFAULTS UPON SENIOR SECURITIES** None.

**5. OTHER INFORMATION** (a) None. (b) Corporate Governance During the period covered by this Quarterly Report on Form 10-Q, there were no changes to the procedures by which security holders may recommend nominees to the Company's Board of Directors. (c) Insider Trading Arrangements and Policies During the period covered by this Quarterly Report on Form 10-Q, no director or officer of the Company adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement as each term is defined in Item 408(a) of Regulation S-K. (d) Table of Contents

**EXHIBITS**

Exhibit No. 1.1 Description 31.1 Rule 13(a)-14(a)(15)(d)-14(a) Certification of Chief Executive Officer 31.2 Rule 13(a)-14(a)(15)(d)-14(a) Certification of Chief Financial Officer 31.3 Section 1350 Certification of Chief Executive Officer 31.4 Section 1350 Certification of Chief Financial Officer 101.1 INS A Inline XBRL Instance Document 101.2 SCH A Inline XBRL Taxonomy Extension Schema Document 101.3 CAL A Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.4 DEF A Inline XBRL Taxonomy Extension Definition Linkbase Document 101.5 LAB A Inline XBRL Taxonomy Extension Label Linkbase Document 101.6 PRE A Inline XBRL Taxonomy Extension Presentation Linkbase Document 101.7 CVR A Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)

**SIGNATURES** Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**NANO VIRICIDES, INC.** /s/ Anil R. Diwan  
Date: November 14, 2024  
Name: Meeta Vyas  
Title: Chief Financial Officer (Principal Financial Officer)

**ANIL R. DIWAN**, President, Chairman, and Chief Executive Officer of NanoViricides, Inc. (the "Company") certifies that he has reviewed this quarterly report on Form 10-Q of NanoViricides, Inc. and, based on his knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

November 14, 2024  
By: /s/ Anil Diwan  
Name: Anil Diwan  
Title: President, Chairman and Chief Executive Officer  
Principal Executive Officer

EX-31.2.3 nvcv-20240930ex31d2.htm EX-31.2 Exhibit 31.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER, Meeta Vyas, certify that: 1. I have reviewed this quarterly report on Form 10-Q of NanoViricides, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

November 14, 2024  
By: /s/ Meeta Vyas  
Name: Meeta Vyas  
Title: Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1.4 nvcv-20240930ex32d1.htm EX-32.1 Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the quarterly report of NanoViricides, Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof, I, Anil Diwan, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge: 1. The quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and 2. The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company.

November 14, 2024  
By: /s/ Anil Diwan  
Name: Anil Diwan  
Title: President, Chairman (Principal Executive Officer)

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and is not being filed as part of the Form 10-Q or as a separate disclosure document for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section. This certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act except to the extent that this Exhibit 32.1 is expressly and specifically incorporated by reference in any such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2.5 nvcv-20240930ex32d2.htm EX-32.2 Exhibit 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the quarterly report of NanoViricides, Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof, I, Meeta Vyas, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge: 1. The quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and 2. The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company.

November 14, 2024  
By: /s/ Meeta Vyas  
Name: Meeta Vyas  
Title: Chief Financial Officer (Principal Financial and Accounting Officer)

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and is not being filed as part of the Form 10-Q or as a separate disclosure document for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section. This certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act except to the extent that this Exhibit 32.2 is expressly and specifically incorporated by reference in any such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.SCH 6 nvcv-20240930.xsd EX-101.SCH 995200100 - Statement - Condensed Balance Sheets link: presentationLink link: calculationLink link: definitionLink 995200200 - Statement - Statements of Operations link: presentationLink link: calculationLink link: definitionLink 995200400 - Statement - Statements of Cash Flows link: presentationLink link: calculationLink link: definitionLink 99940501 - Disclosure - Property and Equipment - Schedule of property and equipment (Details) link: presentationLink link: calculationLink link: definitionLink 99940601 - Disclosure - Intangible Assets (Details) link: presentationLink link: calculationLink link: definitionLink 99940701 - Disclosure - Accrued expenses (Details) link: presentationLink link: calculationLink link: definitionLink 995200090 - Document - Document And Entity Information link: presentationLink link: calculationLink

link:definitionLink 995200105 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - Statement of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - Equity Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 99930903 - Disclosure - Common Stock Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - Organization and Nature of Business (Details) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Liquidity and Going Concern (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Related Party Transactions - Summary of related parties (Details) link:presentationLink link:calculationLink link:definitionLink 99940402 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 99940502 - Disclosure - Property and Equipment - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 99940602 - Disclosure - Intangible Assets - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Equity Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940802 - Disclosure - Equity Transactions - Proceeds of ATM offering (Details) link:presentationLink link:calculationLink link:definitionLink 99940803 - Disclosure - Equity Transactions - Estimated the fair value of warrants granted quarterly to the Scientific Advisory Board (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Common Stock Warrants - Common Stock Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 99940902 - Disclosure - Common Stock Warrants - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - Commitments and Contingencies - Employment Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 99941002 - Disclosure - Commitments and Contingencies - License Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 995200305 - Statement - Statement of Changes in Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Organization and Nature of Business link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Liquidity and Going Concern link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Accrued expenses link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Equity Transactions link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Common Stock Warrants link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 99920302 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Accrued expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 nncv-20240930\_cal.xml EX-101.CAL EX-101.DEF 8 nncv-20240930\_def.xml EX-101.DEF EX-101.LAB 9 nncv-20240930\_lab.xml EX-101.LAB Document And Entity Information Document Information [Table] Document Information [Line Items] Document Type Document Period End Date Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Title of 12(b) Security Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Document Quarterly Report Document Transition Report Condensed Balance Sheets Statement [Table] Class of Stock [Axis] Class of Stock [Domain] Represent information pertaining to Series A Preferred stock Series A Convertible Preferred Stock [Member] Series A Preferred Stock Series A convertible preferred stock Related Party [Axis] Related Party [Domain] Nonrelated Party [Member] Nonrelated party Related Party [Member] Related party Statement [Line Items] Statement Assets [Abstract] ASSETS Assets, Current [Abstract] CURRENT ASSETS: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Prepaid Expense, Current Prepaid expenses Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Property and Equipment, Net Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Other Assets [Abstract] OTHER ASSETS This fact represents service agreements. Service Agreements Service agreements Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities [Abstract] CURRENT LIABILITIES: Accounts Payable, Related Parties, Current Accounts Payable - Related Party Accounts payable Accrued Liabilities, Current Accrued expenses Accrued expenses Liabilities, Current Total current liabilities Commitments and Contingencies. COMMITMENTS AND CONTINGENCIES Stockholders' Equity Attributable to Parent [Abstract] STOCKHOLDERS' EQUITY: Preferred Stock, Value, Issued Series A convertible preferred stock, \$0.00001 par value, 10,000,000 shares designated, 903,216 and 892,625 shares issued and outstanding, at September 30, 2024 and June 30, 2024, respectively Common Stock, Value, Issued Common stock, \$0.00001 par value; 150,000,000 shares authorized, 14,062,813 and 13,144,055 shares issued and outstanding, at September 30, 2024 and June 30, 2024, respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Balance Balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares Issued Common stock, shares issued Common Stock, Shares Outstanding Common stock, shares outstanding Statements of Operations Operating Expenses [Abstract] OPERATING EXPENSES Research and Development Expense Research and Development Costs - Related Party Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) LOSS FROM OPERATIONS Nonoperating Income (Expense) [Abstract] OTHER INCOME (EXPENSE): Other Nonoperating Income (Expense) Interest income Interest Expense Interest expense Nonoperating Income (Expense) Other expense, net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest LOSS BEFORE INCOME TAX PROVISION Net loss NET LOSS Earnings Per Share [Abstract] Net loss per common share/Weighted average common shares outstanding Earnings Per Share, Basic Net loss per common share - basic Earnings Per Share, Diluted Net loss per common share - diluted Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average common shares outstanding - basic Weighted Average Number of Shares Outstanding, Diluted Weighted average common shares outstanding - diluted Statement of Changes in Stockholders' Equity Equity Components [Axis] Equity Component [Domain] Common Stock Additional Paid-in Capital Accumulated Deficit Shares, Outstanding Balance (in shares) Balance (in shares) Stock Issued During Period, Value, New Issues Proceeds from sale of common stock in connection with equity financings net of issuance costs of \$53,875 Stock Issued During Period, Shares, New Issues Proceeds from sale of common stock in connection with equity financings net of issuance costs of \$53,875 Issuance of shares Value of preferred stock shares issued during period as employee stock compensation. Series A Preferred Shares Issued During Period Employee Stock Compensation Value Issued Series A preferred stock issued for employee stock compensation Number of series A preferred stock issued during period as employee stock compensation. Series A Preferred Shares Issued During Period Employee Stock Compensation Shares Issued Series A preferred stock issued for employee stock compensation (in shares) Shares issued during the period for license agreement. Series Preferred Shares Issued During Period For License Agreement Series A Preferred stock issued for license agreement (in shares) Shares issued for milestone payment Value of stock issued during the period as a compensation for consulting and legal services. Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One Common stock issued for consulting and legal services rendered Number of shares issued during the period as a compensation for consulting and legal services. Stock Issued During July Share Issued For Share Based Compensation Consulting And Legal Service One Common stock issued for consulting and legal services rendered (in shares) Value of stock issued during the period as a compensation for consulting and legal services. Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services Warrants issued to Scientific Advisory Board The amount represents the stock issued during the period for payment of director fees. Stock Issued For Payment Of Director Fees Value Common shares issued for Directors fees The amount represents the stock issued during the period for payment of director fees. Stock Issued For Payment Of Director Fees Shares Common shares issued for Directors fees (in shares) Proceeds from Issuance or Sale of Equity Net of issuance costs Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities Amount of preferred shares issued as compensation by the entity during the period. Preferred Shares Issued As Compensation Preferred shares issued as compensation Issuance of Stock and Warrants for Services or Claims Common shares issued as compensation and for services Adjustment of Warrants Granted for Services Warrants granted to Scientific Advisory Board Depreciation Depreciation expense Depreciation Amortization of Intangible Assets Amortization Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense Prepaid expenses Increase (Decrease) in Other Noncurrent Assets Other assets Increase (Decrease) in Accounts Payable, Trade Accounts payable Increase (Decrease) in Accounts Payable, Related Parties Accounts payable - related parties Increase (Decrease) in Other Accrued Liabilities Accrued expenses Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities NET CASH USED IN OPERATING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Net Cash Provided by (Used in) Investing Activities NET CASH USED IN INVESTING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: The cash inflow from issuance of common stock and warrants. Proceeds from Issuance of Common Stock and Warrants Net proceeds from sale of common stock Net Cash Provided by (Used in) Financing Activities NET CASH PROVIDED BY FINANCING ACTIVITIES Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect NET CHANGE IN CASH AND CASH EQUIVALENTS Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] NON CASH FINANCING AND INVESTING ACTIVITIES: The amount of related party non-current liability converted to note payable relating to supplemental disclosure of cash flows information. Related Party Non-current Liability Converted To Note Payable Related party non-current liability converted to note payable Amount of forgiveness of interest on related party debt. Forgiveness Of Interest On Related Party Debt Forgiveness of interest on related party debt Organization and Nature of Business Nature of Operations [Text Block] Organization and Nature of Business N/A. Liquidity and Going Concern Liquidation Basis of Accounting [Text Block] Liquidity and Going Concern Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Related Party Transactions Related Party Transactions Disclosure [Text Block] Related Party Transactions Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Intangible Assets Intangible Assets Disclosure [Text Block] Intangible Assets Accrued expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued expenses Equity Transactions Stockholders' Equity Note Disclosure [Text Block] Equity Transactions Common Stock Warrants Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Common Stock Warrants Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation - Interim Financial Information Earnings Per Share, Policy [Policy Text Block] Net Loss per Common Share New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation Schedule of Related Party Transactions [Table Text Block] Summary of related party Property, Plant and Equipment [Table Text Block] Schedule of property and equipment Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of intangible assets Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Tabular disclosure of proceeds from the sale of stock. Schedule of Proceeds From Sale of Stock [Table Text Block] Schedule of proceeds from sale of stock Schedule of Stockholders Equity [Table Text Block] Schedule of estimation of estimated the fair value of the warrants granted Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Common Stock Warrants Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of common stock warrants activity Tabular disclosure of organization and nature of business. Organization and Nature of Business [Table] Counterparty Name [Axis] Counterparty Name [Domain] Represents the information relating to Theracour Pharma Inc. Theracour Pharma Inc [Member] Theracour Pharma Inc Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Organization and Nature of Business [Line Items] Organization and Nature of Business Number of Reportable Segments Number of Reportable Segments Royalty expense calculated as a percentage of net sales. Percentage of Net Sales Allocated for Royalty Payments Percentage of net sales allocated for royalty payments (in percent) Percentage of royalties on sales. Percentage of Royalties On Sales Royalties on sales (in percent) Financial Condition [Table] Sale of Stock [Axis] Sale of Stock [Domain] Represents information pertaining to ATM offering. ATM Offering [Member] ATM Offering Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent event Subsequent event Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Financial Condition [Line Items] Liquidity and Going Concern Revenue from Contract with Customer, Including Assessed Tax Revenue Liabilities Liabilities Proceeds from Issuance of Common Stock Gross proceeds Line of Credit Facility, Current Borrowing Capacity Line of credit Shares Issued, Price Per Share Average price Accounting Policies [Table] Financial Instrument [Axis] Financial Instruments [Domain] Warrants [Member] Warrants Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Accounting Policies [Line Items] Summary of Significant Accounting Policies Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potentially outstanding dilutive common shares Number of potentially dilutive common shares Stockholders' Equity Note, Stock Split, Conversion Ratio Reverse stock split Represent of percentage of change of control Percentage Of Change Of Control Percentage of change of control Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Related Party Transaction Property, Plant and Equipment, Additions Property and Equipment Series A Preferred stock [Member] Series A Preferred stock Series A Preferred Stock Related Party Transaction [Axis] Related Party Transaction [Domain] Represents the information pertaining to unsecured promissory note. Unsecured Promissory Note [Member] Unsecured promissory note Represents the information pertaining to Karveer Meditech, Pvt., Ltd. Karveer Meditech, Pvt., Ltd [Member] KMPL Credit Facility [Axis] Credit Facility [Domain] Line of Credit [Member] Line of credit agreement Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Represents the information relating to Covid 19 License agreement. COVID 19 License Agreement Title of Individual [Axis] Relationship to Entity [Domain] Represent information pertaining to Dr. Anil Diwan member. Dr. Anil Diwan Dr. Anil Diwan Range [Axis] Range [Domain] Minimum Minimum Maximum Maximum The percentage of direct costs. Percentage of Direct Costs Percentage of direct costs Other General and Administrative Expense Other general and administrative expense Amount for accounts payable offset by advance. Accounts Payable Offset By Advance Accounts payable offset by advance Accrued Royalties Accrued royalties Carrying value as of the balance sheet date of the obligations incurred through Clinical trials. Used to reflect the current portion of the liabilities (The amount has been recorded within accrued expenses in the accompanying balance sheet). Accrued Clinical Trial Costs Clinical trial Costs Accrued - Related Party The number of shares authorized for license milestone payment. Number of Shares Authorized for License Milestone Payment Number of

shares authorized for license milestone payment The amount of milestone payment due. Milestone Payment Amount Due Milestone payment amount due Related Party Transaction, Rate Interest rate per annum (as a percent) Number of shares of stock issued during period shares new issues principle of note convertible. Stock Issued During Period Shares New Issues Principle Of Note Convertible Number of shares upon principle of note convertible Gain (Loss) on Extinguishment of Debt Gain on extinguishment Debt Instrument, Convertible, Stock Price Trigger Debt Instrument, conversion stock, par value Interest Payable Interest on note payable - related party Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Interest Rate During Period Fixed rate of interest on the amount drawn under the line of credit facility Interest Expense, Debt Interest expense Long-Term Line of Credit Line of credit Line of Credit Facility, Expiration Date Maturity of the Company's line of Credit Notes Payable, Related Parties, Current Draw down amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property, plant and equipment Leasehold Improvements, Gross GMP Facility Land Land Gross amount, at the balance sheet date, of office equipment. Office Equipment Gross Office Equipment Furniture and Fixtures, Gross Furniture and Fixtures and Equipment, Gross Lab Equipment Property, Plant and Equipment, Gross Total Property and Equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less Accumulated Depreciation The disclosure information about trademark and patents. Schedule Of Trademarks And Patents [Table] Asset Class [Axis] Asset Class [Domain] Finite-Lived Intangible Assets [Member] Finite Lived Intangible Assets Indefinite-Lived Intangible Assets [Member] Indefinite Lived Intangible Assets Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Trademarks and Patents [Line Items] Intangible Assets Finite-Lived Intangible Assets, Gross Intangible Assets Finite-Lived Intangible Assets, Accumulated Amortization Less Accumulated Amortization Finite-Lived Intangible Assets, Net Intangible Assets, Net Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Representing the member information pertaining to trademark and patents. Trademark and Patents [Member] Trademark and patents Amortization Amortization expense Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Intangible assets with finite lives, licenses and patent costs useful lives Employee-related Liabilities, Current Personnel and compensation costs Accrued Professional Fees, Current Consultant Carrying value as of the balance sheet date of the obligations incurred through Clinical trials. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Clinical Trial Costs, Current Clinical trial costs due to KMPL Disclosure of information about sale of stock made by the entity to investor outside consolidated group by type of sale. Sale of Stock By Entity, Type [Table] This member stands for the Company's founder, Chairman and President, Mr. Anil Diwan. Founder, Chairman, President Founder, Chairman and President Grantee Status [Axis] Grantee Status [Domain] Share-Based Payment Arrangement, Employee [Member] Employees Share-Based Payment Arrangement, Nonemployee [Member] Share-based payment arrangement, nonemployee Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Represents information relating to consulting services. Consulting services Consulting services Director Director Disclosure of information about sale of stock made by the entity to investor outside consolidated group by type of sale. Sale of Stock By Entity, Type [Line Items] Equity Transactions The total value of shares issued or to be sold by the entity in the stock transaction. Sale of Stock, Aggregate Value of Shares Issued in Transaction Aggregate offering price Sale of Stock, Consideration Received on Transaction Net proceeds Estimated period of extension term of employee agreement for share based compensation arrangement by share based payment award, in 'PnYnMndTnHmMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share-Based Compensation Arrangement by Share-Based Payment Award, Employee Agreement, Term of Extension Employment agreement extension term (in years) Stock Issued During Period, Shares, Share-based Compensation, Gross Shares granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Number of shares in a quarterly installment to be vested The amount of Non Cash Compensation Expenses. Non Cash Compensation Expenses Non-cash compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Balance amount of non-cash compensation expense Number of expected to vest awards outstanding that can be converted into shares under arrangement. Share-Based Compensation Arrangement by Share-Based Payment Award, Expected to Vest, Outstanding, Number Remaining balance of shares vest and service for non-cash compensation expense The number of common stock to be issued upon exercise of warrants. Number Of Common Stock To Be Issued Upon Conversion Of Warrants Number of fully vested warrants granted to purchase shares of common stock Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price (in dollars per share) Allocated Share-based Compensation Expense Non-cash compensation expense recognized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of shares authorized Share-based Compensation Stock-based compensation expense Payments of Stock Issuance Costs Less: offering costs and expenses Sale of Stock, Consideration Received Per Transaction Net proceeds from issuance of common stock Representing the information pertaining to scientific advisory board. Scientific Advisory Board Scientific Advisory Board Class of Stock [Line Items] Equity Transactions Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected life (year) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected annual rate of quarterly dividends Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free rate(s) Represents the information pertaining to Stock Warrants. Stock Warrants [Member] Common Stock Warrants Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of Shares, Outstanding and exercisable (in shares) Number of Shares, Outstanding and exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Number of Shares, Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Number of Shares, Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price per share, Outstanding and exercisable (dollars per share) Weighted Average Exercise Price Weighted Average Exercise Price per share, Outstanding and exercisable (dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted Average Exercise Price per share, Granted (dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Weighted Average Exercise Price per share, Expired (dollars per share) Weighted average remaining contractual term for vested portions of options granted, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share based Compensation Arrangement By Share based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual life Term (years), Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual life Term (years), Outstanding and exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Outstanding and exercisable (in dollars) The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Aggregate Intrinsic Value, Granted (in dollars) The intrinsic value of options expired during the reporting period as calculated by applying the disclosed option pricing methodology. Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period Intrinsic Value Aggregate Intrinsic Value, Expired (in dollars) Vesting [Axis] Vesting [Domain] Representing the member information pertaining to June 30, 2025. June 30, 2025 [Member] June 30, 2025 Representing the member information pertaining to June 30, 2026. June 30, 2026 [Member] June 30, 2026 Representing the member information pertaining to June 30, 2027. June 30, 2027 [Member] June 30, 2027 Representing the member information pertaining to June 30, 2028. June 30, 2028 [Member] June 30, 2028 Representing the member information pertaining to June 30, 2029. June 30, 2029 [Member] June 30, 2029 Aggregate amount of warrants are exercisable during the reporting period. Warrants Exercisable Warrants exercisable The disclosure information about commitment and contingencies. Commitments and Contingencies [Table] Chief Financial Officer [Member] Chief Financial Officer The line item information about commitment and contingencies. Commitments and Contingencies [Line Items] Commitments and Contingencies Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance Number of shares granted The number of clinical test drug candidates granted for the use, sale, or offer of sale in India. Number of Clinical Test Drug Candidates Granted for the Use, Sale, or Offer of Sale in India Number of clinical test drug candidates granted for the use, sale, or offer of sale in India Percentage of clinical trials manager fee. Percentage of Clinical Trials Fees Percentage of clinical trials fees Percentage of royalty fee paid. Percentage of Royalty Fee Percentage of royalty fee Subsequent Event [Table] Subsequent Event [Line Items] Subsequent Events EX-101.PRE 10 nncv-20240930\_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document And Entity Information - shares 3 Months Ended Sep. 30, 2024 Nov. 24, 2024 Document And Entity Information A Document Type 10-Q A Document Period End Date Sep. 30, 2024 A Entity File Number 001-36081 A Entity Registrant Name NANOVIRICIDES, A INC. A Entity Incorporation, State or Country Code DE A Entity Tax Identification Number 76-0674577 A Entity Address, Address Line One 1 Controls Drive A Entity Address, City or Town Shelton A Entity Address, State or Province CT A Entity Address, Postal Zip Code 06484 A City Area Code 203 A Local Phone Number 937-6137 A Entity Current Reporting Status Yes A Entity Interactive Data Current Yes A Entity Filer Category Non-accelerated Filer A Entity Small Business true A Entity Emerging Growth Company false A Entity Shell Company false A Title of 12(b) Security Common Stock A Trading Symbol NNVCA A Security Exchange Name NYSE A Entity Common Stock, Shares Outstanding A 14,347,000 Entity Central Index Key 00011379006 A Current Fiscal Year End Date -06-30 A Document Fiscal Year Focus 2025 A Document Fiscal Period Focus Q1 A Amendment Flag false A Document Quarterly Report true A Document Transition Report false A X - Definition Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. + References No definition available. + Details Name: dei\_AmendmentFlag Namespace Prefix: dei\_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Area code of city + References No definition available. + Details Name: dei\_CityAreaCode Namespace Prefix: dei\_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Cover page. + References No definition available. + Details Name: dei\_CoverAbstract Namespace Prefix: dei\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition End date of current fiscal year in the format --MM-DD. + References No definition available. + Details Name: dei\_CurrentFiscalYearEndDate Namespace Prefix: dei\_Data Type: xbrli:monthDayItemType Balance Type: na Period Type: duration X - Definition Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + References No definition available. + Details Name: dei\_DocumentFiscalPeriodFocus Namespace Prefix: dei\_Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - Definition This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + References No definition available. + Details Name: dei\_DocumentFiscalYearFocus Namespace Prefix: dei\_Data Type: xbrli:yearItemType Balance Type: na Period Type: duration X - Definition For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + References No definition available. + Details Name: dei\_DocumentPeriodEndDate Namespace Prefix: dei\_Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as an quarterly report. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a - Details Name: dei\_DocumentQuarterlyReport Namespace Prefix: dei\_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as a transition report. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei\_DocumentTransitionReport Namespace Prefix: dei\_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + References No definition available. + Details Name: dei\_DocumentType Namespace Prefix: dei\_Data Type: dei:submissionItemType Balance Type: na Period Type: duration X - Definition Address Line 1 such as Attn, Building Name, Street Name + References No definition available. + Details Name: dei\_EntityAddressAddressLine1 Namespace Prefix: dei\_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Name of the City or Town + References No definition available. + Details Name: dei\_EntityAddressCityOrTown Namespace Prefix: dei\_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Code for the postal or zip code + References No definition available. + Details Name: dei\_EntityAddressPostalZipCode Namespace Prefix: dei\_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Name of the state or province. + References No definition available. + Details Name: dei\_EntityAddressStateOrProvince Namespace Prefix: dei\_Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - Definition A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei\_EntityCentralIndexKey Namespace Prefix: dei\_Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - Definition Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + References No definition available. + Details Name: dei\_EntityCommonStockSharesOutstanding Namespace Prefix: dei\_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References No definition available. + Details Name: dei\_EntityCurrentReportingStatus Namespace Prefix: dei\_Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - Definition Indicate if registrant meets the emerging growth company criteria. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei\_EntityEmergingGrowthCompany Namespace Prefix: dei\_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + References No definition available. + Details Name: dei\_EntityFileNumber Namespace Prefix: dei\_Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - Definition Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei\_EntityFilerCategory Namespace Prefix: dei\_Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - Definition Two-character EDGAR code representing the state or country of incorporation. + References No definition available. + Details Name: dei\_EntityIncorporationStateCountryCode Namespace Prefix: dei\_Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei\_EntityInteractiveDataCurrent Namespace Prefix: dei\_Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - Definition The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei\_EntityRegistrantName Namespace Prefix: dei\_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei\_EntityShellCompany Namespace Prefix: dei\_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Indicates that the company is a Smaller Reporting Company (SRC). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei\_EntitySmallBusiness Namespace Prefix: dei\_Data Type: xbrli:booleanItemType Balance Type: na Period



[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2): [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3): [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4):

Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap StockholdersEquityNamespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StockholdersEquityAbstractNamespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap RelatedPartyTransactionsByRelatedPartyAxis=us-gaap NonrelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap RelatedPartyTransactionsByRelatedPartyAxis=us-gaap RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementClassOfStockAxis=nvnc.SeriesAConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Balance Sheets (Parenthetical) - \$ / shares Sep. 30, 2024 Jun. 30, 2024 Common stock, par value (in dollars per share) \$ 0.00001 \$ 0.00001 Common stock, shares authorized 150,000,000 150,000,000 Common stock, shares issued 14,062,813 13,144,055 Common stock, shares outstanding 14,062,813 13,144,055 Series A convertible preferred stock A Preferred stock, par value (in dollars per share) \$ 0.00001 \$ 0.00001 Preferred stock, shares authorized 10,000,000 10,000,000 Preferred stock, shares issued 903,216 892,625 Preferred stock, shares outstanding 903,216 892,625 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap CommonStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockSharesIssued Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap CommonStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-13 + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap PreferredStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-13 + Details Name: us-gaap PreferredStockSharesIssued Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap PreferredStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - Details Name: us-gaap StatementClassOfStockAxis=nvnc.SeriesAConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Statements of Operations - USD (\$) 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 OPERATING EXPENSES A A Research and development \$ 1,933,091 \$ 1,466,665 General and administrative 1,234,743 564,926 Total operating expenses 3,167,834 2,031,591 LOSS FROM OPERATIONS (3,167,834) (2,031,591) OTHER INCOME (EXPENSE): A A Interest income 41,023 99,338 Interest expense A (36,493) (203) Other expense, net 41,023 62,845 NET LOSS \$ (3,126,811) \$ (1,968,746) Net loss per common share/Weighted average common shares outstanding A A Net loss per common share - basic 93 (0.23) (0.17) Net loss per common share - diluted 93 (0.23) (0.17) Weighted average common shares outstanding - basic 13,715,959 11,718,791 Weighted average common shares outstanding - diluted 13,715,959 11,718,791 X - ReferencesNo definition available. + Details Name: us-gaap EarningsPerShareAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/214748524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap EarningsPerShareBasic Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemBalance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/214748524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap EarningsPerShareDiluted Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemBalance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap\_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap\_InterestExpenseNonoperating Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(ii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap\_NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap\_NonoperatingIncomeExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap\_OperatingExpenses Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_OperatingExpensesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap\_OperatingIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap\_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap\_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap\_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap\_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionXML 16 R5.htm IDEA: XBRL DOCUMENT V.23.4.3 Statement of Changes in Stockholders' Equity - USD (\$) Series A Preferred Stock Common Stock Additional Paid-in Capital Accumulated Deficit Total Balance at Jun. 30, 2023 \$ 5 \$ 116 \$ 145,946,258 \$ (131,080,749) \$ 14,865,630 Balance (in shares) at Jun. 30, 2023 547,674 11,698,497 A A Series A preferred stock issued for employee stock compensation A 9,617 A 9,617 Series A preferred stock issued for employee stock compensation (in shares) 10,591 A A A Common stock issued for consulting and legal services rendered A \$ 150,599 A 50,600 Common stock issued for consulting and legal services rendered (in shares) 39,103 A A Warrants issued to Scientific Advisory Board A 159 A 159 Common shares issued for Directors fees A 11,250 A 11,250 Common shares issued for Directors fees (in shares) 7,947 A A Net Income (Loss) \$ 0 \$ 0 (1,968,746) (1,968,746) Balance at Sep. 30, 2023 \$ 5 \$ 117,146,017,883 (133,049,495) 12,968,510 Balance (in shares) at Sep. 30, 2023 558,265 11,745,547 A A Balance at Jun. 30, 2024 \$ 9 \$ 1,150,838,832 (139,374,895) 11,464,077 Balance (in shares) at Jun. 30, 2024 892,625 13,144,055 A A Proceeds from sale of common stock in connection with equity financings net of issuance costs of \$53,875 A \$ 9,170,129 A 1,710,138 Proceeds from sale of common stock in connection with equity financings net of issuance costs of \$53,875 (in shares) 893,006 A A Series A preferred stock issued for employee stock compensation A 14,408 A 14,408 Series A preferred stock issued for employee stock compensation (in shares) 10,591 A A A Common stock issued for consulting and legal services rendered A 34,500 A 34,500 Common stock issued for consulting and legal services rendered (in shares) 19,713 A A Warrants issued to Scientific Advisory Board A 229 A 229 Common shares issued for Directors fees A 11,250 A 11,250 Common shares issued for Directors fees (in shares) 6,039 A A Net Income (Loss) A (3,126,811) (3,126,811) Balance at Sep. 30, 2024 \$ 9 \$ 140 \$ 152,609,348 \$ (142,501,706) \$ 10,107,791 Balance (in shares) at Sep. 30, 2024 903,216 14,062,813 A A X - DefinitionNumber of series A preferred stock issued during period as employee stock compensation. + ReferencesNo definition available. + Details Name: nunc\_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued Namespace Prefix: nunc Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of preferred stock shares issued during period as employee stock compensation. + ReferencesNo definition available. + Details Name: nunc\_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued Namespace Prefix: nunc Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued during the period as a compensation for consulting and legal services. + ReferencesNo definition available. + Details Name: nunc\_StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne Namespace Prefix: nunc Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued during the period as a compensation for consulting and legal services. + ReferencesNo definition available. + Details Name: nunc\_StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne Namespace Prefix: nunc Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued during the period as a compensation for consulting and legal services. + ReferencesNo definition available. + Details Name:

nvnc\_StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices Namespace Prefix: nvnc\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount represents the stock issued during the period for payment of director fees. + ReferencesNo definition available. + Details Name: nvnc\_StockIssuedForPaymentOfDirectorFeesShares Namespace Prefix: nvnc\_ Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionThe amount represents the stock issued during the period for payment of director fees. + ReferencesNo definition available. + Details Name: nvnc\_StockIssuedForPaymentOfDirectorFeesValue Namespace Prefix: nvnc\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/214748666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/214748666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6)Reference 10: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(18\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(18))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(9\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(1\)\(d\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(1)(d))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(22\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147485249/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(22))-Publisher FASB-URI https://asc.fasb.org/1943274/2147485249/942-220-S99-1) + Details Name: us-gaap\_NetIncomeLoss Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemBalance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap\_SharesOutstanding Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/214748112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/214748448/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/214748448/946-505-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap\_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemBalance Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(30\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(30))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(31\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(31))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(19\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(19))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(6\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(6))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(iii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 12: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)

Type: duration X - DefinitionAmount of preferred shares issued as compensation by the entity during the period. + ReferencesNo definition available. + Details Name: nncv PreferredSharesIssuedAsCompensation Namespace Prefix: nncv Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of common stock and warrants. + ReferencesNo definition available. + Details Name: nncv ProceedsFromIssuanceOfCommonStockAndWarrants Namespace Prefix: nncv Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of related party non-current liability converted to note payable relating to supplemental disclosure of cash flows information. + ReferencesNo definition available. + Details Name: nncv RelatedPartyNonCurrentLiabilityConvertedToNotePayable Namespace Prefix: nncv Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAdjustment for noncash service expenses paid for by granting of warrants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap AdjustmentOfWarrantsGrantedForServices Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap AmortizationOfIntangibleAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/214747401/830-230-45-1 + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap Depreciation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInAccountsPayableRelatedParties Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionChange in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInAccountsPayableTrade Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in other expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInOtherAccruedLiabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IncreaseDecreaseInPrepaidExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap IssuanceOfStockAndWarrantsForServicesOrClaims Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap\_ProfitLoss Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Nature of Business 3 Months Ended Sep. 30, 2024 Organization and Nature of Business A Organization and Nature of Business Note A 1A a Organization and Nature of Business NanoViricides, Inc. (the "Company") is a clinical stage nano-biopharmaceutical company specializing in the discovery, development, and commercialization of drugs to combat viral infections using its unique and novel nanomedicines technology. NanoViricides possesses its own facility that supports research and development and drug discovery, drug candidate optimization, cGMP-compliant drug substance manufacturing, cGMP-compliant manufacturing and packaging of drug products for human clinical trials, and early commercialization. The Company has several drugs in various stages of development. NanoViricides, Inc. is domiciled under the laws of the State of Delaware, with its principal operations located in the State of Connecticut. The Company's fiscal year begins on July 1st and ends on the next June 30th of the calendar year. The Company operates in one reportable business segment. The Company devotes substantially all its activity to advancing research and development, including efforts in connection with clinical trials. The Company's lead drug candidate is the active pharmaceutical ingredient (API) NV-387. NV-387 is a broad-spectrum antiviral drug that has demonstrated strong activity in lethal lung infection animal model studies and is being developed to treat Coronavirus, RSV, Influenza and even an Orthopoxvirus model for Smallpox and MPOX. The Company plans on developing NV-387 first as a treatment of RSV infection in pediatric patients. At present, NV-387 is in a Phase Ia/Ib human clinical trial for safety and tolerability in healthy subjects for the treatment of COVID-19, sponsored by our licensee and collaborator in India, Karveer Meditech Private Limited ("KMPL"). All subjects have been discharged and follow-up visits have been completed as of approximately the end of December 2023. As topline results of this clinical trial, there were no reported adverse events at all doses studied, and there were no drop-outs either, observations that are indicative of tolerability of the API NV-387. These results are consistent with the results of safety/tolerability studies in animals conducted in support of the clinical trial application. The Company is awaiting the final study report from this clinical trial for further regulatory advancement of NV-387 into a Phase II clinical trial. The Company is now working on developing the necessary datasets, documentation, and clinical trial pathway and trial designs, for a Phase II clinical trial application for the use of NV-387 for the treatment of RSV infection, as the Phase Ia/Ib study progresses into the data analysis phase. On August 14, 2024, the WHO declared a Public Health Emergency of International Concern (PHEIC) regarding the expanding epidemic of MPOX infections in Central Africa. There is no drug currently available for the treatment of MPOX. NV-387 has been found to possess activity against orthopoxvirus infection in animal model studies, making it a viable candidate for clinical trial as a treatment for MPOX infection under the MEURI (Monitored Emergency Use of Unregistered and Investigational Interventions) WHO protocol. The Company is now in the process of defining a clinical protocol for such a Phase II clinical trial with its collaborators in preparation for a clinical trial application to the appropriate regulatory agency. Subsequent to the MPOX and RSV Phase II clinical trials that are at high priority, the Company plans on expanding the indications of NV-387 to other respiratory viral infections including Influenzas, Coronaviruses, and others. Additionally, the Company has previously developed a clinical drug candidate, NV-HHV-1 formulated as skin cream, for the treatment of Shingles. The Company plans on taking NV-HHV-1 into human clinical trials, and further develop the HerpeCide<sup>®</sup> program after the Phase II clinical trial of NV-387 for RSV, MPOX, and possibly for multiple other indications, including Influenzas. In the HerpeCide program alone, the Company has drug candidates against at least five indications at different stages of development. The Company's drug candidates against HSV-1 (cold sores) and HSV-2 (genital herpes) are in advanced pre-clinical studies and are expected to follow the shingles drug candidate into human clinical trials. In addition, the Company has drug candidates against HIV/AIDS, Dengue, Ebola/Marburg, and other viruses. The Company's drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. ("TheraCour"), a related party substantially owned by Dr. Anil Diwan, to which the Company has broad, exclusive licenses. The licenses are to entire fields and not limited to specific compounds. In all, the Company has exclusive, worldwide licenses for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV-1 and HSV-2), Influenza and Asian Bird Flu Virus, Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis virus, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes (restarted), Varicella Zoster Virus (VZV) infections (i.e. Shingles and Chickenpox), and SARS-CoV-2 infections. Additionally, on September 23, 2024, the Company signed a Memorandum of Understanding ("MoU") with all its antiviral drug development with TheraCour whereby it has obtained a right of first refusal (ROFR) for all antiviral drug developments from TheraCour. This MoU expands the Company's abilities to opportunistically and rapidly develop novel drugs to treat viral infections of public health importance, even for those viruses that do not exist today and cannot be predicted. The MoU has also formalized the process of development of drugs for unlicensed viral indications leading later to appropriate license agreements. There was no compensation paid to or due to TheraCour as a result of this MoU. The Parties have also agreed in this MoU that any cash milestone payments related to development activities, that are awardable, will become payable only upon the Company having sufficient revenue, thus extending the provisions previously incorporated in the Amendment to the COVID License Agreement, to all present and future license agreements. In all cases, the discovery of ligands and polymer materials as well as formulations, the chemistry and chemical characterization, as well as process development and related work will be performed by TheraCour, a related party substantially owned by Dr. Anil Diwan, under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed. Upon commercialization, NanoViricides will pay 15% of net sales to TheraCour. Milestone payments were made or are specified in certain of the license agreements, details of which have been disclosed at the time the agreements were entered into. The Company negotiates and licenses specific verticals of therapeutic applications from TheraCour if promising drug candidates are found in early research and development against a virus target. TheraCour has not denied any such licenses when requested. The Company has out-licensed NV-CoV-2 and NV-CoV-2-R for further clinical drug development and commercialization in the territory of India to KMPL, a company of which Dr. Anil Diwan is a passive investor and advisor. KMPL has sponsored the NV-CoV-2 into Phase Ia/Ib human clinical trial, to study the safety and tolerability of the NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies formulations of the API NV-387 in healthy human subjects, described earlier. The clinical trial drug products, NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, were manufactured at the Company's Shelton campus. Under the agreement with KMPL, the Company will pay for the expenses of the clinical trials, and in return will benefit from having the data and reports made available for regulatory filings in other territories of the world. Upon commercialization, the Company will receive royalties from KMPL equal to 70% of sales net of costs to unaffiliated third parties. X - Definition The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap\_NatureOfOperations Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - References No definition available. + Details Name: us-gaap\_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Liquidity and Going Concern 3 Months Ended Sep. 30, 2024 Liquidity and Going Concern A Liquidity and Going Concern Note A 2A a Liquidity and Going Concern The Company's condensed financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets and liquidation of liabilities in the normal course of business. As reflected in the condensed financial statements, the Company has an accumulated deficit at September 30, 2024 of approximately \$142.5 million and a net loss of approximately \$3.1 million and net cash used in operating activities of approximately \$2.6 million for the three months then ended. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future. Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs. The Company has not yet commenced any product commercialization. Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future. As of September 30, 2024, the Company had available cash and cash equivalents of approximately \$3.9 million. The Company's liabilities at September 30, 2024 were approximately \$1,633,000 including accounts payable of approximately \$713,000 payable to third parties, accounts payable to TheraCour of approximately \$637,000, and accrued expenses of approximately \$283,000. Management believes that the Company's cash and cash equivalents balance of approximately \$3.9 million, additional capital raised of approximately \$631,000, net of offering expenses, by ATM sales of our common stock from October 1, 2024 through November 7, 2024, and the Company's existing resources, including availability under its \$3 million line of credit will not be sufficient to fund the Company's planned operations and expenditures for at least 12 months from the date of the filing of this Form 10-Q. As a result substantial doubt exists about the Company's ability to continue as a going concern. The Company believes that it has several important milestones, including data from and final reports from the Phase Ia/Ib human clinical trial for the Company's broad-spectrum, antiviral drug NV-387. This Phase Ia/Ib human clinical trial is for evaluating the safety and tolerability of two oral formulations of NV-387, namely (i) NV-CoV-2 Oral Gummies, and (ii) NV-387 Oral Syrup, as described elsewhere, with COVID as the indication. The safety and tolerability data from this clinical trial is expected to be applicable as Phase Ia/Ib data for other indications of NV-387 as well, including RSV, MPOX, Influenza and others. Additional milestones include Pre-IND and IND filing to the US FDA for RSV and clinical trial application for Phase II clinical trial of NV-387 for the treatment of RSV infection in adults with the goal towards further regulatory advancement and approval of NV-387 for the treatment of pediatric RSV infection. Additionally, the Company believes that NV-387 qualifies for a Phase II clinical trial for the treatment of MPOX infection in Central African nations under the MEURI protocol of WHO because there is no other treatment available for this epidemic that is declared by the WHO as a public health emergency of international concern (MEURI = Monitored Emergency Use of Unregistered and Investigational Interventions.). We plan on initiating the Phase II study for MPOX as soon as feasible if the Company receives the appropriate regulatory clearances. Additionally, the Company continues toward developing the Pre-IND and IND applications for a Phase IIa clinical trial of NV-387 for the treatment of RSV infection in adults, to be followed by a Phase IIb/III clinical trial of NV-387 for the treatment of RSV infection in hospitalized pediatric patients. To this end, the Company is also evaluating the possibility of a Phase IIa clinical trial of a RSV Infection Challenge in Humans. Management believes that as these milestones are achieved, the Company would likely experience improvement in the liquidity of the Company's stock, and such improvement, if any, would enhance the Company's ability to raise funds on the public markets at terms that may be favorable to the terms offered at present. Management is actively exploring additional required funding through non-dilutive grants and contracts, partnering, debt or equity financing pursuant to its plan. There is no assurance that we will be successful in obtaining sufficient financing on terms acceptable to us to fund continuing operations. Management believes that it has on-going access to the capital markets including the At-The-Market ("ATM") agreement with EF Hutton, the Sales Agent. There can be no assurance that the Company's plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The Company will need to raise additional capital to fund its long-term operations and research and development plans including human clinical trials for its various drug candidates until it generates revenue that reaches a level sufficient to provide self-sustaining cash flows. There can be no assurance that the Company will be able to raise the necessary capital or that it will be on acceptable terms. The accompanying financial statements do not include any adjustments that may result from the outcome of such unidentified uncertainties. X - Definition N/A. + References No definition available. + Details Name: nvc\_LiquidityAndGoingConcernAbstract Namespace Prefix: nvc\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for the liquidation basis of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-30/tableOfContent + Details Name: us-gaap\_LiquidationBasisOfAccountingTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 3 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies A Summary of Significant Accounting Policies Note A 3A - Summary of Significant Accounting Policies Basis of Presentation a Interim Financial Information The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying condensed financial statements and the information included under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations" should be read in conjunction with the Company's audited financial statements and related notes included in the Company's Form 10-K for the fiscal year ended June 30, 2024 filed with the SEC on September 27, 2024. The June 30, 2024 year-end balance sheet data in the accompanying interim condensed financial statements was derived from the audited financial statements. For a summary of significant accounting policies, see the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2024 filed on September 27, 2024. Net Loss per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants and convertible preferred stock. The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive: 

Month	Anti-dilutive Shares
Ended	3,126

 For the three months ended September 30, 2024, the Company has 903,216 shares of Series A preferred stock









Data Type: xbrli:integerItem Type Balance Type: na:Period Type: duration X - Details Name: srt:CounterpartyNameAxis=mvnc:TheracourPharmaIncMember Namespace Prefix: Data Type: na:Balance Type: Period Type: XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Liquidity and Going Concern (Details) - USD (\$) 1 Months Ended 3 Months Ended Nov. 07, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Jun. 30, 2024 Jun. 30, 2022 Liquidity and Going Concern A A A A Accumulated deficit A \$ 142,501,706 A A \$ 139,374,895 A Net loss A 3,126,811 X 1,968,746 A A A Net cash used in operating activities A 2,594,863 1,171,694 A A A Revenue A 0 A A A Cash and cash equivalents A 3,866,289 A A 4,797,778 A Liabilities A 1,633,000 A A A Accrued expenses A 283,292 A A 262,467 A Line of credit A 3,000,000 A A A Net proceeds from sale of common stock A 1,710,138 X 0 A A ATM Offering A A A A Liquidity and Going Concern A A A A Gross proceeds A \$ 1,764,000 A A A Issuance of shares A 893,006 A A A Average price A A A \$ 1.98 A A A ATM Offering | Subsequent event A A A A Liquidity and Going Concern A A A A Gross proceeds \$ 631,000 A A A A Issuance of shares 431,108 A A A A Average price \$ 1.51 A A A A Nonrelated party A A A A Liquidity and Going Concern A A A A Accounts payable A \$ 712,864 A A 376,270 A Related party A A A A Liquidity and Going Concern A A A A Accounts payable A 636,550 A A \$ 720,039 A Theracour Pharma Inc | Related party A A A A Liquidity and Going Concern A A A A Accounts payable A \$ 636,550 A A \$ 720,039 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: mvnc:FinancialConditionLineItems Namespace Prefix: mvnc: Data Type: xbrli:stringItem Type Balance Type: na:Period Type: duration X - DefinitionThe cash inflow from issuance of common stock and warrants. + ReferencesNo definition available. + Details Name: mvnc:ProceedsFromIssuanceOfCommonStockAndWarrants Namespace Prefix: mvnc: Data Type: xbrli:monetaryItem Type Balance Type: debit:Period Type: duration X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap:AccountsPayableCurrent Namespace Prefix: us-gaap: Data Type: xbrli:monetaryItem Type Balance Type: credit:Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap:AccruedLiabilitiesCurrent Namespace Prefix: us-gaap: Data Type: xbrli:monetaryItem Type Balance Type: credit:Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap:CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap: Data Type: xbrli:monetaryItem Type Balance Type: debit:Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap:Liabilities Namespace Prefix: us-gaap: Data Type: xbrli:monetaryItem Type Balance Type: credit:Period Type: instant X - DefinitionAmount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity Namespace Prefix: us-gaap: Data Type: xbrli:monetaryItem Type Balance Type: credit:Period Type: instant X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap:NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap: Data Type: xbrli:monetaryItem Type Balance Type: na:Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher



Accounts Payable - Related Party ... 636,550 ... 720,039 ... Dr. Anil Diwan | Minimum ... Related Party Transaction ... Line of credit \$ 2,000,000 ... Maturity of the Company's line of Credit Dec. 31, 2025 ... Dr. Anil Diwan | Maximum ... Related Party Transaction ... Line of credit \$ 3,000,000 ... Maturity of the Company's line of Credit Mar. 31, 2026 ... COVID 19 License Agreement | Related party ... Research and Development Costs - Related Party ... 157,000 ... Milestone payment amount due ... \$ 1,500,000 ... Line of credit agreement | Dr. Anil Diwan ... Related Party Transaction ... Line of credit facility, Maximum Borrowing Capacity ... \$ 2,000,000 ... Fixed rate of interest on the amount drawn under the line of credit facility ... 12.00% ... Drew down amount ... 0 ... KMPL | Related party ... Related Party Transaction ... Clinical trial Costs Accrued - Related Party ... \$ 227,435,227,435 ... TheraCour Pharma Inc ... Related Party Transaction ... Percentage of direct costs ... 30.00% ... Other general and administrative expense ... \$ 2,000 ... Percentage of net sales allocated for royalty payments (in percent) ... 15.00% ... Accounts payable offset by advance ... \$ 0 ... Accrued royalties ... 0 ... 0 ... TheraCour Pharma Inc | Related party ... Related Party Transaction ... 636,550 ... \$ 720,039 ... Research and Development Costs - Related Party ... \$ 644,527 \$ 639,077 ... Number of shares upon principle of note convertible ... 331,859 ... Gain on extinguishment ... \$ 49,808 ... TheraCour Pharma Inc | COVID 19 License Agreement | Related party ... Related Party Transaction ... Research and Development Costs - Related Party ... \$ 935,088 ... Unsecured promissory note | TheraCour Pharma Inc | Related party ... Related Party Transaction ... Interest rate per annum (as a percent) ... 12.00% ... Series A Preferred stock | COVID 19 License Agreement | Related party ... Related Party Transaction ... Shares issued for milestone payment ... 50,000 ... Series A Preferred stock | TheraCour Pharma Inc ... Related Party Transaction ... Number of shares upon principle of note convertible ... 331,859 ... Debt instrument, conversion stock, par value ... \$ 0.00001 ... Interest on note payable - related party ... \$ 36,493 ... Series A Preferred stock | TheraCour Pharma Inc | COVID 19 License Agreement | Related party ... Related Party Transaction ... Number of shares authorized for license milestone payment ... 100,000 X - DefinitionAmount for accounts payable offset by advance. + ReferencesNo definition available. + Details Name: nmcv\_AccountsPayableOffsetByAdvance Namespace Prefix: nmcv\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the obligations incurred through Clinical trials. Used to reflect the current portion of the liabilities (The amount has been recorded within accrued expenses in the accompanying balance sheet). + ReferencesNo definition available. + Details Name: nmcv\_AccruedClinicalTrialCosts Namespace Prefix: nmcv\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of milestone payment due. + ReferencesNo definition available. + Details Name: nmcv\_MilestonePaymentAmountDue Namespace Prefix: nmcv\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe number of shares authorized for license milestone payment. + ReferencesNo definition available. + Details Name: nmcv\_NumberOfSharesAuthorizedForLicenseMilestonePayment Namespace Prefix: nmcv\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe percentage of direct costs. + ReferencesNo definition available. + Details Name: nmcv\_PercentageOfDirectCosts Namespace Prefix: nmcv\_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRoyalty expense calculated as a percentage of net sales. + ReferencesNo definition available. + Details Name: nmcv\_PercentageOfNetSalesAllocatedForRoyaltyPayments Namespace Prefix: nmcv\_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionShares issued during the period for license agreement. + ReferencesNo definition available. + Details Name: nmcv\_SeriesPreferredSharesIssuedDuringPeriodForLicenseAgreement Namespace Prefix: nmcv\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued during period shares new issues principle of note convertible. + ReferencesNo definition available. + Details Name: nmcv\_StockIssuedDuringPeriodSharesNewIssuesPrincipleOfNoteConvertible Namespace Prefix: nmcv\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap\_AccountsPayableCurrent Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap\_AccruedRoyaltiesCurrentAndNoncurrent Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPrice of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective. + ReferencesNo definition available. + Details Name: us-gaap\_DebtInstrumentConvertibleStockPriceTrigger Namespace Prefix: us-gaap\_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap\_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap\_InterestExpenseDebt Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest payable on debt, including, but not limited to, trade payables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap\_InterestPayableCurrentAndNoncurrent Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancellable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap\_LineOfCredit Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDate the credit facility terminates, in YYYY-MM-DD format. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap\_LineOfCreditFacilityExpirationDate1 Namespace Prefix: us-gaap\_ Data Type: xbrli:dateTimeItemType Balance Type: na Period Type: duration X - DefinitionThe effective interest rate during the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap\_OtherGeneralAndAdministrativeExpense Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap\_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap\_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIdentify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties. + ReferencesNo definition available. + Details Name: us-gaap\_RelatedPartyTransactionRate Namespace Prefix: us-gaap\_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap\_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap\_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap\_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt\_TitleOfIndividualAxis=nmcv\_Dr.AnilDiwanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt\_RangeAxis=srt\_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt\_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_TypeOfArrangementAxis=nmcv\_Covid19LicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_CreditFacilityAxis=us-gaap\_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt\_CounterpartyNameAxis=nmcv\_KarveerMeditechPvt.LtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt\_CounterpartyNameAxis=nmcv\_TheracourPharmaIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_RelatedPartyTransactionAxis=nmcv\_UnsecuredPromissoryNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap\_StatementClassOfStockAxis=us-gaap\_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment - Schedule of property and equipment (Details) - USD (\$) Sep. 30, 2024 Jun. 30, 2024 Property and Equipment A GMP Facility \$ 8,168,045 \$ 8,168,045 Land 260,000 260,000 Office Equipment 77,425 63,056 Furniture and Fixtures 5,607 5,607 Lab Equipment 6,501,973 6,469,578 Total Property and Equipment 15,013,050 14,966,286 Less Accumulated Depreciation (7,647,369) (7,453,823) Property and Equipment, Net \$ 7,365,681 \$ 7,512,463 X - DefinitionGross amount, at the balance sheet date, of office equipment. + ReferencesNo definition available. + Details Name: nncv\_OfficeEquipmentGross Namespace Prefix: nncv\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/214748777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap\_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines. + ReferencesNo definition available. + Details Name: us-gaap\_FixturesAndEquipmentGross Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap\_FurnitureAndFixturesGross Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before accumulated depreciation of real estate held for productive use, excluding land held for sale. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap\_Land Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before accumulated depreciation of additions or improvements to assets held under a lease arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap\_LeaseholdImprovementsGross Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap\_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/214748777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap\_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/214748964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/214781372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/214748777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap\_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment - Additional information (Details) - USD (\$) 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Property and Equipment A Depreciation expense 193,546 187,057 X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap\_Depreciation Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Intangible Assets (Details) - USD (\$) Sep. 30, 2024 Jun. 30, 2024 Intangible Assets A Intangible Assets \$ 458,954 \$ 458,954 Less Accumulated Amortization (135,713) (133,646) Intangible Assets, Net 323,241 325,308 Finite Lived Intangible Assets A Intangible Assets A Intangible Assets 153,393 153,393 Less Accumulated Amortization (135,713) (133,646) Intangible Assets, Net 17,680 19,747 Indefinite Lived Intangible Assets A Intangible Assets A Intangible Assets 305,561 305,561 Intangible Assets, Net \$ 305,561 \$ 305,561 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: nncv\_TrademarksAndPatentsLineItems Namespace Prefix: nncv\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/214748265/350-10-545-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap\_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-545-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/214748859/928-340-50-1 + Details Name: us-gaap\_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap\_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap\_FairValueByAssetClassAxis=us-gaap\_IndefinitelivedIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_FairValueByAssetClassAxis=us-gaap\_IndefinitelivedIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Intangible Assets - Additional information (Details) - Trademark and patents - USD (\$) 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Intangible Assets A Amortization expense \$ 2,067 \$ 2,067 Minimum A Intangible Assets A Intangible assets with finite lives, licenses and patent costs useful lives 17 years A Maximum A Intangible Assets A Intangible assets with finite lives, licenses and patent costs useful lives 20 years A X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: nncv\_TrademarksAndPatentsLineItems Namespace Prefix: nncv\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap\_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife Namespace Prefix: us-gaap\_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate amount of recurring non-cash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap\_AdjustmentForAmortization Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap\_IndefiniteLivedIntangibleAssetsByMajorClassAxis=nncv\_TrademarkAndPatentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt\_RangeAxis=srt\_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt\_RangeAxis=srt\_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued expenses (Details) - USD (\$) Sep. 30, 2024 Jun. 30, 2024 Accrued expenses A Personnel and compensation costs \$ 46,857 \$ 23,532 Consultant 9,000 11,500 Clinical trial costs due to KMP 227,435 227,435 Accrued expenses \$ 283,292 \$ 262,467 X - DefinitionCarrying value as of the balance sheet date of the obligations incurred through Clinical Trials. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: nncv\_AccruedClinicalTrialCostsCurrent Namespace Prefix: nncv\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap\_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap\_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap\_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap\_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Equity Transactions - Additional information (Details) - USD (\$) 1 Months Ended Jul. 01, 2024 Apr. 15, 2024 Aug. 31, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2022 Sep. 30, 2021 Equity Transactions A A A A A Common shares issued as compensation and for services A A A \$ 45,750 \$ 61,850 A Consulting services A A A A A Equity Transactions A A A A A Number of shares authorized A A A 19,713 A A Stock-based compensation expense A A A \$ 34,500 A A Director A A A A A Equity Transactions A A A A A Number of shares authorized A A A 6,039 A A Stock-based compensation expense A A A \$ 11,250 A A Warrants A A A A A Equity Transactions A A A A A Number of fully vested warrants granted to purchase shares of common stock A A A 286 A A Exercise price (in dollars per share) A A A \$ 2.35 A A A Non-cash compensation expense recognized A A A \$ 229 A A Series A Preferred Stock | Employees A A A A A Equity Transactions A A A A A Shares granted A A A 387 A A Series A Preferred Stock | Share-based payment arrangement, nonemployee A A A A A Equity Transactions A A A A A Common shares issued as compensation and for services A A A \$ 1,950 A A Founder, Chairman and President A A A A A Equity Transactions A A A A A Employment agreement extension term (in years) 1 year A A A A A Founder, Chairman and President | Series A Preferred Stock A A A A A Equity Transactions A A A A A Shares granted 10,204 A A A Number of shares in a quarterly installment to be vested 2,551 A A A Non-cash compensation expense A A A \$ 12,458 A A Balance amount of non-cash compensation expense \$ 37,375 A A A Remaining balance of shares vest and service for non-cash compensation expense 7,653 A A A A ATM Offering A A A A A Equity Transactions A A A A A Aggregate offering price \$ 50,000,000 A A A Issuance of shares A A A 893,006 A A Average price A A A \$ 1.98 Net proceeds A A A \$ 1,710,000 A A A X - DefinitionThe amount of Non Cash Compensation Expenses. + ReferencesNo definition available. + Details Name: nncv\_NonCashCompensationExpenses Namespace Prefix: nncv\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of common stock to be issued upon exercise of warrants. + ReferencesNo definition available. + Details Name: nncv\_NumberOfCommonStockToBeIssuedUponConversionOfWarrants Namespace Prefix: nncv\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe total value of shares issued or to be sold by the entity in the stock















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end XML 60 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}if(e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p;if(e.style.display=='none'){d='block';p='-';}else{d='none';p='+'};e.style.display=d;if(a.textContent){a.textContent+=p+a.textContent.substring(1)}else{a.innerHTML+=p+a.innerHTML.substring(1)}} XML 61 report.css IDEA: XBRL DOCUMENT /\* Updated 2009-11-04 \*/ /\* v2.2.0.24 \*/ /\* DefRef Styles \*/ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table { font-size: 1em; } /\* Report Styles \*/ .pl a, .pl a:visited { color: black; text-decoration: none; } /\* table \*/ .report { background-color: white; border: 2px solid #ac; clear: both; color: black; font: normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em; } .report hr { border: 1px solid #ac; } /\* Top labels \*/ .report th { background-color: #ac; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, sans-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; } /\* word-wrap: break-word; \*/ } .report td.pl a a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div a { width: 200px; } .report td.pl a: hover { background-color: #ffc; } /\* Header rows... \*/ .report tr.rh { background-color: #ac; color: black; font-weight: bold; } /\* Calendars... \*/ .report .rc { background-color: #f0f0f0; } /\* Even rows... \*/ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /\* Odd rows... \*/ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /\* styles for footnote marker \*/ .report .fn { white-space: nowrap; } /\* styles for numeric types \*/ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /\* styles for text types \*/ .report .text { text-align: left; white-space: normal; } .report .text.big { margin-bottom: 1em; width: 17em; } .report .text.more { display: none; } .report .text.note { font-style: italic; font-weight: bold; } .report .text.small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3.html 109 204 1 false 37 0 false 6 false false R1.htm 995200090 - Document - Document And Entity Information Sheet http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformationDocument And Entity Information Cover 1 false false R2.htm 995200100 - Statement - Condensed Balance Sheets Sheet http://www.nanoviricides.com/role/StatementCondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 995200105 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://www.nanoviricides.com/role/StatementCondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 995200200 - Statement - Statements of Operations Sheet http://www.nanoviricides.com/role/StatementStatementsOfOperations Statements of Operations Statements 4 false false R5.htm 995200300 - Statement - Statement of Changes in Stockholders' Equity Sheet http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity Statement of Changes in Stockholders' Equity Statements 5 false false R6.htm 995200305 - Statement - Statement of Changes in Stockholders' Equity (Parenthetical) Sheet http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquityParenthetical Statement of Changes in Stockholders' Equity (Parenthetical) Statements 6 false false R7.htm 995200400 - Statement - Statements of Cash Flows Sheet http://www.nanoviricides.com/role/StatementStatementsOfCashFlows Statements of Cash Flows Statements 7 false false R8.htm 995210101 - Disclosure - Organization and Nature of Business Sheet http://www.nanoviricides.com/role/DisclosureOrganizationAndNatureOfBusiness Organization and Nature of Business Notes 8 false false R9.htm 995210201 - Disclosure - Liquidity and Going Concern Sheet http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcern Liquidity and Going Concern Notes 9 false false R10.htm 995210301 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 995210401 - Disclosure - Related Party Transactions Sheet http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 11 false false R12.htm 995210501 - Disclosure - Property and Equipment Sheet http://www.nanoviricides.com/role/DisclosurePropertyAndEquipment Property and Equipment Notes 12 false false R13.htm 995210601 - Disclosure - Intangible Assets Sheet http://www.nanoviricides.com/role/DisclosureIntangibleAssets Intangible Assets Notes 13 false false R14.htm 995210701 - Disclosure - Accrued expenses Sheet http://www.nanoviricides.com/role/DisclosureAccruedExpenses Accrued expenses Notes 14 false false R15.htm 995210801 - Disclosure - Equity Transactions Sheet http://www.nanoviricides.com/role/DisclosureEquityTransactions Equity Transactions Notes 15 false false R16.htm 995210901 - Disclosure - Common Stock Warrants Sheet http://www.nanoviricides.com/role/DisclosureCommonStockWarrants Common Stock Warrants Notes 16 false false R17.htm 995211001 - Disclosure - Commitments and Contingencies Sheet http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 995211101 - Disclosure - Subsequent Events Sheet http://www.nanoviricides.com/role/DisclosureSubsequentEvents Subsequent Events Notes 18 false false R19.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 19 false false R20.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 20 false false R21.htm 99920302 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPolicies (Tables) Sheet http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactions 23 false false R24.htm 99930503 - Disclosure - Property and Equipment (Tables) Sheet http://www.nanoviricides.com/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.nanoviricides.com/role/DisclosurePropertyAndEquipment 24 false false R25.htm 99930603 - Disclosure - Intangible Assets (Tables) Sheet http://www.nanoviricides.com/role/DisclosureIntangibleAssetsTables Intangible Assets (Tables) Tables http://www.nanoviricides.com/role/DisclosureIntangibleAssets 25 false false R26.htm 99930703 - Disclosure - Accrued expenses (Tables) Sheet http://www.nanoviricides.com/role/DisclosureAccruedExpensesTables Accrued expenses (Tables) Tables http://www.nanoviricides.com/role/DisclosureAccruedExpenses 26 false false R27.htm 99930803 - Disclosure - Equity Transactions (Tables) Sheet http://www.nanoviricides.com/role/DisclosureEquityTransactionsTables Equity Transactions (Tables) Tables http://www.nanoviricides.com/role/DisclosureEquityTransactions 27 false false R28.htm 99930903 - Disclosure - Common Stock Warrants (Tables) Sheet http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsTables Common Stock Warrants (Tables) Tables http://www.nanoviricides.com/role/DisclosureCommonStockWarrants 28 false false R29.htm 99940101 - Disclosure - Organization and Nature of Business (Details) Sheet http://www.nanoviricides.com/role/DisclosureOrganizationAndNatureOfBusinessDetails Organization and Nature of Business (Details) Details http://www.nanoviricides.com/role/DisclosureOrganizationAndNatureOfBusiness 29 false false R30.htm 99940201 - Disclosure - Liquidity and Going Concern (Details) Sheet http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails Liquidity and Going Concern (Details) Details http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcern 30 false false R31.htm 99940301 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive warrants (Details) Sheet http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWarrantsDetails Summary of Significant Accounting Policies - Anti-dilutive warrants (Details) Details 31 false false R32.htm 99940302 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 32 false false R33.htm 99940401 - Disclosure - Related Party Transactions - Summary of related parties (Details) Sheet http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartiesDetails Related Party Transactions - Summary of related parties (Details) Details 33 false false R34.htm 99940402 - Disclosure - Related Party Transactions (Details) Sheet http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsTables 34 false false R35.htm 99940501 - Disclosure - Property and

Equipment - Schedule of property and equipment (Details) Sheet

<http://www.nanoviricides.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails> Property and Equipment - Schedule of property and equipment (Details) Details 35 false false R36.htm 99940502 - Disclosure - Property and Equipment - Additional information (Details) Sheet <http://www.nanoviricides.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails> Property and Equipment - Additional information (Details) Details 36 false false R37.htm 99940601 - Disclosure - Intangible Assets (Details) Sheet <http://www.nanoviricides.com/role/DisclosureIntangibleAssetsDetails> Intangible Assets (Details) Details <http://www.nanoviricides.com/role/DisclosureIntangibleAssetsTables> 37 false false R38.htm 99940602 - Disclosure - Intangible Assets - Additional Information (Details) Sheet <http://www.nanoviricides.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails> Intangible Assets - Additional Information (Details) Details 38 false false R39.htm 99940701 - Disclosure - Accrued expenses (Details) Sheet <http://www.nanoviricides.com/role/DisclosureAccruedExpensesDetails> Accrued expenses (Details) Details <http://www.nanoviricides.com/role/DisclosureAccruedExpensesTables> 39 false false R40.htm 99940801 - Disclosure - Equity Transactions - Additional Information (Details) Sheet <http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails> Equity Transactions - Additional Information (Details) Details 40 false false R41.htm 99940802 - Disclosure - Equity Transactions - Proceeds of ATM offering (Details) Sheet <http://www.nanoviricides.com/role/DisclosureEquityTransactionsProceedsOfAtmOfferingDetails> Equity Transactions - Proceeds of ATM offering (Details) Details 41 false false R42.htm 99940803 - Disclosure - Equity Transactions - Estimated the fair value of warrants granted quarterly to the Scientific Advisory Board (Details) Sheet <http://www.nanoviricides.com/role/DisclosureEquityTransactionsEstimatedFairValueOfWarrantsGrantedQuarterlyToScientificAdvisoryBoardDetails> Equity Transactions - Estimated the fair value of warrants granted quarterly to the Scientific Advisory Board (Details) Details 42 false false R43.htm 99940901 - Disclosure - Common Stock Warrants- Common Stock Warrants (Details) Sheet <http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsCommonStockWarrantsDetails> Common Stock Warrants- Common Stock Warrants (Details) Details 43 false false R44.htm 99940902 - Disclosure - Common Stock Warrants - Additional Information (Details) Sheet <http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails> Common Stock Warrants - Additional Information (Details) Details 44 false false R45.htm 99941001 - Disclosure - Commitments and Contingencies - Employment Agreements (Details) Sheet <http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails> Commitments and Contingencies - Employment Agreements (Details) Details 45 false false R46.htm 99941002 - Disclosure - Commitments and Contingencies - License Agreements (Details) Sheet <http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementsDetails> Commitments and Contingencies - License Agreements (Details) Details 46 false false R47.htm 99941101 - Disclosure - Subsequent Events (Details) Sheet <http://www.nanoviricides.com/role/DisclosureSubsequentEventsDetails> Subsequent Events (Details) Details <http://www.nanoviricides.com/role/DisclosureSubsequentEvents> 47 false false All Reports Book All Reports nnvc-20240930\_xsd nnvc-20240930\_cal.xml nnvc-20240930\_def.xml nnvc-20240930\_lab.xml nnvc-20240930\_pre.xml nnvc-20240930x10q.htm <http://fasb.org/us-gaap/2024> <http://xbrl.sec.gov/dei/2024> <http://xbrl.sec.gov/ecd/2024> true true JSON 66 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "nnvc-20240930x10q.htm": { "nsprefix": "nnvc", "nsuri": "http://www.nanoviricides.com/20240930", "dts": { "schema": { "local": [ "nnvc-20240930\_xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31\_xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31\_xsd", "http://www.xbrl.org/2003/xl-2003-12-31\_xsd", "http://www.xbrl.org/2003/xlink-2003-12-31\_xsd", "http://www.xbrl.org/2005/xbrldt-2005\_xsd", "http://www.xbrl.org/2006/ref-2006-02-27\_xsd", "http://www.xbrl.org/lrr/arcole/esma-arcole-2018-11-21\_xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16\_xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16\_xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0\_xsd", "https://www.xbrl.org/2023/calculation-1.1\_xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types\_xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types\_xsd", "https://xbrl.fash.org/srt/2024/elts/srt-2024\_xsd", "https://xbrl.fash.org/srt/2024/elts/srt-roles-2024\_xsd", "https://xbrl.fash.org/srt/2024/elts/srt-types-2024\_xsd", "https://xbrl.fash.org/us-gaap/2024/elts/us-gaap-2024\_xsd", "https://xbrl.fash.org/us-gaap/2024/elts/us-roles-2024\_xsd", "https://xbrl.fash.org/us-gaap/2024/elts/us-types-2024\_xsd", "https://xbrl.sec.gov/country/2024/country-2024\_xsd", "https://xbrl.sec.gov/dei/2024/dei-2024\_xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024\_xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024\_xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024\_xsd" ] }, "calculationLink": { "local": [ "nnvc-20240930\_cal.xml" ] }, "definitionLink": { "local": [ "nnvc-20240930\_def.xml" ] }, "labelLink": { "local": [ "nnvc-20240930\_lab.xml" ] }, "presentationLink": { "local": [ "nnvc-20240930\_pre.xml" ] }, "inline": { "local": [ "nnvc-20240930x10q.htm" ] }, "keyStandard": 167, "keyCustom": 37, "axisStandard": 18, "axisCustom": 0, "memberStandard": 17, "memberCustom": 17, "hidden": { "total": 14, "http://xbrl.sec.gov/dei/2024": 7, "http://fasb.org/us-gaap/2024": 7 }, "contextCount": 109, "entityCount": 1, "segmentCount": 37, "elementCount": 429, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 290, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "R2": { "role": "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets", "longName": "995200100 - Statement - Condensed Balance Sheets", "shortName": "Condensed Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As\_Of\_9\_30\_2024\_hSFICV2v6ki90ZSESElhw", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "uniqueAnchor": { "contextRef": "As\_Of\_9\_30\_2024\_hSFICV2v6ki90ZSESElhw", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "unique": true }, "R3": { "role": "http://www.nanoviricides.com/role/StatementCondensedBalanceSheetsParentetical", "longName": "995200105 - Statement - Condensed Balance Sheets (Parentetical)", "shortName": "Condensed Balance Sheets (Parentetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parentetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As\_Of\_9\_30\_2024\_hSFICV2v6ki90ZSESElhw", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit\_Divide\_USD\_shares\_O9FgTYCAYOiq\_LgZo3lrhA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "R4": { "role": "http://www.nanoviricides.com/role/StatementStatementsOfOperations", "longName": "995200200 - Statement - Statements of Operations", "shortName": "Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "uniqueAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "unique": true }, "R5": { "role": "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity", "longName": "995200300 - Statement - Statement of Changes in Stockholders' Equity", "shortName": "Statement of Changes in Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As\_Of\_6\_30\_2023\_us-gaap:StatementEquityComponentsAxis nnvc\_SeriesAConvertiblePreferredStockMember\_7Rh0yAeJv0uHCQpepmXBgA", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "uniqueAnchor": { "contextRef": "As\_Of\_6\_30\_2023\_us-gaap:StatementEquityComponentsAxis nnvc\_SeriesAConvertiblePreferredStockMember\_7Rh0yAeJv0uHCQpepmXBgA", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "R6": { "role": "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquityParentetical", "longName": "995200305 - Statement - Statement of Changes in Stockholders' Equity (Parentetical)", "shortName": "Statement of Changes in Stockholders' Equity (Parentetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parentetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "R7": { "role": "http://www.nanoviricides.com/role/StatementStatementsOfCashFlows", "longName": "995200400 - Statement -



"20", "firstAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true, "unique": true }, "R21": { "role": "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920302 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "policies", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "us-gaap:BasisOfAccountingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "us-gaap:BasisOfAccountingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true, "unique": true }, "R22": { "role": "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "99930303 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true, "unique": true }, "R23": { "role": "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsTables", "longName": "99930403 - Disclosure - Related Party Transactions (Tables)", "shortName": "Related Party Transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true, "unique": true }, "R24": { "role": "http://www.nanoviricides.com/role/DisclosurePropertyAndEquipmentTables", "longName": "99930503 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true, "unique": true }, "R25": { "role": "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsTables", "longName": "99930603 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true, "unique": true }, "R26": { "role": "http://www.nanoviricides.com/role/DisclosureAccruedExpensesTables", "longName": "99930703 - Disclosure - Accrued expenses (Tables)", "shortName": "Accrued expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true, "unique": true }, "R27": { "role": "http://www.nanoviricides.com/role/DisclosureEquityTransactionsTables", "longName": "99930803 - Disclosure - Equity Transactions (Tables)", "shortName": "Equity Transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "nvc:ScheduleOfProceedsFromSaleOfStockTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "nvc:ScheduleOfProceedsFromSaleOfStockTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true, "unique": true }, "R28": { "role": "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsTables", "longName": "99930903 - Disclosure - Common Stock Warrants (Tables)", "shortName": "Common Stock Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true, "unique": true }, "R29": { "role": "http://www.nanoviricides.com/role/DisclosureOrganizationAndNatureOfBusinessDetails", "longName": "99940101 - Disclosure - Organization and Nature of Business (Details)", "shortName": "Organization and Nature of Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit\_Standard\_segment\_xpqqetRhWEKJ1E2kybGY5w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit\_Standard\_segment\_xpqqetRhWEKJ1E2kybGY5w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true, "unique": true }, "R30": { "role": "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails", "longName": "99940201 - Disclosure - Liquidity and Going Concern (Details)", "shortName": "Liquidity and Going Concern (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "As Of 9\_30\_2024\_hSFICv2v6ki90ZSESElhw", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration\_7\_1\_2024\_To\_9\_30\_2024\_y\_ccCt694UKDRbFXC3QmQA", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:LiquidationBasisOfAccountingTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nvc-20240930x10q.htm", "first": true }, "R31": { "role": "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWarrantsDetails", "longName": "99940301 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive warrants (Details)", "shortName": "Summary of Significant Accounting

Policies - Anti-dilutive warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 us-gaap\_FinancialInstrumentAxis\_us-gaap\_WarrantMember\_FuNqSuqzGkSAP88b39OPQO", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit\_Standard\_shares\_7d64PHaTs0Kad57-YP5iMO", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 us-gaap\_FinancialInstrumentAxis\_us-gaap\_WarrantMember\_FuNqSuqzGkSAP88b39OPQO", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit\_Standard\_shares\_7d64PHaTs0Kad57-YP5iMO", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "99940302 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As Of 6 30 2024 us-gaap\_StatementClassOfStockAxis\_nnvc\_SeriesAConvertiblePreferredStockMember\_CdZ\_o6o2BU6Q52ydxUQO", "name": "us-gaap:PreferredStockSharesOutstanding", "unitRef": "Unit\_Standard\_shares\_7d64PHaTs0Kad57-YP5iMO", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 us-gaap\_StatementClassOfStockAxis\_nnvc\_SeriesAConvertiblePreferredStockMember\_7QIrNiO62UuJ4rhRK-gCRw", "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "unitRef": "Unit\_Standard\_pure\_VqPTwO1HuUW-PqxYXOah1g", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": [ "p", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "unique": true }, "R33": { "role": "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartiesDetails", "longName": "99940401 - Disclosure - Related Party Transactions - Summary of related parties (Details)", "shortName": "Related Party Transactions - Summary of related parties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 srt\_CounterpartyNameAxis\_nnvc\_TheracourPharmaIncMember\_us-gaap\_RelatedPartyTransactionsByRelatedPartyAxis\_us-gaap\_RelatedPartyMember\_713T9ndVJU6J0ju1Z5wNpA", "name": "us-gaap:PropertyPlantAndEquipmentAdditions", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 srt\_CounterpartyNameAxis\_nnvc\_TheracourPharmaIncMember\_us-gaap\_RelatedPartyTransactionsByRelatedPartyAxis\_us-gaap\_RelatedPartyMember\_713T9ndVJU6J0ju1Z5wNpA", "name": "us-gaap:PropertyPlantAndEquipmentAdditions", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "R34": { "role": "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails", "longName": "99940402 - Disclosure - Related Party Transactions (Details)", "shortName": "Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 y\_ccCt694UKDRbFXC3OmQA", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration 7 1 2023 To 6 30 2024 i3j2DLfv7kmT4ixH\_tirQw", "name": "us-gaap:InterestExpenseDebt", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "unique": true }, "R35": { "role": "http://www.nanoviricides.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails", "longName": "99940501 - Disclosure - Property and Equipment - Schedule of property and equipment (Details)", "shortName": "Property and Equipment - Schedule of property and equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As Of 9 30 2024 hSFICV2v6ki90ZSESElhw", "name": "us-gaap:LeaseholdImprovementsGross", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As Of 9 30 2024 hSFICV2v6ki90ZSESElhw", "name": "us-gaap:LeaseholdImprovementsGross", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "R36": { "role": "http://www.nanoviricides.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails", "longName": "99940502 - Disclosure - Property and Equipment - Additional information (Details)", "shortName": "Property and Equipment - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 y\_ccCt694UKDRbFXC3OmQA", "name": "us-gaap:Depreciation", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 y\_ccCt694UKDRbFXC3OmQA", "name": "us-gaap:Depreciation", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true }, "R37": { "role": "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsDetails", "longName": "99940601 - Disclosure - Intangible Assets (Details)", "shortName": "Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As Of 9 30 2024 hSFICV2v6ki90ZSESElhw", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As Of 9 30 2024 hSFICV2v6ki90ZSESElhw", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "R38": { "role": "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "longName": "99940602 - Disclosure - Intangible Assets - Additional information (Details)", "shortName": "Intangible Assets - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 us-gaap\_IndefiniteLivedIntangibleAssetsByMajorClassAxis\_nnvc\_TrademarkAndPatentsMember\_X8R7E-tmO0a2CgZBlxJ43w", "name": "us-gaap:AdjustmentForAmortization", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 us-gaap\_IndefiniteLivedIntangibleAssetsByMajorClassAxis\_nnvc\_TrademarkAndPatentsMember\_X8R7E-tmO0a2CgZBlxJ43w", "name": "us-gaap:AdjustmentForAmortization", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "R39": { "role": "http://www.nanoviricides.com/role/DisclosureAccruedExpensesDetails", "longName": "99940701 - Disclosure - Accrued expenses (Details)", "shortName": "Accrued expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As Of 9 30 2024 hSFICV2v6ki90ZSESElhw", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As Of 9 30 2024 hSFICV2v6ki90ZSESElhw", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "R40": { "role": "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails", "longName": "99940801 - Disclosure - Equity Transactions - Additional Information (Details)", "shortName": "Equity Transactions - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 y\_ccCt694UKDRbFXC3OmQA", "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 y\_ccCt694UKDRbFXC3OmQA", "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true } } }

"div", "body", "html", "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "uniqueAnchor": { "contextRef": "As Of 9 30 2024\_srt TitleOfIndividualAxis\_nnvc ConsultingServicesMember\_sRfwS5kapUeAJpudO1CqQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Unit\_Standard\_shares\_7d64PHaTs0Kad57-YP5iMQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html", "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "http://www.nanoviricides.com/role/DisclosureEquityTransactionsProceedsOfAtmOfferingDetails", "longName": "99940802 - Disclosure - Equity Transactions - Proceeds of ATM offering (Details)", "shortName": "Equity Transactions - Proceeds of ATM offering (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024\_us-gaap SubsidiarySaleOfStockAxis\_nnvc AtmOfferingMember\_7akBig\_GAU2eZDS66DdRIA", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html", "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "uniqueAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024\_us-gaap SubsidiarySaleOfStockAxis\_nnvc AtmOfferingMember\_7akBig\_GAU2eZDS66DdRIA", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfProceedsFromSaleOfStockTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html", "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "unique": true }, "R42": { "role": "http://www.nanoviricides.com/role/DisclosureEquityTransactionsEstimatedFairValueOfWarrantsGrantedQuarterlyToScientificAdvisoryBoardDetails", "longName": "99940803 - Disclosure - Equity Transactions - Estimated the fair value of warrants granted quarterly to the Scientific Advisory Board (Details)", "shortName": "Equity Transactions - Estimated the fair value of warrants granted quarterly to the Scientific Advisory Board (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024\_us-gaap RelatedPartyTransactionsByRelatedPartyAxis\_nnvc ScientificAdvisoryBoardMember\_vFOUth6xUjrfy9ubhtWQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html", "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024\_us-gaap RelatedPartyTransactionsByRelatedPartyAxis\_nnvc ScientificAdvisoryBoardMember\_vFOUth6xUjrfy9ubhtWQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html", "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "R43": { "role": "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsCommonStockWarrantsDetails", "longName": "99940901 - Disclosure - Common Stock Warrants - Common Stock Warrants (Details)", "shortName": "Common Stock Warrants - Common Stock Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As Of 6 30 2024\_us-gaap AwardTypeAxis\_nnvc StockWarrantsMember\_IL4t1Rr4r0uuRD4NlnK-rw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit\_Standard\_shares\_7d64PHaTs0Kad57-YP5iMQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html", "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "uniqueAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024\_us-gaap AwardTypeAxis\_nnvc StockWarrantsMember\_qRUTrn4GvkiI5ARIDWOZIO", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit\_Standard\_shares\_7d64PHaTs0Kad57-YP5iMQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html", "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "unique": true }, "R44": { "role": "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails", "longName": "99940902 - Disclosure - Common Stock Warrants - Additional Information (Details)", "shortName": "Common Stock Warrants - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024\_us-gaap VestingAxis\_nnvc June302025Member\_L11bN673WU-mLFjLldqVQ", "name": "nnvc:WarrantsExercisable", "unitRef": "Unit\_Standard\_shares\_7d64PHaTs0Kad57-YP5iMQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html", "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024\_us-gaap VestingAxis\_nnvc June302025Member\_L11bN673WU-mLFjLldqVQ", "name": "nnvc:WarrantsExercisable", "unitRef": "Unit\_Standard\_shares\_7d64PHaTs0Kad57-YP5iMQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html", "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "R45": { "role": "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails", "longName": "99941001 - Disclosure - Commitments and Contingencies - Employment Agreements (Details)", "shortName": "Commitments and Contingencies - Employment Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024\_srt CounterpartyNameAxis\_nnvc FounderChairmanAndPresidentMember\_It9iVdb930a-pkZ9pcvc8g", "name": "nnvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeAgreementTermOfExtension", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html", "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "uniqueAnchor": { "contextRef": "Duration 10 6 2023 To 10 6 2023\_srt TitleOfIndividualAxis\_nnvc FounderChairmanAndPresidentMember\_qKeuENI\_KEmAORf83LPFXA", "name": "nnvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeAgreementTermOfExtension", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html", "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "unique": true }, "R46": { "role": "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementsDetails", "longName": "99941002 - Disclosure - Commitments and Contingencies - License Agreements (Details)", "shortName": "Commitments and Contingencies - License Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As Of 3 27 2023\_srt CounterpartyNameAxis\_nnvc KarveerMeditechPvt.LtdMember\_us-gaap RelatedPartyTransactionsByRelatedPartyAxis\_us-gaap RelatedPartyMember\_1lxEV-eIwEqQdFHidjfuXA", "name": "nnvc:NumberOfClinicalTestDrugCandidatesGrantedForUseSaleOrOfferOfSaleInIndia", "unitRef": "Unit\_Standard\_item\_3rf5btHFkkOumxthj\_uUw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html", "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As Of 3 27 2023\_srt CounterpartyNameAxis\_nnvc KarveerMeditechPvt.LtdMember\_us-gaap RelatedPartyTransactionsByRelatedPartyAxis\_us-gaap RelatedPartyMember\_1lxEV-eIwEqQdFHidjfuXA", "name": "nnvc:NumberOfClinicalTestDrugCandidatesGrantedForUseSaleOrOfferOfSaleInIndia", "unitRef": "Unit\_Standard\_item\_3rf5btHFkkOumxthj\_uUw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html", "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "unique": true }, "R47": { "role": "http://www.nanoviricides.com/role/DisclosureSubsequentEventsDetails", "longName": "99941101 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024\_us-gaap SubsidiarySaleOfStockAxis\_nnvc AtmOfferingMember\_7akBig\_GAU2eZDS66DdRIA", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit\_Standard\_shares\_7d64PHaTs0Kad57-YP5iMQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html", "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "first": true, "uniqueAnchor": { "contextRef": "Duration 10 1 2024 To 11 7 2024\_us-gaap SubsequentEventTypeAxis\_us-gaap SubsequentEventMember\_us-gaap SubsidiarySaleOfStockAxis\_nnvc AtmOfferingMember\_jkIbJ6ZKTkCaHCuzCwmUwg", "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "unitRef": "Unit\_Standard\_USD\_IKVR-9n\_20CgSvi22ibAHw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "div", "body", "html", "reportCount": 1, "baseRef": "nnvc-20240930x10q.htm", "unique": true }, "tag": { "us-gaap:AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth\_ref": [ ] }, "nnvc:AccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "AccountingPoliciesLineItems", "presentation": [ "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWarrantsDetails", "lang": { "en-us": { "role": {

"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounting Policies [Line Items]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "auth\_ref": [ ] }, "nncv\_AccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "AccountingPoliciesTable", "presentation": [ "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWarrantsDetails" ] }, "lang": { "en-us": { "role": { "label": "Accounting Policies [Table]" } } } }, "auth\_ref": [ ] }, "us-gaap\_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.nanoviricides.com/role/DisclosureAccruedExpenses" ] }, "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } } }, "auth\_ref": [ "r22", "r25", "r29", "r710" ] }, "us-gaap\_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ] }, "lang": { "en-us": { "role": { "label": "Accounts Payable, Related Parties, Current", "terseLabel": "Accounts Payable - Related Party", "verboseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } } }, "auth\_ref": [ "r22", "r536" ] }, "nncv\_AccountsPayableOffsetByAdvance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "AccountsPayableOffsetByAdvance", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ] }, "lang": { "en-us": { "role": { "label": "Amount for accounts payable offset by advance.", "label": "Accounts Payable Offset By Advance", "terseLabel": "Accounts payable offset by advance" } } } }, "auth\_ref": [ ] }, "nncv\_AccruedClinicalTrialCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "AccruedClinicalTrialCosts", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ] }, "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through Clinical trials. Used to reflect the current portion of the liabilities (The amount has been recorded within accrued expenses in the accompanying balance sheet).", "label": "Accrued Clinical Trial Costs", "terseLabel": "Clinical trial Costs Accrued - Related Party" } } } }, "auth\_ref": [ ] }, "nncv\_AccruedClinicalTrialCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "AccruedClinicalTrialCostsCurrent", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureAccruedExpensesDetails" ] }, "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through Clinical trials. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Clinical Trial Costs, Current", "terseLabel": "Clinical trial costs due to KMPL" } } } }, "auth\_ref": [ ] }, "us-gaap\_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureAccruedExpensesDetails", "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ] }, "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "totalLabel": "Accrued expenses", "verboseLabel": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } } }, "auth\_ref": [ "r25" ] }, "us-gaap\_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureAccruedExpensesDetails" ] }, "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "verboseLabel": "Consultant", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } } }, "auth\_ref": [ "r25" ] }, "us-gaap\_AccruedRoyaltiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRoyaltiesCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ] }, "lang": { "en-us": { "role": { "label": "Accrued Royalties", "terseLabel": "Accrued royalties", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties." } } } }, "auth\_ref": [ "r59" ] }, "us-gaap\_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ] }, "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less Accumulated Depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } } }, "auth\_ref": [ "r13", "r81", "r389" ] }, "us-gaap\_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ] }, "lang": { "en-us": { "role": { "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Intangible assets with finite lives, licenses and patent costs useful lives", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } } }, "auth\_ref": [ "r192", "r503" ] }, "ecd\_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } } }, "auth\_ref": [ "r586" ] }, "us-gaap\_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ] }, "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "verboseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } } }, "auth\_ref": [ "r34", "r536", "r734" ] }, "us-gaap\_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.nanoviricides.com/role/StatementOfChangesInStockholdersEquity" ] }, "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } } }, "auth\_ref": [ "r415", "r655", "r656", "r657", "r658", "r711", "r736" ] }, "ecd\_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } } }, "auth\_ref": [ "r599" ] }, "ecd\_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation." } } } }, "auth\_ref": [ "r599" ] }, "ecd\_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } } }, "auth\_ref": [ "r599" ] }, "ecd\_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } } }, "auth\_ref": [ "r599" ] }, "us-gaap\_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentForAmortization", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ] }, "lang": { "en-us": { "role": { "label": "Amortization", "verboseLabel": "Amortization expense", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } } }, "auth\_ref": [ "r3" ] }, "us-gaap\_AdjustmentOfWarrantsGrantedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentOfWarrantsGrantedForServices", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfCashFlows" ] }, "lang": { "en-us": { "role": { "label": "Adjustment of Warrants Granted for Services", "terseLabel": "Warrants granted to Scientific Advisory Board", "documentation": "Adjustment for noncash service expenses paid for by granting of warrants." } } } }, "auth\_ref": [ "r3" ] }, "us-gaap\_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfCashFlows" ] }, "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net" } } } }

cash used in operating activities" } } ], "auth\_ref": [ ] }, "ecd\_AggtChngPnsnValInSummryCompstnTblForAplblyrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblyrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth\_ref": [ "r632" ] }, "ecd\_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth\_ref": [ "r558", "r568", "r578", "r610" ] }, "ecd\_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth\_ref": [ "r561", "r571", "r581", "r613" ] }, "ecd\_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth\_ref": [ "r633" ] }, "ecd\_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth\_ref": [ "r599" ] }, "ecd\_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth\_ref": [ "r606" ] }, "ecd\_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth\_ref": [ "r562", "r572", "r582", "r606", "r614", "r618", "r626" ] }, "ecd\_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth\_ref": [ "r624" ] }, "us-gaap\_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails", "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Allocated Share-based Compensation Expense", "verboseLabel": "Non-cash compensation expense recognized", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth\_ref": [ "r273", "r278" ] }, "dei\_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.nanoviricides.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth\_ref": [ ] }, "us-gaap\_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "terseLabel": "Amortization", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth\_ref": [ "r3", "r191", "r195", "r518" ] }, "us-gaap\_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially outstanding dilutive common shares", "verboseLabel": "Number of potentially dilutive common shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth\_ref": [ "r127" ] }, "us-gaap\_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth\_ref": [ "r10" ] }, "us-gaap\_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth\_ref": [ "r10" ] }, "us-gaap\_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth\_ref": [ "r290" ] }, "us-gaap\_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth\_ref": [ "r58", "r68", "r83", "r100", "r130", "r134", "r139", "r140", "r175", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r292", "r296", "r318", "r381", "r449", "r513", "r514", "r536", "r549", "r680", "r681", "r721" ] }, "us-gaap\_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "auth\_ref": [ ] }, "us-gaap\_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth\_ref": [ "r77", "r88", "r100", "r175", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r292", "r296", "r318", "r536", "r680", "r681", "r721" ] }, "us-gaap\_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "CURRENT ASSETS" } } }, "auth\_ref": [ ] }, "nnvc\_AtmOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "AtmOfferingMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureEquityTransactionsProceedsOfAtmOfferingDetails", "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails", "http://www.nanoviricides.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to ATM offering.", "label": "ATM Offering [Member]", "terseLabel": "ATM Offering" } } }, "auth\_ref": [ ] }, "ecd\_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth\_ref": [ "r621" ] }, "ecd\_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth\_ref": [ "r622" ] }, "ecd\_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth\_ref": [ "r617" ] }, "ecd\_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth\_ref": [ "r617" ] }, "ecd\_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth\_ref": [ "r617" ] }, "ecd\_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth\_ref": [ ] } }

"AwardTimingMNPIConsidered" } } } , "auth\_ref": [ "r617" ] } , "ecdAwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ] , "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } } , "auth\_ref": [ "r617" ] } , "ecdAwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ] , "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } } , "auth\_ref": [ "r617" ] } , "us-gaap\_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsCommonStockWarrantsDetails" ] , "lang": { "en-us": { "role": { "label": "Award Type", "terseLabel": "Award Type" } } } , "documentation": "Information by type of award under share-based payment arrangement." } } } , "auth\_ref": [ "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272" ] } , "ecdAwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ] , "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } } , "auth\_ref": [ "r620" ] } , "ecdAwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ] , "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } } , "auth\_ref": [ "r619" ] } , "ecdAwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ] , "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } } , "auth\_ref": [ "r618" ] } , "ecdAwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ] , "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } } , "auth\_ref": [ "r618" ] } , "us-gaap\_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ] , "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Presentation - Interim Financial Information", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } } , "auth\_ref": [ ] } , "us-gaap\_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails" ] , "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } } , "auth\_ref": [ "r9", "r79", "r504" ] } , "us-gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfCashFlows" ] , "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } , "auth\_ref": [ "r9", "r46", "r97" ] } , "us-gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfCashFlows" ] , "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "NET CHANGE IN CASH AND CASH EQUIVALENTS", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } , "auth\_ref": [ "r0", "r46" ] } , "us-gaap\_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfCashFlows" ] , "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "NON CASH FINANCING AND INVESTING ACTIVITIES" } } } , "auth\_ref": [ ] } , "ecd\_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] , "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } } , "auth\_ref": [ "r597" ] } , "srt\_ChiefFinancialOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefFinancialOfficerMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ] , "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]", "terseLabel": "Chief Financial Officer" } } } , "auth\_ref": [ "r666" ] } , "ecd\_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] , "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } } , "auth\_ref": [ "r594" ] } , "ecd\_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] , "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } } , "auth\_ref": [ "r592" ] } , "dei\_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ] , "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } } , "auth\_ref": [ ] } , "us-gaap\_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ] , "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } } , "auth\_ref": [ "r74", "r84", "r85", "r86", "r100", "r121", "r122", "r124", "r126", "r132", "r133", "r175", "r207", "r209", "r210", "r211", "r214", "r215", "r221", "r222", "r225", "r228", "r235", "r318", "r406", "r407", "r408", "r409", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r437", "r458", "r480", "r493", "r494", "r495", "r496", "r497", "r636", "r650", "r659" ] } , "us-gaap\_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsEstimatedFairValueOfWarrantsGrantedQuarterlyToScientificAdvisoryBoardDetails" ] , "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "terseLabel": "Equity Transactions", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth\_ref": [ "r84", "r85", "r86", "r132", "r221", "r222", "r223", "r225", "r228", "r233", "r235", "r406", "r407", "r408", "r409", "r521", "r636", "r650" ] } , "us-gaap\_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ] , "lang": { "en-us": { "role": { "label": "Class of

Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Exercise price (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } , "auth\_ref": [ "r236" ] } , "ecd\_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] , "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } } , "auth\_ref": [ "r598" ] } , "ecd\_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] , "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } } , "auth\_ref": [ "r598" ] } , "us-gaap\_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crd": "credit", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ] , "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "verboseLabel": "COMMITMENTS AND CONTINGENCIES", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } } , "auth\_ref": [ "r30", "r61", "r383", "r436" ] } , "us-gaap\_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } } , "auth\_ref": [ ] } , "us-gaap\_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingencies" ] , "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } } , "auth\_ref": [ "r53", "r200", "r201", "r499", "r675", "r677" ] } , "nncv\_CommitmentsAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "CommitmentsAndContingenciesLineItems", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails", "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementsDetails" ] , "lang": { "en-us": { "role": { "documentation": "The line item information about commitment and contingencies.", "label": "Commitments and Contingencies [Line Items]", "terseLabel": "Commitments and Contingencies" } } } , "auth\_ref": [ ] } , "nncv\_CommitmentsAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "CommitmentsAndContingenciesTable", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails", "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementsDetails" ] , "lang": { "en-us": { "role": { "documentation": "The disclosure information about commitment and contingencies.", "label": "Commitments and Contingencies [Table]" } } } , "auth\_ref": [ ] } , "us-gaap\_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.nanoviricides.com/role/StatementOfChangesInStockholdersEquity" ] , "lang": { "en-us": { "role": { "label": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } } , "auth\_ref": [ "r539", "r540", "r541", "r543", "r544", "r545", "r546", "r655", "r656", "r658", "r711", "r732", "r736" ] } , "us-gaap\_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheetsParenthetical" ] , "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } } , "auth\_ref": [ "r33" ] } , "us-gaap\_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheetsParenthetical" ] , "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } } , "auth\_ref": [ "r33", "r437" ] } , "us-gaap\_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheetsParenthetical" ] , "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } } , "auth\_ref": [ "r33" ] } , "us-gaap\_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheetsParenthetical" ] , "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock, shares, outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } } , "auth\_ref": [ "r5", "r33", "r437", "r455", "r736", "r737" ] } , "us-gaap\_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crd": "credit", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ] , "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, \$0.00001 par value; 150,000,000 shares authorized, 14,062,813 and 13,144,055 shares issued and outstanding, at September 30, 2024 and June 30, 2024, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } } , "auth\_ref": [ "r33", "r385", "r536" ] } , "ecd\_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] , "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } } , "auth\_ref": [ "r603" ] } , "ecd\_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] , "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } } , "auth\_ref": [ "r602" ] } , "ecd\_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] , "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } } , "auth\_ref": [ "r604" ] } , "ecd\_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] , "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } } , "auth\_ref": [ "r601" ] } , "nncv\_ConsultingServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "ConsultingServicesMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ] , "lang": { "en-us": { "role": { "documentation": "Represents information relating to consulting services.", "label": "Consulting services", "terseLabel": "Consulting services" } } } , "auth\_ref": [ ] } , "srt\_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails", "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementsDetails", "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails", "http://www.nanoviricides.com/role/DisclosureOrganizationAndNatureOfBusinessDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartiesDetails" ] , "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } } , "auth\_ref": [ "r103", "r104", "r216", "r223", "r336", "r357", "r380", "r506", "r508" ] } , "dei\_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document And Entity Information", "documentation": "Cover page." } } } , "auth\_ref": [ ] } , "nncv\_Covid19LicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "Covid19LicenseAgreementMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ] , "lang": { "en-us": { "role": { "documentation": "Represents the information relating to Covid 19 license agreement.", "label": "COVID 19 License Agreement" } } } , "auth\_ref": [ ] } , "us-gaap\_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ] , "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } } , "auth\_ref": [ "r206", "r678" ] } , "us-gaap\_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ] , "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } } , "auth\_ref": [ "r206", "r678", "r679" ] } , "dei\_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ ]

"http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth\_ref": [ ] }, "us-gaap\_DebtInstrumentConvertibleStockPriceTrigger": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleStockPriceTrigger", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Stock Price Trigger", "terseLabel": "Debt instrument, conversion stock, par value", "documentation": "Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective." } } }, "auth\_ref": [ ] }, "us-gaap\_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance", "terseLabel": "Number of shares granted", "documentation": "The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date." } } }, "auth\_ref": [ "r18" ] }, "us-gaap\_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails", "http://www.nanoviricides.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation expense", "verboseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth\_ref": [ "r3", "r12" ] }, "srt\_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Director", "terseLabel": "Director" } } }, "auth\_ref": [ "r666", "r733" ] }, "us-gaap\_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommonStockWarrants" ], "lang": { "en-us": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Common Stock Warrants", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth\_ref": [ "r243", "r246", "r274", "r275", "r277", "r523" ] }, "us-gaap\_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Common Stock Warrants" } } }, "auth\_ref": [ ] }, "dei\_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth\_ref": [ ] }, "dei\_DocumentFiscalYearFocus": { "xbrltype": "qYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth\_ref": [ ] }, "dei\_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth\_ref": [ ] }, "dei\_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as a quarterly report." } } }, "auth\_ref": [ "r553" ] }, "dei\_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth\_ref": [ "r585" ] }, "dei\_DocumentType": { "xbrltype": "submissionItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other.'" } } }, "auth\_ref": [ ] }, "nnvc\_Dr.AnilDiwanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "Dr.AnilDiwanMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent information pertaining to Dr. Anil Diwan member.", "label": "Dr. Anil Diwan", "terseLabel": "Dr. Anil Diwan" } } }, "auth\_ref": [ ] }, "ecd\_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth\_ref": [ "r596" ] }, "us-gaap\_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "verboseLabel": "Net loss per common share/Weighted average common shares outstanding" } } }, "auth\_ref": [ ] }, "us-gaap\_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per common share- basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth\_ref": [ "r94", "r110", "r111", "r112", "r113", "r114", "r115", "r119", "r121", "r124", "r125", "r126", "r129", "r286", "r289", "r307", "r308", "r377", "r396", "r509" ] }, "us-gaap\_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per common share- diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth\_ref": [ "r94", "r110", "r111", "r112", "r113", "r114", "r115", "r121", "r124", "r125", "r126", "r129", "r286", "r289", "r307", "r308", "r377", "r396", "r509" ] }, "us-gaap\_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss per Common Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth\_ref": [ "r10", "r11", "r128" ] }, "us-gaap\_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Personnel and compensation costs", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth\_ref": [ "r25" ] }, "us-gaap\_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Balance amount of non-cash compensation expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth\_ref": [ "r276" ] }, "us-gaap\_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth\_ref": [ ] }, "dei\_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1" }

"EntityAddressAddressLine1", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth\_ref": [ ] }, "dei\_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth\_ref": [ ] }, "dei\_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth\_ref": [ ] }, "dei\_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth\_ref": [ ] }, "dei\_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth\_ref": [ "r551" ] }, "dei\_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth\_ref": [ ] }, "dei\_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth\_ref": [ ] }, "dei\_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth\_ref": [ "r551" ] }, "dei\_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth\_ref": [ ] }, "dei\_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth\_ref": [ "r551" ] }, "dei\_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth\_ref": [ ] }, "dei\_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth\_ref": [ "r635" ] }, "dei\_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth\_ref": [ "r551" ] }, "dei\_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth\_ref": [ "r551" ] }, "dei\_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth\_ref": [ "r551" ] }, "dei\_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth\_ref": [ "r551" ] }, "ecd\_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "documentation": "Equity Awards Adjustments, Footnote" } } }, "auth\_ref": [ "r590" ] }, "ecd\_EqtyAwrdsAdjExclgValRprtInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "documentation": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth\_ref": [ "r631" ] }, "ecd\_EqtyAwrdsAdjMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "documentation": "Equity Awards Adjustments" } } }, "auth\_ref": [ "r631" ] }, "ecd\_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "documentation": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth\_ref": [ "r631" ] }, "us-gaap\_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth\_ref": [ "r5", "r75", "r91", "r92", "r93", "r105", "r106", "r107", "r109", "r114", "r116", "r118", "r131", "r176", "r177", "r199", "r237", "r281", "r282", "r283", "r284", "r285", "r287", "r288", "r289", "r298", "r299", "r300", "r301", "r302", "r303", "r306", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r327", "r329", "r394", "r399", "r400", "r401", "r415", "r480" ] }, "ecd\_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "documentation": "Equity Valuation Assumption Difference, Footnote" } } }, "auth\_ref": [ "r600" ] }, "ecd\_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "documentation": "Erroneous Compensation Analysis" } } }, "auth\_ref": [ "r558", "r568", "r578", "r610" ] }, "ecd\_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "documentation": "Erroneously Awarded Compensation Recovery" } } }, "auth\_ref": [ "r555", "r565", "r575", "r607" ] }, "ecd\_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "documentation": "Executive Category" } } }, "auth\_ref": [ "r606" ] }, "us-gaap\_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth\_ref": [ "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r528" ] }, "us-gaap\_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role":

{ "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth\_ref": [ "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r528" ] }, { "nvinc\_FinancialConditionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "FinancialConditionLineItems", "presentation": [ "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails" ] }, "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Financial Condition [Line Items]", "verboseLabel": "Liquidity and Going Concern" } } }, "auth\_ref": [ ] }, { "nvinc\_FinancialConditionTable": { "xbrltype": "stringItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "FinancialConditionTable", "presentation": [ "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails" ] }, "lang": { "en-us": { "role": { "label": "Financial Condition [Table]" } } }, "auth\_ref": [ ] }, { "us-gaap\_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWarrantsDetails" ] }, "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth\_ref": [ "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r218", "r233", "r304", "r317", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r395", "r517", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r537", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r667", "r668", "r669", "r670", "r712", "r713", "r714", "r715", "r716", "r717" ] }, { "us-gaap\_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsDetails" ] }, "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Less Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth\_ref": [ "r82", "r188", "r194", "r518" ] }, { "us-gaap\_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsDetails" ] }, "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Gross", "verboseLabel": "Intangible Assets", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth\_ref": [ "r188", "r194", "r376", "r518" ] }, { "us-gaap\_FiniteLivedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsDetails" ] }, "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Member]", "terseLabel": "Finite Lived Intangible Assets", "documentation": "Assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth\_ref": [ ] }, { "us-gaap\_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsDetails" ] }, "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth\_ref": [ "r375", "r673" ] }, { "us-gaap\_FixturesAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FixturesAndEquipmentGross", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ] }, "lang": { "en-us": { "role": { "label": "Fixtures and Equipment, Gross", "verboseLabel": "Lab Equipment", "documentation": "Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines." } } }, "auth\_ref": [ ] }, { "nvinc\_ForgivenessOfInterestOnRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "ForgivenessOfInterestOnRelatedPartyDebt", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfCashFlows" ] }, "lang": { "en-us": { "role": { "documentation": "Amount of forgiveness of interest on related party debt.", "label": "Forgiveness Of Interest On Related Party Debt", "terseLabel": "Forgiveness of interest on related party debt" } } }, "auth\_ref": [ ] }, { "ecd\_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth\_ref": [ "r562", "r572", "r582", "r614" ] }, { "ecd\_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth\_ref": [ "r562", "r572", "r582", "r614" ] }, { "ecd\_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth\_ref": [ "r562", "r572", "r582", "r614" ] }, { "ecd\_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth\_ref": [ "r562", "r572", "r582", "r614" ] }, { "ecd\_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth\_ref": [ "r562", "r572", "r582", "r614" ] }, { "nvinc\_FounderChairmanAndPresidentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "FounderChairmanAndPresidentMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails", "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAndAdditionalInformationDetails" ] }, "lang": { "en-us": { "role": { "documentation": "This member stands for the Company's founder, Chairman and President, Mr. Anil Diwan.", "label": "Founder, Chairman, President", "terseLabel": "Founder, Chairman and President" } } }, "auth\_ref": [ ] }, { "ecd\_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth\_ref": [ "r595" ] }, { "us-gaap\_FurnitureAndFixturesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesGross", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ] }, "lang": { "en-us": { "role": { "label": "Furniture and Fixtures, Gross", "verboseLabel": "Furniture and Fixtures", "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth\_ref": [ "r52" ] }, { "us-gaap\_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ] }, "lang": { "en-us": { "role": { "label": "Gain (Loss) on Extinguishment of Debt", "verboseLabel": "Gain on extinguishment", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth\_ref": [ "r3", "r14", "r15" ] }, { "us-gaap\_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfOperations" ] }, "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "verboseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth\_ref": [ "r41", "r460" ] }, { "us-gaap\_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Intangible Assets" } } }, "auth\_ref": [ ] }, { "us-gaap\_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusAxis", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ] }, "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth\_ref": [ "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272" ] }, { "us-gaap\_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusDomain", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ] }, "lang": { "en-us": { "role": { "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth\_ref": [ "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272" ] }, { "us-gaap\_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [





"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth\_ref": [ "r598" ] }, "nnvc\_MilestonePaymentAmountDue": { "xbrlType": "monetaryItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "MilestonePaymentAmountDue", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of milestone payment due.", "label": "Milestone Payment Amount Due", "terseLabel": "Milestone payment amount due" } } }, "auth\_ref": [ "r625" ] }, "srt\_MinimumMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Minimum", "terseLabel": "Minimum" } } }, "auth\_ref": [ "r202", "r203", "r204", "r205", "r242", "r279", "r309", "r373", "r397", "r398", "r404", "r427", "r428", "r488", "r489", "r490", "r491", "r492", "r500", "r501", "r516", "r521", "r522", "r529", "r530", "r534", "r538", "r682", "r723", "r724", "r725", "r726", "r727", "r728" ] }, "ecd\_MnpiDiscTimedForCompValFlag": { "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth\_ref": [ "r617" ] }, "ecd\_MtrTermsOfTrdArrTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth\_ref": [ "r625" ] }, "ecd\_NamedExecutiveOfficersFnTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth\_ref": [ "r599" ] }, "us-gaap\_NatureOfOperations": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": [ "http://www.nanoviricides.com/role/DisclosureOrganizationAndNatureOfBusiness" ], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "terseLabel": "Organization and Nature of Business", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth\_ref": [ "r69", "r73" ] }, "us-gaap\_NetCashProvidedByUsedInFinancingActivities": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth\_ref": [ "r96" ] }, "us-gaap\_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth\_ref": [ ] }, "us-gaap\_NetCashProvidedByUsedInInvestingActivities": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth\_ref": [ "r96" ] }, "us-gaap\_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth\_ref": [ ] }, "us-gaap\_NetCashProvidedByUsedInOperatingActivities": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [ "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Net cash used in operating activities", "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth\_ref": [ "r46", "r47", "r48" ] }, "us-gaap\_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth\_ref": [ ] }, "us-gaap\_NetIncomeLoss": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails" ], "lang": { "en-us": { "role": { "label": "Net Income Loss", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth\_ref": [ "r40", "r48", "r64", "r76", "r89", "r90", "r93", "r100", "r108", "r110", "r111", "r112", "r113", "r114", "r117", "r118", "r123", "r175", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r286", "r289", "r308", "r318", "r393", "r457", "r478", "r479", "r547", "r680" ] }, "us-gaap\_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth\_ref": [ ] }, "nnvc\_NonCashCompensationExpenses": { "xbrlType": "monetaryItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "NonCashCompensationExpenses", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of Non Cash Compensation Expenses.", "label": "Non Cash Compensation Expenses", "terseLabel": "Non-cash compensation expense" } } }, "auth\_ref": [ ] }, "ecd\_NonGaapMeasureDescriptionTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth\_ref": [ "r598" ] }, "ecd\_NonNeosMember": { "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth\_ref": [ "r562", "r572", "r582", "r606", "r614" ] }, "ecd\_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrlType": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth\_ref": [ "r589" ] }, "ecd\_NonPeoNeoAvgTotalCompAmt": { "xbrlType": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth\_ref": [ "r588" ] }, "ecd\_NonPeoNeoMember": { "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth\_ref": [ "r606" ] }, "ecd\_NonRule10b51ArrAdoptedFlag": { "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth\_ref": [ "r625" ] }, "ecd\_NonRule10b51ArrTrmtdFlag": { "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmtdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth\_ref": [ "r625" ] }, "us-gaap\_NonoperatingIncomeExpense": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Other expense, net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth\_ref": [ "r42" ] }, "us-gaap\_NonoperatingIncomeExpenseAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)" } } }, "auth\_ref": [ ] }

[Abstract]", "verboseLabel": "OTHER INCOME (EXPENSE)", "auth\_ref": [], "us-gaap NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonrelatedPartyMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails", "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Nonrelated Party [Member]", "terseLabel": "Nonrelated party", "documentation": "Party not related to reporting entity." } } }, "auth\_ref": [ "r653", "r654" ] }, "nncv\_NumberOfClinicalTestDrugCandidatesGrantedForUseSaleOrOfferOfSaleInIndia": { "xbrltype": "integerItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "NumberOfClinicalTestDrugCandidatesGrantedForUseSaleOrOfferOfSaleInIndia", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of clinical test drug candidates granted for the use, sale, or offer of sale in India.", "label": "Number of Clinical Test Drug Candidates Granted for the Use, Sale, or Offer of Sale in India", "terseLabel": "Number of clinical test drug candidates granted for the use, sale, or offer of sale in India" } } }, "auth\_ref": [], "nncv\_NumberOfCommonStockToBeIssuedUponConversionOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "NumberOfCommonStockToBeIssuedUponConversionOfWarrants", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of common stock to be issued upon exercise of warrants.", "label": "Number Of Common Stock To Be Issued Upon Conversion Of Warrants", "terseLabel": "Number of fully vested warrants granted to purchase shares of common stock" } } }, "auth\_ref": [], "us-gaap\_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.nanoviricides.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "terseLabel": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth\_ref": [ "r512", "r515", "r661" ] }, "nncv\_NumberOfSharesAuthorizedForLicenseMilestonePayment": { "xbrltype": "sharesItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "NumberOfSharesAuthorizedForLicenseMilestonePayment", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of shares authorized for license milestone payment.", "label": "Number of Shares Authorized for License Milestone Payment", "terseLabel": "Number of shares authorized for license milestone payment" } } }, "auth\_ref": [], "nncv\_OfficeEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "OfficeEquipmentGross", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Gross amount, at the balance sheet date, of office equipment.", "label": "Office Equipment Gross", "verboseLabel": "Office Equipment" } } }, "auth\_ref": [], "us-gaap\_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth\_ref": [], "us-gaap\_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "OPERATING EXPENSES" } } }, "auth\_ref": [], "us-gaap\_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "LOSS FROM OPERATIONS", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth\_ref": [ "r67", "r511", "r660", "r662", "r663", "r664", "r665" ] }, "nncv\_OrganizationAndNatureOfBusinessLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "OrganizationAndNatureOfBusinessLineItems", "presentation": [ "http://www.nanoviricides.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Organization and Nature of Business [Line Items]", "terseLabel": "Organization and Nature of Business" } } }, "auth\_ref": [], "nncv\_OrganizationAndNatureOfBusinessTable": { "xbrltype": "stringItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "OrganizationAndNatureOfBusinessTable", "presentation": [ "http://www.nanoviricides.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of organization and nature of business.", "label": "Organization and Nature of Business [Table]" } } }, "auth\_ref": [], "us-gaap\_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization and Nature of Business" } } }, "auth\_ref": [], "us-gaap\_OtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsAbstract", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets [Abstract]", "terseLabel": "OTHER ASSETS" } } }, "auth\_ref": [], "us-gaap\_OtherGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Other General and Administrative Expense", "verboseLabel": "Other general and administrative expense", "documentation": "Amount of general and administrative expense classified as other." } } }, "auth\_ref": [ "r41", "r735" ] }, "us-gaap\_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "verboseLabel": "Interest income", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth\_ref": [ "r44" ] }, "ecd\_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth\_ref": [ "r598" ] }, "ecd\_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth\_ref": [ "r560", "r570", "r580", "r612" ] }, "ecd\_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth\_ref": [ "r563", "r573", "r583", "r615" ] }, "ecd\_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth\_ref": [ "r563", "r573", "r583", "r615" ] }, "ecd\_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth\_ref": [ "r587" ] }, "us-gaap\_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accrued expenses" } } }, "auth\_ref": [], "us-gaap\_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsProceedsOfAtmOfferingDetails" ], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "terseLabel": "Less: offering costs and expenses", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth\_ref": [ "r8" ] }, "us-gaap\_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth\_ref": [ "r45" ] }, "ecd\_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth\_ref": [ "r597" ] }, "ecd\_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth\_ref": [ "r597" ] }, "ecd\_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth\_ref": [ "r589" ] }, "ecd\_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth\_ref": [ "r606" ]

}, "ecd\_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth\_ref": [ "r599" ] }, "ecd\_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth\_ref": [ "r588" ] }, "nnvc\_PercentageOfChangeOfControl": { "xbrltype": "percentItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "PercentageOfChangeOfControl", "presentation": [ "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent of percentage of change of control", "label": "Percentage Of Change Of Control", "terseLabel": "Percentage of change of control" } } }, "auth\_ref": [ ] }, "nnvc\_PercentageOfClinicalTrialsFees": { "xbrltype": "percentItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "PercentageOfClinicalTrialsFees", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of clinical trials manager fee.", "label": "Percentage of Clinical Trials Fees", "terseLabel": "Percentage of clinical trials fees" } } }, "auth\_ref": [ ] }, "nnvc\_PercentageOfDirectCosts": { "xbrltype": "percentItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "PercentageOfDirectCosts", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of direct costs.", "label": "Percentage of Direct Costs", "terseLabel": "Percentage of direct costs" } } }, "auth\_ref": [ ] }, "nnvc\_PercentageOfNetSalesAllocatedForRoyaltyPayments": { "xbrltype": "percentItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "PercentageOfNetSalesAllocatedForRoyaltyPayments", "presentation": [ "http://www.nanoviricides.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "Royalty expense calculated as a percentage of net sales.", "label": "Percentage of Net Sales Allocated for Royalty Payments", "terseLabel": "Percentage of net sales allocated for royalty payments (in percent)" } } }, "auth\_ref": [ ] }, "nnvc\_PercentageOfRoyaltiesOnSales": { "xbrltype": "percentItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "PercentageOfRoyaltiesOnSales", "presentation": [ "http://www.nanoviricides.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of royalties on sales.", "label": "Percentage of Royalties On Sales", "terseLabel": "Royalties on sales (in percent)" } } }, "auth\_ref": [ ] }, "nnvc\_PercentageOfRoyaltyFee": { "xbrltype": "percentItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "PercentageOfRoyaltyFee", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of royalty fee paid.", "label": "Percentage of Royalty Fee", "terseLabel": "Percentage of royalty fee" } } }, "auth\_ref": [ ] }, "ecd\_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth\_ref": [ "r590" ] }, "ecd\_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth\_ref": [ "r634" ] }, "ecd\_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth\_ref": [ "r589" ] }, "nnvc\_PreferredSharesIssuedAsCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "PreferredSharesIssuedAsCompensation", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of preferred shares issued as compensation by the entity during the period.", "label": "Preferred Shares Issued As Compensation", "verboseLabel": "Preferred shares issued as compensation" } } }, "auth\_ref": [ ] }, "us-gaap\_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth\_ref": [ "r32", "r221" ] }, "us-gaap\_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth\_ref": [ "r32", "r437" ] }, "us-gaap\_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth\_ref": [ "r32", "r221" ] }, "us-gaap\_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "verboseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth\_ref": [ "r32", "r437", "r455", "r736", "r737" ] }, "us-gaap\_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Series A convertible preferred stock, \$0.00001 par value, 10,000,000 shares designated, 903,216 and 892,625 shares issued and outstanding, at September 30, 2024 and June 30, 2024, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth\_ref": [ "r32", "r384", "r536" ] }, "us-gaap\_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current", "verboseLabel": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth\_ref": [ "r87", "r186", "r187", "r505" ] }, "us-gaap\_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsProceedsOfAtmOfferingDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Gross proceeds", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth\_ref": [ "r1" ] }, "nnvc\_ProceedsFromIssuanceOfCommonStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of common stock and warrants.", "label": "Proceeds from Issuance of Common Stock and Warrants", "verboseLabel": "Net proceeds from sale of common stock" } } }, "auth\_ref": [ ] }, "us-gaap\_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Net of issuance costs", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth\_ref": [ "r1", "r406" ] }, "us-gaap\_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Notes Payable, Related Parties, Current", "terseLabel": "Drew down amount", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth\_ref": [ "r7", "r651" ] }, "us-gaap\_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth\_ref": [ "r76", "r89", "r90", "r95", "r100", "r108", "r114", "r117", "r118", "r175", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r286", "r289", "r291", "r294", "r295", "r308", "r318", "r378", "r392", "r414", "r457", "r478", "r479", "r525", "r526", "r548", "r647", "r680" ] }, "us-gaap\_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract" }

"PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property and Equipment" } } }, "auth\_ref": [ ] }, "us-gaap\_PropertyPlantAndEquipmentAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAdditions", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Additions", "terseLabel": "Property and Equipment", "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth\_ref": [ ] }, "us-gaap\_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.nanoviricides.com/role/DisclosurePropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth\_ref": [ "r51", "r70", "r71", "r72" ] }, "us-gaap\_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "totalLabel": "Total Property and Equipment", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth\_ref": [ "r52", "r80", "r390" ] }, "us-gaap\_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails", "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth\_ref": [ "r4", "r328", "r379", "r390", "r536" ] }, "us-gaap\_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.nanoviricides.com/role/DisclosurePropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth\_ref": [ "r4" ] }, "ecd\_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth\_ref": [ "r587" ] }, "ecd\_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth\_ref": [ "r587" ] }, "srt\_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "auth\_ref": [ "r202", "r203", "r204", "r205", "r240", "r242", "r269", "r270", "r271", "r279", "r309", "r347", "r356", "r373", "r397", "r398", "r404", "r427", "r428", "r488", "r489", "r490", "r491", "r492", "r500", "r501", "r516", "r521", "r522", "r529", "r530", "r534", "r535", "r538", "r541", "r676", "r682", "r714", "r724", "r725", "r726", "r727", "r728" ] }, "srt\_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Range [Domain]" } } }, "auth\_ref": [ "r202", "r203", "r204", "r205", "r240", "r242", "r269", "r270", "r271", "r279", "r309", "r347", "r356", "r373", "r397", "r398", "r404", "r427", "r428", "r488", "r489", "r490", "r491", "r492", "r500", "r501", "r516", "r521", "r522", "r529", "r530", "r534", "r535", "r538", "r541", "r676", "r682", "r714", "r724", "r725", "r726", "r727", "r728" ] }, "ecd\_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth\_ref": [ "r555", "r565", "r575", "r607" ] }, "us-gaap\_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementsDetails", "http://www.nanoviricides.com/role/DisclosureEquityTransactionsEstimatedFairValueOfWarrantsGrantedQuarterlyToScientificAdvisoryBoardDetails", "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartiesDetails", "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Related Party [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth\_ref": [ "r144", "r241", "r333", "r334", "r382", "r388", "r430", "r431", "r432", "r433", "r434", "r454", "r456", "r487" ] }, "us-gaap\_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementsDetails", "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartiesDetails", "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "terseLabel": "Related party", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth\_ref": [ "r101", "r102", "r333", "r334", "r335", "r336", "r382", "r388", "r430", "r431", "r432", "r433", "r434", "r454", "r456", "r487" ] }, "nnvc\_RelatedPartyNonCurrentLiabilityConvertedToNotePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "RelatedPartyNonCurrentLiabilityConvertedToNotePayable", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "The amount of related party non-current liability converted to note payable relating to supplemental disclosure of cash flows information.", "label": "Related Party Non-current Liability Converted To Note Payable", "terseLabel": "Related party non-current liability converted to note payable" } } }, "auth\_ref": [ ] }, "us-gaap\_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth\_ref": [ "r333", "r334", "r720" ] }, "us-gaap\_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth\_ref": [ ] }, "us-gaap\_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth\_ref": [ "r144", "r461", "r462", "r465" ] }, "us-gaap\_RelatedPartyTransactionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionRate", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction, Rate", "verboseLabel": "Interest rate per annum (as a percent)", "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties." } } }, "auth\_ref": [ ] }, "us-gaap\_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "auth\_ref": [ ] }, "us-gaap\_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementsDetails", "http://www.nanoviricides.com/role/DisclosureEquityTransactionsEstimatedFairValueOfWarrantsGrantedQuarterlyToScientificAdvisoryBoardDetails", "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartiesDetails" ] }

"http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Related Party [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth\_ref": [ "r144", "r241", "r333", "r334", "r382", "r388", "r430", "r431", "r432", "r433", "r434", "r454", "r456", "r487", "r720" ] }, "us-gaap\_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactions" ] }, "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth\_ref": [ "r330", "r331", "r332", "r334", "r337", "r411", "r412", "r413", "r463", "r464", "r465", "r484", "r486" ] }, "srt\_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails", "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementsDetails", "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails", "http://www.nanoviricides.com/role/DisclosureOrganizationAndNatureOfBusinessDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartiesDetails" ] }, "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth\_ref": [ "r103", "r104", "r216", "r223", "r336", "r357", "r380", "r507", "r508" ] }, "us-gaap\_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.nanoviricides.com/role/StatementStatementsOfOperations" ] }, "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and Development Costs - Related Party", "verboseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth\_ref": [ "r280", "r503", "r513", "r729" ] }, "ecd\_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date" } } }, "auth\_ref": [ "r556", "r566", "r576", "r608" ] }, "ecd\_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth\_ref": [ "r557", "r567", "r577", "r609" ] }, "ecd\_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth\_ref": [ "r564", "r574", "r584", "r616" ] }, "us-gaap\_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails", "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ] }, "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "verboseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth\_ref": [ "r35", "r55", "r386", "r402", "r403", "r410", "r438", "r536" ] }, "us-gaap\_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity" ] }, "lang": { "en-us": { "role": { "label": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth\_ref": [ "r75", "r105", "r106", "r107", "r109", "r114", "r116", "r118", "r176", "r177", "r199", "r281", "r282", "r283", "r284", "r285", "r287", "r288", "r289", "r298", "r300", "r301", "r303", "r306", "r326", "r327", "r399", "r401", "r415", "r736" ] }, "us-gaap\_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails" ] }, "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Revenue", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth\_ref": [ "r65", "r66", "r130", "r135", "r136", "r138", "r140", "r141", "r142", "r143", "r238", "r239", "r374" ] }, "ecd\_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ] }, "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth\_ref": [ "r625" ] }, "ecd\_Rule10b51ArrTrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ] }, "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth\_ref": [ "r625" ] }, "nnvc\_SaleOfStockAggregateValueOfSharesIssuedInTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "SaleOfStockAggregateValueOfSharesIssuedInTransaction", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ] }, "lang": { "en-us": { "role": { "label": "Sale of Stock, Aggregate Value of Shares Issued in Transaction", "terseLabel": "Aggregate offering price" } } }, "auth\_ref": [ ] }, "nnvc\_SaleOfStockByEntityTypeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "SaleOfStockByEntityTypeLineItems", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureEquityTransactionsProceedsOfAtmOfferingDetails" ] }, "lang": { "en-us": { "role": { "documentation": "Disclosure of information about sale of stock made by the entity to investor outside consolidated group by type of sale.", "label": "Sale of Stock By Entity, Type [Line Items]", "terseLabel": "Equity Transactions" } } }, "auth\_ref": [ ] }, "nnvc\_SaleOfStockByEntityTypeTable": { "xbrltype": "stringItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "SaleOfStockByEntityTypeTable", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureEquityTransactionsProceedsOfAtmOfferingDetails" ] }, "lang": { "en-us": { "role": { "documentation": "Disclosure of information about sale of stock made by the entity to investor outside consolidated group by type of sale.", "label": "Sale of Stock By Entity, Type [Table]" } } }, "auth\_ref": [ ] }, "us-gaap\_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureSubsequentEventsDetails" ] }, "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth\_ref": [ ] }, "us-gaap\_SaleOfStockConsiderationReceivedPerTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedPerTransaction", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsProceedsOfAtmOfferingDetails" ] }, "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received Per Transaction", "terseLabel": "Net proceeds from issuance of common stock", "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor." } } }, "auth\_ref": [ ] }, "us-gaap\_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureEquityTransactionsProceedsOfAtmOfferingDetails", "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails", "http://www.nanoviricides.com/role/DisclosureSubsequentEventsDetails" ] }, "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth\_ref": [ ] }, "us-gaap\_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.nanoviricides.com/role/DisclosureAccruedExpensesTables" ] }, "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth\_ref": [ ] }, "us-gaap\_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTableTextBlock", "presentation": [ "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth\_ref": [ "r10" ] }, "us-gaap\_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of intangible assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth\_ref": [ "r518", "r672" ] }, "nnvc\_ScheduleOfProceedsFromSaleOfStockTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "ScheduleOfProceedsFromSaleOfStockTableTextBlock", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of proceeds from the sale of stock.", "label": "Schedule of Proceeds From Sale of Stock [Table Text Block]", "terseLabel": "Schedule of proceeds from sale of stock" } } }, "auth\_ref": [ ] }, "us-gaap\_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth\_ref": [ "r19", "r20", "r461", "r462", "r465" ] }, "us-gaap\_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Summary of related party", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth\_ref": [ ] }, "us-gaap\_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsCommonStockWarrantsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth\_ref": [ "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272" ] }, "us-gaap\_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of common stock warrants activity", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth\_ref": [ "r16" ] }, "us-gaap\_ScheduleOfStockholdersEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityTableTextBlock", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of estimation of estimated the fair value of the warrants granted", "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented." } } }, "auth\_ref": [ "r5" ] }, "nnvc\_ScheduleOfTrademarksAndPatentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "ScheduleOfTrademarksAndPatentsTable", "presentation": [ "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The disclosure information about trademark and patents.", "label": "Schedule Of Trademarks And Patents [Table" ] } } }, "auth\_ref": [ ] }, "nnvc\_ScientificAdvisoryBoardMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "ScientificAdvisoryBoardMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsEstimatedFairValueOfWarrantsGrantedQuarterlyToScientificAdvisoryBoardDetails" ], "lang": { "en-us": { "role": { "documentation": "Representing the information pertaining to scientific advisory board.", "label": "Scientific Advisory Board", "terseLabel": "Scientific Advisory Board" } } }, "auth\_ref": [ ] }, "dei\_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth\_ref": [ "r550" ] }, "dei\_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth\_ref": [ "r552" ] }, "nnvc\_SeriesAConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "SeriesAConvertiblePreferredStockMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets", "http://www.nanoviricides.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Represent information pertaining to Series A Preferred stock", "label": "Series A Convertible Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock", "verboseLabel": "Series A convertible preferred stock" } } }, "auth\_ref": [ ] }, "us-gaap\_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails", "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Series A Preferred stock [Member]", "terseLabel": "Series A Preferred stock", "verboseLabel": "Series A Preferred Stock", "documentation": "Series A preferred stock." } } }, "auth\_ref": [ "r645", "r646", "r683" ] }, "nnvc\_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationSharesIssued", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of series A preferred stock issued during period as employee stock compensation.", "label": "Series A Preferred Shares Issued During Period Employee Stock Compensation Shares Issued", "terseLabel": "Series A preferred stock issued for employee stock compensation (in shares)" } } }, "auth\_ref": [ ] }, "nnvc\_SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of preferred stock shares issued during period as employee stock compensation.", "label": "Series A Preferred Shares Issued During Period Employee Stock Compensation Value Issued", "terseLabel": "Series A preferred stock issued for employee stock compensation" } } }, "auth\_ref": [ ] }, "nnvc\_SeriesPreferredSharesIssuedDuringPeriodForLicenseAgreement": { "xbrltype": "sharesItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "SeriesPreferredSharesIssuedDuringPeriodForLicenseAgreement", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Shares issued during the period for license agreement.", "label": "Series Preferred Shares Issued During Period For License Agreement", "terseLabel": "Series A Preferred stock issued for license agreement (in shares)", "verboseLabel": "Shares issued for milestone payment" } } }, "auth\_ref": [ ] }, "nnvc\_ServiceAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "ServiceAgreements" }

"ServiceAgreements", "cdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "This fact represents service agreements.", "label": "Service Agreements", "terseLabel": "Service Agreements" } } }, "auth\_ref": [ ] }, "us-gaap\_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "cdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth\_ref": [ "r2" ] }, "nvc\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeAgreementTermOfExtension": { "xbrltype": "durationItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeAgreementTermOfExtension", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails", "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Estimated period of extension term of employee agreement for share based compensation arrangement by share based payment award, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Employee Agreement, Term of Extension", "terseLabel": "Employment agreement extension term (in years)" } } }, "auth\_ref": [ ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "terseLabel": "Number of shares in a quarterly installment to be vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth\_ref": [ "r263" ] }, "nvc\_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedToVestOutstandingNumber", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of expected to vest awards outstanding that can be converted into shares under arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expected to Vest, Outstanding, Number", "terseLabel": "Remaining balance of shares vest and service for non-cash compensation expense" } } }, "auth\_ref": [ ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsEstimatedFairValueOfWarrantsGrantedQuarterlyToScientificAdvisoryBoardDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected annual rate of quarterly dividends", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth\_ref": [ "r270" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsEstimatedFairValueOfWarrantsGrantedQuarterlyToScientificAdvisoryBoardDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth\_ref": [ "r269" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsEstimatedFairValueOfWarrantsGrantedQuarterlyToScientificAdvisoryBoardDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk-free rate(s)", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth\_ref": [ "r271" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Common Stock Warrants", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth\_ref": [ "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth\_ref": [ "r524" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Number of Shares, Expired (in shares)", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth\_ref": [ "r257" ] }, "nvc\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodIntrinsicValue", "cdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The intrinsic value of options expired during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period Intrinsic Value", "verboseLabel": "Aggregate Intrinsic Value, Expired (in dollars)" } } }, "auth\_ref": [ ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Number of Shares, Granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth\_ref": [ "r254" ] }, "nvc\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue", "cdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value", "verboseLabel": "Aggregate Intrinsic Value, Granted (in dollars)" } } }, "auth\_ref": [ ] }, "nvc\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options granted, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share based Compensation Arrangement By Share based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual life Term" } } } }

(years), Granted" } } }, "auth\_ref": [ ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "verboseLabel": "Aggregate Intrinsic Value, Outstanding and exercisable (in dollars)", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth\_ref": [ "r17" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Shares, Outstanding and exercisable (in shares)", "periodStartLabel": "Number of Shares, Outstanding and exercisable (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth\_ref": [ "r250", "r251" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price per share, Outstanding and exercisable (dollars per share)", "periodStartLabel": "Weighted Average Exercise Price per share, Outstanding and exercisable (dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth\_ref": [ "r250", "r251" ] }, "us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsCommonStockWarrantsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth\_ref": [ "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272" ] }, "us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price per share, Expired (dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth\_ref": [ "r257" ] }, "us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price per share, Granted (dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth\_ref": [ "r254" ] }, "us-gaap\_ShareBasedPaymentArrangementEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedPaymentArrangementEmployeeMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Employee [Member]", "terseLabel": "Employees", "documentation": "Recipient of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth\_ref": [ "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272" ] }, "us-gaap\_ShareBasedPaymentArrangementNonemployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedPaymentArrangementNonemployeeMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonemployee [Member]", "terseLabel": "Share-based payment arrangement, nonemployee", "documentation": "Recipient of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth\_ref": [ "r244", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsEstimatedFairValueOfWarrantsGrantedQuarterlyToScientificAdvisoryBoardDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected life (year)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth\_ref": [ "r268" ] }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted Average Remaining Contractual life Term (years), Outstanding and exercisable", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth\_ref": [ "r57" ] }, "us-gaap\_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails", "http://www.nanoviricides.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Average price", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth\_ref": [ ] }, "us-gaap\_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth\_ref": [ ] }, "us-gaap\_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth\_ref": [ "r49", "r98" ] }, "us-gaap\_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails", "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets", "http://www.nanoviricides.com/role/StatementCondensedBalanceSheetsParentetical" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth\_ref": [ "r74", "r84", "r85", "r86", "r100", "r121", "r122", "r124", "r126", "r132", "r133", "r175", "r207", "r209", "r210", "r211", "r214", "r215", "r221", "r222", "r225", "r228", "r235", "r318", "r406", "r407", "r408", "r409", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r437", "r458", "r480", "r493" ] }

"r494", "r495", "r496", "r497", "r636", "r650", "r659" ] }, "us-gaap\_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth\_ref": [ "r5", "r33", "r36", "r37", "r75", "r91", "r92", "r93", "r105", "r106", "r107", "r109", "r114", "r116", "r118", "r131", "r176", "r177", "r199", "r237", "r281", "r282", "r283", "r284", "r285", "r287", "r288", "r289", "r298", "r299", "r300", "r301", "r302", "r303", "r306", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r327", "r329", "r394", "r399", "r400", "r401", "r415", "r480" ] }, "us-gaap\_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets", "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth\_ref": [ "r105", "r106", "r107", "r131", "r327", "r374", "r405", "r426", "r429", "r430", "r431", "r432", "r433", "r434", "r437", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r459", "r460", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r480", "r542" ] }, "us-gaap\_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statements of Cash Flows" } } }, "auth\_ref": [ ] }, "us-gaap\_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Condensed Balance Sheets" } } }, "auth\_ref": [ ] }, "us-gaap\_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Changes in Stockholders' Equity" } } }, "auth\_ref": [ ] }, "us-gaap\_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsEstimatedFairValueOfWarrantsGrantedQuarterlyToScientificAdvisoryBoardDetails", "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets", "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity", "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth\_ref": [ "r105", "r106", "r107", "r131", "r327", "r374", "r405", "r426", "r429", "r430", "r431", "r432", "r433", "r434", "r437", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r459", "r460", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r480", "r542" ] }, "ecd\_StkPrCOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrCOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth\_ref": [ "r559", "r569", "r579", "r611" ] }, "us-gaap\_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth\_ref": [ ] }, "nnvc\_StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne": { "xbrltype": "sharesItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "StockIssuedDuringJulyShareIssuedForShareBasedCompensationConsultingAndLegalServiceOne", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a compensation for consulting and legal services.", "label": "Stock Issued During July Share Issued For Share Based Compensation Consulting And Legal Service One", "terseLabel": "Common stock issued for consulting and legal services rendered (in shares)" } } }, "auth\_ref": [ ] }, "nnvc\_StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period as a compensation for consulting and legal services.", "label": "Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One", "terseLabel": "Common stock issued for consulting and legal services rendered" } } }, "auth\_ref": [ ] }, "us-gaap\_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails", "http://www.nanoviricides.com/role/DisclosureSubsequentEventsDetails", "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Proceeds from sale of common stock in connection with equity financings net of issuance costs of \$53,875 (in shares)", "verboseLabel": "Issuance of shares", "documentation": "Number of new stock issued during the period." } } }, "auth\_ref": [ "r5", "r32", "r33", "r55", "r406", "r480", "r494" ] }, "nnvc\_StockIssuedDuringPeriodSharesNewIssuesPrincipleOfNoteConvertible": { "xbrltype": "sharesItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "StockIssuedDuringPeriodSharesNewIssuesPrincipleOfNoteConvertible", "presentation": [ "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during period shares new issues principle of note convertible.", "label": "Stock Issued During Period Shares New Issues Principle Of Note Convertible", "terseLabel": "Number of shares upon principle of note convertible" } } }, "auth\_ref": [ ] }, "us-gaap\_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Share-based Compensation, Gross", "terseLabel": "Shares granted", "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth\_ref": [ ] }, "us-gaap\_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Proceeds from sale of common stock in connection with equity financings net of issuance costs of \$53,875.", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth\_ref": [ "r5", "r32", "r33", "r55", "r415", "r480", "r494", "r548" ] }, "nnvc\_StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period as a compensation for consulting and legal services.", "label": "Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services", "terseLabel": "Warrants issued to Scientific Advisory Board" } } }, "auth\_ref": [ ] }, "nnvc\_StockIssuedForPaymentOfDirectorFeesShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "StockIssuedForPaymentOfDirectorFeesShares", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The amount represents the stock issued during the period for payment of director fees.", "label": "Stock Issued For Payment Of Director Fees Shares", "verboseLabel": "Common shares issued for Directors fees (in shares)" } } }, "auth\_ref": [ ] }, "nnvc\_StockIssuedForPaymentOfDirectorFeesValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "StockIssuedForPaymentOfDirectorFeesValue", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The amount represents the stock issued during the period for payment of director fees.", "label": "Stock Issued For Payment Of Director Fees Value", "terseLabel": "Common shares issued for Directors fees" } } }, "auth\_ref": [ ] }, "nnvc\_StockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "StockWarrantsMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommonStockWarrantsCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Stock Warrants.", "label": "Stock Warrants [Member]", "terseLabel": "Common Stock Warrants" } } }, "auth\_ref": [ ] }, "us-gaap\_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets", "http://www.nanoviricides.com/role/StatementStatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth\_ref": [ "r33", "r36", "r37", "r50", "r439", "r455", "r481", "r482", "r536", "r549", "r652", "r671", "r718", "r736" ] }, "us-gaap\_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract" }

"StockholdersEquityAbstract", "presentation": [ "http://www.nanoviricides.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS' EQUITY:" } } }, "auth\_ref": [ ] }, "us-gaap\_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Equity Transactions" } } }, "auth\_ref": [ ] }, "us-gaap\_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactions" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Equity Transactions", "documentation": "The entire disclosure for equity." } } }, "auth\_ref": [ "r54", "r99", "r220", "r222", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r234", "r237", "r305", "r483", "r485", "r498" ] }, "us-gaap\_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [ "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Reverse stock split", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth\_ref": [ "r56" ] }, "us-gaap\_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.nanoviricides.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Events", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth\_ref": [ "r325", "r339" ] }, "us-gaap\_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails", "http://www.nanoviricides.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent event", "terseLabel": "Subsequent event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth\_ref": [ "r325", "r339" ] }, "us-gaap\_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://www.nanoviricides.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth\_ref": [ "r325", "r339" ] }, "us-gaap\_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails", "http://www.nanoviricides.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth\_ref": [ "r325", "r339" ] }, "us-gaap\_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails", "http://www.nanoviricides.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth\_ref": [ "r325", "r339" ] }, "us-gaap\_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth\_ref": [ ] }, "us-gaap\_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.nanoviricides.com/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth\_ref": [ "r338", "r340" ] }, "us-gaap\_SubsequentSaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentSaleOfStockAxis", "presentation": [ "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails", "http://www.nanoviricides.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth\_ref": [ ] }, "ecd\_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth\_ref": [ "r605" ] }, "nncv\_TheracourPharmaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "TheracourPharmaIncMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureLiquidityAndGoingConcernDetails", "http://www.nanoviricides.com/role/DisclosureOrganizationAndNatureOfBusinessDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information relating to Theracour Pharma Inc.", "label": "Theracour Pharma Inc [Member]", "terseLabel": "Theracour Pharma Inc" } } }, "auth\_ref": [ ] }, "srt\_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails", "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth\_ref": [ "r666", "r719" ] }, "srt\_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.nanoviricides.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails", "http://www.nanoviricides.com/role/DisclosureEquityTransactionsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Relationship to Entity [Domain]" } } }, "auth\_ref": [ ] }, "ecd\_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth\_ref": [ "r597" ] }, "ecd\_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth\_ref": [ "r604" ] }, "nncv\_TrademarkAndPatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "TrademarkAndPatentsMember", "presentation": [ "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Representing the member information pertaining to trademark and patents.", "label": "Trademark and Patents [Member]", "terseLabel": "Trademark and patents" } } }, "auth\_ref": [ ] }, "nncv\_TrademarksAndPatentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.nanoviricides.com/20240930", "localname": "TrademarksAndPatentsLineItems", "presentation": [ "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.nanoviricides.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Trademarks and Patents [Line Items]", "verboseLabel": "Intangible Assets" } } }, "auth\_ref": [ ] }, "ecd\_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement" } } }, "auth\_ref": [ "r624" ] }, "ecd\_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth\_ref": [ "r626" ] }, "dei\_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.nanoviricides.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth\_ref": [ ] }, "us-gaap\_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.nanoviricides.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth\_ref": [ "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164",































{ "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } ZIP 67 0001410578-24-001991-xbrl.zip M4\$L#!#0 (, ^#;ED.!WYJ^>?EBI^U;R(A\*5\*!0 MMOK7WP(@)5(D)\*2\$Z;%ULB%@LL? HO%+@NWO T,O?DCL. ^U> T6HCX M2C2W2K>L6D :IUTX=#/ ^G^ WVJQ?>?I! ;<& ^YC&!7/L,Q0P!18L% MIM\$188QZKI@U)T2A]JISKM.KS.XO>WV!7C.G.H\$.A.3OJL. (RXA=X^A M?K;?LJZAVI06 />L=G1Z?HX3XF0(>3;B5^H6I9R9D3E& K,I\$1\_QG/!% M=LAY;R:\$XJS;?Y7^IOC8#Y:448>ZA>><8\*Z8I0;ZKY^H^M^D9M)-B^S^=@4N/3ZW= OIQY5%v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

[Z<4 M6P]1.(1K"4+VUV+V&# MFE4@H!>F):[Z:15N;>?R]!DP<":8"++H5;E> MJ94<3%WF\$?IZ511+OWO>+OW+VWZY +5< NOZI=

[OF#1>8BH=EV,DL]>[3\$EP MGMEFA#CS#7-@!"YYL1I08Y3KU7!5\*4\*0IE!&#JZ1@#..J&R1J4>?]&#

MU#%ZX=3KU7JKVJ@U6LJ91:UYT3AU'KJ'@M -I D2@:\$ GVA?KS '1T 2<7% M5)"KTD\*\*T46U^O:V5GEK5AA A>:U>O6O; =/[ /49E0(1%U<N-

F0J0)FHOC.X22RNOB49 M@DL\_DU\_9S/ZNUVNOQ!<6 KRB~<1114B740J3H/L:HSJKV!J&#=#@8LSQ V2>5OG>H=[M?>D%)H'/=H;!

[COIWIU@R4B03'D M.IG?=(S3HY =7LE+@#M'0(?:#KQ6VVR=>5R7CFV.WOVIO+&E.IVRHL!"VO"V M8X#1QIDJ KOD-

#2:U4BB\*!:#89@=R@3Z5BG7:&V%9M HXL"=QS, =4KX>#S MVZKVF:4R700'.E7YNPF=R<@X\*G\$.(7-KQ"1QIM)NGZCIN59SRLY<'WR>JW0B MG4IA

4\$A5(PP=VFOO WTC\*~L,U3E( \$ZAN+!BM'HW#V4<6!%/&5\_."1#OT87 M?LSZOZPTO'XN'K%#ZL'4JYA@P\_U5J-971B<M')%\_7S8?

(C=6'P7O9C'NYC+W+3EC 4-PD;H'DK;R"O M OE^LU2U'@(@X#ZIO:"0K4:-F17<3YR.LT3!&O(6IK!VGF#W3NCE, M^A^X'B\$2Q9/>15-

DEG->LJ'9'2:PKKH:R.OO59@KRRXPGS'7%OYY7C MV61UA9T1(3N86\_&L:~S=N8~W'HF!F!&#MENIB;Z)K1OMQ'OS6-> MOE:Q^F#YI=0-

QFK;Z'MCWAL) @USDUM9WC!&3+7N80"2HA01\$BP@%)D M<\_>L "L%"HLY?L'B GBIS, >UQ=%UPFI \$CUID!@LS4 \_GP\_1BWT0H6D<;

MDZ:5MX.[@GRDKP\*%X;23S!>>8>#>D>0#?/3!\$>B9-P=DW UK-^GII!~C; M)D(8:K&+5A^\*1C":X8S:ZL@1=(O@IRD+J<-

[F7KLLN&OT5J5L6.A#AL>": C5>V5Y65Z5=GG61#U0\_SUK;JR= M-2U4.LOW-CJEWVN\$?>R1\$S^Z)U3W-E>\_V06<4W\_D.(K7+J'1T#1I&V<\_DU

MJIDZ1E9RSVB\*Q>U4<@2112CBISV@07QG'V5P#J8MJJC\$G.L='VW^IH1V=/

MY7IYHV'K10O@7&LQE89;J'9U!L:&#&V'XXP\*CF+41&YO!P\*2VYV[ ^SVYO#SHGT\_N]Q<;P!50069?UEXU-F!F2 MRQA:@+U4R=T4Q=9'

9Q0>5Y>3\_1R=H6 \*0\$9U&4'LSI-V!P46JTN<&3W# MPGPI'R'V=921C'Y25N#K%5HW SJ'Z8 /\_ / (61(\*!%2N6?2\_P3GM#H.>C:>5LKR8=3M'G!?

9>NKE2E B158+);/BHL7E'PG)\P) MAR'16DFT&(\~@KRJ"G 79SA#A L4WT'C'+7\$5TV5\*~@Z\*\*TDER# M9LL83UJ-

YLDPO+D5?M6;O.WP\_/B#7\_1MQCB'UW3>E3+&N/B QU M#B0CB-BIWYPKIVHWG!O:GK81V.T715'!5 :< A31H?>51LX03IBI5O M(ACEZ2-

#6DB1TYM+M2(P)./&#=#:W1OQ'7M0B7YVA\_WU'MJ=#=UZLQ&1\X'N' C.M.#BU6- 96URUORNFYD/I/9D'<N6 >>5BT(I X MQ19A02W+OCD%WOS5-

M\$NO!O)=5L#I4P\*ZX ?55L;%EO\_L%1Q\$ Q@AT1FE MOD-WA"+J;G'BD\*+ CM'PIJ3!U&/I>CL\$V.=BI(7%.(N-M<3C\*%XGMM?I=;O/V

M=H3C@A:A.VZ!>I@\_V%39H'2C\$<@X6R2\_5 V1I:U2&8= M%WRU>@'VCMI=">7Q@KLB\*\$=.9ERLKF=(\QKXCZBK8F8W+XXT\*;YIMVHGM;I3

M=A:WA#1B0OZBGC/7K\*IRHENKFI014/C/A?X9&? O6R8MU'K05\*%MTI[466#QO

MM1C@A\|!#OL19+;P\$43QZ14+ >FLP.53)APO/\*:AHJ#;Y1+!#KCIJD7SE6>6 MR0T^IO1L \$FDW7' :F15YJ;10:PCI>C(KJ.RB5= #DJWH&J=

[X]@5MR MW\_/OJR\_2OCI&RG2PIK4IT=@XN+.%\*F5.R(^BF&T;Z:U~^42/4\*;^K=D:GZ\_ME)D7M?'Q.EF6.VK!HIM-IW\*:.679I#RK#VZ;DMA-

6D4&@/BV#1/Q\_P7.\*> MKB1Q\$SJ=F5+[%ZYW!+HEOB<3M3.RIJ+1E>#.#\$IYWEI!DITSLY09T4'>?GN MA1O@LF\_ZF0\$CL:~!+R+VZQ1=

(3.%T&~!O=I>:DIA^&#;FL\_7\$\*E^<33 K\_QOL@O:##&JIMO:X2A@ISBNXCI[6YN.SMZ92X?R0ZY&::/23J15Q&IGNI' M0H2H6W#ERIK&GU'<C<

I+>9HMAQYXQD\*HIY+D1\_AK\_>\*HVG0BIQ=?/2 OCUL'FNTF\*~OIR&>

MS7W>J0AM2M'XVT\$00+^B'7%?9Z?"/\_D9\_Y=R8+D@C@H819QKGC=0E41J!D:A?604/9MRF'L.OX M36)OW :P6RDI&C&Y\_!9^

M)6S.8J!(AILAIBT5AM0^/9S\*~&?>13P/V IE.S=U!E1Q!#BVIS!@=(A M^L2^W&\$71O#J6:~@U@1 N8%'Y3.W.KAW )A@3.A-&WHFM W;S-

@#(OD" MB WBT>\*)Z2IT7,Y3N,23(V MA-2W<8@":8="5B%>A.PU=H\$/\_MH&(9HVY%# M61L\$:"WT\_&I-V!"LD);FUL+8JC:"

Q1W%B(N2%#H \$PFHW&8T39:-VT(2- MP!#51CA&1^:KAU;W/WAF\*WULAG5\_ | R/OOF(U:B/J+)\_+OC.VL%LNB1 MX)#0Q3EQJ-

>TX)IERH:@+AL1I(0V.XY?M%V%Q#2!B;@#(JMR\*+5@!B.H MVH>K98UL,OCY\$ 5=7K&:R0\_&DXH\$K0!DRC3F/ !'+>7YVW\$ JZL;L!&:>

M0\_1GS/BX>MD>MK\*VJM \$IOF^>JRP)9'/OF8N\_CB,R&SXAL+G.PZYOC) :%

MZVP;R9D7D!(F1/3OAIQ>@AQO'D\$WFZL.KMXB9'E W7070%#QM-SBIT(1U M7GN837BV;WO 7HLYUS'W"W^4?G:MN>?\*

9O:APD\_02DDI\_95~\N.J.EPAE;=2U6SENQWNT9G3>JIL\_HL.E&IJD5IUCIEEF M(#C R< 4 %H%\_ART>UC+G=LMAC[>:M>P3M1'B Z&HLU!#&

MO8?)SVRG<I^&S)@^Q6E 7T'ILITA>>IGMIW5G9IYS0XIJF2F5Q&ICG/I||>> MI.I>1'H&5<8AJXK.DIW#06L..%L= \_KMX/B@1R1B;PIX=K

NL&S.Y112\_~SA M\_BL3Z'TPU&P^NT.K7< 8 I4? :T(C'V'DX#\_S&HTL!\_E;.)JHOBS,Z^E= MJ

E\_IM=\$I2>U.W.YIP50TX!+^GZ<X%#DU4T1.58CZ9'UM>LJXF^M&M&G1.E9I

M3Z2G9\$U\$A9L/UF#'#D6(=LO3AK;8790N\*M0'MIAHTDZ^3#\_UNRWE'5YHX:. MQ@HFOQ1TS%\$39&L4^4;LXUJFY9TXG(M\$ -

^8E&6;-8E4AJ6ALIK^X!5<?Y MYXO@XDU5R^8BJY\*08ASKI' M^O>?0\$S F>\_YDWP'B&K&E\*N.9L'GO M/U@IT81H'HO\_Q'J51!\*\$@NXA&#;&(?

\$9L1'1^8-M.1F.)B^\$38R.4YV MB3:J3B78-7VNF&9O9!6I9COKO1.>=LEH.6.W5(HYSALJ161L\_~6\*W+ET4 M.&PAJUN3R6C6UW~FJY0I(W^&#

(YI[X>8- 8W2)OI=BP:~\$SBN563H C^~ B>6S\$1 M:#ARTX"4"@8N^=A21J2P9M \*R11'S/M^#^2:L@KJZN+L.D?MA0EZ.L(03 MQV- K/3\_ OAYBR:?

Q5\$6'J'H/B:1?&L?VW=VZ0Q^094BG:=O8^V3.YE32) MEOM'!\$2QIK&3+2)2I=1|XCR/OC>!AU^P%SN^O^BT-)E264YC'70.)J\*B8F?

MFTSO\_(E+)=F:17RLM+V!F02+\*M)/^\*+VU^2\_2K~@%I\_!%;%#KYYOJP\*M. MFI(N1)J2\*W/YI<^>27S>J7>Q2JV"+03BN0+

(HL.W^\_DH+=9W.)KHD ML42'F4"1) WICR)P+D3XO!0-AFGKXSSZ.A^=OO#Z3P.4^@O//11VRI MF779-MX.B.ZML'O2F7P5G; (5Z&\_X/T\*\$A-

AZY=4^U\$'5QB.XI=I^E!|B'!F!5ALM MD8N-E'(CPC:~V%17A:L^@LV:+QDBIT43@;~1Z;..SAM X1MSZA@\_P'-8I;O

M=SB#9%#F61X.R.IPX#6H55@TM'~E'K+P+SGX2-M00JQXHV)I&UAV\$66E-8-M-X%+9NC>4MJKO04^42D=%! \*4U+R3 ]-MXB4:(;B)37V

JNT.36AW0MLX8: CR6G&N8E15)'E'K@0IW\_V+912%TYXT2VDV6? M4J5\$UE6H1H#M?J&8\_52^9(2IO/FF^ 6RMD\_L-A3P/L.3)%12K(4OIGB6

MVICT6Y%O^Q8F\$RW1YZWKUQQ;EYKQ2!9EQAM+YU(N2!9\_Y9?D^R^V>1<:F6\* MK^OK@MO;1E%0%A=\$V\$O?9GKD) LBO^5F^O^O^NF5#X

MBB&Q(A+YR;.#Z3GB/+>6.@KD-EO^RUEJ1F2V!TI%PVEU)KI05C=O# MS9#%B0TI08X%&-\*6>0!A.^3QB-<|L^F2=1Y/Y5N0T-

KI>;HO\$WSI2NFR)3104&GR\_VIHIOAM#ICE2N(5\$&9MWQEV;FTH/I(5E29-@ITRE

M#4'J5T!OGW&8%/U3>@=1LV^TM)P/IIG.C9&M6IVR2JE6UMZJU\$4)5VH MZ4B\*:(U\$HM;HUHZ(T98"QN<\*NV(\$T!\_9"Z2BX0.WO386%P)TA-

NOGH+Z.U MB33W=D7MFQO%3/H+ FVWMMRQIOMH<3<E18WJD>ZDK+C5L,EFXSM >3=IY 03 M\_NAKDC@?/?'=^2>ARJUUI9\*K5W#.2\*2R8HIY?

EIS+=ELI&7MOJ\$364#(-O' M9^WE&E;WQJG.L.O^NDM'2:1?J+1D60)5\*4D\_!(>Y\*>2\_)?K\_OZH\$8PBHD M8954U:U:51\$DN^6A:1L4Q/DGK\$

%Q:D0WMPVQZ\_BDH&.Y1A\$&C-ZOQR; MCXJ!X)DMZOK%+2XJ41\*6@V1D' H6Q+D@M+5\QO.YCQ\$5 H8C8IK\*6S2U

M\*ML:868.EUOLVJ;REL);\_ \$N&Y(\$VKMAZ7K5Y \*:=V'9!"AN3+!;Q8:~\_V!>-M#.5\$U; # MFI2UA)8'9HUKNYUJUL\*Q2B55HQYX.C-

Z2VU14UW9J>J|FXGH@IVJB:=\IX MI#8UK6R\_!7!IY(C;TNO=F/I12)?<5D2\*:#6"34/FH<4 MNA#X0>7S(X\$G.5IU!>34\$1V"? .IX3N.AOBMC\$4-

PZ015!19ANG@OXONGVW\_8D' M1BK\_2YWHR Z+Z3T2D10!O09X!WNOZJ!7'69W2X!AY4Y;U9KG8QU9S^\*M.W>KC3P^A^B6^A+

=^>>#I0=0^&K#\*JP>#) V%4%\_OT^N73Y\_IQYR^U^ MG WZ\_<|=Z"2;.E15BA3-GI2!^0^ (LJOT'E#2.EPEC:BUX7.O+@2\*J&QVE4Z=>MU/I?

TZXM56"146|EWR..R:~9UBA M\*1'SS08\*0\$19!>#\_ FD2S.S3M):D6\*TI;LW5+VIG2F!S\$R;P92RC^8CJ.5 MOHRP2DK9A4SR~7EPO1>HNN?

\$Z12!\$ ZU7>A.CI=A#1N/M?>+!S'Z:XEFA>6;6 MBO!TIC/KJ#\_&#I^U@D;Q=JMHK&LXN8K9<#R(C16\_0 I@\_Y:~SJ8\$~WN\$HXL0 MIV

X\_A5R=?^D.T@RG.-@ (FXWJ\_~W9F7!\$A;H5!O1DD./ICFJZY@IVK M-YIX&J4(%?I2T (8SHSUHX 1Q%) "8#6K?R/IU2\_FNLPY&IA(X'5)W!UT1

M\_+U'WOUTS'.IH9SVT@K&79!E0R!77W%QJ\_0DEE1\_U(URTS^T-HJFB!JM MD^647>1D4%6Z05+1A'SX@&L>N#DDF#HT5B0D?7E5

M.U11#\*IRT@2%X.VSX#ZWDHY&@AB88W1CG (1E'70&'DY\*4Z=&#V\*8J14 M.HYCF%5B6Q>\*&<90%!"5<#QF.QQE=>LOB,BMB@\*7<:OR\*NI\*

.LB52<7+38X M2JN<@\_~5MM&9:NO9BO&NF<IE\* N'.EJ1HH'C#M/25'JBTRR\_~;J1&M M' &#%H>AY.6IQWLW007SAQ^CLK1J\*0&.(15TXD2"1S5"\*

(H4=>1F046U#& MLUBS;EPR;M8=8% 3M>~RF.L~0<2WB-A1 MJ'DOCAA@JOY\_>KXVM@IPS=O4Q1A=S5) =T^!VAXIZSW;X4V\_N\_!DI8 DI8

M\_DXB8#1\_9TP\$G^<= \_00F\*K).V\$9M/V=L+ W\_G;I!0#CD@/BP;#ETH@\* M)IP;F0O&QOYUM2%07AY3/1!&@C.AJC(L6\_O);1E+VWUJKY-

7:9B\$0'J' M^MH\$ EM/XBG\*\*CK\*\*@#8K;73P8"MFY<<11&3L1%#2LHJ? \*A.NGK18"2."H M^N=>KSA7&97L4F62ME&9\$1J0.C"1U93'3)3&Y-

L5JZH9E=M&K+4=B=O:8TGK M6U70-OZTPLKQ4%FMW61M\$C.'GOIP\_@:~NWTI 4X=IG7< GK:6WW7J!Y8Q MVNPPS^CH

[M]216C8AO@#IU5!21D C=91 14#5Y\*424X.P/5IK P5AOU MW/XX3JF=>8DUW.J8\*7;.H:F.O\*39:N#;1!..F\$>B4ON.J;N7NVX")= \_L

MO8HOE+J'R\_!15RD' UYB<5U\_Y&9TY6C.%U\$&\$#K9E6FV3O>BK0?/7@#^&APQ= 913H1;J1W^UPFI(9P3>@M

M=GDL\_3\*;S1;ZEM&\_I1P:X2MZW)4OG/V%\_DOA&U.JIW+S)79 @C^U^IWL8 M+~HXOAIZ)1L'Y.TV9#X(ABVP10Q3@\$HUT8Q\_8-

=>J%F16.K9'WIEU>V MZCS+@IDUWD-G-E' +142 |~@?%WRRZ2(9+3)+ZKA&#?3=YZ18ME/U7). M500\$0'V)=742U:X474E=5103'#W\*HIO )3-

T2!\*5N\_-IE.U;.656F@\_MOE#6)0ZYSZE:5OG3H# \$E.I?^#BY/CDJZ MAU5>R/2L!\_J222\_1BMKIO=O:4-M73!6#!4E7&4A617\*~!E0AKEN@OI

M:155V\+\_WBZ.T3G\_/T2\_NRT) !+368IYJR'G@G4N-I?L JD?X#FL?4G3JY M[>LZ9!\*8GXIE[49DE9E9I!~@-ZGHO^A3&?)X^\_AQZL%;CRI:~&#-IS1% M

3:~9TF3.FL2^&EIK48DU7!D)9K-C6D'F1=,@\_0&4J3(2B1V.C.2;F%:M-L16MJ\$\$(F1F-O1\_QLD!)('HWA.N.M.NLC4%+(9\_U~N":ZV=ZCW;

(7\$6G(F.MCF%F7AT!0.25&#Y\*01D(7C1XMTKR;M>10KLAUBIV&C.N>CQ>28O(3WEQE5)NM^K&N\$2P2IWIYNL#=@%57V=2

M1@CC^FIU2U1'L1UBTT4AR13P?IP:GU:~CO!ORB@9DS0\*NJK<-NA3IA1-.IREYP1RSA< 6/^"49L>@J( M^UUL!\_B'F53Z!6X MMA-M659@P-CD8?

\$)L@8W3-8//7JOES^I C:'H1A0&S M&K,T(YNIOA)^+V^ )>5..BS5JLIC7I-Y 60.C&5\$^&3/DK/!^H4+VP7 MSI\_~KNE=#\_8UCYE%;68BZ3.@HU1

5'A:EW+O6\*E18S'021QT%WN\$(G;V M>1)@>\_AL^&+V(J9T.L;1)!(%~"IU5&# 4HK:~\_@Y6RF5\$!>QL.FKJ1H\$ MCGK80LA^R OY9.GO.O-G:D?

C7/I8Y?QE"YT>=1:-7/N]0\_IC -&S)DXI%(N>J!&L;N^VT\*27E?24G;I3"YM."; M(OHS)=~?2ZF8HMYA\*Q)?(Y5\$K\$Y;

(CYDC'CK6U2Z18MA&8TES(9^4 M?I?>.#2:!(S @1(CSNND62A!8S%OHGCB\$O!\$@OFHL&2^4E%8M6FTGE<& RP M1@\_@Z^&-GI?7^1KB-HI<-

V:NC86D?O%P:SL^P@#1\*LA14\_07GP\$7WJER' MVY\*!;?C;PC4?LTN/G- MDZ9=V%L/W6Y4^3% (ZX6<(>F2MDR[KV>13R-45&#P/CEF

M@\_Q18FHW43&=Z)GU=F1>:SQ"J(BJX^NM-8;MXV\$#8\_!XMIGT> M(I)XW!%6!&:5"~2N\$F18%E6355O@DTDI2P&JZNC=@C.MKIV^YLUZ3Y\$

MC?NJJ!%~!^!>5D.#3DI8VA0A=MT&OX.R:~;U9!&8&(C.;2 %Q1^H@AQ00 M-P25CTO>F?\*"Y\$U1E|X|%FAC>P20.-

@9B8&M<1Y.FJ2:TU/G@GQ5RI\_Y4%5\_~:9@LJ(I3^ \$SC.T92D#ZT?O9I^0PMI=J.U+^1F'J'=;~ZI<1FWWJ5P+C.E'Z6%FSU5?W?I=%H<\_9XA1

M)36EIZEF%08(UWPQ!SFZOR!SFZOR!M@CJ(C5) 0 S6TT?>Z>2A!V!O!YX\$ MH\_X

X&#6.SX^F>I@JIR>Y32Y.=I1I1?I@.3W'.@4SY\_(51"1"O^U;K#O.M.M5.HE)9;C>O^Z^@\_D Q 36ECEZ6%N8N"IIAV&\_4OZ@3JV4I&9=F!6M/Z

MEM.3#1+T^ WM^WGE2TOSRAH.P\*7&O7&5\_LIF@WK\*COKM&R!#B.#XJ MUXZVY1D1^VW>G?

N=P&~^V\_AZN02)2TR1+U0V4/&G(K48D+L.B+7@X&31W(4 M31"1%06(OXP;I=C\$DWC^C'PTR>OR^\_N2.CV5E>A2+8K3Q4K1+I2G< MZ357#

@.NA-G(L+1HE=OW^BXE?700!0JRE\$A2^ISI2 6G;?'Q0S1)OD MF!\_&T90UIY<84-/(C>^8#01'5 ZLLKT4>6+A5UUI'BZN"\$P^HI O.4U9

MSI\$Y+@G(JN?/@&84193AQ!)\_RV>U2VFX"5X2#W7GC^=>?562W#IV21 M;YO.E5@\_A2L,K0&WK=KU 2#)&792Q>@&N).%=\_Z\$.#Z1A4(KJ@>

U8S0^8 ME.A440UX+8Q M3X IPNFSTVZU!UT%OV:~?T9\* @QN76>G MJFS D=&0;#A=IUE;MSP\$\*=:K;GP> M%#!T! G9\_6<~|(A \$R&W01VIO,JLI

C2H5=\*K1!MPE=3#"4>T-ORO)O?B MN8\*)\2H9\*?~\_IY8@0.CA9O<1<0LTN+Z4'M.~&40+&AY<\*9LR\_10J'.E5T MJM<&\_#U4)6<&C?&

&F77R)44+~ZBDX5W( ?IOY\*.K\_>@Q1%91%0D92RTUM M^ATV4C!PM^W)H;NU:~\$&HPA\*~J8'L.S:~P53K!L>=U@ M^IOCC^A)

(40J4BYK+HUIZ^YGO^M^JEGPWTN'R.L(M^4H\_CMR>#\_P1L\$3RS\* MEYSG3HC#P%Y#A#X?N@GDIH9LW&JHGX+\*N 7"SO"LFMY7"?&

H%K@~WUXH+V.9U\_~P.VMOM5P6\* M)6+9ZY J OF5M6U8#D"1?9<~\_Y1\*G\_ E<)>NHC2U@\_FKOD#G=V# 4.P.24U6 MD:MW144S;/Q\*2:A<I)

<6L|@9JVG7!(<+X>PZJQK<8> V&T(C<@84JK M45F1Q3LVC6M6"7(G='V5&ZMLD(6|ILTGD.!")1G^WOFTO%0@C&A!156MW= MM?&VY\*;

[Z!W:JR7:VWO!VMNP2JUNO?I=>?&A)9YORK7LM\_&L^IH@1O3Y-NF MD: \*ISRVI@F& ZNFF520NASIU?S12\_~8\_?P'E3S(XU2'72YKYU-911'B)1 M\$P-

P+6UAP:MW2=0|JFA='O+BK/CI/A4WS415^C&OL^T+42@25/Y!/+5/ M/5^SD'M'=KOW:~I|X9AQ%GYIIO Q>HAGIG2^@+^'K' KC



VR!2@!@5):("B<H\.)UA[KY(28LK)N7@]WJROJ+20I;B1& MNYXF. ?0I/!@Z.../Q1/I1\*#X3Q0<@<C9@?@-HAI|DJJ+@7<%Q!..S1<-MEY M4"\HR  
^&AOSTYI@R@V@Q 2'8@>^="1&8&TLZIV'DAO%6L!(R5I)B=G|KIM 8QVNYW&|I9'G'RCPOG"N#X#@#ZOB|@W#+13+M@9,981+.,=8Z1-WM-  
<) + KWAEA^&=UEE.)8P"FCP MG6(B\*Y^4/2=@F|X=FA!#JR:8V'VOPHWE)S4YV2(0I9|K#|187'G.MHG4"3 M\*  
\_RC\_P+5OPL6#4C?Q:0%CE>1^E^M^M^W5ISMF?JR 7# M7J3AE.Q6B=2)EX9#<Z@;B-A@Y;Z4,+D>C^IR ZVILQV9&N9 R2^/1#4F  
M9TSE\_F07':2143T&\*D(W+B\_I5V1J38C\_D00%&;4?&0ERODJG-PVE|GCK.8 MOV'T'F!F?S>AOG6FC9BUV1AH";T=!\$APFECY|!#O^!SZS(9?  
%Y4B6^T0X^'MCIL\_B7I2G8O38'M)H+AF^DW\$NXQV(W^8NHOUA|J.129.9'Z1G5(.P^\*9 &. M:01A9;>31-  
PVW<[KZ4\_\*M+1>"U9>.>ONPVWZM,":\*H;|J|'65!2.3?@ M%\*4)-2Z0="R#MM5+>3)N|>XF@Z'J|W\$J\_8=Z>|M LUZ;WX%FTH,J%U!,9I  
M&%1^!\$7V(ZY95U3F(;\_?Y+AI^VQR)J|\_3CGS44F)OZO^3MLAU@S|/ M56^0AHK6UTR?GP2T.3&^+90NR|E\_G"(O\$B)-  
EF|J99%3V4>E>@S'F!#EO;M+OFKTI@?>I>54Q664UJUMJONI|!#(375=<=IK,KGZ\$%?SE7\*#99M M?@>M 8\$M' \$A")Q/KN9&TA,U  
M4)'QV.9.JLW\$K?@>N^"W2VF=AE?NO\_FFI/N>XII48O(-#A;CA?G|\$/KO MTF)Y:4G-  
YAFXS5F|VTIM;=EPO:~K002<& E4NIBE;8Z%JDO4QVAX=>T>5\*J M.;3N@|JOA0QE:(#UE#H%IU.33V'P5' M @|R|F|X.?<br>227 C#&+ON0)NO@HLO|H|I=SI;Y ID 1U6725|I-VWVX M|B^F+TEB'/S-~5;3IY(%6.NV7C&LJ\_QF;G+N>|Y\$1^\_I=DZ=8(U02'OR7E9T5Y="V#<br>^&IG86;/4 M>AE;+& RFY8?&50\$A M;BSL\_XYA=M|6I|WJLW7\$09N-11+(J6J>UT X'4Q\_=@88A )-IX3^\*%#:OAM M2W9G(?!:30NR-T@S-PXOETN|<br>.:D>-23&2.1+251-K\*F04M+& M\_DE\_C\_ YJW=3"Z-8GXZK8)UDQ9I.NX=(\*H;#=#1^B22DUJG ^ M'IQ\_Q)O"AZ99(R4YMIJW+NVX10-(FR"\*H#=#UDX6<br>M%)EIG?JIX-W?P?&F\$QMS!+?@PN&V-KUS\$S2IP<#K%7I5TMI&|J7;910 MHO.8DXOGGMH.N?<br>@G:FI(Q>5D5V1\_4R=O4=9W.1(9OVE,BEO0MBCY791HNYUF ?1|E|V|ZOV2^0 M=KH'SB)'2S1"\_\$S0%:!SV(+XWQBL:(7GVWC.V@|M<br>%DU%:XHZY7^Q2%=@J|X&I;DGO6B7S1+|O^0%5)9F|@&A NXY;SA?@<(YE \*18>2:K2>|>K|KES?C>D-"X..X" DYTICFZ0,+6M\$E 9D(SYR4<br>:#U4.868.VO#83SA.9;SBOV|>|ZOMZ/L\_ M40 P%U>B\*^M|R9E|A?@<(YE \*18>2:K2>|>K|KES?C>D-"X..X" DYTICFZ0,+6M\$E 9D(SYR4<br>@|X55GI|IQ+<>580 MLH1=1\$#M%V:IA9)T0VD& F@) ^)\$,13<..TKALRDI24A"S@=3Q2\_\*.@90' M )P.M:ALZ@.IMMES"\*24>1C#)HK(TDH+Z<br>%1225"HI C=9L=RR5\_0D9XM\*FO+ M#WY2/CD4 +\_DFS@/10Q|SBR5Z2%=@Z^&C+A>><8Y>|BX9#PX7/L/M.1C^&..S0.)4\*>EAP&?AQ\$9B<10?<br>5WA76GIM7B2!/WJG|L3E|B\$J|>13R>OY=>B5#^@P5L06|OUMOT4PU09K16(I90 MZ&)>BFB\*1#2%<5<br>P\*Z5M%=@Z|FV>=%|X4#X"W5D.EI.HG:@2&V#<-9FGL'5.1 M.-TB.S,2A520.(>|U'2B2R\_5<9>419S@>LV+V^MBC"1CO0HWEN\_0SA=W|FU<br>M8EZKYVP?<.:175|G2|S<|J1SIOG'6F520=@TQ^3SS&A9;D+\*(P| MGO?|UG'KOJOK7+Q^VED"|>8J3|2ISMW)U"!!>0^6BX)G|Z?<6C93#AW;>Z<br>M.M:Y|I/R/=M|P;IEI&(M3394XS(BV4#D@5 KV?V>^Y^\$H8.(GWNX>5\$#<T= MGMS\$ YB%U05PFH M|E.M.09)>|M7&2X'R+<br>+H)B+2KP766=U69+?6^\*+D2Z+M#(EAT (&#%E\$ M\$P#'|6.F:FX+Y|P6H0\$7SHHT?@ M^Q0|04RVEG@|UBN- #IX5T5#FEWC>+^\*TL|15 (?<br>G2B.U|29@Z+>|0E4O1\_H\_MAA^22K\*+C1-P>F)U7DO50:2C>U..M#?V>..(5NIJH'#F8'Q\$=W M-(OZ(=&:>9Q;&L-R&C|<0C4NOK"^^!@>?SAK2I?<br>Y|<Z@<|HT|DD05->L PH("7\*N=..\$|MS2NDQ#<3". MDOFXR1H\_ /1|16BGCY/ RB53|F5Y|F\$O+|4^0ZKA4>"F^M.M:DI(=<.:CU%#E3|ME^VL^X|6=9)<br>|7|4|QO8<|P2|BZ|F M.2.SYVI|>1>J4>X\$>:2|R|57F0;3&K;OZL|Z2.IJNC|V|LXN|U|O>CZ&\_EY M>=>T@G+K8S%YSA^+0+Y-D..|PIE|P?P|J<br>Q|4M.O)>|YGN";S3|B+&9OAX M24&27XBOLV^IG"MHJ\_3(4+5\$9\_6C<7H412X;&B|E0Q&O8RT\$C|5?B |DDI'9\_M,9\_-05G#^<E|T.<br>0A|X|T=>^"JU|G@>?86ELIK6-G96V|>=MC0-GHZ4C MK2?#&40QV4ZISFM-L+|J.G.FZ|K>LW#<313\*V-|/!>BM88/F# M\_#>FE^?|\*ZV-<br>+SFZL|H^\*Q|A|C|K9^WH|PFPGD|U.L6 I@<80.'\$&;Z MY|S\$XSKOOC<J^B\*=>T\$RS'1%631AN(WK301F9<~\*% K(2@91'X#;Z^FZ^OESX M&|>1UA'9?<br>V7\*8|DOIFEXF:K-2592%&KLL2B#KM:BS@X^Y&(0&4>-J-2YKS2 MXZ1Y\$EX#5'=10(>30K'8% ><(A8K^OGJ<V? 0A|X26X#&SZOG 4TA9-|E<br>MV>|6#N2I|(3|64\$8!\_8 G|N|I=@W4|JVC|P|WB>?>117ECY\$U\_Y|U#<#\_IB M@.5S="3%MR|1I^A' E.OTNX\_8')VOB|B1.\*-|%(HV31M.RM^L#>:<br>QVWP M|T=>E+&L&X|7F=<|%9&E;DE|+^!YU5S16U;+LDH4.)|U|U@.4|K. M/\_=>^Y24I23D0W\$E\_L\_46G^G'XS\$J|VMY5NA7G>\_5;:\$Y2R)?<br><U\$<L.. MA@LS|M\$X15.1RZ+|EPS%|Z6| \\_L@!&|POPZ^SKMGBL/2=|OJ^\_..OQ-|R# M7)7|&Y|1/5-2Z0&1D%:I/O(<^B^8'D)Z\_Q%>R3(N-<br>C%>Z2NK&A-EX3|H| M.3:U'17UOC0 K^+6D|E7|\*S3KK>"DDI|1P|7.K<~TZ= Y.Y\$4>6S85M|Q.Y;R|J4\_0&F&C&|VG@\_1\_U^|<9D72V=W#<br>|LMLXK|/77N|&=|>N#7W|X1^ M(O8.ADEZ\_!|.O|AN+ROVM;ZT0G|%4)HN46| L M'6|10QF5M4BP&L;\_AAON#0N>|U|48\$M^D|
|4CK2F<9)6#\*2UYV9|!>U#& MTK+&+94#2+0U|Y9:9=06A\*@IKF M#&NV\$P0\_|&^GN?>YX#-91TQ\$1R|H4|F00G<7"IOX^9+KB MZ->A.<br>(UW4D\$OFZ,2|8FX.E.5R|9FNE"X;+4F M CK ESX^U>N6:616X4>=N)/C/>4U0.^@TFA7\$MT=BAIH|13NALLG%YM% G5 M=V\_L AQ\$#.(G=Z13\*U8<br>\* = )F7'K|HXNXFK\$\*5 M)N^V:77>?Z|26F;AM>L M |XE|+ A^P|VY9C3%&-DO+8GY+^\_N)PF(8N MC99W#|H^0^KPK\$-S89G&B-68^4@ K^X|7?<br>?6(|AV\_?|"?|G+|I= P^F@ MZKQFIS-HYS2V:C1|D^Y^H+Y7+Z|U^\*|S 3^ @|B-DVMN)|>J6102|L M.;+G|E0<5W|6|=S27ZSPA=>+P(S<br>IO;SW40YB9VY%Z193QBIZ3">.:3F@8C M=FE\*|&OW2 D5)"5C08"016&D3.N3M|(C@4N#3DDORQ\_O;DS\$<\_5B%0V;T|J| M./U2.V\_%\$YX%-<br>ZX08^60H|7|EB<+M99|YQERD9.B=UE|A;|-125'VDK> M\*?7|Z/WA:(C<:\*M0-QJZ<-UG^@RQ6L-Z M Z404H<^<\$&MD3>2(MODI M-<br>764|T\_<5^LEO|K=)92(K^ON)"VND<2^8.Z@7CMKIGO+C.Z|L;UZ9^1)2|B|A;5-P\*G ZKQFV;+&T0CVX;=|JO?<=EC.XMKR9|Q|TV|);.0-<br>#E0|M^<JTD|I7 SE4V\$D M<.>..N|J|/2AX.20L^P^N|O^X^\*96FE?A|FI+5|J|I|<\_TF6BZ(A.#+CTD MH&M\$< UO\$<L7X9NE|WH7|B?+EP=M).M-<br>P;FP+5UDX=>P\$>0S40#|P|Z|R;T\* & ME!>PA\$G9>F#7?T<|&|F:OK3OZE9R7K94WL\_F3Q^M%#; Z2QJ.4>7KNP+GS02<br>M.7F|W0|\_A30MB.5QUBXXQ|BUYWC|;R:6&+|6&1A\$1HT|KE:BPY|9|E+K^5 M.E'U|OQZ5.M|JDFE+W|J4CVY?;4|@3;|J|C5% J.P7|M-H;|X|B-<br>H8Z3S|B\* M7R(UAEH2>ZN1@#;1.4S Q4A#E2I1#%M66+Y4-QVH \*?|6%E KCD.IE MVZCNG3|H6Z20Z'3FP /^VN51>Y1" C+AH.V62M+8\_\$W-<br>"TSHO|U"? MA|V|)VELV5+>Q2+AS+UO?|\_J^R|Z|E| ML(AS|Q|>DB R|+I|Z0AEL "C^PRC^M3(8WO<@NK.4|J|M5Y^#X|+)|T?+E; MY^A:9^TX<br><|<5A|>2(8C#RP4B>|>9K7;";K("16|HGL"JV4 \$N#MF'60& MF@YHXSOE-X%|!)-R B "F.=|I25+V^N C=P#M.UP3YWX&|Y4\|Z0@K+GS9 MX@^)-<br>U>=&=U|81|>8\*03|0.4^T^0(N9B0Q3LAI^6|T67 #H^Q\$& 4C0<2+73WOF|GA>#!\$M#?+&|B|71?A^?N<br>M'3Y9'BP|J|E|5QK|BFWP|GKL1|J|T&@P|>#R^\*G->@OWDF^8DD|AJC-^2G MI+>24U(|L|T (;S; DV6DD8<+^G6D\_P)@K^\*T%R|-<br>+!#C/C^HG2^H^QV\$ M3M|)7HZ|7.3A.1!<=<T=|V9\_F|FGZ5\*7D=&HGR51 M\$OR1E/F3>0!#0J+?M9V1O265&F>V|O>Z>|9#%MN&Z2^'<br>M&Y|W|P("7+L|F32B^098I)@GMYK&I5.1|T9S|I=6>1)9C(M|;:3|B3|G^ M8^80I2.1^|U|VNH>XMR3P8V|Z|C(SV4^G^)|K|V-<br>\4513W>Q#Z%W+PW=PI!Q MT2W|W|+^\*|M@WMKN^U#H4S|\_MUY+WN/ /6#|Q|F06H\$|L0BD\$ D8.)"O M\_77A.EZ<0>\_M|BP&<br>(KC)N^>I4U+P\$W+!|S4=QR?K@E|C3|Y|)L^ANF M(RT8U D\_>BOO+HNBN:O|OFOW/7CH\_1J5H2(YK40Q|SA;3G.\$.)#HY^!|U)Q<br>M^P^O|T|("Q=D|T5BD-ASX|BWB\$FEZDZ7" M2FXG;\_W3@ON@4%#A|O9=B|^< MUTB0&+R21EEYLR#<?32X(SH07M\_7|>F|V9M^F<^T"&<br>|R.LL)/@PM2 MSJT=>R8^2\$38\$01N8^C#UD%VI;Y>V\_%OB6DBV|@+\*|16N?|8\*=&3(DUN.9\*9 T|OQJ1 MN-U\$ W=U6XC".+Q&WT3LX.@Y<br>:K0EAM4WBAH8: \*915W%QX7>M.KXD:VP M@>(VIELK^>V3@;TX::@EY:72^H^XW?^YU8Q|<4>TS";M=Y5 T9=6Y>"V|P>|J|U\$EX|>\$^ E:C(4<br>MY!>.Q\$A^G?8+7.=W^N|I3<2M^>X|J5Q;PEEEX|T|H|9HTG8-1).9?H63 M2F"728"FE<br>(Q|BFCZSGPG.OM+@>1^NO^V\$0R6R|<0)NFI|GM;3#E(|&^\* M-/?>3Z.@21^V@G#HAYJ:F3WP>|>\_I|LO"Z99Y|O+Y";FL%<DM6O3Y;#1%<br>MZGI;|<B|)NBB?H!#%6Z|5K|T|P|V\$M8F|AU|656K|G'6#&D^L^B2YMS<# M\*F\_?D&L6%0%\_9N8 3D\$=%TSZ%T|L^>%H(=4TLFM.Q9V\*|O-<br>|OAOOQKB M|BOW%|2|5&.8VC.2VX<9|R39E@Q^9B0) RZ<=R.86PY8N|CP|K|9G<.&L M%7130DB1\$KCOF| B6J 4J|F0BC;-)KU,&&^&|&+TZ09H?<br>%2H5(Y#L#|D%M|P3XF<8J:6\_U\_X)Z|X|M(\$WRGB<9|JL:2D|(|N-Q|H)|G|WV@|@('<^6K?3>F-^X+>:Y9 M|-<br>OH&1^JR: M=>=YBSW^67.RWGLEDF(34&9|Y|Y:6 MPHBY+TD;U6V;..R010)0FX#1?>5Z\$%C;.3I(37:|SV.=0\$4^27&<E+&^\*P M%HM0+8D/P|OAN?<br>MH3|=1^E<8.83^<CC.ON?C|'2O9|3|PDV40|A#R|>6L M4Q0D\$=-.MX1AP>Y9.MN+B+<: 0VZ^T1A&1K^0=BO=(H.L.E^+|U|D|O31 M(M1|E?2-1<br>WH2@|1=>E+/-|O|)"|:Z=TSH-IP?MRK?B@?>Y70|EOR7L<S\$? MX-^/9#+|S:=%<N|X|+M#FBVQMBX7TSET^9|4-HXT67BRB>+1<1.SQ|L^DU<br>M=\$GHZ|B|O0RF?2^H&VE3B=M..M9R^S9X|UWT'8=M#>?OIN^<X|IE?H\_3A#K42H>4M1S&H U40^J2|FL:C=%+\*G);>HL@&XUUF MVTGN?<br>==.5Y|/3D|7.F^V|O|E=V|DB=AGWW7ZF|>89L&A.WM;^\_172|I|V|< MM:RXYD^OR.UY|'F5\_Y\_UAX?<br>8\*8S5?|9@Y;|>DS^G|1|L.PNM%.\$30\*#5DE4V^W&K|/;\_<^O-W|98DL9B02.Y& MNK;E:8;N9Y9#5Z@W1=4Y."VO\$|=9MK%M<br>O\*DHS+Y0=72"L.#915YGW.6|J- M7YK3;?|S^>N^<4^N^0(C#O@B# >:9I)22&S&B-WD 03R\_Z.CWV|W|J6'8| MG@G<^<(65+ ^LY@AH%4Z?VP8;<br>MPV0|Z&AE|/FQ#5 E.EGC.3,4=!. XS8=!#E|2J61 ^K|M.HO^|N|JRG M845%8.1^U5302&0V#D?M|/=>+^N9?7BB#<br>MMWNM|J(^+X)@+>T9&L|YS^L>N.NB|G|08=&G^W2FGX1-B^R^OY^\* |L|U^<9G MP|S|J|C|B1^OUM|O&:1^\*81<br>=/S@Y\$@00#&@PH;\$OJ^W|G;W\_ERV2|% MY8#N^\*R8U/U8?B^K.@FQI2OSG)E|ZPSD-|J.?\_J.6Z4M)&+^1W(L)LO|S<br>M;RW(8^MS0H@XSDQ|69^X1NR9A^V7+>B^+|J|8HOZL|X^N<1^F#%|AEGIN M\$W\$E#R;5+Z>3QEWV1KL6X<3H\_6REDQ\_7.T^&\_14YJ\_X|'"(1<br>W>%"RQ MUG@3L|D|C|1|1|Z|O1M|A^F^DFA5=318J^>A;V0K|9E;N..\$\$@L0T;M802 M2<9.9<5J|XO.V.E05U<br>'8|I>0^H158=P|&^>D'.AC:W4\$")US|HDL3E|LN MD8M5E(N^HS1R^N|'KN-Z^|A|H010|Y ?7R^<BOHGT.<.<@|D:=8K2^M\$&YO<br>M1W|W>#&SW|OP|@8Y:(L;YV|61^I^M4R;HR4VOV1KFS.WFQOC9I\$|L>Z|E|U"8X3|0.6U;<.:M;G.Q.'54BX290@G\_@>AOSY>>371.89" |\_F|MF<br>M.;%019+|E:5^I|?+|R0V|O4K9N1^8#3MAY 8=R\_ "V-;^|YQOY7| 2X24UE<br>M.C|O|TMTTU1G56\$3.MOHO";O#;F11<52; 7\_>+NM|O&D^>+7>.;O1636U> M|I|4S#RW-F"(A|I8?63;\_LZO%Q2TWFY"7B>-M.MB'D|"(KJ-<br>H#V\_F"NA;1% MSCO<86?|U+^E'92\$S<9G=6>I 6PNN'D.C4G'"=P<1T9GD5G^="Y(A)C^G8A2XB4\_H|B|@-^L|O-2+I5@O;0 M^H|C|L0K;|G^BF0L<br>|GMLM0^Y)=Y3F+CY56#^X+Z^3^B21THEF?P#X=GS# MV|C|<90PDAOE"QX^TYFSP|Y|?K-) M+U|LF0/C\_Q|N#%VM+U|C|D2V?<br>FM\$AM.33"/C|;3A0E|8#B=|J|X|'AVMWR5 MOF|>+>^>^ 8Z.E|A|'<|>L|B.N.R.N|'W<br>M@\*C|JRSO^\_Y\_>+1\_S|/S|71"0"AP?%?48;K|@HT|\_JMW^TVAOOLP|MS0 M>16M51CH-?>D0&WZ|H)!@%G;>#\_SY^XO^T\_NVPH|8EC::NZXM6|X|7=<br>(JT M>\_IP\_|8>Y5' (S9Z;R 5Y3)0G(11 S(O6Y^L|3|B|J|O4S#M^CZ^L^C M3;\$#6) <.&R/\_>\_PBQUZ@>7%\_7F |@<^Z=8F|I(W\_4X(4^\_46^&QGE.;<br>MR=Y^H^8'R^9V"?>3>|@>2G0V^F|6@W(C)^1=CPIPR\_V20>7:T|U3P^?^U\$< M^C|L6K&X(Q)MOS5CB>KX)P3=TB|L6\_7B^D^G^+A3TH|XIT\_Y72S|<br>WR24+Y@F2TP^Y4&\_XPCC^7^>=V\$Y|S|P^X^H^C^E^W^N+ M;8="#PX^HMCR/YKB-."%CMMOY(C.FEW@7|N1<1%45V\*2K2UEP6^A^<TG;|<br>M9OFOAK^|OHJE|Y^\*V^P=|GNWF^B0^|JL^|D4V|A|>3.?T^<=>Z8@ O MI:R1P<+4Z7X\_N9=8|I|D9U<(|<^A: %|' MU^&1\_H\_1M8-|\_Z#R@-| MG?<br>AP^L)Q^U7=W9T9^A#1O|TLZWP|^\*A^X^T\$@>W|T:DP.-24| IHA|@W70.4G MWL.D|E^&^@H|C|N|5^>@8|3:3TEP|Y6:A S.D.NOQ|1ZK@9W59<./WF|<br>(> MX8^N^1^R:%8|V.W;33!!+LS^"WB^"WB^U3G+!-CHG-MLI/ "+|P^W%)IE- M279|O(A37AN+F=@FN4|O^B|
|DK0M2).M;I50.1V!;Y=TF; 26GQO M.D5X/V.PH-3?B M=08|H6#R|D1(25K2&L-|D|<1C0.YH>D (R.F.O;G^U7DR^B2G>N|Y MAR3\_FVE^>C<br>(B05C\_#ZS2\_F|KNB>B00|W";26.5WY|D|HML\$X^<@R|N|N3; MZ?2R|D1>1^Z?C'D5"Q:1^+T|X\$R;#V.E?2|1TZ@:9FX7&APV|)G^G^("V B M.)<br>6|Z301.2.K#\*!<'<\_%|4\$WB>%49P:5\$X(2-7)8>ATN=>^B |29+>9^D| M&;=Z2;#4M44I9EX^4='^GL\_P4G12^\*K|8=\$ICH+32.'QC.C\$F9YU%G=7\$|#<br>M|7Y;K|F.G.PX=A(|Q|<|D6;9\$>Y|R|#M=M=I26-UC\$^(|.FW|IK46|YU22XQ MYN3-ZV^0-B5?2?^Q9|RZ'|L|27.FGDO= )Q;Z2KY|4=U7C5|@>>9%>+<br>|HUY?& M9>5?&Z.CZ.>^|+HT@>N\$("&|K|B>3+D41RA#P>H"> M?.@MBV^OH|>+>.@BH41""@K|Y5+3|P^|S(KF39+E3X6;OYTGEOHR|G 5L M?<br>R&OA=LV\_?1J\_..W|W|J^HWD^F-|L^U<=<55(EHJR>C89QY^O?").DMHV^J>54N^PY|U!|O MO-%.|N#"4K'|.%04B^7XQ2R^"N|R)BZO+H?<br>DQ>B6+>39BD>.V05" M&FYE5RVT|L3M|O3+^BC^J^4;7HCG ^9>@PIN;=BV<63:3#P/E.( U1#IK5T2)W MOQ.QC|D|OYR03H|G11.NWR(3V\$&L|I-<br>QU!>NB^MOWYG:35?P\_A.ZZ3K)W21 M1:3 9 ZEG7|CDE^#-SS|/^>#F|P+>\_26XQ|187XOCTA)T^GN/Q?^ \*Z\_ M7X647ON.,OK^4|E|L^=Y (I?<br>=>|EM+KL.Z3^|RVYD;^!GH|S\$O2BK7Y;6< M!^J? H^>K\$>X^>X^E566;>#.GPI.5/PRES|3^<+|V-K\_Q\$^7@.|G|D|HH|





[L48PVB%ETJMC&R6.DV/VZZ-W4E.69MU=GJ(GWOI)##I;4] ^K@59XJ-ZNY<6>H00 MESS'??=>G-||'GV8 ;9C&?A;E^K0C0M= -H= M >L%LO9H>3&9CH?";%4I54I2&RG ?LEGI#1^IGGI?+6%Q#N"4H0)O|<0 M\*\*J( "'80 ^&S/N#7YH02^OE<= S1J>DP3QI|FBJ89MHZ.8.1?)ZZR8>/ M7\$.?WG\_F>.\$V^NPNV^Q W|= /K5U0T:YVW)-45>L1/ KZUWP\*:33<!! ) MH%BN&N.S^3QO.B1Y6|7.LZ5B\* 9 +U0ZP2P? "Q^ \*X6M?..PY@GZNV0? 2.M20\_Q2X%O4#IABX8 'QKWHM#? \_DHIJMKPIVO:1.JIN>IV#D+ZUA! =&XK M21-@S@I+(ZRR?@:0J|207^7/SG 2\_M4\$BGO== SA>F0K+N(D7U?>JHJL%8:/^+4>&3? SJB^((@0N|LRFWU!/=U":6:&9 0-\$TZ9UT-#@L|I)I) M\_16D"JO>YV8'(MY^YQX#2G)I\_ UZQ|B5\$)SD/L6%)^D9%|C\*FA^H2<-!6! MK/(4TU?I@& TRY6^OIA6OE7D-K?>19.[SR M|+E1DP3>6#%T9"ZI POV:0A^"D.Z M|KB8/P38( 1#W#N):.8\*8# 8UP-.V ^OW^1/<@\_O\_6D\_+Y:3#H:8LE|G M /%:ORD^Y?7.5:Y8RZ\_X)-NLTF|ZB5<!)I225&HWYFSCO A- E.F@B4L, MC>MT5O1F01K+D^RI^A3D.%5%U^L^B18L:T""#HX<SG4-16B<\$/\$.9& MKUR|<4LZ>\*=T^WIO\$|>6127GV|@KZDW|L8 MFC= "9V:L4V@&YZ:O:A-D6 :!6K TC4XHV6 R JM?Q YI/E8O^F ?6>+>RRG:G@ZIAQE7%0 M^ Y G"IC#9^FOBX)=# ;:G:UA)CFE2V\*;<RK?;=(%W?2?IA?+BF>|V-|YI M^A,|7&|^>89BH+741&^\*^M156+D3\*B|J|^&S&B>G.G.I=?FA'I(77/HST?6TS MN/#:|HP@U|H&OZ9UFVIR^E^Z|K2S4OY^0WE^D|OHS^CPT L^W M47^N2GH^"6PKB|(ZJ^& 6VI&#%|6GH>=9HV1+|PID>=<>0PZRA0^VC7M ^MCL4)EF.2/>B OT?>:-+\*^R9 %ZAM^\$1HW! ;|H8^+60+7#0C7% ; MQSM|I|W6=@:B^C1AD&E.3&<=);5KSEC5N? KS >H:3^A>V=LSSJA:KJZBAMW MRL IRBA)Y#S)H7:J"CW^B^K7WV3F\$S3-19ZW\_J=L V(#|SUGZ^|+ET|QDN| |B.Z6\$9UYB|+TQZ?>9#T ?7FMVVOY9V%LEFAK8 1 M+K\$AAK^V3:(Z=CBEU|TK O#4F M^X%0R!)=HS|JO.D&1^O>59TBE6B56?U- +%"8)GG^L^..^ K E&:9>)"Q7 MF^@EIA9 #<=APHJ|L6\$|AVP-N.S,ED.4:~|5PA7#OXF2GMAA%JL\$1P@?) (M#^2.(V0I1306:^5E>EIRR^F=F:|P7CB- /16)///P8G|GT%EVH^M2^SKV?H9W M0^LJA|J6""FGW:5<6K M|TIC|5YFL-9DGXV|IT77^!<:G..B) @^3^C? MF&"" (+9(4LND>- JLA9P2Q2H&M:&H>#!&#\*YK|VVL(SEX<^<0% M^@A25^\*K|U)@ | F|W8#9T|^10AY@T=E.S=K?Y0?2?E&MOJR?@ M |P.D>L|:HO"/IQ08:/^" (X2|ZVAT^BP:PI0M17CB.<#&R^YV.L|>14Y;> MU6=8Y^H^2>@: M^P23F. J(FI2S>=)I6:=!#VIOK^0EVB|GEYK=WBZ7P@G+T M@(<=)I->ZV>WVN T?P6T|V 206LM:3@U/28:F%O/>P3W?TO(NW?U:=>PR) M.6VL<7^S=N|7DS^DJE#3+|Z >H?ML3+#ZE"\$2R(MH CTP5Z%"VIC?Z ON:|P MBJ|NUBWH|&NXTS0.LIQ0&@&|O>XL|K O:4#|J|-L#M#B.&KRUZX1K8M% M S^L(E+C^9W#<4QU7|@HU-^/F\_)@MVVWT+M5S 3/@P.5U05F1+CC""MNFEN^>O@JL4.7|@|^"U@QI& DX?>D7YMF+9X6>GR.AFB&7C=<8JR: MEH:IA3 TWV=%JDCI+##4.1^9\$O4\$M:\$U8K|+MKO:V%ZX^S)4K>@@|I|EVY.:V8 MDI:0L9N=<4^S3:%5Z|^T.8647|ZD|J\$>ELB?6RR:47+'38 MIOXY%3QCKJ7 M#R|FY+)=^N5B%Z^PUSR|9Y^PI? 5:Q6I|>DT^ >O:RY?HH|L=I9B/OG9 M0CB^LJV7^X#10I,EL^GNE? GJT+9(O)=|SEB1+>+>QT^MW.P06)9RC5")MGHC3.E%K.&(NC;|VBA R08VQBY1RO^V-V1@S3|LNO3^UE,^=J31 M|U0T7<80/NX> <B>P|JFEC3HK\*(F>K#9#11^Y MM.R:3..%Z/FEW4F?@|I\_ OKN5OHZ(SJM=| 3|UOX#^1^CU-M0:L\$ M7.C03=5K|J.U:Z:LD&L>DR9<- R9>:13NT^A^0BGDE6GW0I4.OY@.2920+ M@V2R<A916#J|T|<2N>|27SH:=L.F^X'O4.#XYF=9H+M5R=B|XDR%|B^+W+ M73\*\*7SPW%I2M^E#G(9<="I|W5I03 ^\*-SF<-386Y N|S^T|5 6 G A^M M /ZA+VW=X51-13Z?^F|:K#8%|J2\*^0%F%2965T=77I&V /8><"2?4 I U17^<=9:FEJMP6.Z4W^T|T|OJPEL^@VOC@QZ.B&|^\*E MJO+3.CNCS^C3=C:F8:=EMT&S/M^B^\*3 +5P%=<+C#P|P5^+\*SEBRH4|OT M.YAW&X.V7B?&#>Y^8PYNN8=V0I05.@1 MH%KDU =GRE G\$0|^!>I0?U54 6:N^OY 4^-)JEOM^ MK-|SD?N@-1^|)BN\$JX\$6%>^7IX?19: <0RMH+DKGCUKO:BNSTB^@ \$V|B< M=>J'(PWUOFIY\$8Z|?&H&9A|R^FXP?>.L(=T4=Y%SX^8R^X% 7^\*K1TU| MPKT^\_ JH^)=W|S-0? 3LINS0|ODCO|6^BR%523D.855^OOH^%|I-5.C:B21-MBYR88|H|BU6N3 MNP|G:|6 &AE4KRUIWZ/X+6YRKO9.XUJ=%)&BGUX&? Z)S;1CHOPDV#5F:T^M^1%,6%)1M&^|Y^J%.)JZS.^\*R^')K:4JZZJN6.HK&>H-V^IC|I3DMLH. M+WO:~#5T|<Z%#0\*?7:U|<5F;-V|I|H9H|L ^G:G#63B|.^K1728 M^X76N:V-|H582G=N. V#4#=#Z:|3Q&^ WY0S<|).3NC|UN&:3:6Y&V^F M YGH/O663.ME# |J>Z|34%;&:0|O|U&|^\*#43YXK.Z:~\$%SEU\_U)S?>")ML<.%A |Z|UT Q08BI-H^7K3.RKE|=J\_2UT\$|8.RK@K&O^N|8|2^|TN?S MR:(Y|O=&6+1.Y4&#%JD#0."98PK M SC^:16<\*TMSO9)D|HIB-L|I|W:A46 PR+%V.OB(ZX|O^V\$;ZX|O&N6-8Y M|^1+|TE-962>J@RPR89.3G@- |F0^L|W2:4 2ZM|YK6.NJ8C|= S|Z^A|1 M36\$Z6|V:VKWO>^X|V^\*ZJENO7V=2P|5=^XJ4FAOM(62)Y|!>YW@C:N@ M=D|PGK|JBG MWQLF6 U#5|<=F.Y|P1^7J|7F#Z?^H13M=3X8X^\*WWH M:P3^8O/>GE|?&2R5Q1W^<1^7@1%OB&7)7IR' M4:18 :00%|O|>&|^?N4>O|6V1X^A6Q@20MYZ\$;Y.L.R^9Y^W2|B MPGHW3|1^PH^L.CL9N08 :?G0Y:2+|O@|J4^<8>87=|X|L|=|O#10P5D1%6 M#150@(|48D)K|JTA !?SA1+T.GWX0.Y#5T<|F&K?Q\$5|UBBH M5 K^JL M4#WE6|AAG48F^#K7L 8CR|20BPHKQY UX|N 3. (/!^R6(#V8Y|T27X4 M6^XZ1ZG^A^|O:T^UX2@ 5G^"1CBN|^/0@N D7O|8PZ+L^C^ATC3HPXWQMO MG\$Z^W?&#&:MUX:C^L#UO&D >2> ^IY^GS6KT^2+92^MBY3B^U^&N|2BZK. MQ+@4X|+WQB7H":45.Y|O@G:GDGD3|S6?LD^L>L:#|I|P\$.Y.AXT)P:< M;PDXU5|+5K|:QXOY3WU;S:OMELO2|.%OIP>JN^NGOG?:IV@T^L\$ M^4JX&S|B^F64(+6>JB^8BOZRIHSAJ<&XOVTG&40:5<>@9T:|I? 6\$FBKK""M^|Q?>W|X>B<.%Z%O)P^M\$S(M^\*JE-|HT@-|>8CS^"WOUZR|A|BNSYIM@/1.Z M(OG5=@Z+X6.\*%0S|\_R^J|H94NUU|2P|80UJA#50? 2P#15(A^S.W2 M^)(5.OPO0.O^A|P^A^I^W^R7^C|C|PXM=|PAO=#R2:&82=>J|6:MW^P4F 6 MTE)&:HHP: (H^IWK4R&D.%DX8HEAXGO^|(KR+\*8\$JA0P%#E&JN M)3.)@J#YC^VU+0=5>^1^@#T =W)^F\*4B^B^Z(\$56:8|I0:HM.=.2RF^\*K MEA4:4J:=XEF|5EH^|36QW^JDKU5|1^EF^M^|NOM^\*O5(E&GK\$=PUO.38 M\$F+AO^058|M:J+%;|#420\$7F69|)Z6.IV @1(NM4@3 M5 \$- Y:C;F^M>|9?P.2.Y16 O^#H6|J|^R8KMWO|8^@2-|TB3|S>|!&KK^ M^\*OT1@8^B!;:R08.2 \$1UIQ8#Q1L!(^5&^8;A8|@1->^JX77.13L564Y MP|CE(A1(CK2BE^BC2C|BC?Y0|JKO:LD)CN^\*3^TF(LE>8N|A^COO>>N<7NE?| MOV6V|I AEL1+WOXL^|@L8K^XEF#1^N2|OCN.1|21|OW(W|@M|Q1)07C% MC^Q4GPC+\$@CL@:H^K25%NYO:+? TX+|W^L^AB|I\$F3&9%AG^A42C(NK:P2 M2EQ:~2Q+\*W.:3P+U^0^ODKY\$RPPA46D.&+F?I)A(-70)^&^+UO9\_)\$F MV\_WL%84VCU>%>%N^89WW%Z^POY7U|JRVDMX|53USH=K\$QD8>G/D^I4OEP@| M2:GE)ZYWW2+J6NVNGJ|V# F#/"QV|.E|2^>^)\*!D 470LBJ? KKZ1)N7W6C MQ>X4^8|I|OGEFP+\$<#V0: IH^@D+;+^R2|LDS:U# B:T7;HJW^FIZ9#V2X MK4" NURU|JO\*(%\$1UAOW|^+9W9J^ SO&^& <56URD@WE+M,AHZU>LV| 6LJ.6>^<+UIDK9C+J0R+E?2L2?>L\*=>I|ZUW^=2001519IG+|J MR8XEY|:^U)D:O M^4F=B>(-62& EQ8U32@N&#3NZW:0+!^7%: \$3J|I5&|0>BYN4P^N^A6K^86HPZOM|96D=-/5<>Y0L-E:3VFQ) +@CR^HQ?C=N MU=MEI>I^ KKJ9|^I4.7^:5.GQLKX^+E6|^X9^E|D#W#>+3CU(X)TDDDD|EZZD150T\$W^L|42+|^/!(^M^>Y|6T^FL^5|^IL:9NZE- !^Q9SU)TLYB8:|^!L|8XV|^97FC?>D 4 M|0+@|IWR^TT=<=>HF=-PNB5\_8^M|OC.PE.E:1!|-M K UW0|8^J^W)BHO3+ MMWD=-TCRVM.FY7R8:J |9^5O^Y|B9|U@N(|XH|3|E MV)3<T W8>HGNJU|E)R|OXNB:2U:&A^M |>U+)^33^FC>^\*|S2Q0^-J|P M5WJ :2|S|I9WB|Z\$6SD26\$F^620""L|H (\$W3B7)N8+6UR.C7+5+>CTS<@ M.& \$00 <9BG)9<93O|5W:|@BSL|8^TJ 3G)(B8XG74A4AV0 M5K00K^V\$PO16.NQ4>3&N%\$^T\$ 7C.TUI0S7S? \*W|I;HY?AYHW@:|T|8.^ M2^U6\_99C IXA|J|^@\*#<=|^8^C^E.1C|XW(TDX(C-|P|B5^R^=C|+< M26G19Y 5C:1^Y\$4EQ?: |L|I|THUR19FM:DI^6V^602RA670T|B|@9INU.7I M7L D5<|S|I4.XOU^T|D|P|G|3PXFEM:OWI:|J^784.^U94^9PI^&|SO(|O58@4XI Q#GZ| MJ|G#D98S7=J7Y^W\$5|/5 \*:GO^DE (WS.CI:C.%|P|ZY.W?YK86TMYO5 M>|VA59+;+>:09?L)WY-1K|?RX2 @NA.#PT|D06T1L\$= 2(B(7^+US? #Z?Q C\$-FX3=)A|IDH3RMRMPY|7E28.V+|2^\*^O= Z+| MLV/L^O |82H^H.^?@3P)|YNI<1NS|G:W\$M=1 WVF ML+UH0|L.P=|5S| GY@S|J|U9|E:|X35|6M?2:22O) |IE11S.Q?8>DNV^1\$-SNN.MVAHQ^PB^V|AL>Z| MB|B6L|3\$E|D\$QX5A<|^R|9B|\_) <=SEQR7?:>OT4H^L@M|J:M@HA@:|A83 M=+>O>-|3X2|JKUN CB!+5|J#W=2R) @\*>RJ-96ZVX.MITX+K0U@|@WE)H+&B M|V&D0N6^EQM=>@T%|1@>3 DEI@D:2|T LO40<8 6(\$^9OZ^+A8 84F5|H MRMAQ@-PD: ^C.S6+|HU+&(\$Z|C)^ I/6&4FEPE|CEN^C^8F+|BHN8XGD@ MSLN(RX3%&9 H&2^B/C25^&LEF2|J>ZSD^1608U6.5?FS-I\_9RO<647C MFR4)9P+|6H: D=|&B0EJ7WV|>^"W2+OM+9Z>K?|F|O5|UM>6%E@W5|L7|U M<6.\$57#(RVYK-%@2TX GIOFIV+<=;U04=509\$8W^"7-B|9|G^V+&QQ|I M%2L%:S+^4@E 3E5|J4|F1Q?>D<3X4^F86&7."|X9|KE5PSAFC-.-"( M8^:O^\*1=8E<^Y|2.Q=LZ^3H|J|I0^J|JCL^E..|>S^"9:=SX4G.RK5%|GJ- :\$M^Y HJ^D@X:(Y-M.C:J+PB:WVO2E>K0=-U^7+>N2K=NP^64PC(T:1.9=.\*2)|LJ@\$TS#.-WX\$ MR7^H #WE&JOR^9V|74-G^).RVLVALMLBCCCV2|CVCLOOG1|J|PY7|J|MQZ1^N^P^OGKSC5(NV ST^\*G: N|A^TFN^J8W4:>Y20MLKX#&9|O.D5 ; MGJG7:Z.5|FWY0#|HLEPX07|P|O(|O%>9|EH^\*O#W5B+SE|3EV0B/GX=FWYL M^N>3^WZUZ<^\*^+PPJ6^I^C|.W.X^M>\$R)R#31P>OFNX /6 M7W^DDH98H^D|VC+P%6|DC35AGBRVPMX M:MO 1H|^H2<^ GPUO(I?-B9YA |A@F|>1^"IX?T^YQJ|V|U\_Z@:O?BY MJ|G|^2%5^12:|&.%>=4.UFK7|T5|K9P1FRW\$Y+|^Q.A^|=BZ\_OBA<1(I2(M&^\*70ZK^0U311Z^7\_5P2 =:67^46=VA%U1/V/#B^276V%ACOV1>B^Z|VAK ME:~J<+^2^ATV4I=(W0>S1?2>+KZIV7 M6FY (RP.I Z1JE |6|I5@>4^KEP4G^S0^I8|J#>+>:6?|^B5W\_WL|A.LK M^WZZV^M^\*5:~+LY!#|MNK4<15B5X TAF6HT^H\$R|O+D#\$@Q#PPO+AT0\$A M.Y|>D/8^BR(HBW=@V;J3?7|E|>|P@+KEYOU:OFCX.R5!"(L\$-N^O^)|T M L=>+4MQ9%7|^@3^A?E=|B|J+37X.1|:\*\$8#S-2713|5|V^M;< M(6I=NU+.-8OEBGYZ=R?1='M\$LAN8|^68^OSIL135: @4B=P=EF8O\$XGGT^VV M|BROXME^|5U.6#9:=S\$W2E584)OROR>Z>8TN3 \_O677M^6DAWD.^T-O^M^\*#^H:~+|^N5X^\*2(BA)^|MKAGY:<O-P^IM+XT@NOK+GZZG|DP|V1:RE=F6 M#2549 |^|N&R;S^O4|DSK^\*0:~)A0QV94|9LEF^@|S^)\*\$A>LR18>GXRY9 MFKK#9.U26%ORESDDK|DOK|W#\$>|1^GTT6E70^RP\$@)R)+1D;+=I&| MY+CG+D.V\$2^08E|EXCIZ:(C|4GOV%<B+|:ZU^L^P&|I L\_#N MWF=T-|PPPX^#S=#|J8@|L.LDT<=<S^N^Y ?^A26V4>3G>OKOY6N@1QE0NZ<.:|X77^35|^X^<@|P.L.FXGUF00N.^R# MCLJ^RRN|A|0#3?4-26+|^:T0:G^YUHMXXHP9\_9VGD^M+N.OBA>Y MN7#QF4^J^N|@3>+>^IEO4G^+ 9&LOK|25^ EK>7:(R|3S2MLC2HJ6X|^/ M/6%4M\_2\$+A>4+@#QT7|D|^\*>M^O@QB:R7|MA6+3.\$SL.&L^16^F>IO\$J M5C^WA5^+R:S8JY=38U&1^<CN /P^A5H\$NC (UG%BNF0- \_JA<8^MXKT+M^ MGA<|(6B^3J|O3(S5N&T|P|D44>VYCS^"G^IK|9\_&J| MIR^H^IV4^"WQ61|N)|K2%RTIL^V:+4GQ2AP)(=2C.H^|I35\_1A? J|Y\$!^FJM/UM52 MUQ|= #9^U:ZDSZ@G<|G2?&F|J|Z^X^><2MUG92R9^1<OZCSH|O1NHO<O4 M^V|B1|J\_83EQBRBY|O< &|Y|<8E |!)@#|S 8R8RUC> ZIWQ|5<+BA9| ME@OPEKYSV2N(8YP#FV2U4^\*4P^X|^5M-1N2|BPN4TF#?ZY\$|TQ\$|P MGS\$?| 0\_%.3^SA4|E9D^H56@:R3IV^26ZU^I^BL|ITYP@SV>R^#MRV<^7SUN|^819D?GVO%KS:NG?|F37DEH|>|Y5.KI<|7|2|LO+EDRJ? MPX- QKZE|IM&S^ZT^|JW^34Z5^W+>?X5D>S)"57P52FKJ6:|4VS^W%:EF^ M^5680HK6/R7<4+>O7E8R(C4^E^FOA:7<57=+=> |>@T9&|S^ZNE^OQ1^5U M^J+>E>R:3|B<=H3L|IOL\$W69T=IRG:6(5>@)"6H^E+I^DHT^X813^ATXR0811N^QO|5F1B^ M8L:9|^438 7U2+J<3P88|W:7%KZ5O |A9-9WO%P(PA+Y|S4LAIFLGM?1 ML)#CD: N68^ DEDO" |VK2TY7A<|>| E13:/+<X33&1H|>|ADDY>FA\$O &M&A:|RHDFZ23| |FBM|QO:USI^> "E87D&A@8^B^T=9^T^|=YR.80|T MSLI5:02.6R|B3|K0|T9Y6U:861DA1#|(|ZC|7^ \$H2Q@B?|JZ9>|>@G^7 MRYLC^&7D^F|^728|F|5RS|CT X>IOUGLL|I(%3^2X? X&JRI391J>|BZ5| MJU.:6S^9JX8@%9D8/S.9)=?G|I|\_SRLQ\$#P|B^"XN: ^51=O7SP:Q#<0V M|SULX^M|3M75(3|48>."5TV;U/6|4P#(|YF|+L\$ C|FQC KE8G^EAV^H2T= M<CAHY(\$Y\$E#RK5.2V6XY|A+08 =^=5<4D2W^7|^T20^IOR.9MR~(KZ6) M5QGIS|3=6^ 2 M=DM|I>T=O0^ "AT>X#X.F+&#^CW:|LYTU^O 0G6&.:HJE|02VA M.E.VX|\_W^P|E#P2^3AX^Y6C8P+ 56S7^Q8YU|H4|ZV8 MAMB ):Z2R7|C# |B9NQOTE(6^!:=ESQU5.^CT(\$VWSF%.%NXFL7F HZ^XOZ MWNDU%(KO3^X|H|H|D4P>|O3T@P3^5K^ABW#P7^U.^FE=?|@=|L|^#>8.L#2? MU=18UFI|^OFLTH9KLD+|^P293 PXP^I) MGK|8>(>X@MP60!|)"|A8E6Q8|A&J|A>JRM:17L-6K4^XK(NZK27G.H#8| MKH+HJF2.2=(D^:6#? Q@9TJZ|L|T|B-|Z|H^6PDTZ\$|I?YFF6A|G^EL\_M\$+LP@:VKYPBUD|JK^C:J^F^3+|A.P.E91Y?@!D^L^F+^TF2?7=8R^W1|+4 M= (4^J|MQ|L|14>1:2%94:RV55^!&?N4EMOY KHQ=U4W3+V^1V71\$(>|2E)2 M:G^I^ETF9>MRR.C3X O^.-S295HD^?EJ7|P6.DG.26L:\$&V-^>D0!7L





..P:FU&QA.XO.C6:TUWY>M23L2L.0G9J\$T-1M1^<>BS13WJ/GEN=&NWZ W IZ5%E<<?T?>:N9^\_08Y  
MWX6+\*#0/K<?>:UFCVFBX^J9L|D0LJA>V10V:AJ5G^/4I&9!#A^OISLCA#5 M->EJMN98T#MRT#(,=#HGFZ=XJ2:"VSUL"/JGT<%"  
(WMO10\$W>FL M:6^V)SG\_VZ(WG6IHW)"\$E)W"OJ|GFW\*\*PC<^,76ALBO\*1I04/OU+&|5Z 8 M.=2YR.NJBVQ(85.#^03@Y^YN!^I+CS\$  
|G3F84^MMS4\_6X3I|=L22WVWZ9FL2 M'DH=>I8ZRH:520IQX\_77&G46F M\$9Y^TZ^YI\_4&PW5GKI#\_7I5IUH:#92S^0FOQ|G7322;J&:QD7^9^F.W M: -  
|RZ:U^T-LF-2^139B2XLMA+IUKM#3L1D^H=>LGRZ^F^L^I\_ G5^<2 M\$5.V3JPO#Q3^T^IOWN^4D9!|+4-9I\_ GV^2OW^G;V30O\$PAG^T^I^-- M2  
2K\$0^\*YV/B^M/M(C.=TN(H\_W\$A@:..D\*3F<=&8."JH<->RK.CF|JVL| @!\_! MWU|ME4Y|\_IZRH<SMMJ?&|\_ (U^VGV\$95M|2KK@ZJG3\$&947Q M-D0  
2G:3+E\*MT:2^W^E^EO\*8@F2N\*\$|C:RTUYB|);Z#D=X&GG>^WCX>C) M^48>RC6:G2B93W^TF^U-|:4G 846-Q88(EA^0W29)^16IVW<.#+YN-  
S="N50.2N-Y.NF|P7/ZH4V.K(FN:O^:TLH95?@QV:|M7AV8!;#B MJ-9D:ZLW>AN6^!T+<>8./Y|\_#S\$|L;CKJ:(1^Q^H^F^&A;TM3\_SZ  
M6^"P0+^#M5|3T^ES\_&P7^71KPP|\_9V15Q0^|VN39^TTI3Z-ZV M3<|SZ.NM&APXRW|U|I7F^26W(YII^8L:RA#B|2.V:|QNHTS0!^\_:=O/R  
MT13^RG(I7C.6.W@JWDZ MG^Q>^L|3^M):V4P3|G2WLLXN9@O^YR37>^1^OYRF|TQJEFQ0!;G?BIW8|;%FR\$|HCAO^MJE^3EEN>F|>-T.GBYDZ\*  
(A^\*E|TERP^?I<^|V:K-FN6V)W9=6\*\*N<@:V^|VD3Q22K^?6S^+^;G3)3Y+^I8Z.^+%A+^H>U?^I\_M87G63^3X|HCV|0^S)B?>R|=#AR=EV^D:~  
\*Q#V:.\*OBF^\*V.K#;K9|H|BP\_U^#B9C|JZ|WE:EJO M&C|JXA:|I=Y1DN5;5FCOZ^19@|JLGVUJ^2^&Z:RCZ\$XT|K|IRM^Q|  
(.+\_2;X4WROM+5|M=-29.L^1^/5(3%4&?O\$1\$|;ZS8..ZD?3F(HU;|9IWL1SU9Y%V@HKD6<M\*\*|PH7 P;GC^5.W%KYWE=KXO<&6SQ X:0%1L.DIL+  
N\_8^=^W|2@0 M0IP\_L\_Y9>99/9(091;" XI"?@P:JDV+;S.R3^C/L^5)=WBSS^7|F =  
M+&(OH)MWR^B^K.DRIWY|ST^E5GIH=G(>V^Y^FR)854A.RTC^>B!<#7|C5|YF & M=<&;#0R:FEGW19ASSX#1L@%A|3.D>  
|QWU00;%GRAXZR..1^|>1)X7^S|= M@X#Y|LV^:Z=(^PI>O+V6(+7BE26I\$S6|JY>|8G\_W BU@M@%\_\$/|VZ6R\$'+; M/S1M.'P@:;M\_O#W#R8P&3-  
0A>=|I:;X^2=>R.IZ(2^R^1^P%|D\_\$(0%>1|X;3 M#(B6;HY)|G|>3J3R<C>GM-^L^>1^GZT>T^#MG="|YH<^OZ+^\_T8X3N|S\_MFAD@ZDPR5%#H;JW  
18085B+&WB&<\*^I4;|KXWY(C:HAG)| MV^1+2;1^&|PM|OC4.KM|ATJ;SN4  
MF^!|0>:8;J2FFD^K\_3\_Q=R2;VWPF:8F2XW^HM2S|2TM#R#E#\_HO\_02PV^\*3 M/7(> PVB8D)\_8/%F\_-F2-#MIY&G^IUI^NS.W<@R|OX:1X(CG  
3K9Z| M2C1=0V\_|2F#\_5E@P>C|(JG+^&G8Y^\*ZJ|0|@); &TB&5;-/1 K^D.MG5<M.M.R7.@JAD>6AJC^DDJ^92 M@O5LNF5\$=DWDG\_5WJM#UB3)  
|=SUIK (WV\_VV21Y0P-M^BPEL|V|VN>K7@N^MT78^2|YYILNECY|FTGH-N1^NV=>?I04^.;2!%\_WD|\_#J.G.MTD^&L\_O|WG-7KR@A-2 C M)%@^<-  
>#A(D+QV:4G&T:6|WNE5?W^L|IES0?^S3QM|J(MU95NA;+P-O M.=)OP0S:~N.7:2A+L^/HPASA>@L(%^Q1>@>@4-^\*7^V^A;B;|QPDPO:9  
M>W>HHT^>^>R>#UN^.;2Z^K^|A1 M.V@(:).X1L.A\*5 L:5MN.5!\$ -Y(R#V-)\$X(2^/H&B=^LF="|1(^>.CT.M:Ts@L:;#T%#H96^>B^?  
WZMX<^&B3J0=0%Y^A^1 F^1\*2ER@2)Q>+<^<^?B|J|0@| M!#6O18:H9?>?FZ(NH4WT&D)%=\$L^7BK^3P^VCJ|PINO@U\$.48XWTDVM <\$^0 MXJ0?  
U\_IR2DX24GWI|=.\*-0BA^DF^W@=;4\$2G9QP^4K6N^8U<SMT-OUCF MP.250M^J;T>NYS\_ZA^5^JW^D-1|Q|@|IYDZD21\_0NU@0OE  
^ORL(6RXY<O MR+^6^F+<^%N|Z7E)ZHVSO>OEO.Y.U=4Q5L+^G1XK>|US^D2+K^N4.UD\_0ASO) M+  
L.C0^>1X<+O|WGBWX^I^JWHR:P4^+&@&1FIO>+^J.CF|FL>HS:C^5B!| MMP#?K."A|S^Y|5G@^LBT\_5|A#G&:|YF4#Z8(HN:5D4\$EJO87%M6B16|M@L  
MD7=|1X-4Q1W8)44TXO^+IUUP|(K|G\_A^N88V+^F^E;S^T&ZEEQ115|L|E5& M|^O6INV@SQ>\_9 IV4D6JY7."JI.WE#2FV@?  
(EH:YA:QJ\$O|S=&)WVZ+ MM0-H^CA5 "1\_-JS6="=IF;\_ HF43PVD-#>\$P166^KA:I>W:X|4E^J|;SG< MP.@T^O+YK:D/7>DM.\$@|1J|6;B@.B>9|  
>9^KF5H|2H^2OX|J0T1^5>\_95H M02L0+XG|0E^R^+O^7J|G; C.D|E%:RFB|@O^T@%|U7E#7@|L M&3U08^Z|OUI\_38ZHU|D/5^T:=IF:\$  
M3N>S9&4^ZT^7 AR3|0<0|K|I|BWP69IG7SVH|B+WE\_UA^1^TM&^>FCTM5^MY ID.>^OXW@+GLD14)V7>@J|@O2K;HS:J\_"SJE  
4L#;L)SM@P7UAF<\_M02A4H3R\_7D3#0^FC1- BQ";"AKB%\_1^>^\*E#RK;I^>GB^AH|OW|W 9GXXN  
MXZ+^\*^X&Z\_|G4V917H0E|>9Q^3@|5V.M|AANX.51>|L:MR%\$| WJ=6V\_& M73|V>EJG:Q2X|LKRUVLX\$C^<^\*1;STNMNW| MCM:X>;E7|73T^C<<  
<=>SEDFM+HN|;EI9EAD|>=>E2\$NPVLE M|EUN4W2|=P.S.PIXXSF=AXW\$QQL9=>J\$^FMUOE0BO|J^B^;Z;V^\*/\*\*;H3UEV^RGD\_7;FZP(1QI-  
F9VWY+FX-M:T M^H^D8G.%F|R!&M^#R8^D^I)QW^5QP/L^1^93SIOH8=XS982=34IO ZDR@ M?F8>SYM5W>G93F4S!^?<-  
UV/7I3=<Q>Q^&NOVL(19DB^YXB|:(4|M8Z0#V#@D|\*|OSV^|>|>FTAM=^\$@F|O+SOPU=V+VY@IZ CEJZCJ61TE%|(V7@N|)+?>21  
MHOW@TV^P21W-Y1+^FPC=|Z\$C\_RBF\_U+8M|JPA="O1AC^+O+LO^WAS M+SM^5M|5V^XO|(C:#W#&:LW#0)|O^9E89V54G)63=TOQ^8D^F' <=>  
O+W= MVP<^%30-4^VZ^<BR-(W^MG7CX69G+VL\_0GE|E\_C|4TZ8E0E0712R+L)W^Z> M;IDQ^2V1Y%Q\$V^B=C&A> TKYP\$\*  
;5C9^SZT&|Z21X54^+^O^\*LG13QU9.TIO^%SV.OWL|.;Z:9&ZX|A^H"(ISX^?@.%;3 ^E^<(K|D^A\_ QU<6|)WB=|^< MIFU:F(OZ^+^9QC\_T^A  
|/3JL^V^GWL^301SG|Z)ZP.-\$<\$<3 M^BMO-#S=LU>|4R\$E|O^P^9)ATAYO(0S^;9<|0.4PR0LS^|E-0OT&P.CX|P^6GN7|D|OIRGG=# B^">1W|\_8  
M\_GW\_#EB.BCGLW2^NU@-R-@BPDK%F^?2^\*\*%B^>\_10^A(4\$0G^B|5^GG^L M^X^M^\*5RS0^\*0D81|EBP6.IGQPL3DWD4|7)Q^>^|DXD6^".S9(0>  
IU#L MIV@< OM|4L 3@=> GL&H;|;H-B?7Z0L L\_U4DYZ433/\*\$ SW\$|:UW^2|@|5 M|8#1Z+S2|BE8I+SPH@JEE L#@.L^R8ZC|>WSQP-9  
Y4T^G|S=AS\$|L.PE M^1^#N\$|O:2% XK<^&257@F|=RUZ8K|I|QOO-A^9K0:K+@5\_.;7F|@EM?=-S^0W^;9N|U)!+^YJM5K 49E^>>SUEW/>%98DSE.%Q  
M6V|S|PRJ|ZD|SLOM|2J;|+K^5 Q|\_R^J^R M:1\_5@>Z^XZLV^V^1C^2J^R@&|VB/PA:6^2+G8Z.L M^2N+O)0 =S;|J^EVR\_Q|R MZV10^M^5U2  
U\*JY^18D#;W\$;-|MOXT\$|75KSI|FHNO3\$B\_HUTL.MDE)1Z& M?> %5GZY>P&9\$;2Z;N9J^NE|2B4^&6T)7L MPO5W|>F?  
WU\_S8PFDZ219=>:TAL);Y|U|NQ^?29|M|=B95Y+GGD^;6Y@V7E< M|J|5YB^T.X2|3E:|J|+:(M.^VDFH M6|?  
D6^1A88Z2B.1|5C#93YQM\_ML\$Z>F&CS&(7+35JX=|@^B93\$ AU^@42)  
MX:);T:QUEPZ#\_9E01\$D|U@SNOX83NH0W|@ 4\$<41RO(\*@3TFZ332E2LH8W#G MYR|9DSIJ@F|L:@^RZEA).4(Z-MELO\$6T%USQ\$W.C%&  
(&|L8EC|\_K<6^T^Z;.<\$A^6A/PWHD|3 MFH@2M36\_@\*2>|SD9+^ |J3B6Y#^3:367+3#\_H2I0P^/3YP#!;W^O^TGRSL MURLV!:=|V8?  
7\*=>6R\_G@GHYW<.<^V5?29.W0D|AXTY;V>E5=O^NT\_0X|\_6\$ MN:=MH;R0!U@(&D^RWGM8<^59T^A7|QQ9QM#6%<|9042\_7%2N\$PA>@J70JN  
MQQ=IE#0G|10|D|MB1+^%K%|J^8#552^P2PEE +=^7F|@EXS3^ (2K; MAZT^0@&#%)H^<#1XM - MH4B7QW^&HKW^2&2V7^V:;P5^)!|PS4D-;  
|@W\*DPXV|B|/Y:;%2EQC5 =-& M340^Z|ZKA#OYQ#T0-1^N^?IOW?CH88/UP#E=^VOB^:TBLH9?MU< VNT3:02KT MKV8FC^HWF1CC|VDA)-?  
DP87/B=#6\$SMKS^2WLMEO^\*6N\$N^%Y|Q5V\_L&TK M; >O|J^/EK+RECSW&TL&(V)U<^1N3^V+;(-BQ+034^10A^PMJF^=<O5^  
M|3|V:78%9|Z^W>Y= W^\*|CLL^|HAN+6+Q3JEY>W:IM>;1.K&Q+4AVN2!^M2K.ZGZ^F.L^O|BCB\_B|UV(S^#5A(4N%3COV+21#N5J@|!Q|:5M|U|\_)E7  
MV38<8^T^LH^KD\$|3#A/P+^GI#3 ID.ER#%562H^3.V&|DS^MB^\* M^#RSX\$\*E|>^5TV50^\*8\_\*TJDD7QRM3;S4O+D^\*X(^=<+^%C&\*(=)U#;  
\*YI|^14M#&F^+F^66T^11 M|ES.Y.^2J+Z@1^7^\*3|W^T^VR5^|U0PX@|FV|D8S^1^M|80HR|@Q6&..?^#|B0Y|J^V^G0V^3GH>^\*W7PKJ2Q^R8^BH  
MDE|AR|K5|O|2^96X^|^/7FX|5E2|MC|I:Q&4M0S|IUS2^D^%XV^PGW|O.MT|JHT|S|O|I;Z.BRKZU&JG7^/2G4S+^F!!!NRSF>@OC\_H8|>|C^7F@8  
MA.BG\$ 62^\*30BQ?G|>W>FF:#E;KB4^-KE+L^?&R0^1N3PPA0G;XH-)^C> MNM:12|>^6E5\$3|N|E15^ZK^@|8%(8&%03^!QJ=Q1?  
T9RXC=>PU|L^Q>Q^2V M@:;R^M=B?+5^Q^@MXL @O?P2= R|C^YQM^YCG(-D&F<.<|S|@N0^:R-;L M-CYB|F|&-2^1^GNU\_Z.GU4?V@H:;  
|J^KFO16^/ GDDGL=4|/L@I^Tj65 MKKB2VAMQ M#1#1Q024B3^P^|EJZ9|D|I#;G3>W^X@05ZRL:;#77D^|XU^@2?  
M=\$|E^OV9)A^38^;T/C@|+HS|I-YG^G|Z700H@)D:DVT^;ORY7PF^?PX5:8,2J;|3V M#^MWX=C;PNOHV&O^XL4E#;4#EKNA:Y.LMI^E|CW.  
(#M^AL3N^W:CPCI-G^;A01GW0XC:2#SEK M==< WMU|SOCPP^Y^4ADK|+K^SO^\*(|UA) HZL&4C^90^M^V| BRJV@QW  
M2|OE=>Z76K\$9^!Q|S^;1.MB^B|1TN:9=M^M^N&4L #72+1&F&K\$SP=WD|>@\*O M3=(^EKZL13+^D2SN27^H|I|AVDYB;|TH6NW4V56 ->EQW|HM5"?  
\*\$LP+|=Y^A".3AR/5UM1(Q.IF M22DKW^5\_16&1\$|DB6^\*2.9K6C.-=B+S<%PEAH96=\*:2\*TX.BC.3.Y.M(C\_XD%|>F5N1|N;X>9Q6TM  
M3|\_6Q96DDBOM^Z|4ACCI(RV^:S^CE^UDMGW4YXZ\$|K^|9V.N.W^G.O%\_DDV M2012\_@>|\$.E.4BEDV#^\*2R=3\$\*RRR^AW^|S16^C|  
|<^?Q269=L0^E^8T\$L\_5S2Z3=BZXUPK#U93+^\*ELM\$S^L^9S|9|Q|DV)B^HJKMDKIW<|W|H\$N M2FNEDUC^=:K|7L.58&G^G^/NM22W5E#K>G;  
<^|6Q|CB&(-^2EA^C^0%2L^#S M^CV004(9I|A\$D|%3JL^SW\_OX?^;SXB|W3DHF:;22|^V@.I^1Y^N^JTP7.GE=JTN^E.Z\$7; M7=|TRLMN9AW: 9=|K4?  
-3:DAY|P6^G)EG/WG4PHK9)6M(KF^:<KDP7L|H MGO7GY5^|F#E2520YXH^8@KM+T^("VP M:9Y695Y)T^=>045D6|IY|6\_EDHB:8H;A2^DK-  
=JW|L6^7F@W&= MS9JK\_P|CT^>^?^\*--Y.A.F)^2^9^&6JM7\_ZN?|<@K2FMJZ:S#HAPJ M^G)G^\*J8K\_Z=^N L>  
>GJ=6(7R5309N9T|^2+>=%<S^NEDU|>I<|BNXLFO MIO 3:39U4XO2KPMY(G^K#N#IR?>=WG^Y5:MVRS=IT2PCAN^I830U^N5A MJD=K|7\$|V#GZ-  
2+N MSE20MNE:17\*CB\_1Q5CM@FLW\$DXY|JINWCSU<1^#B|Y5ZU\_/A ATT&8KODKD|GKEIAU&P.65HX|2XUEM:%XO715WRS;<@99  
M5+T=6A;Z\_(-IE87&@0% TMA+AN(UR+;3U6|BZS^7ZSU^@?7)HOA MNFE^O2E+OKEQ|S|WB55|KZV|V|N|R:1+&U=^  
AS14+^?/Z>SND@ZL6G\_W MTOU|SUC="T=CYP^WE4^\*Y|RO|P02PK^OOPCF13|T|1.73^GJ<^<52-6:E-6|I0R^V|B..<|O|Z|E@2|PA%L  
M4C\$VS;RTJ\_2%R(PH.;AAD2.1%L+G|)X9|\_R#Z|O^R<^C+Q|O/S>3X|+Q M\$LFQR1+),K+P;^POO?";\$BQZ|OLGA(O|\*EH^M\$F M<5CFZ^O\$1D>  
<3^+UR>4K4409<=73#;YT0|U|D|P|C>U M|Q08%#IG^2^..|D|W^54^@MG^GCL|>53591CSK^!2|ET+>M^%2I=>DX^\*0R|J5W<6M^Z7H;L-MM  
MO(C^E^<+>=>CZ:08>7&E|KEV|2SF0|W5=NHE|LU|G|1#|@S|^\*MM#6X|+^&F|7^38U|^6\_6=@S^12^C|M+^I^77%\$;  
@ZJ:2WP^3S\$O|B|9J|ZR M|\_OKBYN^@\_\*%#H#8W\_L5?|^\*J4+>HD0C5=N#AU9\_|RL(PC^\$S^H#>:5 MC^96?U-\_7\_#L:(3 ("=Z9\_/(H  
&S^C)^<^DO^Q|2 QYB^B|V|4W.X.V68 M^U.RT4(4V+^+YCGK&4&XMF=|5@KEV^T^V|NUO^W:ACQAO|L15&K=205^&M^2N^"  
\_YU.M=V9.07<|R^<|880>\_4W^S|U^CK\$D>@|:(M^C^H|MHXSK+ DSKLN M-7#E5ADTKE^\*W> 5L=9V|IWN|SUAZ|(HS\_A^#2%|C|S^&4|WR^H0|GWPO  
M:8P (#E?\*-WKX N;L>RKE-#0^DN&3;W3E?@O^0:35/|I|8#AZ&K|N@Q-#1 M&J^>80^>YS+X.9J^1^D03WS|Y?>UO>@|PBL^+I-  
^0Q075>@0UVI^P8\$| M/4<=AA=CM%.RVDU;UOK6|L^XV2N;B|U|C6K\$|L^C;4^AUE>^\*X|JZAW @ MOISBRH61-  
M#%=\$.1^MC|J307F=LX+@Z)|@D OWS^MZU^N M00P&|P/W|+ V%|F|O^0|F|DK&R%#^6N9^U9X|(-@-^)-0?S^9UX^O@SFU1 MUTT^5063^M-  
@378|0N#E+Z;|@MD IS^K^7^6G3^YPA#|444S.6)AYI(FDCS<Z^ MMEVJ|2Q|Z.^\*%<^TB/6D04PM^S9VE\_BYODR|2YU|JHG@XC|JOJ^Q71M.H@:W  
M2UD\_I|2^8M|\_&F|I| MPPS)-3I4\$#X=F\_A^C\_\*\_O6K^1^P@>PDA M(T^HCB9|1C2^0Z;^>V5U1T^ME/R3^C^X^23#<12^#H+A06?  
<Q.9B;P|H4U^E.G;|B<#>F(O).^SD W&81>F MX83D70XW8U?7-1^|DY:=9AK^4G1;1^|JLY36Z7R^H8DDN|D;M-|L8KTA^>^E8S27\_MRD|  
|E+W^NVHTV3^2>WG:2AP6^\*^QV<^<L^Y2.5%J MWP6D\$S^U^6072|>H^T^1^BY+RD^K@N^P|LOEX2628V>|ETB.729>(CEV4.GC MSYG^R)?  
ZY(BARXP=3SQK=^1^J^7&AQ>7Y|Z7\_Y|Q\$|\_@Y>DS+W|W%UR:>QR M^GSRB^I^&K5\$007BV.1R\$HJ\_59V:CTICTC@:Y+^\_QL\$O^W|6^<^SY13W@8V  
MD^UE@>=1^3^V^5|N|1^PPG8^<2<=<@%|0%9J|?|I.P=UOVKA-K\$1>=1H|52 |8722L:;MTD2:G^H@X66HUFKZL9>YMNZU9-2|3  
M2NN:9Y|&VKT(WL|N|J|L|S|);<E;S^MKC0BKS\_UEZ286?K^DZ\$3S^H|M.C(232W;SRN+^\_B3^Y^GSV X?^1&|Z|CV7^<UMR-G^I=IU#\_9A8(PH|^?  
\*+^+TI@?? 6 MI^156&MOT>6T&5\_5^9=9=ZU|GL8\$Q2T ON^;33PFL^\* 4M2D&|H)G^X|L M |FY&A>&B)^G^%AB|BYV1@7AHA^C^T(B+1="&  
%B33OR+BTN.52^D|4|5.A MI<^%DCX>@GL08OP3KZ> Y:(B)^K^<2#&|AX^<^H7B^0^A|MW)?\_O@ MXP7A|T6W?|L:B;K00-GH^  
OK.F\_A95A|P.FWC6;|YVQ4|EDX|L&ZEH.M)=D1WVA1U3N^9A;|=YB4^WPW^2G^V|Z>#YFR  
(I4\$1=|6>&RNH>;7|+L|EAV|RPO:P8\_NEUJQNT^41%60=^FG|Y^>|<^<^)=ES|7 MH0S3H3; 13N|J^XZ@GEGS8D.513(V;@R|I^G=FHD|J|A5^XO&  
|N\$UOET^T M^@N="|ZAZC^\*^S|J R#0.7#;7P|\_#\_47^XN|^ZN.^O.REG=TIWAR|QVU^V(2&2G|V63<9X|KA3 M9B2.(E\$4^<-  
/3|GY1^4ZQ:W^M^RNL5PIUY9.17M^L1ZM3#;9^\* K|JG M5.FE-WD^V|MEJ|T6R<=Y7ACMY>.@80CFN^9-RER^<CAO6C^P-|DBH.9 MQ  
MY<1^J^S^Y|KW|%%&1C|P|+> C^HIS^8P|O&|B|ZMVO<=(46V472B5CVL..-|M<^2="RD^R^D:|F|A|J+2W48VUO^%M|X|&8E-  
|SWU|OKU|X|L3P|I|5O|G-GZ)^5B^\*89^&FJW6@^>NP.W.MP^7\$5.(EZK|1%Q|! 2\_%XB?^H#X^N+V^%7R00+1(|I|:#G@R|A@-Y8 SS  
MM4^D^>|I076M^HY=LO3>H^\*LAR\$^L+Y+THB^<^HG.<^+>Z6KGI=TW1@.Z8! MJ|  
%\*ZAP0SR|O|W7M^Z0Z^L^B803^7R|I0K0LF.MY@>8WD^GEZH9^7.7J6S|C|2+>









M2W8[M%PT<=M5R85.A=(\$[BMS\$R1+\*@:PR8MTZJX]0W:527:HTUT\$+1+1+34 M18KR1:%H202=YG@|!F/OI0ML+O7\*P7IGX+IC\_NJ  
M\$A9%AL^N7G\_W^7>|KN#40#10.#Q 6G%ERLHQ'918'88@OYTT>,35AEBYF M.W:CD90 KY1%#/#H72\$&EDSDI.P2BZ1#^(H%  
[MSEAB=U\$MZN%419@0..M:1.M^19)IU;F@-1 M-M>7-1,2=Y7:19G-YS.%N3 7JK)'ZSNV?K MS/ H(8T\*TKG\$%A IX4?  
8AA\*6S75%K1W^1T^OQA;V;HEJ;HEA(3 MY6 )0ISHC\_I^2^5>1160)A.E.1.1>|GH/(19.S:19.KA+1)B9N(P+L1 M2IGSCS@P:  
<L1)GORET.F<175^1+H9#0>11B(6.12HDEFA.P(6X7-JBE.XLY.1>|P@T#D89B\$%#/#1+T)9.YF1#EJ\$;U+;^1@=9X&=8<M0^&%  
GDPK10>2/H#PSC^Y1J#VNMZK30QA.K5HIQ&T^JD L\$72X&D^YB; M2?2(G/?>VPCM.EY.FYVHID:QV7>9E|U9D8'M+<1>1Y?<1-6H:A(WF3-  
MGS^181#;GSLP@.E.FE3BIA5.HK9UOKGN@/D>A^G/8@-PQ^\*SW/O1A M719#4J9T^>1+<(D%.8.5-\*\*\$.4%K)LC9 3IO=N4HZ.&+;1-P 4O+Q!OHHN  
M\_X:Z58CWVY712XR1.MIG.M@+!1<7A.DUL+@7XHVD7UZ.#15)AZSE^11T#)2@-MK47/7:0JO@MFNF9B+166>8E=8\$XD^1#AB3TI>  
&LWMMH\$X^WT81Q.M.ZFC00U1.DUL\$QJA=RH2H9=13F1+1.M^2Y1#4 GR^\* MLKD\$TMR1#<18DM&WG6;J=PD+1B.  
H.L1\$;H788LW&\*UR&RDSH\$T5@.MA;TWMU625!#(41\*!L\$#U1/1)RH(88P4W&31^O\*)C.F71/3^CAI5IOB2@H.MIKO:H)21+16  
7%.C'D9E19G6'8.#=H.0TSD4.6K^!P\$%O/L<+!+!#S.MR91@F.N)610!IO\_2!F9NZG\*M.NBM9\*!A'XFX%SB(MJ;V)XMX%ADE  
M%#%Z@J^V^N)";\$.6H@X=HBB'L%W.L^&3^O<5;B8H#9V1@UYU7M^&M8AD-DO1@Y@1=H1D^X>D6R8H(H=O13 M#F1.  
RETNZ9E03!:=1%|HDWP|HC? M^ERR;&08<(CN(XMJ@QIU@Y5Y08;EM?2T' 1G@G=W;015JAS^YK\$S^NNO;8 MU;X;LJR=1BA-X(VL+/\_ES)1S0.2  
IV1.ANXL1)N%2)Z99#(P-R.%2.MF^0#J;91+1+<.\$Q)GLA31/UO9J9V\_8N13^32>Y2CW4JOIG@E618MP1) MB1VZ+ZG-  
L.@(8.S.MR0BZ74=(F8DY)YOR^KV.77QG.H9T1Y2S;IOP\$G.MB1.5EU@PO:7H/QO>ZOMIK(U;J/G(6^W^T80)1%|(CH0)YVOZMMH8HS  
M96\$J77#E.FML15\*EEG%#H9@S%3=O+7+XPG^RP.M?(@%60(&^\*IGWAV\$-89X)M0!\$EZRS?1.#"Q485-MM1OS0R^\*P.HW4-UE1T@IB^U^\*M  
8H+N(E5HAAD2FB16SM.2Y#.#"N^KV^4XTEW?2^H6^WN(C.M)M@8P1L+81Y26LY.BYH14U\$.^<=>#;HS1WE9VAIZ>#1;YTOOZQG^D3  
M1VC.F@K?JWPM13LTFEG(A..Y8M4@2(DFI+W9H I6^C5T^T\_1\_+J15-MW2H1DZ95M18JXAE/2HRKM4S<4HRS5P^\*A#.B7A>4@M7&R7&R4%  
>X\$1 M0X5^" S;T0.K+&8.D.9>C^<7P\_%EJ=8U=J5XXA1M9 MP)=F3|XLFV&X7+&+S%.B#EY010N01<Z=#ONE)%G(GJ,BO%1^00.311^MR;1  
|Y)C+T62HT1#=#21#H.LO7P.0E.M^Z#;#1L^M.B#M)O@|KPKZ6^Z^TC.KUS5%#ZHKIE%0%#H 3(C+1+GPR+1DAKS(U M5)  
NV.C>2;#H=V>#SU0(OR1BUOR.40W.N+1)7L.M]5\$ #2VY#=#<04.P;0#D@IA^HDY%&A2.15^..<5.C0+16D(LS7-  
M.9;.61G.%1%#R10+T6<#UIX|+9R9\_03MH2V9^YZ>#P+&+1GRY8B MC^A\$0.CZZ4!|!TGV=H#13G;6)=-4 HW7.ZM<^!RAAQ7B641V6)HQ?  
MJJ+H<4^8\$15M^N>1<K/PFDX<.&M5X3WB=V83B+HCL^HCV.PQU6P(7N1S+);/Q(14=MABO\$#<EA\*PEJ-B.O6K5.W\$YK.ZF17XTE3^<#Z@ZZ|B;9L  
YX1Y0:LTE\$MFC.NN1^\*2^NA.LS4=@.1^J.Z#H#J#E8@|>HJ1J^#XII&HG0^/A)Q)J-LK-MJ(S+100%KY3><#CLG2OJAI.4?EGX9^ZFLW^+7/AZ|8^IE9  
M1XZ.G.DT5E.LZC2GHC\$54.1.57M.^TJZ.^DB5HG&117F=M0AR^\*4+&+TR^EL1\_B.ZAB1\$X=8^B^N^42GVH^GCH^Q45L3JH0<#1^XU(CMP<6>8.2?  
H5OS.0GM.6L\_+198?H>OIK;7+>\_14#^O\*H(X+T+A)IK2G.MU^MC31\$2EG.T2SK(Q9C@DJ1^1.RR%)NEDB^\$TF^PGIX/1 D^N.SF2.#K^X\_0  
M/4+810=;\$PJ4616^M+D^A.8TUCAB6E4\$00151D^T71K^Z.DK=AX.FWC1UZ M(%@72415!  
XQE6.#RRH1(O^N934HT^1ZADDWR@<0!>^@H1YT3^V^X/L M2<0^3DO\$VECO.Q+ B10+1HMV?CFKY=&+P.)7KX?^0+R^R^1=>P!|T>3  
M8^Z#F.V)X@/PW>H.7&=IG@/2<8\*H7R1OD(2.\$1^9.A>#(1-23?EHW\$ L M U  
C;E.#R5R4#K4M50&#5#SGW:GLIPV3C.&X+7;G@#VDG.LZDMB9T#1+7W.ME05=2U\$J055)>A^LGL;NZ?V1:T4?<TP@6&0-  
@ATP^B51+8LELZ(G7%T.MHA %34V@.@1219<7W6F%."AF&C+Y^#M167%T3^@.(6H3^2^9%Y(#1 QZH  
MBY1.POU8\_HY^1;E5#0IZYPI^6F0(S@5W?2VS.GS1366VZIS2RDX\_3W(C.M\$18YBV5\_=-).7D%(%5E1XSDOX(WM-&  
#R^R.1E^VZ6Q.K71P2Y3SOX78 MY9P.WED^CO>W5UJZ.T8N2PK^<29 UVB%SV2F/W)YUXR@P^19^E1R^2^E.MQ338L^Z^\*O?@.IB(CG.A4ZEL.U9&<67-  
/RPA+QO^QVDP^XKX1YRPQTZ.G.ME44=U^100!%?14H^13 ULB<K822.1\$1=2.W7S;S0/5=-2.MN39YKMGJENZU^K@SSG82SBF\$>>+8H64:>  
D.X^Y@L.25\$1WN3R3Y@=6C^PURLFO=1.#>DZR2=C^XIJ-U\$ MX&8 H#K+O<10.5#.#X=A\$%.P0S1^9L>V@10(>8.&.)\$QG<.  
(LQM1#IXCWA1P^CX21^VZO Y^?#K2<GU\_U@O;ZVZ7@00)3#5!M.M.RG;SY^R.#W:A@U.MDQ&GB;1^A&8IQOS^11&3G\_L1E1\_H=RG\_Q@@@BT.M9>)  
(B1!>MAO(+O=K^>Y9R0#DE?2 4.@8J0;CH91=AA.<J)=4 PE1CBX.  
ML1^O^S\$5&#R74P=>G3LZW#9IQR9Z.59HQ&84N#GE3B%KGI#44Q%&E.%Y5-G<=&L;UH-C.MK(3CJEA^P.  
(E5H+G2BZ<^O>\$ZRYTQLWKA=X.ZIZPK.28;<#<#2L(N? MY2\$1BL)&A.QM^AZM=I.FIHV 8U3\$ CESH W0#&RHW/OWK4^%1=JH+) MT^)&  
M%VOS:1&TJ.MI^O#82&L0;Z=EY.0.8^J=OGQY9K.AWC73#\_D39238&A.MYND^NR^YXM3A>%J<1>RWS+;A1BN1VH12250+49P.#3\$3>  
(SDSEHN@& MXV=F=NJ2551!>CPS%5<.(AU^1VPP.T5187.CD9Q/DM0& AP^1CO3@&^3C.MRIQWS^UYGQOBDZR^IQS2AC^JML/DFLG\_HL?27H.  
(WWU^7\_91^E71;(#1Q0.MIQ^GY\$1VS.@DEVBP\$P3D&@65H>>X^2?PT@1&61R2R>U404Y? T?>K7;Z:W6IK2G#1\_14 B#176.  
M3N>AH\_B^15>5KU615.B3JF7.HGIM<^1TL9@#^1+1R^/H2@2(O.DA.M.DL1XJ^1BO&.&XPEFTU70S8! M.2Z?P\$T!<^D>FYO>31\$-  
V8@9^9&H40A12>#.#\*H1.B0CH5L^2^AX.M1OJ@R0;Y;39D.9T^5<=&M^AAGM4^1.D1+Z76BK&V@.KO.YSHK^C.M1.3#@1J\_12^A+  
G&E04D\_076.GHGVB/#<^+>.OQ?H2/<)+Y.MY.HO^H\_9\_N4MC^V.8JTB\_JUMKK(KV1&0N3I?A.B5@DNCQC27-4AY)\$5= MJV\$JUR\$P.(P0.K1ARWE-  
C4?<52>/90^&#25N1(C^513)25Q57^L70R@.MT^M^P.#<Y#1EPT9284W1L=2)JAL\$S@+2.PCA1^3^Q.M1.OIX^GR^VT8R.#+13W7ZYVW^1+2  
WA5239LM>7F44?2237P6&M.GYOS2FL M=D@X64\_90RLSC+U601#0.X#BDD^G/G4E1T@05^H 1(5\_1+)\*RUE5Y^\*K.M06H0MK.GY2XNER?>  
>X^F>Z\$0^4=18U;K.Y.X7OT\_6SHEX.<1^LS&>)>R.M.O+OIG4.SEY31^H=\*.OQBW^Y^%\_SIZDO\$A#1;>FI4GZ2-RFO1+SC16152.M67^TG5L!  
V1;GZ7H1LKW4KK&SKS3153.XM.0501=OZ:4Z1?2SOY255O1L&M\_XQ>MIGIQH1>CO^IXMJ\_K1\_810#@&1^W@61CR20^3\_#@IV@YCPW1\_W#\_M  
MISW1OZ.S@1+O1^KOH1\_10M>3@+1U7H<COHQLO1&8.LTE6^PW10^2^GG.OIMJY:3^K^<ZSR>82R1!&G^G  
ML^LFW<+>Z/HUYO=RU(KG+NY4ZN+1S&4.KXNY^<JGPX.^EJYC(XH^Y11 M<1^V6W\_IV+6?KV>DZCOYL=-VST76EC.Y1^WWZG^YOT?  
<^>Y.APIA+>S.G.M.MEX9.8.GS=)A1W^L^M/K916%NIS;Y;S.(KL>J56X^S^\_SDH3@SZE.9=6G.M7+\*RZE/PD<^?  
>+1.5NOD310^Q00T\_UOKS&#%2;S2^L&1C2-B-M9L0.S#(M>GYV\_L2PIC0.XU71MZ=ROLK^M^E0C\$.WD.O.MN04U2^KOI=8!L@\*GE-?  
07SD6)HRGKR^T\$KA.&U5#G820JF5N480.0312^>316\_/1<141=).M5V1#8Z.M?#NEWL&01GYG7/PWG.C761H20^TYAGP^UOH.E.NE%1\$&  
16=0.GY054JYZ.M4IKIUEH9YGI1^>4013^MQC7\_5/22LOIN:QZRDUJ.MU(1UZK52UUV.SY.OW1<7^\*K9U\_1\_Z;EA^OR<L)\$\$+(<6QI&86(3ISM01Q  
M&UQJ8@TJE2)&@SP>O>Y^14G>FYK34B=#3Z>YHOE1#&ACIHW7XN.O.M%E 3 L@29D!>T=ML+SE!HNL@B.DJ1-  
NUB(MA=UMXV5>UNKU^1TM10V38 MK^TQBTBY(UJXJ.DJ14E-685PYBFVCG^FF)\$:DHZL\_AYR22.MN1U7L8G^Y!  
(^FA80Y3V6%#\_H7L#6\$AZ1+ODC#2.JNGENJ9<#1#1\$;MYC=V42C0QQ92B;JO=689A=HPIM1)GGC(O@Y@Y1.OOI:(=IDE4!(QK)O  
M81#1="C27H9";P.O@IPG=C+8^C^N^IRX;7D@=&9F6BE210;2.8<141.MDDUB9U9P67D@&\$67.ZM5F.C18T2U\$Z5Z2MA^#1B@1.YE)NA.MJ^"  
M1^#N&Y;IGXG114&2C5X&5^TRE=E^PB2B^W#1+VGI5BR25;8BLWN.M9@)1)3#H1D=PNDK &PU=1+AWK^KVS8&%2<50E^1FO4V1?  
MO<C;G5)5WU&P.MF%3\_&SYMMUL/>GR#^E3E^VPY)3;^A+;^HDM2\_1^HJ2J3.M.;Y:6A55.W@?)2K52K+^S1U<2EF;M)124AV+L1!\$0)1?  
%0RO(SK5;TM.D.G1+Y1@R=B89@K13JH58^0Q1.M1=H>PMT944@N.X.H.S^R&L^C^V1F=0.;IX^\$N\$2C.LDX1W^RYDI.M.O1-  
<CZKA.HYK&17OZ:WH^VSNZ&S<P0L.UOE2\_X)F.#1^OJ@B.W1M(Z+4C30)3.36PNKE312G1%#E1DVUE@C23Q!(LOXC%#&SX%1^N\$G>U#  
MCHP/\$0BAI^1#SK1>G1^HU=O.JZAI^KX<^V4&J%4.65^XG^1^N=HIS7=T?Y^MFW^GWI+1NS\_IA!  
X\$\_.1U#M^EVMV(F@O+FB#;71VH^Y8BCM^1^AXL.HWZ#MY\$H157UP9)PS^Y^B\$81Q\_1WF9M&WS^096K=@;A5^2>3&#H3L3(R19M>Z^Y  
M2^YODNM\_W>3Z@12%#1DRD.H0.;=NK)LF=14H15-MIG.E33\$Y=31/(1^1MBY3<@&@&4.0+@6ZU)-519J1+H13&RP!1P6+@DX  
IR=4\$E^YQ\$V.MBETB^JEA@B^1^CN^1+(1D45T)10\$+&C&=TX^YTS1^#A=31MLD@)MY^08;MOYY+77KE99)>SEWG^N^A^W^K6&1VWX+NIN#\*  
#SK\$@#5;P(#)=16FC1Y/P#1MAQY^>7NP^OR+38T^X^T/026OMOR^GH/O^V5ER-C+#+6WCA24P^V/OY  
M.;0%1)7EMZ+13;=FSVY^3YFK(@D^OS0;\$.X32?GX?)2MF2.OF!%\*1.GP.MB51@+T+7^M\$A.KU+S>=+X+1^\*XK/-HPG1M2^6C0.;PP12&ITM-  
C1@X7.MN.0@9C9\_K+X^E.6L)D16P@/8.@M2;0294BT7T?O=P>(D)TEJW;\$R\$GX.MB+10>+K.V.67&A+BI7&JL1%OKT-  
(HN5ZQ1Z#0)1XN;@W^K^1ZJX.C1M<^26P.OMJGJ.TM>+7)H#=#YX(FK2SORH2#(.#%0V1>Z^1^HA35Z(>@=M4^1X^GOQ21|MG7VTD<@PIYU  
PJ@=(?2R&B^TUCW)XN)2ZY^O.MV.ML.CG(T+5X\_EE)HML20^CB^\*#ALSM@O(BSD<^0^A.MB15Z/6&+2^M9HP1?U^VP;A2-S^PU^N3817^I  
MR\_T6L=JH?2^O\_Q..6M72DEB<55B)R.PTMGO=AGIM^W2041DB+X4(MLTC)H1U6&W8^DR(CMP.L&1^V^<3)WDR#C9)1#%;SC3  
V95M8>#8)M@\*38\$4NP1^1J9^0.M3F0C^+/-SR0W-5AD0UCIK/FG\$+<+5@^OF#.\$@)AA.M2?#N+9XV&XL5Q\_XKCY)+=XM^&A>1X6KB+AWB18^W  
M@4)1+1<21^PY+8\_#E@5JQ.OQ.6#16IGCF#M)=YCDQ&PAT.M.C.N^PI(6%);(N)@H8M.9(U#8^3+AJD1-6J@C1BOD4@&R&S^08Y.M@-10  
G&R^P.3B.&K^4#\_01YO1&4T\$P^AP1N=(C1525RFOETBND1.M5Z.#\$EH#P^SKRL42Y(CW1N.S1E9K^YQ;OG1)6^V^1XOY&1E8\$;B02  
MH^Z^A\$7>FZ7.ZV1DSTBBP<\$.H1^1<+2/2D^1.#>4;0W?..IC8?NICH06S.ML1%NP<U(F6DSNEB\_8X.5R0V\$V)8(GTH^#;M@A?0-K\$361KO&\$1W-  
P%)M<+X3^P\_1BR0K115G1EB\_H15J4A.31@E.0P^02S/@P?1#P#N#P.O1BX^&@WT^R^HES/A4YK61P&4YKT4/DX1QDA9+00B.M^S1  
DP.MX^DP.P(>1+P.KDDH)4+1EFD(X5X7L0S2UW1531^R&87C.#^R8D9J9B.MGNT\$1995^TDD1)=ALB&B^1XU.C2^JM^1^#22?  
Z(W1+1^0YT<#%#Z7EM%HF.METU^CDOEQIR.Q+AS;1^7BW)7@IP.H1+A.U;1%1H2PT&4^&YO@W1AWBSK<M6#%&3170F5T+W5C@GB1^T-  
100%OB423A=Y@W4.2!D51F+16.&H1K1C).MGB1KY1YK.LY80\_S1RO\_S1V20^IK^L1%<L5;3T1)1L=1^BYA5O\$1A  
M+H3@Z^6+7X^1UOP^Y19E7P0&L51+F9N9A)MRI#&@EC&R+Z1^IRC+5^\*68.M4&#;RF\$;1XM^1^1^2D.&0%BW%1D1@ODOO<0FZWGR!^#Z-  
G.%14+L&2.M;8AT^7R35P.#E7PCA^H.O^S27Y=N.N4G^4GVMR8>9J9#G(YH@DX1MO1X91#1>#A^C8>W+D17\_Q^F9?  
3/7B1NEP.86G.D.SWB8^G;H@W#93G>MFA2ZK^G^1VC^Q8QFVN\_HXP=21E.(N8+Z4.G^Y(N2?DL1L;OK^VRX03G^@;4KS.M5%#OKNY8-B@82  
>861^1Z.G.9@YAU\$>2\$>DM^1=B2\$;NAGM).\$5.CV.MX\$4>2^FP1Q5+&LDC214^1;MNP7=N/<8W^R8<+4S\_N02G1U.V@MGHO.Z7NQJA^%8?  
M\$^J<3%;XU59.C9AJM7R5QH72L+4\$;URIP.#945=+A#1.MHSH(W\_&H3H2-MR2/HPS=8)M^2YR\_8191TG.(DDTRMDR+11QQK  
SA+3)ABSW&@1E%1+Q>E.MQ1.R1S=2FZKE/EQ@;KQU^B>YHHJ7@3X37.ISARZ=SH&1MHFIZCBYXG^V  
M1^N/L4/GH\$01Z^4.C>Z6.C183\_42A9/1OGX49<1W17>@IGO^1/3N^AF^HLXE.&#>NO&X\$7H^18^(P^>D^H3E1=MDDD%;1Z\_1G>146X.PVAR?  
H1.H19K+2ISOMYGF645MG7.H1QW11^%M2C%PMO@1@>LG@1H1ZYT=21O>W12Q1R\_8.^KN^Q\_U1RC1R^=17E25@)MXJM1=PO1WK0@3/P  
Q1OQ\_TWAQ\_@L^1DX^1V1P?1#Y6G1.8C8;1^W4P.M^HG>.4HS45^0V^XRS+##11^VZGL5MY63BN4/6C%1/QE^=&J\$KDH(8^1JP.MA?2G1G-  
O4;TG#1)9VW<5^HS^L1WAK7Z>.;Z:IX;NWO>.;1^C2UG165F^M.M.INIQT=GI>2^W)Z2^N.ML^WG16H147M>4MFL1#)6E\$@1VJ216^M?2  
9)DBU1HCF3P^\*G.&2^N1A1A1+B9\_0=3C7?1G81^1/CY3B4;6)MYP^Q-10^BO\_P1QIG2C^1Y^H&2A1=29)9LB(K<5W.Z1=O&T2AS.M\$N49T7%@1Q;.  
1)XH8^U(K>27^D1@BY4H\$GOG(+1Z;1J4M@A.^1^75.MK2HYT.YU\_ZPQR/^;U1^\*#6^2^2SUR#B9^<05F%99.EC.6)S@/O7SP1C1<59  
&93&G^12H6^9+AX>7^2K1Z+1(48W.U=F.A.1HW^Q42HE3C.M#Y&2A7^MGPS22+0PHBFYH.21VC0.0KYL12&KF^7^L^69;17T1AY^MJ  
M3&G^1^US1=O^WD<B^Ud6\$1N+6Y+13^+1^UPE^3D1)X7.0\_2M2  
MTU9B(\$60XKZ.I<(81E+L.\$31(<=>)@R@O^A9X1UBK/M244TFLXX@N#4\_T\_5 M\$W/S.\$9R=#;GLM.#0#B.  
VUNPY^K2B54SZ^@HW^4Z^GYS.M@<13.6/S.M9L9\_P=+S1T\$SERP3D\$>U:GLH8YUNJ)HTJ\$G\$O(DMAREF8@:EH02.MOLPD%  
<4FH.A&129J\$;Y6^&HDITE4Q1M)W;T72OR314+N2G8E^10)WWW.M^2=QWS.O1C^#P1J^#PD7E1%1^BBME&2:(E1+ZA?ZS5.M1^1/6\$;(\*5MK.M+  
(N@=1C^10Q242^6\_HJZ1^T3E.C04^1@P6QH&S.L1=1%#9&6;6U&U1K6S\_7

M438P)V=5G^N0Q7(HIW SRN5ARP+VX&EURAT\*Y,Z>WUV4Y8S\*/ZM+Z\*G#110 MW@I+SL@U140S3JUG0H5\*WB LJ/VWZ0Y31R^HN#@.D4E.;  
(="Y;ZJ=<@.MM1=2X.XP3Y.5JH#Y.T.2YXC.\*YW.Y@^T-W>9PW&=<ZF/E2!J3=&P.M40.U6B<JXV<QTZFWTVYT.X;EYX#A.HJ.0F9'DH!+@T  
-GL.89MZ^NVN^N1XA MAHWWPZ.WO7/FZUJM=%I7F^N6B7<0;.0=YLWB+I6H02(5X\$G:>NOU8'X\* M&?0;J135!=\$4#144.ODUX=\$  
G5432VMVY\*^I24I7^LXOZPREZMH".0AW6M^M%T>JPF!<JH38I!>2K#I=D(Q!>7Q^5S;+V@<\*1.G8F++VZ^N\$W'D>#>#9P'  
MIR\*U>19J>FZMHV.HHP4PIO.WOLOQWN48X0#IGH;B+I\$R25C2!\$ 3=-MBO.VB.J1=^A5H;#BD\$56VB.9.JMGQZ>HT:INU.K.MY?  
S^H2%ARA!CR^=H;TBK;H^5515YDZUW@A;W;S<9Y<10.G@.43N<=<M=9N=3EL-IM7&SM&USI=C>Z>.B2P9.NI.5IA.OIXI2IOWXZ.MW?  
W.WT^G!M^V<^%JEL^U50)WS\$.GA^&I^P.SMN3^M^ZN.#AVP=^D^<L.A#CFEKE: MJZAFWZ. "&(!.I=IC2C58)!+352CV^LC2+&390M.H6.M@^"  
ZALI.A5W^N7FKE\$SN;3.M+HVP4K7.7C4HS\$.%(50J7R@JBB7@F^M8GZ1+&47E./A^X.L+T;H)9\$WGW^ZH?F^C3>1/OYSQ\*^D&CT2C7  
M=VKG4+2PWY?L\$XZK7.6#M^A%.@66\*O9.Z>(7X3A6E\*9S@Z4=FH\$<BC7.M0.AXS.\*HPPML<5\*^2<4.L.FG^U5.AAFS@Q7P.WGW!&J.  
ISU@QYR5!-M^W)OQ.CG=I?7.AHK%Y89-^%8RSG+U&OY#W?P<^?E6S;EZN51GP.MLBW>075G.DTM.)>?  
J&O330M)CCAV@HID/YI#MY+LM77CN5HMFAMCWBH.MGW!WU\*J.B@ROTU&M00XJX5<N4<^MZW/+1KU<@F1HS&YO^YX0^T.\$  
M10IUW0#.#V.QUW>E^?MCGY&B4?2#A1Z!\$!WJ=2KWCVNCV.\*OY6K15>823H.MJBID06FUU9.GOL@.(\$X8%)^T\$OCB;7GOM(\$BV+Q\*  
IE6.I7<>BX>ELDC#D.MDPG%8Y>O./5.4E.B;A4.HTAZN."#IJ:1KP.M/V)X0=::NK5IA.&+PH%U&O@!;V(MJZ.O%412#C4=\$.LU.BB^0VUQ)!5BX  
M7FJU.N:M<6^YXX^HJV>V+V-^VIAWYEDC19MLR!R8002M\*QB@=<Q4!M.E;Z3?>.D059.TCE(\$W^\*C&I9A!EP3!<Y8L7ASA^ZJ5FZ\$44TF:IK3:  
M5:FIUJ.3.E@SL@9.2O54R1XWBF6PU9Y^MD!<4#77L8QES3#J.B;IVQB.MP>KW>8NIM@CYMIJ&E^DI^H^C3!<C%<C<  
^PIY&XKH.+H.T>HARS.JHO.M\$M?3<0^5^>OIKK)3R.3JR.>@<M.S>F^L7DFE;FWSSD.Y5%&\$1%>2@IVF2WO)0%L)R4DP8=%Y&\*4.>7F  
EUGI&=XZ>W12M#3IACN+L>@5ANIYB4V9P@K#W.M^P\*%.\*\$PZ.F@BP9R9OC!)2I2^+&^YKS>SU  
M56H(Q)CHC:00!#I9I(Q)E637M<3U%A>LHFVE;UPBU;83.9.(O8ER3M;\$J<R7+  
I\$>SHQFK:J!K?<C6<I.VMC^C2WYIE^TKS40&.>M!\$<+NFX.HIC^I1J73^M\$X..HO?H..FEKW=).K;&J  
MEQ:K18!450:88!T(BB1B;101^WAEHIOB7.VHLXVC+U2VT.SU^H^L.96L\$V.P.MB^H\$6^3!8JB%6!3CT\*U1^ONT\$W9>6>7Z.HVNG>55#1@VT?  
IP@>N>JU6J^C^T.MP!YVO3>Q-1.909R9)3SOE.+.ZT\$XPR+E.L.9=3<K4>WZML^U#(PC-#YD8.GMZKMKO^X)08.M<Q>^I26)R(=5GJ<Y58(C.-1?4  
4TH)2.A!R1+B>KN.NPOU85CR!9E.MH8F5PB).P>4R!)^T%ICO?>?JZ)F0UQC.A!&SMXZ^!STP8S@A.DD3E&<..<M%!\*W%O\$8\$\*SQ.TIX^T^R.P9<  
+RDEW^RNC?4(CUES?XZRK6Z.F=^N8KM.M#EHH)T^(&..J.0M3)M#KJM71PW5!>?FYW&+RYH\$KGG7.0GM>J@X8:#@M.MG29X^FNL?MO?  
A\$S.Z>3XJ+I=^HJ?2SKOMIJTEH^\*W!+FN40EDS\$.M.J1I.XAUCPO.MWK\$<2+164W.^/O8#@.I6Z@-F6V>AUO5>Iq1)3J15W.M&WATA8T/QX<I?<  
=I.2(NUPW)WU.HU.XYFM2;2P&.#&JU+R2>S.SYW3K!M^C#U.A^<+W9L.9W.S0774&0ZXW.5\$9@16V\$>  
M25@UM^UPJG\$6YX8!ZL55H5H0A@6N^ITG!=\$BJM.UQ\$8W^A3Z.WL.T\$;M^Y\$SGO:8.30Y67+>6I4Z1^WYV!K\$S=7ZL3P\$H/H.MI^@&UCZ9J#>  
>AY..13\$VM7^TJ.JM10CXFHG=>7D01&B;Y0C.Y.PHN?M4.U.<#FAY420^146.M#ZJ.MH3^FXWQZ+RFOHJ&G.C.C^QTVRTJDM?T^OIX?  
O^DXZYW=NK\$SC.#6E7.M.AF?<=>3H>A/D?F697.ML+ESMWX(PO3^170.W^J=28G2<I=7.6BJKH.MS7J>JY123;7^C8NJEI23+70&GW  
MWZ(1)+T+>\_1=INJ7.4UHL:622GW["5WUT^T3IQRJ!6!-WSE;Q^D.OH.YZ5&892W?JH7R2R7KIZ.OO+3WPA  
MB>.K8LEB\$=5NHWQ;AJU4.UR:91675!>.\*O7FD@KL^<#7VY>O/G.HZV.MOJDY^C^O5FKUBH^I.V^#S#.#Y;H6.O-Z2%40X48>MGD\*  
I(3H=OT^T^Q^Y#^V2B5C1#1BIE#;MIAZ>OJGL0=>M.\$!&QGZX77\*H2V-1AZ>OJ<=>FWE>Q\*2(IH^<^\$!#Y&Q5L  
M14^C1BY#2&RW(5YHCUC.R1)P^PLF^4.NJLVLZ)Y>^6/H?7J60&79&U>M)A1-P.%@NR@)XD5-.73;7=>G7/5H/EX->ZM5KOGI!!?  
0/WAWUSA^\*K6M6M-JU14!N.MP/P@9P.YSG:A^PZH(T\$X^JH-N?N2)M.M@!G!H/@ZPS^LX.X07^KHZ(KN.=OR/Q^U^Y2D!  
M&K=RLI.2^SDMO<^M75)PGZVQ^O47N6T/N3UJ53.2)JBB\$8QI^\_5!MJT.N52UO)HWF648CGE^QXV3@IV#.#V^Z7@X&BWAIXY.L<XAT>  
IQ&N\$M^W>B>TJOL5="HTEP6@GVNHNL?CFIL0<B^<#(ZV;5V^UBIT^02%<CT/110.MBJ.PJEX-.9DX9I!%ZH.U#FN^K?M-W&59-)HFXVZ3  
A6P&T?2L19.MIOH^OND+\$(OYVBQ>.YF=>LDC>A+LGRVY3^4.H9N4W#LTYH15&H>HIO.MP^SE.7&FWF>WLO+^E6-  
\*.8&NQOUU)BEA517^G>30WMB&JS.M^I^Y5#>=0.E+<@G.3.H.D/9XO4JBT8JXWB+I+K?Y.E^YI^U+M.P04^#/@YV9^AKGGE0("!\*&  
&Y.N.E.M.C.R.#.Y.S1X97@S.M.600+FAE>U>6..+!^PLIHH.MF7G93>PW0HZF.C.M&DNS3QO^?2BW=CM49+Q(1I.CWQX.MSU=5+DH\$N1X  
ZM^<DR.M%ER0QV01@CE6)OC\$Q\$K%>M.KH=U.FYVR=#.MZ^JKI^EBSWJH<8I72W#U.GWMMWVH.KLHL/23Y&S/BL!>#;Y\$14HS^OQ  
MZYQB>&E&EDIK^\*H&YSML)W.NJ?18K^H.M+XZVLRB664N5P=1DIK^\$J12W=AM2^3!2DV\$N^=>)OHT5I07.HFHC^D.MC1\*G  
RCU7>0C76Z^FFB2G9B+MM.E.Z!N@%&INC>DKEN+V3J.MJ.RJU<-IR=-4%K.V\$E7/7^H<H^T&3G+UFTZ+^UOA).S^ZLFA.E."FVN7  
M#;8GN&MDN1HUU85K3WDNU+>.B)S8=FY6+1+G?B52NTX.L\*(Z>O!E!R0)M.J.RG+AV;ID#;K)UD%8?OHC^YI^<^\$S1AOS+@0?  
FV05BDZ119C^\*5CHU.M.O.CQ^V+3R4UO.@%AAOM7&L1E9/QN?8Z&7H19Q^L8O+V2G9^+T4O1>W3V.M:3+8X1F2(PN^V1  
ZVLDI^E%08Q^C30BKV5BYXT6\$).#2.N8R!N^YMD.MD6^<I^WCHMH&(TK.U)I26725DH68AVK^IRU=1/1=&H.MH.DPG2.1WD;@D4(A^6^X.%J  
(2C85!9P.N^EQJDMX\_BZ#-.?EE.23IE=/O.5)5^X#3.M&+H).4=TKXG2+4.8C6V.RAH=FAJP3SU5)%)\$I2(&J@Q4I603T)MOE;  
M^KVP=9.9/6@7PYQJDOV.TK6PVPV94QMZQP=M^X^UP^V^3#>2XY2C=YO.M.UCLJCB8&#^!T="IQN60W.2&C10A.0\*2RU@)B43<LL.UH;  
(GEB)4>D.MFY4H;2N.HIAIM@8^U8T8IERW;L50>.#HYMPL+UP2G^TF6E<I^X.W>M.TE.X(502.TG.5+65QMR^E.OSBET-I  
8LD2WWGFBZ=\$4\$!\$ZMQ\$."YM+ZH.HJ5;R^/OR<%1NB#5KJ\$=U.MO."R.B4@:3T=21)M4F^Z@S48!E^!;#D6X9\$0+X#>G%KR1^Q^P6.#X7?  
M9.N.HSE7E815Y^PQG8@RCG<8N)@>FLN<8.8&R!OYXG^KAB(N&D#PXQV3YO.MP7VR.U+Z^T!N>#BV(N^<#A1A)V#^@)2.(Z1\$)=N1S@S.N  
N@H+^D^FY<MYTID246<EVGJL.NM4@.#15@FL47U+E7(BI9!H^IUU;0.(IR:RIL@OMZJNE.U=C.MOE^%MH^<+<=TOVGF@%>OJEEU@050P.A6!  
6V=16.9R)72^+J1^MG=GSY0^4E.19.6!MNJD^HLLA+I9<^O8M.AQ#<0^A#T(+@H^L)U9>LZK=82^3^M.L.M%^^M^Z^1^T@&3!170\$F)/C=U  
MODP&:CY=J1+>EA.\$QO!VOI^3^IV^O^C+5S.J1^&8^6UXM4N/+GL.7M>0QWJ@Y.C%X^L7N23>%C^QP6^6.AU1VUNX!P2U>>O.GG8  
M0FEA.Y0Z6;Z@M(I)HWGS<=<GMP.L)0^G^A!TWZ@L.MG.>B^<H^&IVU1Q8.M.R+I47/@J0>T33!Z4C.O#.@H\$5.6.INX!5Y@+1E^DV^J1^?<  
M8(NC.Y%4=K)H;P&+199.G:07.Z4527&A..K\$DD3ZYFE=2D12F.XJ.MO#2>=SLJ.DDJN&IKTKJZU52+Z56+YW.M.MTKH)Q!>=<U\*IMZ?  
<9^C^TK^U?>)4\$!#H0(,^#EEL.K\$&9@.M.\$J.8.FY8RTR.#(T.#DS.AE#.#Q9(N:1M15L.HX\$OJTO!2W  
M30#;LO.CS)#+4G91WZ>T^P^MNRDW60W\$\*#M!(AMDR^L.#.HHH^IKL^O7Z>S2^KLFD^I#A@\$@U^M^IS IO.MP.Y>VA7N.S\$MCI3G;  
<<@+DVF+T)O>2WW;^<G^I4PN0HR6^3H0.Z4\$W\$MDEM^YKJ^#)T.#0EK.XXH(I^V^K!<2L.P@#^VTNGD:XM0+1B19XT2.67&  
MSG/OJO@EJ67:NJ<^I^V2%&INC>D+GMSF1BLW#0I\_!S6!\$DD>5U.O>I#0IZ.MAX>K)BVOLV6^DL+MX:62W&LJTW907.I^!  
MKR>R\$G=BOF14@407W+^I^Z^T#H!73210Y70^66916M!P?<7D.YV3KZP.1MQ^A.L.M.TS1VHPSX=86J3OY^EMBO-IV=Z@MSL^(FO:10U.C%8H?  
<LC2>G.M5Y/QV2CD>#\*;<^<79^SR.GO^XJ.LG.ON?^I(E2?Y^>0.+UZXC5V>O!J!<M.2.7.3=>%@MM93IG;  
N.V.#;^>T!2^298)JCO<^I5R:1%I6B12%/E?I!M.I>EZ\$YBF.^NDV6%...AHT^Y5JY>6Y2I)45@J7?AV9!TJ1U.-B.NHX  
M.KI&+1.3P.282C2U+1.9.SWFFN@\*Y^CO5+!(KJO.VA^<O^PE3^SGFFI5.MQC(1<6XC0#Q^ID8MV.  
USTGAN78@Q9S>EFN4^J.C@=7X)USP13(81C.M9PES218&65FLLC4(M8&.AUG\$0^M2B.P.TNG05L^8SIE3JN@.4@EAI9%6+  
(LP.6)\$\*S62.CC)F/E.C9T^+1@DM.MH)@P9RAL.#6IA^Q.Y.TEO!>15@E5..2U@T.V.#"P2?"HJ^X6@8^DLX63"MRJH>/XNC6K7Y9J2?TC=^QWF=0">  
T)@I?3%)&@NE91FG1FWK.RT.MP&86QMRQI@503X6W.OVA3=<I.KPIW^Z%I\$40.PH1^DTE+K2.  
GO?/!Z=I\$2=6XB&A^4VY^1^V!>1.4NFG^I3RGT64A&EL)9.M+J2L.9(ZE&Y7IN^Z&1%PF@HIG)9U)5:RA>)>)\*XX<I\$3H!1;7H7+=LGU.M^1-  
UJ32%50Z33BEFH0\$5N.RF7B^EM31T8FDEM^Y^X:LD4^#FVE.2>C^F.M<1G.A444HS(H:4.5C^RKC.45V+L.9L4KF&.&I0901X%!(S@UP3K22  
<QL@.3X^UY.M^IY3>JYN6:BV.PLB.9HJ4L@.M#L!>X.D.5Q3X2X9#>B>F?>I065WOUILUS>B+PY.MB0L^SE+7IFG/>9=C14Y5AIDPQ6=PEG568  
MHJC91NH8A^6L\$H!8174<1-8J;9.IWC5.95%(X7X2DZ% @%J2<2ICDE.MV.SOK^A\$(OJM.#(JOHM.#FU#7DN8IVZXNH\$=0F>WELI879UO#=#JY.1^Z-  
L62+MP3Y7B@48L.H7ML=D05.P.P.C.YX&+1.0=PIG)>+9?>>GOVIR?>9E!72.MUJQD^M^U<=4W^T@ZE.SWJRG^A^BCUE2RZ.57734  
4196KN4#0#%>^I(UQ)A.M3(+>M.D<=RF(Z@.W.YG="G5:HR4"MR(7NOBK/>65\$N/C1MH.OD^D7T>>6CXV=OUA.AFX.BBYE2HR3!K&2+Y6  
M\_1BT^0JH1X^T.FE.U46.VVKMG@MK=<K=I^7^TMOGG<<I^P>.#.0ZC.MEPC<I@8V>=BBOOV:UJOI^P29=1^&RPs^EK515>I2PW\$S3>15W?  
+IAJ#<M^T^G^AK2P^908H+6X^A1(16ZPTJ^9ZP13+OHV+T+WW#\*228\$S.VL!K^B+D1HM.D^53I)Y^YV.O=M7Y^AW19W+SWZ.R=JY9^  
02P.\$%@SX.N6>4=X^4!@^AD!@M^N:G9C+3(P.C0P.3.P>5X.S)D.2YH=&WM66U3VS@0.BLZ.FUA)GY+@4G.MS4P(8/LB^W.A3+E11^JM??  
KNP\$A^\*YB002M2#1\$OKU;O7N^S.MPIQG^I1R4^\*2D02?2(4IG.9ZPP^M&.&EA<=3)2E1<@G1A07@ARJGDx9.M8^OIK!>I2U^6?  
0UYV^B99A^0(O^2KMD^UYE.C00K3^>1@YD^1@MZ&P423X25^>>7QY^E^H1+M^Y1^>2B1^>+E9B.XG13.34VZ>CC^OQF  
W79)O0DN14.6>M.UU&OIX^2IAN!!OTO=5G)10+=#GHI.R:.;4I/W6C^HI+OPCR!^CEZ8^=WJP.M?2FOEGPU.LAX/NO>R5-  
4UY.<=&R\$^ZZ<NW2X1A.6:K&P+1^I4N&N&M.M\$&H^F^DMJ=<ZILUS=EIG^..I#=<S.WT9QCOY90MR(6>T>N15N13.168.MMSTKK2E?  
#&2#&8=&(<S/>E1B+57V1^L^?H%WH!@22&R53P#@ROEJH^OWA^O4!R2!&B=G)U^#E+H>G88R.M2+1H(MV.W+19#RRRT^GUVH  
(.OINJPOH9^9^?1^&C#BA7V.W^GIV3Z.8.M3(87A/V3!<OY^<C^#9CB+<?M^<^EL^W.N#<^6#QAW4!\$%@5+I^<K8F-R  
M1KJ!U@OKE^51K3\$)F14UW(CWB@.4^9;I&3G<@J>7:ONID9Q!D5K.MJZ^W  
T6^CJL@RVE^HRJ9J^2M21%35AHVB^&ZXI<@UJH6H9ID7^PJ^J\$S.M816RN(02:RA(K:5.X\$L&O@C^\*X6M68!TG?U9YM^VBH2I&ZG  
M.^L@WV.2.O/2<G2ZFY(N^I70R28ID>1%AMLY\*%#=#5C4EBJOS1EE.5.MJ9C&B+90DS\*7I.H&4@ITL(L619^S>0+^ZZ.ZM>106U9.BZJA)  
E4.9T.MO4^NK.YWS?2.QS%Z1AG2VX688Y3R%.(15U>TUKXJQ.%AQ71%L856RD.M^I.2\$DN5.N4DA@A.A.N.FCBPG54^PM4%?@PLW&R<S^N  
DVW2-10+P8.4.MZ1H.5MJ\$BCKIH&6KQ;L!KN#UTW+AK+SR!9T.E=26&^K5&L^ZSC/HQ#O.MNMUGOQNX#2118=>K25F&  
H4V=AX&^IUU+PE+SR1=>2S6M.G&SJK.L@^@MUI>X17^C@U^F3M^/E.T.8!B/SR)3NE.A<M\$Z91Z.3Q222=049(MJ+^IF#PKS-  
X17)LEIDE.K7/8S\$5X>Y\$LDPO.YXM^8E^=9C6<@Z<.!^CG+M.@I>=>2GBVU5E^@ZOANP%Z#MVRI.KLZF\$Y.04%P)FJUN2!08^.  
MDJD<#%G1SU7.^#Q.C.MEDI>V2\$3^86FL<@82XWRA9R@Y^L.L.8\*WC.<SLL1044&89E9>P@C^9.M.147J0H.<15FOHJ&J^0(4D^I)PA4:(RS  
S=J@<C6!>G!7UBCDTO^CU.M2G.^2G<^7HJN+P18.D9.8.FYV8R.C#(T.#DS.AE.M.#.R9(N:1M15E.HLVSXK71M^6^IV4Z;RXXUW&P  
&V2O4JW?0DRF)+MBODQ.%>Y(V9:#+NZ.MV&%DT/3G?GX7>>ZU^6F4L)SIF!<O.M7&+;L.R12C!E97W0DD75^\*6\*<6%  
(45S>D.^D^CTG.M1H@/6IT^V3.MYB99Q22@I?>=>NGXOQXK.71R^Y2(L.KV).RM^3.MR:8R7X^&.&AVJPG>W6PHQ&K.^NAT%MI6  
G0LWY&Y1581.R78&GXJ&F.MYKN^5.8^<@/MXM^3XOMY02F18K)JCA.PQUMHIF@E\$5H^4@H.W^=GO.FO.MD7Q^KK@<8Z.3?  
B^7+5N1^+FCUM.6X%.SQ8NG.RNM^>1.5(YAMT.CPH^M!^6(=>#LCV/X\$4=7.@B>G>B2ME.4NER&%S>EORE!O2Z.K=89^T^HO.#\$#  
MQC+5POA7L^2J^3LH&PR3LXNSH!5H/KI7E^D@L2.9.K^2.9?>#3NONU^L^M.X^<6.Y=SPCYI.RV1ZLE^26!00+^FY^7)CU.R&U^IUI/9!  
I^+V^FOX+Q!M.&=AA^P.B1YK#B.4@QU5!)5Q3+DL4VH3DMR55X16Q)HK54ADB^W).M^F.^YIQG.D..LRGORB!/CKO=<  
<#^1^TA2.WL5#9Y\$B^G4BT@2WD.D4^J.MMF+JASRU(S5ABU2N.2%8^YJ.D.H)@47R^I^O8ME3PH(\$7)63Z2WDD.KR.M^ORXX^HCQ>W@JW)+  
<PHV8).FQ9K.MJ&2^S!HSN(O&Y6I0.&QEBEIS^L\$KQB7BIDH^M^/G.MG^4X^\*@>.>NGIDEKM\$17\$Y%BT^IHFJ6#4>0/1P8.1^?  
9PME@N^J^E.MO.YL<38.TNN&+YF.09.<R>H<4.\*M(=28/JL<><^?..2\$WVDY%<+MZ^@DMUJ(LFK.K=M4^)[&K&Y+I2?VHJ^>K6C&  
\$>V@((1^10.^13M<0.M8MVQIO!@GH+UT%&M.2.JV.UO(X0LB^7NZW!@R6W^9XSZT?OAFMX9PMN.MUG^+V^T<M&2!01+&OUN^!<\$

^V73CC2V"L\*%#?SD6 R8:3J&M)R:=(HU-Z+UY^MWI:4\A\SQPN?OUI\WZWWN>IYYV\^N;IQI^JIIY#U<#RCI+KRJ>:OVMA+Y>QWA+8;IO=IP  
FI9(Q=OY:040I< (DM>UXHAWI/ID@4W#Z#W4 MK12X. CGS24ZR7C6%#:2W-4H;+Q5)57)=0M4-9PK"IOJ=9GVTFM@?:18W01S;L&\$W  
44G38&G&G88T0PUA\*B.NG\$(ZMO-MZIK!C02I^3B&@%.(68(FY68531?LDZ0\$-S^IY?84#G7MD)Q:ZYRCGA1;M4R^0VJ=JV6>@H  
MNN<S=INQVAI 6\IIF:LR#DH@3(ENL2740"(.L:UB<"3R5YF+6RZQLM.GN.HP:GB43#@IPH=""/<+1%3@;I44@-F2J9EBG/QMH<4R80  
MK96IX:E+5^N^M^8YX=<("8Y^FN8:E.R5V3V^C8#F<IPJF:1%098UK.I.MHWSHLN;IG>IMTJ53I.%:31+I5J>).I^O.IO.#TK00+LH\*.YWK00I8E  
MLI(>-I^J&F<^EBMS^BT.4S&ID3Q0WC:QWZWO^V&UL4\$!LMA0#%#@SX-N68I^8V.06I^#14(I^NAD^YNM=F.M.C.R.#Y.S.I?  
9&5F+GAM.%!+04Q0(L^#;EFD@T0C.F.I.MI05"2+IN:G9C+3(P.COP.3.P7YQ0A8BYX:6Q02P5" M%.4" #@VY22SHFTB\$YD^P.%0@%4G;FYV  
M8RTR.#(T.#DS.%IP&UL4\$!A0#%#@SX-N6:B9^6NTM\$%\*1M14(I^4^6YN=F.M.C.R.#Y.S.IX.3IQ+BAT;5!+04M00(L^#;ED>&N.>5@ (I^J-8  
9R\*#@IN:C9C.M+3(P.COP.3.P>#5X.S^D.2YH=&U02P4%\$.4" #/VY9J3^QBF(I^M\*#@& \$9DP(;FYV8TR.#(T.#DS.^AE>#.Q9#(N:IMM4\$!L  
A0#%#@SX-N6>4=X^4I@^AD!@ (IKYL" M^&YN=F.M.C.R.#Y.S.IX97@S.FQ0+FAT;5!+04Q0(L^#;EG>N.+P.MIP8.D98"7FB  
@!N;G9C+3(P.COP.3.P>#5X.S^D).BYH=&U02P4&H"@"F@5JD" end XML 68 nvue-20240930x10q.htm.xml IDEA: XBRL DOCUMENT 0001379006  
us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:SeriesAPreferredStockMember 2024-07-01 2024-09-30 0001379006 us-  
gaap:RetainedEarningsMember 2024-09-30 0001379006 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001379006 us-  
gaap:RetainedEarningsMember 2024-06-30 0001379006 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001379006 us-  
gaap:RetainedEarningsMember 2023-09-30 0001379006 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001379006 us-  
gaap:RetainedEarningsMember 2023-06-30 0001379006 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001379006 us-  
gaap:CommonStockMember 2024-09-30 0001379006 nvue:SeriesAConvertiblePreferredStockMember 2024-09-30 0001379006 us-  
gaap:CommonStockMember 2024-06-30 0001379006 nvue:SeriesAConvertiblePreferredStockMember 2024-06-30 0001379006 us-  
gaap:CommonStockMember 2023-09-30 0001379006 nvue:SeriesAConvertiblePreferredStockMember 2023-09-30 0001379006 us-  
gaap:CommonStockMember 2023-06-30 0001379006 nvue:SeriesAConvertiblePreferredStockMember 2023-06-30 0001379006 us-  
gaap:SubsequentEventMember nvue:AtmOfferingMember 2024-11-07 0001379006 nvue:AtmOfferingMember 2024-09-10 0001379006  
nvue:StockWarrantsMember 2023-07-01 2024-06-30 0001379006 nvue:StockWarrantsMember 2024-09-30 0001379006  
nvue:StockWarrantsMember 2024-06-30 0001379006 srt:DirectorMember 2024-09-30 0001379006 nvue:ConsultingServicesMember 2024-09-30  
0001379006 nvue:ScientificAdvisoryBoardMember 2024-07-01 2024-09-30 0001379006 srt:DirectorMember 2024-07-01 2024-09-30 0001379006  
nvue:ConsultingServicesMember 2024-07-01 2024-09-30 0001379006 nvue:AtmOfferingMember 2024-04-15 2024-04-15 0001379006 us-  
gaap:RelatedPartyMember nvue:Covid19LicenseAgreementMember 2023-07-01 2024-06-30 0001379006 nvue:TheracourPharmaIncMember us-  
gaap:RelatedPartyMember nvue:Covid19LicenseAgreementMember 2021-07-01 2022-06-30 0001379006 nvue:TheracourPharmaIncMember  
nvue:UnsecuredPromissoryNoteMember us-gaap:RelatedPartyMember 2023-07-19 2023-07-19 0001379006 nvue:TheracourPharmaIncMember us-  
gaap:RelatedPartyMember 2024-07-01 2024-09-30 0001379006 nvue:TheracourPharmaIncMember us-gaap:RelatedPartyMember 2023-07-01 2023-  
09-30 0001379006 nvue:Dr.AnilDiwanMember us-gaap:LineOfCreditMember 2024-07-01 2024-09-30 0001379006 us-  
gaap:SubsequentEventMember nvue:AtmOfferingMember 2024-10-01 2024-11-07 0001379006 nvue:SeriesAConvertiblePreferredStockMember  
2024-09-30 0001379006 nvue:SeriesAConvertiblePreferredStockMember 2024-06-30 0001379006 nvue:AtmOfferingMember 2024-07-01 2024-09-  
30 0001379006 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001379006 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30  
0001379006 nvue:Dr.AnilDiwanMember us-gaap:LineOfCreditMember 2023-11-13 2023-11-13 0001379006 nvue:Dr.AnilDiwanMember us-  
gaap:LineOfCreditMember 2023-11-13 2023-11-13 0001379006 srt:MinimumMember nvue:Dr.AnilDiwanMember 2024-09-20 2024-09-20  
0001379006 srt:MaximumMember nvue:Dr.AnilDiwanMember 2024-09-20 2024-09-20 0001379006 srt:MinimumMember  
nvue:Dr.AnilDiwanMember 2024-09-20 0001379006 srt:MaximumMember nvue:Dr.AnilDiwanMember 2024-09-20 0001379006 us-  
gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:SeriesAPreferredStockMember 2024-07-01 2024-09-30 0001379006  
nvue:TheracourPharmaIncMember us-gaap:SeriesAPreferredStockMember 2023-07-19 0001379006 2023-07-01 2024-06-30 0001379006  
nvue:TheracourPharmaIncMember us-gaap:RelatedPartyMember 2023-07-01 2024-06-30 0001379006 us-  
gaap:IndefinitelivedIntangibleAssetsMember 2024-09-30 0001379006 us-gaap:IndefinitelivedIntangibleAssetsMember 2024-06-30 0001379006 us-  
gaap:FiniteLivedIntangibleAssetsMember 2024-09-30 0001379006 us-gaap:FiniteLivedIntangibleAssetsMember 2024-06-30 0001379006  
nvue:FounderChairmanAndPresidentMember us-gaap:SeriesAPreferredStockMember 2024-07-01 0001379006  
nvue:FounderChairmanAndPresidentMember us-gaap:SeriesAPreferredStockMember 2023-10-06 0001379006 us-gaap:WarrantMember 2024-08-  
31 0001379006 2023-09-30 0001379006 2023-06-30 0001379006 us-gaap:WarrantMember 2024-07-01 2024-09-30 0001379006 us-  
gaap:WarrantMember 2023-07-01 2023-09-30 0001379006 us-gaap:WarrantMember 2024-07-01 2024-09-30 0001379006  
nvue:TrademarkAndPatentsMember 2024-07-01 2024-09-30 0001379006 nvue:TrademarkAndPatentsMember 2023-07-01 2023-09-30 0001379006  
srt:MinimumMember nvue:TrademarkAndPatentsMember 2024-07-01 2024-09-30 0001379006 srt:MaximumMember  
nvue:TrademarkAndPatentsMember 2024-07-01 2024-09-30 0001379006 nvue:TheracourPharmaIncMember us-gaap:RelatedPartyMember 2024-  
09-30 0001379006 us-gaap:RelatedPartyMember 2024-09-30 0001379006 us-gaap:NonrelatedPartyMember 2024-09-30 0001379006 us-  
gaap:RelatedPartyMember 2024-06-30 0001379006 us-gaap:NonrelatedPartyMember 2024-06-30 0001379006 nvue:TheracourPharmaIncMember  
us-gaap:RelatedPartyMember 2022-06-30 0001379006 nvue:June302029Member 2024-07-01 2024-09-30 0001379006 nvue:June302028Member  
2024-07-01 2024-09-30 0001379006 nvue:June302027Member 2024-07-01 2024-09-30 0001379006 nvue:June302026Member 2024-07-01 2024-09-  
30 0001379006 nvue:June302025Member 2024-07-01 2024-09-30 0001379006 nvue:TheracourPharmaIncMember us-gaap:RelatedPartyMember  
2023-10-27 2023-10-27 0001379006 nvue:TheracourPharmaIncMember us-gaap:SeriesAPreferredStockMember 2023-07-19 2023-07-19  
0001379006 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001379006 us-gaap:CommonStockMember 2023-07-01 2023-09-30  
0001379006 nvue:StockWarrantsMember 2024-07-01 2024-09-30 0001379006 nvue:FounderChairmanAndPresidentMember us-  
gaap:SeriesAPreferredStockMember 2024-07-01 2024-07-01 0001379006 nvue:FounderChairmanAndPresidentMember 2024-07-01 2024-07-01  
0001379006 srt:ChiefFinancialOfficerMember 2023-10-06 2023-10-06 0001379006 nvue:FounderChairmanAndPresidentMember 2023-10-06 2023-  
10-06 0001379006 us-gaap:RelatedPartyMember us-gaap:SeriesAPreferredStockMember nvue:Covid19LicenseAgreementMember 2023-01-27  
2023-01-27 0001379006 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001379006 us-gaap:AdditionalPaidInCapitalMember  
2023-07-01 2023-09-30 0001379006 nvue:SeriesAConvertiblePreferredStockMember 2024-07-01 2024-09-30 0001379006  
nvue:SeriesAConvertiblePreferredStockMember 2023-07-01 2023-09-30 0001379006 nvue:AtmOfferingMember 2024-04-15 0001379006  
nvue:TheracourPharmaIncMember 2024-07-01 2024-09-30 0001379006 nvue:KarveerMeditechPvt.LtdMember us-gaap:RelatedPartyMember 2023-  
03-27 2023-03-27 0001379006 nvue:SeriesAConvertiblePreferredStockMember 2024-07-01 2024-09-30 0001379006  
nvue:TheracourPharmaIncMember us-gaap:RelatedPartyMember us-gaap:SeriesAPreferredStockMember nvue:Covid19LicenseAgreementMember  
2021-09-07 0001379006 us-gaap:WarrantMember 2024-08-01 2024-08-31 0001379006 nvue:KarveerMeditechPvt.LtdMember us-  
gaap:RelatedPartyMember 2023-03-27 0001379006 nvue:FounderChairmanAndPresidentMember us-gaap:SeriesAPreferredStockMember 2024-07-  
01 2024-09-30 0001379006 us-gaap:RelatedPartyMember nvue:Covid19LicenseAgreementMember 2023-06-19 0001379006 2023-07-01 2023-09-30  
0001379006 2024-09-30 0001379006 2024-06-30 0001379006 nvue:KarveerMeditechPvt.LtdMember us-gaap:RelatedPartyMember 2024-07-01  
2024-09-30 0001379006 nvue:KarveerMeditechPvt.LtdMember us-gaap:RelatedPartyMember 2023-07-01 2023-09-30 0001379006  
nvue:TheracourPharmaIncMember 2024-09-30 0001379006 nvue:TheracourPharmaIncMember 2024-06-30 0001379006 2024-11-14 0001379006  
2024-07-01 2024-09-30 shares iso4217:USD nvue:item pure iso4217:USD shares nvue:segment 0001379006 --06-30 2025 Q1 false true false  
892625 903216 13144055 14062813 P1Y 10-Q 2024-09-30 001-36081 NANOVIRICIDES, INC. DE 76-0674577-1 Controls Drive Shelton CT 06484  
203 937-6137 Yes Yes Non-accelerated Filer true false false Common Stock NYSE 14347000 3866289 4797778 175133 172742 4041422  
4970520 7365681 7512463 323241 325308 10153 14562 11740497 12822853 1933091 1466665 123473 564926 3167834 2031591 3167834  
2031591 41023 99338 36493 41023 62845 3126811 1968746 -0.23 0.23 0.17 -0.17 13715959 13715959 11718791 11718791 892625 9  
13144055 131 15083882 -139374895 11464077 53875 893006 9 1710129 1710138 10591 14408 14408 19713 34500 34500 229 229 6039 11250  
11250 3126811 3126811 903216 9 14062813 140 152609348 -142501706 10107791 11740497 12822853 1933091 1466665 123473 564926 3167834 2031591 3167834  
10591 9617 9617 39103 1 50599 50600 159 159 7947 11250 11250 0 0 0 0 -1968746 -1968746 558265 5 11745547 117 146017883 -133049495  
12686510 -3126811 -1968746 14408 9617 45750 61850 229 159 193546 187057 2067 2067 2391 -122204 -4409 -37 336594 72147 -83489 146031  
20825 195863 -2594863 -1171694 46764 8291 -46764 -8291 1710138 0 1710138 0 -931489 -1179985 4797778 8149808 3866289 6969823 0  
1500000 0 49808 <p style="font-family:Times New Roman;Times";serif;font-size:10pt;font-weight:bold;text-align:justify;margin:Opt Opt 12pt  
Opt;">Note 1 - Organization and Nature of Business<p><p style="font-family:Times New Roman;Times";serif;font-size:10pt;text-  
align:justify;margin:Opt Opt 12pt Opt;">NanoViricides, Inc. (the "Company") is a clinical stage nano-biopharmaceutical company specializing in the  
discovery, development, and commercialization of drugs to combat viral infections using its unique and novel nanomedicines technology.  
NanoViricides possesses its own facility that supports research and development and drug discovery, drug candidate optimization, cGMP compliant  
drug substance manufacturing, cGMP-compliant manufacturing and packaging of drug products for human clinical trials, and early  
commercialization. The Company has several drugs in various stages of development.<p><p style="font-family:Times New  
Roman;Times";serif;font-size:10pt;text-align:justify;margin:Opt Opt 12pt Opt;">NanoViricides, Inc. is domiciled under the laws of the State of  
Delaware, with its principal operations located in the State of Connecticut. The Company's fiscal year begins on July 1<sup style="font-  
size:7.5pt;line-height:100%;top:Opt;vertical-align:top;">st</sup> and ends on the next June 30<sup style="font-size:7.5pt;line-  
height:100%;top:Opt;vertical-align:top;">th</sup> of the calendar year. The Company operates in one reportable business segment.<p><p><p  
style="font-family:Times New Roman;Times";serif;font-size:10pt;text-align:justify;margin:Opt Opt 12pt Opt;">The Company devotes substantially  
all its activity to advancing research and development, including efforts in connection with clinical trials. The Company's lead drug candidate is  
the active pharmaceutical ingredient (API) NV-387. NV-387 is a broad-spectrum antiviral drug that has demonstrated strong activity in lethal lung  
infection animal model studies and is being developed to treat Coronavirus, RSV, Influenza and even an Orthopoxvirus model for Smallpox and

**MPOX.** The Company plans on developing NV-387 first as a treatment of RSV infection in pediatric patients. At present, NV-387 is in a Phase Ia/Ib human clinical trial for safety and tolerability in healthy subjects for the treatment of COVID-19, sponsored by our licensee and collaborator in India, Karveer Meditech Private Limited ("KMPL"). All subjects have been discharged and follow-up visits have been completed as of approximately the end of December 2023. As topline results of this clinical trial, there were no reported adverse events at all doses studied, and there were no drop-outs either, observations that are indicative of tolerability of the API NV-387. These results are consistent with the results of safety/tolerability studies in animals conducted in support of the clinical trial application. The Company is awaiting the final study report from this clinical trial for further regulatory advancement of NV-387 into a Phase II clinical trial.

The Company is now working on developing the necessary datasets, documentation, and clinical trial pathway and trial designs, for a Phase II clinical trial application for the use of NV-387 for the treatment of RSV infection, as the Phase Ia/Ib study progresses into the data analysis phase.

On August 14, 2024, the WHO declared a Public Health Emergency of International Concern (PHEIC) regarding the expanding epidemic of MPOX infections in Central Africa. There is no drug currently available for the treatment of MPOX. NV-387 has been found to possess activity against orthopoxvirus infection in animal model studies, making it a viable candidate for clinical trial as a treatment for MPOX infection under the MEURI ("Monitored Emergency Use of Unregistered and Investigational Interventions") WHO protocol. The Company is now in the process of defining a clinical protocol for such a Phase II clinical trial with its collaborators in preparation for a clinical trial application to the appropriate regulatory agency.

Subsequent to the MPOX and RSV Phase II clinical trials that are at high priority, the Company plans on expanding the indications of NV-387 to other respiratory viral infections including Influenzas, Coronaviruses, and others.

Additionally, the Company has previously developed a clinical drug candidate, NV-HHV-1 formulated as skin cream, for the treatment of Shingles. The Company plans on taking NV-HHV-1 into human clinical trials, and further develop the HerpeCide™ program after the Phase II clinical trial of NV-387 for RSV, MPOX, and possibly for multiple other indications, including Influenzas. In the HerpeCide program alone, the Company has drug candidates against at least five indications at different stages of development. The Company's drug candidates against HSV-1 "cold sores" and HSV-2 "genital herpes" are in advanced pre-clinical studies and are expected to follow the shingles drug candidate into human clinical trials. In addition, the Company has drug candidates against HIV/AIDS, Dengue, Ebola/Marburg, and other viruses.

The Company's drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. ("TheraCour"), a related party substantially owned by Dr. Anil Diwan, to which the Company has broad, exclusive licenses. The licenses are to entire fields and not limited to specific compounds. In all, the Company has exclusive, worldwide licenses for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV-1 and HSV-2), Influenza and Asian Bird Flu Virus, Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis virus, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes (restated), Varicella Zoster Virus ("VZV") infections (i.e. Shingles and Chickenpox), and SARS-CoV-2 infections.

Additionally, on September 23, 2024, the Company signed a Memorandum of Understanding ("MoU") for all antiviral drug development with TheraCour whereby it has obtained a right of first refusal (ROFR) for all antiviral drug developments from TheraCour. This MoU expands the Company's abilities to opportunistically and rapidly develop novel drugs to treat viral infections of public health importance, even for those viruses that don't exist today and cannot be predicted. The MoU has also formalized the process of development of drugs for unlicensed viral indications leading later to appropriate license agreements. There was no compensation paid to or due to TheraCour as a result of this MoU. The Parties have also agreed in this MoU that any cash milestone payments related to development activities, that are awardable, will become payable only upon the Company having sufficient revenue, thus extending the provisions previously incorporated in the Amendment to the COVID License Agreement, to all present and future license agreements.

In all cases, the discovery of ligands and polymer materials as well as formulations, the chemistry and chemical characterization, as well as process development and related work will be performed by TheraCour, a related party substantially owned by Dr. Anil Diwan, under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed. Upon commercialization, NanoViricides will pay 15% of net sales to TheraCour. Milestone payments were made or are specified in certain of the license agreements, details of which have been disclosed at the time the agreements were entered into. The Company negotiates and licenses specific verticals of therapeutic applications from TheraCour if promising drug candidates are found in early research and development against a virus target. TheraCour has not denied any such licenses when requested.

The Company has out-licensed NV-CoV-2 and NV-CoV-2-R for further clinical drug development and commercialization in the territory of India to KMPL, a company of which Dr. Anil Diwan is a passive investor and advisor. KMPL has sponsored the NV-CoV-2 into Phase Ia/Ib human clinical trial, to study the safety and tolerability of the NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies formulations of the API NV-387 in healthy human subjects, described earlier. The clinical trial drug products, NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, were manufactured at the Company's Shelton campus. Under the agreement with KMPL, the Company will pay for the expenses of the clinical trials, and in return will benefit from having the data and reports made available for regulatory filings in other territories of the world. Upon commercialization, the Company will receive royalties from KMPL equal to 70% of sales net of costs to unaffiliated third parties.

**Note 1 0.15-0.70**

**Note 2 – Liquidity and Going Concern**

The Company's condensed financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets and liquidation of liabilities in the normal course of business. As reflected in the condensed financial statements, the Company has an accumulated deficit at September 30, 2024 of approximately \$142.5 million and a net loss of approximately \$3.1 million and net cash used in operating activities of approximately \$2.6 million for the three months then ended. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future. Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs. The Company has not yet commenced any product commercialization. Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future.

As of September 30, 2024, the Company had available cash and cash equivalents of approximately \$3.9 million. The Company's liabilities at September 30, 2024 were approximately \$1,633,000 including accounts payable of approximately \$713,000 payable to third parties, accounts payable to TheraCour of approximately \$637,000, and accrued expenses of approximately \$283,000. Management believes that the Company's cash and cash equivalents balance of approximately \$3.9 million, additional capital raised of approximately \$631,000, net of offering expenses, by ATM sales of our common stock from October 1, 2024 through November 7, 2024, and the Company's existing resources, including availability under its \$3 million line of credit will not be sufficient to fund the Company's planned operations and expenditures for at least 12 months from the date of the filing of this Form 10-Q. As a result substantial doubt exists about the Company's ability to continue as a going concern.

The Company believes that it has several important milestones, including data from and final reports from the Phase Ia/Ib human clinical trial for the Company's broad-spectrum, antiviral drug NV-387. This Phase Ia/Ib human clinical trial is for evaluating the safety and tolerability of two oral formulations of NV-387, namely (i) NV-CoV-2 Oral Gummies, and (ii) NV-387 Oral Syrup, as described elsewhere, with COVID as the indication. The safety and tolerability data from this clinical trial is expected to be applicable as Phase Ia/Ib data for other indications of NV-387 as well, including RSV, MPOX, Influenza and others. Additional milestones include Pre-IND and IND filing to the US FDA for RSV and clinical trial application for Phase II clinical trial of NV-387 for the treatment of RSV infection in adults with the goal towards further regulatory advancement and approval of NV-387 for the treatment of pediatric RSV infection. Additionally, the Company believes that NV-387 qualifies for a Phase II clinical trial for the treatment of MPOX infection in Central African nations under the MEURI protocol of WHO because there is no other treatment available for this epidemic that is declared by the WHO as a public health emergency of international concern (MEURI = Monitored Emergency Use of Unregistered and Investigational Interventions.). We plan on initiating the Phase II study for MPOX as soon as feasible if the Company receives the appropriate regulatory clearances. Additionally, the Company continues toward developing the Pre-IND and IND applications for a Phase IIa clinical trial of NV-387 for the treatment of RSV infection in adults, to be followed by a Phase IIb/III clinical trial of NV-387 for the treatment of RSV infection in hospitalized pediatric patients. To this end, the Company is also evaluating the possibility of a Phase IIa clinical trial of a RSV Infection Challenge in Humans.

Management believes that as these milestones are achieved, the Company would likely experience improvement in the liquidity of the Company's stock, and such improvement, if any, would enhance the Company's ability to raise funds on the public markets at terms that may be favorable to the terms offered at present.

Management is actively exploring additional required funding through non-dilutive grants and contracts, partnering, debt or equity financing pursuant to its plan. There is no assurance that we will be successful in obtaining sufficient financing on terms acceptable to us to fund continuing operations.

Management believes that it has on-going access to the capital markets including the "At-The-Market" (ATM) agreement with EF Hutton, the Sales Agent.

There can be no assurance that the Company's plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The Company will need to raise additional capital to fund its long-term operations and research and development plans including human clinical trials for its various drug candidates until it generates revenue that reaches a level sufficient to provide self-sustaining cash flows. There can be no

assurance that the Company will be able to raise the necessary capital or that it will be on acceptable terms. The accompanying financial statements do not include any adjustments that may result from the outcome of such unidentified uncertainties. <p>-142500000-3100000-2600000-0-3900000-1633000-713000-637000-283000-3900000-631000-3000000</p><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 3 - Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Basis of Presentation - Interim Financial Information</i></p><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying condensed financial statements and the information included under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations" should be read in conjunction with the Company's audited financial statements and related notes included in the Company's Form 10-K for the fiscal year ended June 30, 2024 filed with the SEC on September 27, 2024.</p><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The June 30, 2024 year end balance sheet data in the accompanying interim condensed financial statements was derived from the audited financial statements.</p><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For a summary of significant accounting policies, see the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2024 filed on September 27, 2024.</p><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Net Loss per Common Share</i></p><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants and convertible preferred stock.</p><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><table border="1" style="width:100%; border-collapse:collapse;font-size:10pt; height:100%;><tr style="vertical-align:bottom;"><td style="width:58.38%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.37%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:58.38%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:39.19%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="border-bottom:1px solid #000000;margin:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Potentially Outstanding Dilutive Common Shares</b></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:58.38%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the</b></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.37%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the</b></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:58.38%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months</b></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.37%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months</b></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:58.38%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="border-bottom:1px solid #000000;margin:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2024</b></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="border-bottom:1px solid #000000;margin:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif;font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></b></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.37%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="border-bottom:1px solid #000000;margin:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></b></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:58.38%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="background:#ceefff;margin:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="background:#ceefff;border-bottom:3px double #000000;margin:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6,577</p></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="background:#ceefff;margin:0pt 0pt 0.05pt 0pt;"><p style="font-family:'Times New Roman','Times','serif;font-











<p style="margin: 0pt;">For the three months ended</p>	<p style="margin: 0pt;">2024</p>
<p style="margin: 0pt;">September 30,</p>	<p style="margin: 0pt;">2023</p>
<p style="margin: 0pt;">Research and Development Costs Related Party</p>	
<p style="margin: 0pt;">Development fees and other costs charged by TheraCour pursuant to the license agreements between TheraCour and the Company for the development of the Company's drug pipeline. No royalties are due TheraCour from the Company at September 30, 2024 and June 30, 2024.</p>	
<p style="margin: 0pt;">644,527</p>	<p style="margin: 0pt;">639,077</p>



the year ended June 30, 2023 representing the fair value of the shares on the date of grant. On June 19, 2023, the Company was notified that the Company's licensee, KMPL had commenced volunteer recruitments for Phase 1a/1b clinical trials of the NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies. Pursuant to the TheraCour-Nanoviricides COVID License Agreement a milestone payment of \$1,500,000 became due 5 days thereafter and was recorded as a non-current liability and research and development expense.

On July 19, 2023, the Company entered into an agreement with TheraCour to accept the Company's unsecured convertible promissory note (the "Note") in payment of the milestone award. The Note accrues simple interest at the rate of 12% per annum and is due and payable on January 19, 2025, the maturity date. The principal of the Note is convertible, at TheraCour's option, into 331,859 shares of the Company's Series A preferred stock, par value \$0.00001 at the conversion price, specified as the fair value of the Series A shares on July 19, 2023 in the terms and conditions contained within the promissory Note. Interest of \$36,493 was accrued under the Note for the period June 19, 2023 to September 30, 2023. On October 27, 2023 TheraCour exercised its right to convert the principal of the July 19, 2023 convertible promissory note into 331,859 shares of the Company's Series A preferred stock. TheraCour cancelled all of the accrued interest on the Note totaling \$49,808 which has been reported as a capital transaction credit to additional paid in capital for the year ended June 30, 2024. Total interest incurred under the Note for the year ended June 30, 2024 was \$49,808.

On February 12, 2024, the Company entered into an Amendment to the COVID License Agreement with TheraCour dated September 7, 2021, whereby any further cash milestone payments that would be earned upon milestone event would only become payable upon the Company having sufficient revenues, with only a portion of revenues to be used for satisfying such milestone payments.

**Line of Credit - Related Party**

On November 13, 2023, the Company's President and CEO, Dr. Anil R. Diwan, entered into a Line of Credit Agreement whereby Dr. Diwan agreed to provide a standby Line of Credit to the Company in the maximum amount of \$2,000,000. All amounts outstanding under the Line of Credit, including principal, accrued interest and other fees and charges, will be due and payable on December 31, 2024. Amounts drawn down under the Line of Credit shall bear interest at a fixed rate of 12%. Advancements under the Line of Credit will be collateralized by an Open End Mortgage Deed on the Company's real property at 1 Controls Drive, Shelton, Connecticut and a Chattel Mortgage (U.C.C. - 1 filing) against the Company's equipment and fixtures. Any draw down under the Line of Credit requires the approval of the Company's Board of Directors. On February 12, 2024 the Company, pursuant to Article 2.5 of the Company's Line of Credit Agreement with Dr. Anil R. Diwan, signed an Extension Agreement which extended the maturity of the Company's Line of Credit from December 31, 2024 to December 31, 2025.

On September 23, 2024 and becoming effective as of September 20, 2024, the Company, pursuant to Article 2.5 of the Company's Line of Credit Agreement with Dr. Anil R. Diwan, signed an Amendment Agreement which increased the available line of credit from \$2,000,000 to \$3,000,000, and extended the maturity of the Company's Line of Credit from December 31, 2025 to March 31, 2026. There were no other amendments to the original Line of Credit. The Company has not drawn against the Line of Credit facility as of September 30, 2024.

**Related Parties**

**Chairman, President, CEO, significant stockholder through his ownership of TheraCour, and Director**

An entity owned and controlled by Dr. Anil Diwan

Karveer Meditech Private Limited ("KMPL")

An entity where Dr. Anil Diwan is a passive investor and advisor without operating control





**font-family: Times New Roman; Times; serif; font-size: 8pt; text-align: center; margin: 0pt 0.05pt 0pt; font-weight: bold; For the three months ended**

**font-family: Times New Roman; Times; serif; font-size: 10pt; margin: 0pt 0.05pt 0pt; font-weight: bold; 2024**

**font-family: Times New Roman; Times; serif; font-size: 8pt; text-align: center; margin: 0pt 0.05pt 0pt; font-weight: bold; 2023**

*Research and Development Costs Related Party*

	2024	2023
Development fees and other costs charged by TheraCour pursuant to the license agreements between TheraCour and the Company for the development of the Company's drug pipeline. No royalties are due TheraCour from the Company at September 30, 2024 and June 30, 2024.	639,077	

**font-family: Times New Roman; Times; serif; font-size: 8pt; text-align: center; margin: 0pt; font-weight: bold; As of**

**font-family: Times New Roman; Times; serif; font-size: 8pt; text-align: center; margin: 0pt; font-weight: bold; 2024**

















Roman', 'Times', 'serif', font-size: 10pt; text-align: right; margin: 0pt 3pt 0.05pt 0pt; "> 305,561</p></td><td style="vertical-align: bottom; white-space: nowrap; width: 1.48%; background: #e0e0e0; margin: 0pt; padding: 0pt;"><span style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; margin: 0pt 0.05pt 0pt;"><span style="visibility: hidden;"></span></p></td><td style="vertical-align: bottom; white-space: nowrap; width: 0.92%; background: #e0e0e0; border-bottom: 3px double #000000; margin: 0pt; padding: 0pt;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; margin: 0pt 0.05pt 0pt;"><span style="margin-bottom: 12pt; visibility: hidden;"></span></p></td><td style="vertical-align: bottom; white-space: nowrap; width: 7.72%; background: #e0e0e0; border-bottom: 3px double #000000; margin: 0pt; padding: 0pt;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; text-align: right; margin: 0pt 3pt 0.05pt 0pt;"> 325,308</p></td></tr></table><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; text-align: justify; margin: 0pt;"><span style="margin-bottom: 12pt; visibility: hidden;"></span></p><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; text-align: justify; margin: 0pt 12pt 0pt;">Amortization expense amounted to \$2,067 and \$2,067 for the three months ended September 30, 2024 and 2023, respectively.</p><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; text-align: justify; margin: 0pt 0pt 12pt 0pt;">NanoViricides, Inc.'s intangible assets include acquired licenses and capitalized patent costs representing legal fees associated with filing patent applications. Intangible assets with finite lives, licenses and patent costs, are amortized using the straight-line method over the estimated economic lives of the assets, which range from <span style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; text-align: justify; margin: 0pt 12pt 0pt;"><span style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; font-style: normal; font-weight: normal;">seventeen</span> to twenty years. The Company's intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.</p><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; text-align: justify; margin: 0pt 0pt 12pt 0pt;">Intangible assets determined to have indefinite useful lives, primarily patent costs, are not amortized but are tested for impairment annually, or more frequently if events or changes in circumstances indicate the asset may be impaired. The Company accounts for patent costs in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") ASC 350-30, <i style="font-family: Times New Roman', 'Times', 'serif; font-size: 10pt; font-style: italic;">General Intangibles Other than Goodwill</i>. The Company will begin amortizing the patent costs when they are brought to the market or otherwise commercialized.</p><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; text-align: justify; margin: 0pt;">The Company does assess the recoverability of intangible assets with indefinite lives annually in the fourth quarter of each fiscal year, or more often if indicators warrant, by determining whether the fair value of each of the intangible assets, as a unit, supports its carrying value. In accordance with ASC 350, each year the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of each license is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments.</p><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; text-align: justify; margin: 0pt;"><span style="margin-bottom: 12pt; visibility: hidden;"></span></p></td><td style="border-collapse: collapse; font-size: 16pt; height: max-content; margin-left: auto; margin-right: auto; padding-left: 0pt; padding-right: 0pt; width: 100%;"><tr style="height: 1pt;"><td style="vertical-align: bottom; width: 26.91%; margin: 0pt; padding: 0pt;"><div style="height: 1pt; overflow: hidden; overflow-wrap: break-word; position: relative;"><div style="bottom: 0pt; position: absolute; width: 100%;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; margin: 0pt 0.05pt 0pt;"><span style="font-size: 1pt; visibility: hidden;"></span></p></div></div></td><td style="vertical-align: bottom; white-space: nowrap; width: 1.21%; margin: 0pt; padding: 0pt;"><div style="height: 1pt; overflow: hidden; overflow-wrap: break-word; position: relative;"><div style="bottom: 0pt; position: absolute; width: 100%;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; margin: 0pt 0.05pt 0pt;"><span style="font-size: 1pt; visibility: hidden;"></span></p></div></div></td><td style="vertical-align: bottom; white-space: nowrap; width: 1.17%; margin: 0pt; padding: 0pt;"><div style="height: 1pt; overflow: hidden; overflow-wrap: break-word; position: relative;"><div style="bottom: 0pt; position: absolute; width: 100%;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; margin: 0pt 0.05pt 0pt;"><span style="font-size: 1pt; visibility: hidden;"></span></p></div></div></td><td style="vertical-align: bottom; white-space: nowrap; width: 1.48%; margin: 0pt; padding: 0pt;"><div style="height: 1pt; overflow: hidden; overflow-wrap: break-word; position: relative;"><div style="bottom: 0pt; position: absolute; width: 100%;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; margin: 0pt 0.05pt 0pt;"><span style="font-size: 1pt; visibility: hidden;"></span></p></div></div></td><td style="vertical-align: bottom; white-space: nowrap; width: 1.21%; margin: 0pt; padding: 0pt;"><div style="height: 1pt; overflow: hidden; overflow-wrap: break-word; position: relative;"><div style="bottom: 0pt; position: absolute; width: 100%;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; margin: 0pt 0.05pt 0pt;"><span style="font-size: 1pt; visibility: hidden;"></span></p></div></div></td><td style="vertical-align: bottom; white-space: nowrap; width: 1.17%; margin: 0pt; padding: 0pt;"><div style="height: 1pt; overflow: hidden; overflow-wrap: break-word; position: relative;"><div style="bottom: 0pt; position: absolute; width: 100%;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; margin: 0pt 0.05pt 0pt;"><span style="font-size: 1pt; visibility: hidden;"></span></p></div></div></td><td style="vertical-align: bottom; white-space: nowrap; width: 1.48%; margin: 0pt; padding: 0pt;"><div style="height: 1pt; overflow: hidden; overflow-wrap: break-word; position: relative;"><div style="bottom: 0pt; position: absolute; width: 100%;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; margin: 0pt 0.05pt 0pt;"><span style="font-size: 1pt; visibility: hidden;"></span></p></div></div></td><td style="vertical-align: bottom; white-space: nowrap; width: 0.93%; margin: 0pt; padding: 0pt;"><div style="height: 1pt; overflow: hidden; overflow-wrap: break-word; position: relative;"><div style="bottom: 0pt; position: absolute; width: 100%;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; margin: 0pt 0.05pt 0pt;"><span style="font-size: 1pt; visibility: hidden;"></span></p></div></div></td><td style="vertical-align: bottom; white-space: nowrap; width: 9.76%; margin: 0pt; padding: 0pt;"><div style="height: 1pt; overflow: hidden; overflow-wrap: break-word; position: relative;"><div style="bottom: 0pt; position: absolute; width: 100%;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; margin: 0pt 0.05pt 0pt;"><span style="font-size: 1pt; visibility: hidden;"></span></p></div></div></td><td style="vertical-align: bottom; white-space: nowrap; width: 1.48%; margin: 0pt; padding: 0pt;"><div style="height: 1pt; overflow: hidden; overflow-wrap: break-word; position: relative;"><div style="bottom: 0pt; position: absolute; width: 100%;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; margin: 0pt 0.05pt 0pt;"><span style="font-size: 1pt; visibility: hidden;"></span></p></div></div></td><td style="vertical-align: bottom; white-space: nowrap; width: 1.06%; margin: 0pt; padding: 0pt;"><div style="height: 1pt; overflow: hidden; overflow-wrap: break-word; position: relative;"><div style="bottom: 0pt; position: absolute; width: 100%;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; margin: 0pt 0.05pt 0pt;"><span style="font-size: 1pt; visibility: hidden;"></span></p></div></div></td><td style="vertical-align: bottom; white-space: nowrap; width: 9.76%; margin: 0pt; padding: 0pt;"><div style="height: 1pt; overflow: hidden; overflow-wrap: break-word; position: relative;"><div style="bottom: 0pt; position: absolute; width: 100%;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; margin: 0pt 0.05pt 0pt;"><span style="font-size: 1pt; visibility: hidden;"></span></p></div></div></td><td style="vertical-align: bottom; white-space: nowrap; width: 1.48%; margin: 0pt; padding: 0pt;"><div style="height: 1pt; overflow: hidden; overflow-wrap: break-word; position: relative;"><div style="bottom: 0pt; position: absolute; width: 100%;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; margin: 0pt 0.05pt 0pt;"><span style="font-size: 1pt; visibility: hidden;"></span></p></div></div></td><td style="vertical-align: bottom; white-space: nowrap; width: 0.92%; margin: 0pt; padding: 0pt;"><div style="height: 1pt; overflow: hidden; overflow-wrap: break-word; position: relative;"><div style="bottom: 0pt; position: absolute; width: 100%;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; margin: 0pt 0.05pt 0pt;"><span style="font-size: 1pt; visibility: hidden;"></span></p></div></div></td><td style="vertical-align: bottom; white-space: nowrap; width: 7.72%; margin: 0pt; padding: 0pt;"><div style="height: 1pt; overflow: hidden; overflow-wrap: break-word; position: relative;"><div style="bottom: 0pt; position: absolute; width: 100%;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; margin: 0pt 0.05pt 0pt;"><span style="font-size: 1pt; visibility: hidden;"></span></p></div></div></td><td style="vertical-align: bottom; white-space: nowrap; width: 26.91%; margin: 0pt; padding: 0pt;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 10pt; margin: 0pt 0.05pt 0pt;"><span style="font-size: 8pt; visibility: hidden;"></span></p></td><td style="vertical-align: bottom; white-space: nowrap; width: 1.48%; margin: 0pt; padding: 0pt;"><div style="height: 1pt; overflow: hidden; overflow-wrap: break-word; position: relative;"><div style="bottom: 0pt; position: absolute; width: 100%;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 8pt; text-align: center; margin: 0pt 0.05pt 0pt;"><b style="font-weight: bold;">September 30, 2024</b></p></div></div></td><td style="vertical-align: bottom; white-space: nowrap; width: 12.38%; margin: 0pt; padding: 0pt;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 8pt; text-align: center; margin: 0pt 0.05pt 0pt;"><b style="font-weight: bold;">September 30, 2024</b></p></td><td style="vertical-align: bottom; white-space: nowrap; width: 1.48%; margin: 0pt; padding: 0pt;"><div style="height: 1pt; overflow: hidden; overflow-wrap: break-word; position: relative;"><div style="bottom: 0pt; position: absolute; width: 100%;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 8pt; text-align: center; margin: 0pt 0.05pt 0pt;"><b style="font-weight: bold;">September 30, 2024</b></p></div></div></td><td style="vertical-align: bottom; white-space: nowrap; width: 9.1%; margin: 0pt; padding: 0pt;"><p style="font-family: Times New Roman', 'Times', 'serif', font-size: 8pt; text-align: center; margin: 0pt 0.05pt 0pt;"><b style="font-weight: bold;">Total</b></p></td></tr></table><td style="vertical-align: bottom; white-





**September 30, 2024**

Personnel and compensation costs

June 30, 2024

	2024	2023
Consultant	46,857	23,532
Clinical trial costs due to KMPL	227,435	262,467
	274,292	286,000

**September 30, 2024**

Personnel and compensation costs

June 30, 2024

	2024	2023
Consultant	46,857	23,532
Clinical trial costs due to KMPL	227,435	262,467
	274,292	286,000



**Less:**

Gross proceeds	1,764,000	
Net proceeds from issuance of common stock	54,000	
Expected annual rate of quarterly dividends	\$4.18	
Expected volatility	0.00	

As of July 1, 2024 the Company and Dr. Anil Diwan entered into an extension of his employment agreement for a period of one year from July 1, 2024 through June 30, 2025 under the same general terms and conditions. The Company granted Dr. Anil Diwan an award of 10,204 shares of the Company's Series A preferred stock. The shares shall be vested in quarterly installments of 2,551 shares on September 30, 2024, December 31, 2024, March 31, 2025 and June 30, 2025 and are subject to forfeiture. The Company recognized non-cash compensation expense related to the issuance of the Series A preferred stock of \$12,458 for the three months ended September 30, 2024. The balance of \$37,375 will be recognized as the remaining 7,653 shares vest and service is rendered for the remaining nine months ended June 30, 2025.

For the three months ended September 30, 2024, the Company's Board of Directors authorized the issuance of 387 of fully vested shares of its Series A preferred stock for employee compensation. The Company recorded expense of \$1,950 for the three months ended September 30, 2024 related to this issuance.

There is currently no market for the shares of Series A preferred stock and they can only be converted into shares of common stock upon a change of control of the Company as more fully described in the Certificate of Designation. The Company, therefore, estimated the fair value of the Series A preferred stock granted to various employees and others on the date of grant. The conversion of the shares is triggered by a change of control. The fair value of the Series A Convertible preferred stock at each issuance was estimated based upon the price of the Company's common stock after an application for a reasonable discount for lack of marketability.

The Scientific Advisory Board was granted in August 2024 fully vested warrants to purchase 286 shares of common stock with an exercise price of \$2.35 per share expiring in August 2028. The fair value of the warrants was \$229 for the three months ended September 30, 2024 and was recorded as consulting expense.

The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option Pricing Model with the following assumptions:

Expected life (year)	1.54	
Expected volatility	0.00	















*Legal Proceedings*

From time to time, we are subject to various legal proceedings arising in the ordinary course of business, including proceedings for which we have insurance coverage. There are no pending legal proceedings against the Company to the best of the Company's knowledge as of the date hereof and to the Company's knowledge no action, suit or proceeding has been threatened against the Company that we believe will have a material adverse effect to our business, financial position, results of operations, or liquidity.

**Employment Agreements**

As discussed in Note 8, as of July 1, 2024, the Company and Dr. Diwan, the Company's President and Chief Executive Officer, executed an extension of his employment agreement for a period of one year from July 1, 2024 through June 30, 2025 under the same general terms and conditions. The Company granted Dr. Anil Diwan an award of 10,204 shares of the Company's Series A preferred stock. The shares will be deemed partially vested in quarterly installments following the grant date and fully vested on June 30, 2025.

As of July 1, 2024, the Company's Board of Directors approved the extension of the agreement with Meeta Vyas, Chief Financial Officer of the Company. The Company and Meeta Vyas signed an extension of the agreement for a period of one year from July 1, 2024 through June 30, 2025 under the same general terms and conditions as the current agreement.

**License Agreements**

The Company is dependent upon its license agreements with TheraCour (See Notes 1 and 4). If the Company lost the right to utilize any of the proprietary information that is the subject of the TheraCour license agreement on which it depends, the Company will incur substantial delays and costs in development of its drug candidates. On November 1, 2019, the Company entered into a VZV License Agreement with TheraCour for an exclusive license for the Company to use, promote, offer for sale, import, export, sell and distribute products for the treatment of VZV derived indications. Process development and related work will be performed by TheraCour under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed.

On September 7, 2021, the Company entered into a COVID-19 License Agreement to use, promote, offer for sale, import, export, sell and distribute drugs that treat COVID-19 infections, using TheraCour's proprietary as well as patented technology and intellectual property. The discovery of ligands and polymer materials as well as formulations, the chemistry and chemical characterization, as well as process development and related work will be performed by TheraCour under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed.

On March 27, 2023 the Company entered into a license agreement with KMPL wherein the Company granted to KMPL a limited, non-transferable, exclusive license for the use, sale, or offer of sale in India of the Company's two clinical test drug candidates titled as NV-CoV-2 and NV-CoV-2-R for the treatment of COVID in patients in India. KMPL has engaged in further drug development in India including sponsoring of drug candidates for human clinical trials in India and has acted as clinical trials manager for such clinical trials. KMPL shall provide NanoViricides with all reports of the clinical trials and the Company can use such reports for further advancement of the drug candidates with regulatory authorities outside India. In consideration, KMPL will receive a customary clinical trials manager fee of thirty percent (30%) of such costs and applicable taxes. Upon commercial sales of any resulting approved drugs, KMPL will pay the Company a royalty of seventy (70%) percent of the final invoiced sales to unaffiliated third parties.

On February 12, 2024, the Company entered into an Amendment to the COVID License Agreement with TheraCour dated September 7, 2021, whereby any further cash milestone payments that would be earned upon milestone event would only become payable upon the Company having sufficient revenues, with only a portion of revenues to be used for satisfying such milestone payments.

On September 23, 2024 and effective as of September 20, 2024, the Company entered into a "Memorandum of Understanding for All Antivirals Drug Development" (the MoU) with TheraCour that granted to the Company, a limited, non-assignable, non-sublicensable, exclusive Right of First Refusal to License to any antiviral drugs in development or to be developed by TheraCour for research and development purposes only, for all as-yet-licensed viral infection treatment indications. The MoU also clarified the roles and responsibilities of the Parties and essentially codified the process that the parties have adopted since inception. The MoU further codified the treatment of all future milestone payments arising from any current or future license agreements to TheraCour to be consistent with the principles adopted in the February 12, 2024 Amendment to the COVID-19 License Agreement.

P1Y 10204 P1Y 2 0.30 0.70

**Note 11 – Subsequent Events**

As discussed at Note 8 to the financial statements, on April 15, 2024, the Company entered into a sales agreement with E.F. Hutton Securities (now EF Hutton, LLC), the Sales Agent, pursuant to which the Company may offer and sell, from time to time, through or to the Sales Agents, shares of common stock At the Market or ATM Offering. From October 1, 2024 through November 7, 2024 the Company sold 431,108 shares of common stock at an average price of approximately \$1.51 per share. The shares were issued pursuant to a prospectus supplement dated May 5, 2023 and filed with the Securities and Exchange Commission on May 5, 2023 in connection with the Company's shelf registration statement on Form S-3, as amended File No. 333-271706, which became effective on May 22, 2023. The net proceeds to the Company from the offering from October 1, 2024 through November 7, 2024 was approximately \$631,000 after placement agent fees and other estimated offering expenses.

431108 1.51 631000 false false false false